Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Release Notes Frontmatter Part 1 - General Pathology Part 2 - Diseases of Organ Systems Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Release Notes Frontmatter Part 1 - General Pathology Part 2 - Diseases of Organ Systems Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 1 - Cellular Pathology I: Cell Injury and Cell Death 2 - Cellular Pathology II: Adaptations, Intracellular Accumulations, and Cell Aging 3 - Acute and Chronic Inflammation 4 - Tissue Repair: Cellular Growth, Fibrosis, and Wound Healing 5 - Hemodynamic Disorders, Thrombosis, and Shock 6 - Genetic Disorders 7 - Diseases of Immunity 8 - Neoplasia 9 - Infectious Diseases 10 - Environmental and Nutritional Pathology 11 - Diseases of Infancy and Childhood Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 12 - Blood Vessels 13 - The Heart 14 - Red Cells and Bleeding Disorders 15 - White Cells, Lymph Nodes, Spleen, and Thymus 16 - The Lung 17 - Head and Neck 18 - The Gastrointestinal Tract 19 - The Liver and the Biliary Tract 20 - The Pancreas 21 - The Kidney 22 - The Lower Urinary Tract 23 - The Male Genital Tract 24 - The Female Genital Tract 25 - The Breast 26 - The Endocrine System 27 - The Skin 28 - Bones, Joints, and Soft Tissue Tumors 29 - Peripheral Nerve and Skeletal Muscle 30 - The Central Nervous System 31 - The Eye Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Ab -- Ad Af -- Am An -- Ao Ap -- As At -- Az B -- Be Bi -- Bo Br -- By C -- Cap Car -- Ce Cf -- Ch Ci -- Com Con -- Cr Cs -- Cy Da -- De Di -- Dy Ea -- En Eo -- Ey Fa -- Fi Fl -- Fu G -- Gi Gl -- Gy Ha -- Hem Hen -- Hi Hl -- Hyd Hyg -- Hyp I -- Ins Int -- It J K La -- Le Li -- Lo Lu -- Ly M -- Mel Mem -- Mi
Ml -- Mu Mya -- Myx N O P -- Pa Pc -- Phe Phi -- Pla Ple -- Prn Pro -- Pyo Q Ra -- Res Ret -- Ru S -- Sep Seq -- Sm So -- Sta Ste -- Sy T -- Th Ti -- Tre Tri -- Tz U V W X Y Z Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
proudly presents... Robbins Pathologic Basis of Disease, 6th Edition
(c) 1999, W. B. Saunders Company
- Release Notes Source: MDConsult Ripped/Converted by: ZD Rip Date: March 2002 Release Date: March 11, 2002 Release Type: Reference Book
Version: No Images (4.1MB) Platform: PalmOS Required: PalmOS PDA, 4.3MB free internal or external RAM, iSilo v3.0 or later. Recommended: 33MHz+ PalmOS v4.0 or later PDA w/ expansion and hi-res, 16-bit display.
- Release Info First a word from the publisher: --Presenting the latest edition of this popular, comprehensive and practical text of pathology. Written with great clarity for easy readability, this reference offers detailed discussions of genetic disorders, cellular injury and death, neoplasia, the skeletal system and soft tissue tumors, and much more. Completely revised and updated, this edition is even more user-friendly with the use of text boxes for key topics in each chapter and a new full-color design. Features 1200 excellent 4-color illustrations! 1,440 pp. 1548 ills. 1438 in color ISBN: 072167335X Price: $85.00 --Another iSilo release a few people may want is here: Robbins (as provided by MDConsult). If you're new to this, take a look at the fully functioning Table of Contents and Index. Also give the "navigation bar" at the top and bottom of each page a try. This "nav-bar" allows you to quickly jump to the table of contents, index, and each section of the book from anywhere in the document. It also allows you to go to the previous and next page in the text (the left and right arrows). A quick tip: to get to the nav-bar from the middle of a long page, just use the top and end of page shortcuts (/0 and /Z respectively) via grafitti. This release is best viewed with the following iSilo settings: Set "Font" to "small" under Display Options; set "Title bar" to "hide" and "Scroll bar" to "none" under Interface options; And "Region 1" set to "Line Up", "Region 2 and 3" to "Drag" and "Region 4" to Line Down" under Region options. There may be two versions of this release, one with images and one without. With images the file right now balloons to about 135MB (the book has A LOT of images). I am starting to realize that iSilo is not the ideal platform for having a massive amount of images (well atleast without making major sacrifices in image quality). I am looking into what other options are present on the Palm to best resolve this issue. Shrinking the images in my opinion makes them pretty useless. I would like to hear your opinions. - Conversion Info In order to cut down on size, the thumbnail images (those pretty useless miniature
versions of the full figures) were removed and replaced with a standard icon. Otherwise, with the exception of a few minor formatting changes and making the hyperlinks that point to tables actually work (they don't on MDConsult), *NO* TEXT CONTENT WAS ALTERED OR REMOVED IN THE CREATION OF THIS FILE. What you see is what I got from MDConsult. - Known Issues Since you're not reading this on a PocketPC, you'll have to give the tables a few seconds or (a lot) longer to correctly render depending on the complexity and length of the page. You can still scroll and "click" while it is doing this. Palms just were not made for this kind of stuff. Using the iSilo toolbar page-back and page-forward buttons (the ones surrounding the current page number) won't do you much good since the page numbers in the book don't follow that order. Use the page-back and page-forward buttons on the nav-bar instead (that's what they are there for). - Greetings Respect goes to MedScut (the iSilo king), the PDA People, the "group" moderators and those that have made and still make the Skyscape stuff possible. - Comments Please send your constructive comments/criticisms to: E-mail:
[email protected] Web: http://zd.pros.at/ You may also find me on the "groups" and where the PDA People stay. Look for more MDConsult titles coming soon. And remember, IF YOU LIKE IT, BUY IT!!! - ZD '02 Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Frontmatter Title Page Copyright Page Dedication Contributors Preface Acknowledgments Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
1A
3A
Robbins PATHOLOGIC BASIS of DISEASE
Sixth Edition Ramzi S. Cotran M.D. Frank Burr Mallory Professor of Pathology, Harvard Medical School, Chairman, Department of Pathology, Brigham and Women's Hospital, The Children's Hospital, Boston, Massachusetts
Vinay Kumar M.D., F.R.C.Path. Vernie A. Stembridge Chair in Pathology, Department of Pathology, The University of Texas, Southwestern Medical School, Dallas, Texas
Tucker Collins M.D., Ph.D. Professor of Pathology, Harvard Medical School, Pathologist, Brigham and Women's Hospital, Boston, Massachusetts
W.B. Saunders Company A Division of Harcourt Brace & Company Philadelphia London Toronto Montreal Sydney Tokyo
4A
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY
1
Chapter 1 - Cellular Pathology I: Cell Injury and Cell Death INTRODUCTION TO PATHOLOGY Pathology is literally the study (logos) of suffering (pathos). More specifically, it is a bridging discipline involving both basic science and clinical practice and is devoted to the study of the structural and functional changes in cells, tissues, and organs that underlie disease. By the use of molecular, microbiologic, immunologic, and morphologic techniques, pathology attempts to explain the whys and wherefores of the signs and symptoms manifested by patients while providing a sound foundation for rational clinical care and therapy. Traditionally, the study of pathology is divided into general pathology and special or systemic pathology. The former is concerned with the basic reactions of cells and tissues to abnormal stimuli that underlie all diseases. The latter examines the specific responses of specialized organs and tissues to more or less well defined stimuli. In this book, we first cover the principles of general pathology and then proceed to specific disease processes as they affect particular organs or systems. The four aspects of a disease process that form the core of pathology are its cause (etiology), the mechanisms of its development (pathogenesis), the structural alterations induced in the cells and organs of the body (morphologic changes), and the functional consequences of the morphologic changes (clinical significance). Etiology or Cause. The concept that certain abnormal symptoms or diseases are "caused" is as ancient as recorded history. For the Arcadians (2500 B.C.), If Someone Became Ill, It Was The Patient 's own fault (for having sinned) or the makings of outside agents, such as bad smells, cold, evil spirits, or gods. [1] In modern terms, there are the two major classes of
etiologic factors: intrinsic or
2
genetic and acquired (e.g., infectious, nutritional, chemical, physical). Knowledge or discovery of the primary cause remains the backbone on which a diagnosis can be made, a disease understood, or a treatment developed. The concept, however, of one etiologic agent to one disease--developed from the study of infections or single-gene disorders--is no longer sufficient. Genetic factors are clearly involved in some of the common environmentally induced maladies, such as atherosclerosis and cancer, and the environment may also have profound influences on certain genetic diseases. Pathogenesis. Pathogenesis refers to the sequence of events in the response of the cells or tissues to the etiologic agent, from the initial stimulus to the ultimate expression of the disease. The study of pathogenesis remains one of the main domains of pathology. Even when the initial infectious or molecular cause is known, it is many steps removed from the expression of the disease. For example, to understand cystic fibrosis is to know not only the defective gene and gene product but also the biochemical, immunologic, and morphologic events leading to the formation of cysts and fibrosis in the lung, pancreas, and other organs. Indeed, as we shall see throughout the book, the molecular revolution has already identified mutant genes underlying a great number of diseases and promises to map the entire human genome before too long. Nevertheless, the functions of the encoded proteins and how mutations induce disease are often still obscure. Thus, the study of pathogenesis has never been more exciting scientifically or more relevant to the development of new therapies. Morphologic Changes. The morphologic changes refer to the structural alterations in cells or tissues that are either characteristic of the disease or diagnostic of the etiologic process. Functional Derangements and Clinical Significance. The nature of the morphologic changes and their distribution in different organs or tissues influence normal function and determine the clinical features (symptoms and signs), course, and prognosis of the disease. Virtually all forms of organ injury start with molecular or structural alterations in cells, a concept first put forth in the 19th century by Rudolf Virchow, known as the father of modern pathology. We therefore begin our consideration of pathology with the study of the origins, molecular mechanisms, and structural changes of cell injury. Yet different cells in tissues constantly interact with each other, and an elaborate system of extracellular matrix is necessary for the integrity of organs. Cell-cell and cell-matrix interactions contribute significantly to the response to injury, leading collectively to tissue
and organ injury, which are as important as cell injury in defining the morphologic and clinical patterns of disease. [2]
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS
493
Chapter 12 - Blood Vessels Frederick J. Schoen Ramzi S. Cotran
Vascular disorders are responsible for more morbidity and mortality than any other category of human disease. Vascular abnormalities cause clinical disease by two principal mechanisms: Narrowing or completely obstructing the lumens of vessels, either progressively (e.g., by atherosclerosis) or precipitously (e.g., by thrombosis), often inducing downstream deficiency of blood flow to the tissue perfused by that vessel Weakening of the walls of vessels, leading to dilation or rupture
494
NORMAL VASCULATURE The architecture of the vasculature varies with and reflects distinct functional requirements at different locations. To withstand the pulsatile and higher blood pressures in arteries, arterial walls are generally thicker than their venous counterparts. Arterial wall thickness gradually diminishes as the vessels become smaller, but the ratio of wall thickness to lumen diameter becomes greater. Veins have a larger overall diameter, a larger lumen, and a thinner wall than corresponding arteries. Arteries are divided into three types, based on their size and structural features: (1) large or elastic arteries, including the aorta and its large branches (e.g., aorta and innominate, subclavian, common carotid, iliac, and pulmonary arteries); (2)
medium-sized or muscular arteries comprising other branches of the aorta (such as the coronary or renal arteries), also referred to as distributing arteries; and (3) small arteries (usually <2 mm in diameter) that course, for the most part, within the substance of tissues and organs. The basic constituents of the walls of blood vessels are endothelial cells, smooth muscle cells, and extracellular matrix, including elastic elements, collagen, and proteoglycans. They are arranged in concentric layers--the intima (adjacent to the lumen), media, and adventitia (externally)--most clearly defined in the larger vessels (Fig. 12-1) . In normal arteries, the intima is composed of the lining endothelial cells with minimal underlying subendothelial connective tissue. It is separated from the media by a dense elastic membrane called the internal elastic lamina. The outer limit of the media of most arteries is marked by a well-defined external elastic lamina. In the large and medium-sized arteries, the smooth muscle cell layers of the media near the vessel lumen depend primarily on direct diffusion of oxygen from the vessel lumen for their nutritional needs. Diffusion is facilitated by holes ( fenestrations) in the internal elastic membrane. Because diffusion from the lumen provides inadequate oxygen to the outer portion of the media in the large and medium-sized vessels, small arterioles arising from outside the vessel perforate the external elastic membrane and send vascular twigs into the outer one half to two thirds of the media. These vessels that nourish the vascular walls are called vasa vasorum
Figure 12-1 Diagrammatic representation of the main components of the vascular wall, seen here in a muscular artery.
(literally vessels of the vessels). External to the media is the adventitia, a layer of investing connective tissue in which nerve fibers and the vasa vasorum are dispersed. The relative amount and configuration of the basic constituents vary along the arterial system owing to local adaptations to mechanical or metabolic needs. In the elastic arteries, the media is rich in elastic fibers, disposed in fairly compact layers separated by and alternating with layers of smooth muscle cells. The elastic components of the aorta allow it to expand during systole, thereby storing some of the energy of each heartbeat. Following and in between cardiac contractions during the diastolic phase of the cardiac cycle, elastic recoil of the vascular wall propels blood through the peripheral vascular system. During aging, the aorta loses elasticity, and these vessels expand less readily, particularly when blood pressure is increased. Thus, the arteries of older individuals often become progressively tortuous and dilated. In muscular arteries, the media is composed predominantly of circularly or spirally arranged smooth muscle cells. Elastin is limited to the internal and external membranes. In the muscular arteries and arterioles (see later), regional blood flow and blood pressure are regulated by changes in lumen size through smooth muscle cell contraction ( vasoconstriction) or relaxation ( vasodilation), controlled in part by the autonomic nervous system and in part by local metabolic factors and cellular interactions. Arterioles are the smallest branches of the arteries (generally 20 to 100 mum in diameter). Changes in the state of contraction of the medial smooth muscle of arterioles
cause dramatic adjustments in lumen diameter that regulate systemic arterial blood pressure and significantly influence blood flow distribution among the various capillary beds. Because the resistance of a blood vessel to fluid flow is inversely proportional to the fourth power of the diameter (i.e., halving the diameter increases resistance 16-fold), small changes in the lumen size of small blood vessels can have a profound flow-limiting effect. Thus, arterioles are the principal points of physiologic resistance to blood flow, inducing a sharp reduction in pressure and velocity and a change from pulsatile to steady flow. Moreover, small arteries and arterioles bear the brunt of blood pressure elevations; abnormal stresses alter their structure, with important consequences detailed later. Some pathologic lesions involve arteries of a characteristic size range. For example, atherosclerosis affects largely elastic and muscular arteries, hypertension affects primarily small muscular arteries and arterioles, and specific types of vasculitis are associated with certain vascular segments. Capillaries are approximately the diameter of a red blood cell (7 to 8 mum) and have thin walls. Since many capillaries arise from each arteriole, the capillary bed has a large total cross-sectional area, and blood flow is quite slow, analogous to the decrease in flow rate seen at the wide regions of a river. Lined by endothelial cells, capillaries are supported on the outside by a thin basement membrane, and the media is absent. Slow flow, high surface area, and thin walls only one cell thick render capillaries ideally suited to the rapid exchange of diffusible substances between blood and tissue.
495
The structure of capillaries varies at different sites, particularly in the degree of continuity of endothelium and basement membrane. Muscle, heart, lung, skin, and nervous system capillaries have a continuous endothelial layer. In contrast, in endocrine glands, renal glomeruli, and some vessels of the gastrointestinal tract, the endothelium is fenestrated, which allows more rapid transport of larger molecules and fluid (e.g., hormones or the glomerular filtrate) than do capillaries with a continuous endothelium. Some capillary vascular channels (called sinusoids) have a discontinuous endothelium with partial or no basement membrane, as in the liver, spleen, and bone marrow, facilitating the passage of cells across the walls. Blood returning to the heart from capillary beds flows initially into the postcapillary venules then sequentially through collecting venules and small, medium, and large veins. Postcapillary venules are an important point of interchange between the lumen of the vessels and the surrounding tissues. For example, because the pressure in the venules is lower than that in the capillary bed as well as lower than interstitial tissue pressure, fluid can enter the circulation from the tissue surrounding the venules. Moreover, both vascular leakage and leukocytic exudation occur preferentially in venules in many types of inflammation (Chapter 3) . Veins are large-caliber but thin-walled vessels with a poorly defined internal elastic membrane and media not as well developed as that of arteries. Veins collectively have
a large capacity; approximately two thirds of systemic blood is in the venous circulation. Veins have relatively poor support and are predisposed to irregular dilation, compression, and easy penetration by tumors and inflammatory processes. Reversed flow is prevented by the valves found in many veins, particularly those in the extremities in which blood flows against gravity. Lymphatics are thin-walled, endothelium-lined channels devoid of blood cells that serve as a drainage system for returning interstitial tissue fluid to the blood. They also constitute an important pathway for disease dissemination, however, through transport of bacteria and tumor cells to distant sites.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 1 - Cellular Pathology I: Cell Injury and Cell Death INTRODUCTION TO PATHOLOGY DEFINITIONS CAUSES OF CELL INJURY CELL INJURY AND NECROSIS APOPTOSIS SUBCELLULAR RESPONSES TO CELL INJURY REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 2 - Cellular Pathology II: Adaptations, Intracellular Accumulations, and Cell Aging CELLULAR ADAPTATIONS OF GROWTH AND DIFFERENTIATION INTRACELLULAR ACCUMULATIONS PATHOLOGIC CALCIFICATION HYALINE CHANGE CELLULAR AGING CONCLUSION REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
31
Chapter 2 - Cellular Pathology II: Adaptations, Intracellular Accumulations, and Cell Aging In Chapter 1 , we discussed the morphologic expression and mechanisms of reversible cell injury and cell death. As noted, however, cells can respond to excessive physiologic stresses or pathologic stimuli by undergoing a number of physiologic and morphologic cellular adaptations, in which a new but altered steady state is achieved, preserving the viability of the cell and modulating its function as a response to such stimuli. Some of these adaptations involve changes in cellular growth, size, or differentiation and include hyperplasia, an increase in cell number; hypertrophy, an increase in cell size; atrophy, a decrease in the size and function of cells; and metaplasia, an alteration of cell differentiation. Pathologic adaptations may share the same underlying mechanisms as physiologic adaptations, but they provide the cells with the ability to survive in their environment and perhaps escape injury. Adaptive responses also can include the intracellular accumulation and storage of products in abnormal amounts. In special situations, storage becomes the primary mode of responding to substances that cannot be metabolized or excreted. These intracellular accumulations may consist of (1) normal substances, such as lipids, proteins, glycogen, iron, melanin, and bilirubin; (2) abnormal endogenous products, which include the proteins generated by genetically altered genes, such as alpha1 -antitrypsin in alpha1 -antitrypsin deficiency; or (3) exogenous products, which include environmental agents
32
such as anthracotic pigment or soot. These accumulations can give rise to both structural changes and functional impairment. There are numerous molecular mechanisms for cellular adaptations. Some are due to direct stimulation of cells by factors produced by other cells or to the cells themselves as is the case in cell growth (see discussion in Chapter 4) . Others involve up-regulation or down-regulation of specific cellular receptors involved in metabolism of certain components--for example, in the regulation of cell surface receptors participating in the uptake and degradation of low-density lipoproteins (Chapter 6) . Still others are associated with the induction of new protein synthesis by the target cells, as in the heat-shock response or the chronic response to hypoxia. Adaptations can also involve a switch by cells from producing one type of a family of proteins to another or markedly overproducing one protein; such is the case in cells producing various types of
collagens and extracellular matrix proteins in chronic inflammation and fibrosis (Chapters 3 and 4) . Adaptations then involve all steps in cellular metabolism of proteins-- receptor binding; signal transduction; transcription or translation; or regulation of protein synthesis, packaging, and release. This chapter discusses common adaptive changes in cell growth and differentiation that are particularly important in pathologic states--hyperplasia, hypertrophy, atrophy, and metaplasia and the intracellular accumulations of lipids, proteins, carbohydrates, and pigments. We also discuss the manifestations of cellular aging since they represent adaptations to environmental determinants of cell structure and function.
CELLULAR ADAPTATIONS OF GROWTH AND DIFFERENTIATION Hyperplasia Hyperplasia constitutes an increase in the number of cells in an organ or tissue, which may then have increased volume. Although hyperplasia and hypertrophy are two distinct processes, frequently both occur together, and they may well be triggered by the same mechanism. Estrogen-induced growth in the uterus involves both increased DNA synthesis and enlargement of smooth muscle and epithelium. In certain instances, however, even cells capable of dividing, such as renal epithelial cells, undergo hypertrophy but not hyperplasia. Growth inhibitors, such as transforming growth factor-beta (TGF-beta), may be involved in this phenomenon. In nondividing cells (e.g., myocardial fibers), only hypertrophy occurs. Nuclei in such cells have a much higher DNA content than that of normal myocardial cells, probably because the cells arrest in the cell cycle without undergoing mitosis. Hypertrophy does not involve cell division, but hyperplasia takes place if the cellular population is capable of synthesizing DNA, thus permitting mitotic division. Hyperplasia can be physiologic or pathologic. PHYSIOLOGIC HYPERPLASIA
Physiologic hyperplasia can be divided into (1) hormonal hyperplasia, best exemplified by the proliferation of the glandular epithelium of the female breast at puberty and during pregnancy and the physiologic hyperplasia that occurs in the pregnant uterus, and (2) compensatory hyperplasia, for example, the hyperplasia that occurs when a portion of the liver is removed (partial hepatectomy). Mechanisms of Hyperplasia: Lessons From Hepatic Regeneration.
In the myth of Prometheus, the ancient Greeks recognized the capacity of the liver to regenerate. Having stolen the secret of fire from the Gods, Prometheus was chained to a mountain, and his liver was devoured daily by a vulture, only to regenerate anew every night. [1] The experimental model of partial hepatectomy has been especially useful in examining mechanisms of compensatory hyperplasia. In the normal mature liver, only 0.5 to 1.0% of cells are undergoing DNA replication. After partial hepatectomy, all the existing mature cellular populations composing the intact organ proliferate to rebuild the lost hepatic tissue. Hepatocytes are the first cell type to
proliferate, and remarkably, these cells can maintain their normal metabolic functions while proliferating. [1] An increase in the number of DNA-synthesizing cells begins as early as 12 hours after hepatectomy and peaks between 1 and 2 days later, when about 10% of all cells may be involved in DNA synthesis (Fig. 2-1). Initiation of cell proliferation is associated with specific and sequential increases in proteins involved in an intracellular signaling cascade leading to DNA synthesis, as will be detailed in Chapter 4 . [2] These include the induction of transcription factors (e.g., c- fos, c- jun, nuclear factor-kappaB [NF-kappaB], signal transducer and activator of transcription [STAT]) as well as proteins linked to the cell cycle (e.g., myc, p53, and cyclins) (Fig. 2-1) . [3]
Figure 2-1 Expression of protooncogenes after partial hepatectomy and its relation to DNA synthesis by hepatocytes. (Courtesy of Nelson Fausto, University of Washington, Seattle, WA).
33
Figure 2-2 Postulated sequence of events in the compensatory hyperplasia after partial hepatectomy.
Subsequently, DNA synthesis declines, and by the time the liver mass is restored (at 1 to 2 weeks), the liver cells become quiescent again. There is substantial evidence that cell proliferation in this setting is dependent on the action of polypeptide growth factors and cytokines (see Chapter 4 for a detailed discussion of cell growth). Factors implicated include the following: Growth factors: Hepatocyte growth factor (HGF) and its receptor c-Met are key factors for liver growth and function. [4] HGF (also called scatter factor) initially identified in the serum of hepatectomized rats as a potent mitogen for cultured hepatocytes, is produced in the liver by nonparenchymal cells and by mesenchymal cells in many organs. Plasma HGF levels rise rapidly after partial hepatectomy. Both TGF-alpha and epidermal growth factor (EGF) are also mitogenic for hepatocytes in culture, and experimental studies suggest that EGF may play a mitogenic role in the early stages after partial hepatectomy, while TGF-alpha acts at later times. Cytokines: Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha ) are important components of the early signaling pathways involved in regeneration. The functional relevance of IL-6 was demonstrated in transgenic mice lacking the cytokine. In these animals, defective hepatocyte regeneration results in massive hepatic necrosis after partial hepatectomy, which can be prevented by administration of IL-6. [5] None of these growth factors or cytokines, however, are sufficient to induce proliferation in normal liver cells in vivo, and it has been proposed that an initial priming signal to the
remnant hepatic cells is necessary for the full effect of these mitogens (Fig. 2-2) . Such priming signals include degradation of the extracellular matrix, which would convert inactive matrix-associated HGF to its active, receptor binding form. Certain hormones, such as norepinephrine, whose blood level also increases after hepatectomy, and insulin, may function as adjuvants for cell proliferation. Cessation of cell growth, after the liver mass has been restored, appears to be caused by growth inhibitors produced in the liver itself. One of these inhibitors is TGF-beta, which is produced by nonparenchymal cells of the liver. In addition to proliferating differentiated hepatocytes, adult livers contain a small population of stem cells located in the junction between hepatocytes and the smallest segments of the biliary tree. [6] These stem cells have a variety of developmental options, including differentiating into hepatocytes and biliary duct epithelium. Stem cells do not play a major role in the hyperplasia after hepatectomy but may participate in the regeneration that occurs after certain forms of liver injury, such as hepatitis. PATHOLOGIC HYPERPLASIA
Most forms of pathologic hyperplasia are instances of excessive hormonal stimulation or are the effects of growth factors on target cells. An example of hormonally induced hyperplasia is hyperplasia of the endometrium. After a normal menstrual period, there is a rapid burst of proliferative activity. As is well known, this proliferation is potentiated by pituitary hormones and ovarian estrogen. It is brought to a halt by the rising levels of progesterone, usually about 10 to 14 days before the anticipated menstrual period. In some instances, however, the balance between estrogen and progesterone is disturbed. This results in absolute or relative increases in the amount of estrogen, or both, with consequent hyperplasia of the endometrial glands. Although this form of hyperplasia is a common cause of abnormal menstrual bleeding, the hyperplastic process remains controlled nonetheless: If the estrogenic stimulation abates, the hyperplasia disappears. Thus, it responds to regular growth control of cells. As is discussed in Chapter 8 , Neoplasia, it is this response to normal regulatory control mechanisms that differentiates benign pathologic hyperplasias from cancer. Pathologic hyperplasia, however, constitutes a fertile soil in which cancerous proliferation may eventually arise. Thus, patients with hyperplasia of the endometrium are at increased risk for developing endometrial cancer (Chapter 24) . Hyperplasia is also an important response of connective tissue cells in wound healing, in which proliferating fibroblasts and blood vessels aid in repair (Chapter 4) . Under these circumstances, growth factors are responsible for the hyperplasia. Stimulation by growth factors is also involved in the hyperplasia that is associated with certain viral infections, such as papillomaviruses, causing skin warts and a number of mucosal lesions composed of masses of hyperplastic epithelium. Hypertrophy Hypertrophy refers to an increase in the size of cells and, with such change, an increase in the size of the
34
Figure 2-3 Physiologic hypertrophy of the uterus during pregnancy. A , Gross appearance of a normal uterus (right) and a gravid uterus (removed for postpartum bleeding) (left). B, Small spindle-shaped uterine smooth muscle cells from a normal uterus (left) compared with large plump cells in gravid uterus (right).
organ. Thus, the hypertrophied organ has no new cells, just larger cells. The increased size of the cells is due not to cellular swelling but to the synthesis of more structural components. Hypertrophy can be physiologic or pathologic and is caused by increased functional demand or by specific hormonal stimulation. The massive physiologic growth of the uterus during pregnancy is a good example of hormone-induced hypertrophy involving both hypertrophy and hyperplasia (Fig. 2-3 A). The cellular hypertrophy is stimulated by estrogenic hormones through smooth muscle estrogen receptors, which allow for interactions of the hormones with nuclear DNA, eventually resulting in increased synthesis of smooth muscle proteins and an increase in cell size (Fig. 2-3 B). Similarly, prolactin and estrogen cause hypertrophy of the breasts during lactation. These are examples
Figure 2-4 Phenotypic changes in hypertrophy, shown here in myocardial fibers subjected to hemodynamic overload (see text).
35
of physiologic hypertrophy effected by hormonal stimulation. Hypertrophy as an adaptive response is exemplified by muscular enlargement seen in two settings. The striated muscle cells in both the heart and the skeletal muscles are most capable of hypertrophy, perhaps because they cannot adapt to increased metabolic demands by mitotic division and formation of more cells to share the work. The most common stimulus appears mainly to be increased workload. In the heart, it is usually chronic hemodynamic overload, owing either to hypertension or to faulty valves, and in skeletal muscles, heavy work. Synthesis of more proteins and filaments occurs, achieving a balance between the demand and the cell's functional capacity. The greater number of myofilaments permits an increased workload with a level of metabolic activity per unit volume of cell not different from that borne by the normal cell. Thus, the draft horse readily pulls the load that would break the back of a pony. Not only the size, but also the phenotype of the individual myocytes is altered in hypertrophy (Fig. 2-4) . [7] In volume overload in the myocardium, genes that are expressed only during early development are re-expressed. For example, in the
embryonic heart, the gene for atrial natriuretic factor (ANF) is expressed in both the atrium and the ventricle. After birth, ventricular expression of the gene is selectively down-regulated. [8] Cardiac hypertrophy, however, results in the reinduction of ANF gene expression. [9] ANF is a peptide hormone that causes salt secretion by the kidney, decreases blood volume and pressure, and therefore serves to reduce hemodynamic load. There is also a switch of contractile proteins from adult to fetal or neonatal forms. For example, the expression of the alpha-myosin heavy chain (alpha-MHC) is replaced by that of the beta-MHC, which leads to decreased myosin adenosine triphosphatase (ATPase) activity and a slower, more energetically economical contraction. A number of other genes are likewise activated during hypertrophy, including those encoding some of the early regulatory factors (c- fos, c- jun, egr-1); growth factors (TGF-beta, insulin-like growth factor-1 [IGF-1], fibroblast growth factor [FGF]); vasoactive agents (alpha-adrenergic agonists, endothelin-1, and angiotensin II); and components involved in receptor mediated signaling pathways, such as receptors (e.g., IGF-1 receptor) and kinases (e.g., protein kinase C). [10] These factors are discussed in detail in Chapter 4 . What are the triggers for hypertrophy and for these changes in gene expression? In the heart, there are at least two groups of signals: mechanical triggers, such as stretch, and trophic triggers, such as polypeptide growth factors and vasoactive agents (angiotensin II, alpha-adrenergic agonists). Current models suggest that growth factors or vasoactive agents produced by cardiac nonmuscle cells or by myocytes themselves in response to hemodynamic stress selectively regulate the expression of genes leading to myocyte hypertrophy. [11] Whatever the exact mechanism of hypertrophy, it eventually reaches a limit beyond which enlargement of muscle mass is no longer able to compensate for the increased burden, and cardiac failure ensues. At this stage, a number of degenerative changes occur in the myocardial fibers, of which the most important are lysis and loss of myofibrillar contractile elements. Myocyte death can occur by either apoptosis or necrosis. [12] The limiting factors for continued hypertrophy and the causes of the cardiac dysfunction are poorly understood; they may be due to limitation of the vascular supply to the enlarged fibers, diminished oxidative capabilities of mitochondria, alterations in protein synthesis and degradation, or cytoskeletal alterations. Atrophy Shrinkage in the size of the cell by loss of cell substance is known as atrophy. It represents a form of adaptive response. When a sufficient number of cells are involved, the entire tissue or organ diminishes in size or becomes atrophic. Atrophy can be physiologic or pathologic. Physiologic atrophy is common during early development. Some embryonic structures, such as the notocord or thyroglossal duct, undergo atrophy during fetal development. The uterus decreases in size shortly after parturition, and this is a form of physiologic atrophy. Pathologic atrophy depends on the basic cause and can be local or generalized. The common causes of atrophy are the following: Decreased workload (atrophy of disuse): When a broken limb is immobilized in a
plaster cast or when a patient is restricted to complete bed rest, skeletal muscle atrophy rapidly ensues. The initial rapid decrease in cell size is reversible when activity is resumed. With more prolonged disuse, skeletal muscle fibers decrease in number as well as in size and can be accompanied by increased bone resorption, leading to osteoporosis of disuse. Loss of innervation (denervation atrophy): Normal function of skeletal muscle is dependent on its nerve supply. Damage to the nerves leads to rapid atrophy of the muscle fibers supplied by those nerves (Chapter 29) . Diminished blood supply: A decrease in blood supply (ischemia) to a tissue as a result of arterial occlusive disease results in atrophy of tissue owing to progressive cell loss. In late adult life, the brain undergoes progressive atrophy, presumably as atherosclerosis narrows its blood supply (Fig. 2-5) . Inadequate nutrition: Profound protein-calorie malnutrition (marasmus) is associated with the use of skeletal muscle as a source of energy after other reserves such as adipose stores have been depleted. This results in marked muscle wasting. Loss of endocrine stimulation: Many endocrine glands, the breast, and the reproductive organs are dependent on endocrine stimulation for normal function. The loss of estrogen stimulation after the menopause results in physiologic atrophy of the endometrium, vaginal epithelium, and breast. Aging (senile atrophy): The aging process is associated with cell loss. Morphologically, it is seen in tissues containing permanent cells, particularly in the brain and heart. 36
Pressure: Tissue compression for any length of time can cause atrophy. An enlarging benign tumor can cause atrophy in the surrounding compressed tissues. Atrophy in this setting is probably the result of ischemic changes caused by a blood supply that has been compromised by the expanding mass.
Figure 2-5 A , Physiologic atrophy of the brain in an 82 year-old male. The meninges have been stripped. B , Normal brain of a
36-year-old male.
The fundamental cellular changes are identical in all of these settings, representing a retreat by the cell to a smaller size at which survival is still possible. Atrophy represents a reduction in the structural components of the cell. In muscle, the cells contain fewer mitochondria and myofilaments and a lesser amount of endoplasmic reticulum. By bringing into balance cell volume and lower levels of blood supply, nutrition, or trophic stimulation, a new equilibrium is achieved. Although atrophic cells may have diminished function, they are not dead. Apoptosis or programmed cell death (Chapter 1) , however, may be induced by the same signals that cause atrophy and thus may contribute to loss of organ mass. For example, apoptosis contributes to the regression of endocrine organs after hormone withdrawal and the shrinkage of secretory glands after obstruction of their ducts. The biochemical mechanisms responsible for atrophy are incompletely understood but
are likely to affect the balance between protein synthesis and degradation. The regulation of protein degradation probably plays a key role in atrophy. Mammalian cells contain multiple proteolytic systems that serve distinct functions. Lysosomes contain acid hyrolases (e.g., cathepsins) and other enzymes that degrade endocytosed proteins from the extracellular environment and the cell surface as well as some cellular components. The ubiquitin-proteasome pathway is responsible for the degradation of many cytosolic and nuclear proteins. [13] Proteins degraded by this process are first conjugated to ubiquitin and then degraded within a large cytoplasmic proteolytic complex, or proteasome. This pathway is thought to be responsible for the accelerated proteolysis in a variety of catabolic conditions, including cancer cachexia. Hormones, particularly glucocorticoids and thyroid hormone, stimulate proteasome-mediated protein degradation; insulin opposes these actions. Additionally, cytokines, such as TNF-alpha and IL-1beta, are capable of signaling accelerated muscle proteolysis by way of this mechanism. In many situations, atrophy is also accompanied by marked increases in the number of autophagic vacuoles. As stated earlier, these are membrane-bound vacuoles within the cell that contain fragments of cell components (e.g., mitochondria, endoplasmic reticulum), which are destined for destruction and into which the lysosomes discharge their hydrolytic contents. The cellular components are then digested. Some of the cell debris within the autophagic vacuole may resist digestion and persist as membrane-bound residual bodies that may remain as a sarcophagus in the cytoplasm. An example of such residual bodies is the lipofuscin granules, discussed in Chapter 1 . When present in sufficient amounts, they impart a brown discoloration to the tissue (brown atrophy). Obviously, atrophy may progress to the point at which cells are injured and die. If the blood supply is inadequate even to maintain the life of shrunken cells, injury and cell death may supervene. The atrophic tissue may then be replaced by fatty ingrowth. Metaplasia Metaplasia is a reversible change in which one adult cell type (epithelial or mesenchymal) is replaced by another adult cell type. [14] It, too, may represent an adaptive substitution of cells that are sensitive to stress by cell types better able to withstand the adverse environment. The most common epithelial metaplasia is columnar to squamous (Fig. 2-6 A), as occurs in the respiratory tract in response to chronic irritation. In the habitual cigarette
37
Figure 2-6 Metaplasia. A , Schematic diagram of columnar to squamous metaplasia. B , Metaplastic transformation of esophageal stratified squamous epithelium (left) to mature columnar epithelium (so-called Barrett metaplasia). C, Differentiation pathways for
stem cells. Activation of key regulatory proteins by growth factors, cytokines, or matrix components leads to commitment of stem
cells to differentiate into specific cellular lineages. Differentiation of myotubes requires the combined action of several factors (e.g., myo D, myogenin); fat cells require PPARgamma; the osteogenic lineage requires CBFA1, while factors for endothelial cells and fibroblasts are not yet known. ( C, Adapted and redrawn from Rodan GA, Harada S: The missing bone. Cell 89:677, 1997.)
smoker, the normal columnar ciliated epithelial cells of the trachea and bronchi are often replaced focally or widely by stratified squamous epithelial cells. Stones in the excretory ducts of the salivary glands, pancreas, or bile ducts may cause replacement of the normal secretory columnar epithelium by nonfunctioning stratified squamous epithelium. A deficiency of vitamin A (retinoic acid) induces squamous metaplasia in the respiratory epithelium, and vitamin A excess suppresses keratinization (Chapter 10) . In all these instances, the more rugged stratified squamous epithelium is able to survive under circumstances in which the more fragile specialized epithelium most likely would have succumbed. Although the squamous metaplastic cells in the respiratory tract, for example, are capable of surviving, an important protective mechanism--mucus secretion--is lost. Thus, epithelial metaplasia is a two-edged sword and, in most circumstances, represents an undesirable change. Moreover, the influences that predispose to such metaplasia, if persistent, may induce cancer transformation in metaplastic epithelium. Thus, the common form of cancer in the respiratory tract is composed of squamous cells. Metaplasia from squamous to columnar type may also occur, as in Barrett esophagitis, in which the squamous esophageal epithelium is replaced by intestinal-like columnar cells (Chapter 18) (Fig. 2-6 B). The resulting cancers that may arise are glandular (adeno) carcinomas. Connective tissue metaplasia is the formation of cartilage, bone, or adipose tissue (mesenchymal tissues) in tissues that normally do not contain these elements. For example, bone formation in muscle, designated myositis ossificans, occasionally occurs after bone fracture. This type of metaplasia is less clearly seen as an adaptive response. Metaplasia is thought to arise from a reprogramming of stem cells that are known to exist in most epithelia (called reserve cells) or of undifferentiated mesenchymal cells present in connective tissue. In a metaplastic change, these precursor cells differentiate along a new pathway. This is brought about by changes in signals generated by mixtures of cytokines, growth factors, and extracellular matrix components in the cell's environment. Tissue-specific and differentiation genes are involved in the process and an increasing number of these are being indentified. For example, bone morphogenetic proteins (BMPs), members of the TGF-beta superfamily, induce chondrogenic or osteogenic expression in mesenchymal stem cells, while suppressing differentiation into muscle or fat. [15] These growth factors, acting as external triggers, then induce specific transcription factors that lead the cascade of phenotype-specific genes toward a fully differentiated cell (Fig. 2-6 C). Such transcription factors include MyoD for muscle, PPARgamma for adipose tissue, and CBFA-1 for osteoblastic differentiation. [16] How these normal pathways run amuck to cause metaplasia is unclear in most instances. In the case of vitamin A deficiency or excess, it is known that retinoic acid regulates cell growth, differentiation, and tissue patterning. [17]
38
Certain cytostatic drugs cause a disruption of DNA methylation patterns and can transform mesenchymal cells from one type (fibroblast) to another (muscle, cartilage). Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 3 - Acute and Chronic Inflammation GENERAL FEATURES OF INFLAMMATION HISTORICAL HIGHLIGHTS ACUTE INFLAMMATION CHEMICAL MEDIATORS OF INFLAMMATION CHRONIC INFLAMMATION MORPHOLOGIC PATTERNS IN ACUTE AND CHRONIC INFLAMMATION SYSTEMIC EFFECTS OF INFLAMMATION REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
50
Chapter 3 - Acute and Chronic Inflammation GENERAL FEATURES OF INFLAMMATION In Chapter 1 , we saw how various exogenous and endogenous stimuli can cause cell injury. These same stimuli also can provoke a complex reaction in the vascularized connective tissue called inflammation. Invertebrates with no vascular system, single-celled organisms, and multicellular parasites all have their own responses to local injury. These include phagocytosis of the injurious agent; entrapment
51
Figure 3-1 Intravascular cells and connective tissue matrix and cells involved in the inflammatory response.
of the irritant by specialized cells (hemocytes), which then ingest it; and neutralization of noxious stimuli by hypertrophy of the cell or one of its organelles. All these reactions have been retained in evolution, but what characterizes the inflammatory process in higher forms is the reaction of blood vessels, leading to the accumulation of fluid and leukocytes in extravascular tissues. The inflammatory response is closely intertwined with the process of repair. Inflammation serves to destroy, dilute, or wall off the injurious agent, but it, in turn, sets into motion a series of events that, as far as possible, heal and reconstitute the damaged tissue. Repair begins during the early phases of inflammation but reaches completion usually after the injurious influence has been neutralized. During repair, the injured tissue is replaced by regeneration of native parenchymal cells, by filling of the defect with fibroblastic tissue (scarring), or, most commonly, by a combination of these two processes. Inflammation is fundamentally a protective response the ultimate goal of which is to rid the organism of both the initial cause of cell injury (e.g., microbes, toxins) and the consequences of such injury (e.g., necrotic cells and tissues). Without inflammation, infections would go unchecked, wounds would never heal, and injured organs might remain permanent festering sores. Inflammation and repair may be potentially harmful, however. Inflammatory reactions, for example, underlie life-threatening hypersensitivity
reactions to insect bites, drugs, and toxins as well as some common chronic diseases, such as rheumatoid arthritis, atherosclerosis, and lung fibrosis. Repair by fibrosis may lead to disfiguring scars or fibrous bands that cause intestinal obstruction or limit the mobility of joints. For this reason, our pharmacies abound with anti-inflammatory drugs, which ideally would enhance the salutary effects of inflammation yet control its harmful sequelae. The inflammatory response occurs in the vascularized connective tissue, including plasma, circulating cells, blood vessels, and cellular and extracellular constituents of connective tissue (Fig. 3-1) . The circulating cells include neutrophils, monocytes, eosinophils, lymphocytes, basophils, and platelets. The connective tissue cells are the mast cells, which intimately surround blood vessels; the connective tissue fibroblasts; and occasional resident macrophages and lymphocytes. The extracellular matrix, as described in Chapter 4 , consists of the structural fibrous proteins ( collagen, elastin), adhesive glycoproteins ( fibronectin, laminin, nonfibrillar collagen, tenascin, and others), and proteoglycans. The basement membrane is a specialized component of the extracellular matrix consisting of adhesive glycoproteins and proteoglycans. Inflammation is divided into acute and chronic patterns. Acute inflammation is of relatively short duration, lasting for minutes, several hours, or a few days, and its main characteristics are the exudation of fluid and plasma proteins (edema) and the emigration of leukocytes, predominantly neutrophils. Chronic inflammation is of longer duration and is associated histologically with the presence of lymphocytes and macrophages, the proliferation of blood vessels, fibrosis, and tissue necrosis. Many factors modify the course and histologic appearance of both acute and chronic inflammation, and these become apparent later in this chapter.
52
The vascular and cellular responses of both acute and chronic inflammation are mediated by chemical factors derived from plasma or cells and triggered by the inflammatory stimulus. Such mediators, acting singly, in combinations, or in sequence, then amplify the inflammatory response and influence its evolution. Necrotic cells or tissues themselves--whatever the cause of cell death--can also trigger the elaboration of inflammatory mediators. Such is the case with the acute inflammation after myocardial infarction. Inflammation is terminated when the injurious stimulus is removed and the mediators are either dissipated or inhibited. This chapter first describes the sequence of events in acute inflammation as well as the structural and molecular mechanisms underlying them, then reviews the various classes of specific mediators that contribute to these events. This is followed by a discussion of the major features of chronic inflammation. Inflammation has a rich history, intimately linked to the history of wars, wounds, and infections, and we first touch on some of the historical highlights in our understanding of this fascinating process. [1] [2]
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 4 - Tissue Repair: Cellular Growth, Fibrosis, and Wound Healing CONTROL OF NORMAL CELL GROWTH EXTRACELLULAR MATRIX AND CELL-MATRIX INTERACTIONS REPAIR BY CONNECTIVE TISSUE (FIBROSIS) WOUND HEALING OVERVIEW OF THE INFLAMMATORY-REPARATIVE RESPONSE REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
89
Chapter 4 - Tissue Repair: Cellular Growth, Fibrosis, and Wound Healing The body's ability to replace injured or dead cells and to repair tissues after inflammation is critical to survival. A variety of injurious agents--at the same time that they create havoc within the cell--set in motion a series of events that serve not only to contain the damage, but also to prepare the nonlethally injured cells for the replication necessary to replace the dead cells. We have seen, for example, how the initiation of apoptosis may delete cells bearing damaged DNA (which may be potentially harmful to the organism). Injurious stimuli also
90
Figure 4-1 Mechanisms regulating cell populations. Cell numbers can be altered by increased or decreased rates of cell death (apoptosis) or by changes in the rates of proliferation or differentiation. (Modified from McCarthy NJ, et al: Apoptosis in the development of the immune system: growth factors, clonal selection and bcl-2. Cancer Metastasis Rev 11:157, 1992.)
trigger the activation of genes that are involved in cell replication. Repair of tissues involves two distinct processes: (1) regeneration, denoting the replacement of injured cells by cells of the same type, sometimes leaving no residual trace of the previous injury, and (2) replacement by connective tissue, called fibroplasia or fibrosis, which leaves a permanent scar. In most instances, both processes contribute to repair. In addition, both regeneration and fibroplasia are determined by essentially similar mechanisms involving cell migration, proliferation, and differentiation as well as cell-matrix interactions. The latter are particularly important. The orderly regeneration of the epithelial tissue of the skin and viscera requires the presence of the basement membrane (BM). This specialized extracellular matrix (ECM) functions as an extracellular scaffold for accurate regeneration of preexisting structures. Maintenance of BM integrity provides for the specificity of cell type and polarity and influences cell migration and growth. In adult tissues, the size of a population of cells is determined by the rates of cell proliferation, differentiation, and death by apoptosis. [1] Figure 4-1 depicts these relationships and shows that increased cell numbers may result from either increased
proliferation or decreased cell death. The impact of differentiation depends on the circumstance under which it occurs. The progeny of stem cells in the bone marrow, for example, may divide several times but eventually become terminally differentiated and cannot multiply further. Replication of differentiated cells occurs in certain adult tissues; for example, after partial hepatectomy, liver cell division continues until the signals for such division are abrogated (Chapter 2) . Apoptosis is induced by a variety of physiologic and pathologic stimuli and is controlled by a number of genes (Chapter 1) . In this chapter, we first review the major mechanisms involved in the regulation of cell growth, including the important interactions between cells and the ECM. We then examine in detail the process of fibroplasia--the replacement of injured cells by connective tissue. Finally, we discuss wound healing as an important clinical example of both regeneration and fibroplasia.
CONTROL OF NORMAL CELL GROWTH Cell proliferation can be stimulated by injury, cell death, and mechanical deformation of tissues. It is key in regeneration. Cell replication is controlled largely by chemical factors in the microenvironment, which either stimulate or inhibit cell proliferation. An excess of stimulators or a deficiency of inhibitors leads to net growth and, in the case of cancer, uncontrolled growth. Growth can be accomplished by shortening the cell cycle, but the most important factors are those that recruit resting or quiescent cells into the cell. [2]
Figure 4-2 Cell populations and cell cycle phases. Constantly dividing labile cells continuously cycle from one mitosis to the next.
Nondividing permanent cells have exited the cycle and are destined to die without further division. Quiescent stable cells in G0 are neither cycling nor dying and can be induced to re-enter the cell cycle by an appropriate stimulus.
91
Cell Cycle and Proliferative Potential The cells of the body are divided into three groups on the basis of their proliferative capacity and their relationship to the cell cycle. The cell growth cycle consists of G1 (presynthetic), S (DNA synthesis), G2 (premitotic), and M (mitotic) phases (Fig. 4-2) . Quiescent cells are in a physiologic state called G0 . With the exception of tissues composed primarily of nondividing cells, most mature tissues consist of some combination of continuously dividing cells, quiescent cells that occasionally enter into the cell cycle, and nondividing cells. Continuously dividing cells (also called labile cells) follow the cell cycle from one mitosis to the next and continue to proliferate throughout life, replacing cells that are continuously being destroyed. Tissues that contain labile cells include surface epithelia, such as stratified squamous surfaces of the skin, oral cavity, vagina, and
cervix; the lining mucosa of all the excretory ducts of the glands of the body (e.g., salivary glands, pancreas, biliary tract); the columnar epithelium of the gastrointestinal tract and uterus; and the transitional epithelium of the urinary tract and cells of the bone marrow and hematopoietic tissues. In most of these tissues, regeneration is derived from a population of stem cells, which have an unlimited capacity to proliferate and whose progeny may undergo various streams of differentiation. Quiescent (or stable) cells normally demonstrate a low level of replication; however, these cells can undergo rapid division in response to stimuli and are thus capable of reconstituting the tissue of origin. They are considered to be in G0 but can be stimulated into G1 . In this category are the parenchymal cells of virtually all the glandular organs of the body, such as the liver, kidneys, and pancreas; mesenchymal cells, such as fibroblasts and smooth muscle; and vascular endothelial cells. The regenerative capacity of stable cells is best exemplified by the ability of the liver to regenerate after hepatectomy and after toxic, viral, or chemical injury. Although labile and stable cells are capable of regeneration, it does not necessarily follow that there will be restitution of normal structure. The underlying supporting stroma of the parenchymal cells-- particularly the BMs-- is necessary for organized regeneration, forming a scaffold for the replicating parenchymal cells. When BMs are disrupted, cells may proliferate in a haphazard fashion and produce disorganized masses of cells bearing no resemblance to the original arrangement. To use the liver as an example, the hepatitis virus destroys parenchymal cells without injuring the more resistant connective tissue cells, or framework, of the liver lobule. Thus, after viral hepatitis, regeneration of liver cells may completely reconstitute the liver lobule. By contrast, a liver abscess that destroys hepatocytes and the connective tissue framework is followed by scarring. The connective tissue and mesenchymal cells (fibroblasts, endothelial cells, smooth muscle cells, chondrocytes, and osteocytes) are quiescent in adult mammals. All proliferate in response to injury, however, and fibroblasts in particular proliferate widely, constituting the connective tissue response to inflammation (see later section on wound healing).
Figure 4-3 General patterns of intercellular signaling (see text). (Modified from Lodish H, et al. (eds): Molecular Cell Biology, 3rd ed. New York, WH Freeman, 1995, p 855. © 1995 by Scientific American Books. Used with permission of WH Freeman and Company.)
Nondividing (permanent) cells have left the cell cycle and cannot undergo mitotic division in postnatal life. To this group belong most nerve cells and the skeletal and cardiac muscle cells. Neurons destroyed in the central nervous system are permanently lost. They are replaced by the proliferation of the central nervous system supportive elements, the glial cells. The situation is somewhat more complicated with respect to the neurons of the peripheral nerves, as detailed in Chapter 29 . Skeletal muscle does have some regenerative capacity, and most of the regeneration appears to occur from transformation of the satellite cells found
attached to the endomysial sheaths. If the ends of severed muscle fibers are closely 92
juxtaposed, muscle regeneration in mammals can be excellent, but this is a condition that can rarely be attained under practical conditions. As to cardiac muscle, it is fair to state that if cardiac muscle has regenerative capacity, it is limited, and most large injuries to the heart are followed by connective tissue scarring. Scarring regularly follows myocardial infarction in humans. Molecular Events in Cell Growth Molecular events in cell growth are complex and involve an increasing array of intercellular pathways and molecules, but they are important because it is now clear that aberrations in such pathways may underlie the uncontrolled growth in cancer as well as abnormal cellular responses in a variety of diseases. This section outlines different general types of signaling systems and cell surface receptors, then examines in some detail several intracellular transduction pathways, in which the binding of signaling molecules to cell surface receptors leads to activation of particular transcription factors and changes in gene expression. The explosion in understanding of these molecular events has stemmed largely from the discovery that growth factors induce cell proliferation by affecting the expression of genes involved in normal growth control pathways, the so-called protooncogenes. The expression of these genes is tightly regulated during normal growth and regeneration. Alterations in the structure of such protooncogenes can convert them into oncogenes, which contribute to uncontrolled cell growth characteristic of cancer; thus, normal and abnormal cellular proliferation follow similar pathways. [3] Oncogenes are discussed in detail in Chapter 8 , Neoplasia. There are three general schemes of intercellular signaling--autocrine, paracrine, or endocrine--based on the distance over which the signal acts. [4] Additionally, some membrane-bound proteins present on one cell can interact directly with receptors on an adjacent cell (Fig. 4-3) . Autocrine signaling: Cells respond to the signaling substances that they themselves secrete. Several polypeptide growth factors (or cytokines) (Chapter 3) can act in this manner. When the same cell produces a growth factor and the corresponding receptor, an autocrine loop can be established. Autocrine growth regulation plays a role in compensatory epithelial hyperplasia (e.g., hepatic regeneration) and, particularly, in tumors. Tumor cells frequently overproduce growth factors that can stimulate their own growth and proliferation. Paracrine signaling: A cell produces molecules that affect only a target cell in close proximity. Paracrine stimulation is common in connective tissue repair of healing wounds, in which a factor produced by one cell type (a macrophage) has its growth effect on adjacent cells usually of a different cell type (e.g., a fibroblast). Endocrine signaling: Hormones are synthesized by cells of endocrine organs and act on target cells distant from their site of synthesis being usually carried by the blood.
CELL SURFACE RECEPTORS
Cell growth is initiated by the binding of a signaling agent, most commonly a growth factor, to a specific receptor. Receptor proteins can be located on the cell surface of the target cell or found in either the cytoplasm or the nucleus. A receptor protein has binding specificity for particular ligands, and the resulting receptor ligand complex initiates a specific cellular response. Three major classes of cell surface receptors are important for cell growth (Fig. 4-4) . On ligand binding, they deliver signals to the nucleus by using a variety of signal transduction pathways. Some pathways are more or less unique to one family of receptors, whereas others are shared. We first describe the receptors and then their connections to signaling molecules. Receptors With Intrinsic Kinase Activity
Receptors with intrinsic kinase activity have an extracellular domain for ligand binding; a single transmembrane region; and a cytosolic domain, which can have either tyrosine kinase activity or, less commonly, serine/threonine. For example, epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) bind to receptors with intrinsic tyrosine kinase activity. Many such growth factors are dimeric proteins, contain two regions for receptor binding, and form stable receptor dimers by simultaneously binding two receptors (Fig. 4-5) . Dimerization of the receptors is followed by receptor autophosphorylation, a process in which one receptor molecule phosphorylates the other in the dimer. [5] Receptor autophosphorylation creates binding sites for a series of cytosolic proteins endowed with src homology 2 (SH2) domains, which are recruited to phosphorylated tyrosine residues on the activated receptor. Such cytosolic proteins include (1) a series of adapter proteins, which couple the receptor to the ras signaling pathway; (2) components of the phosphoinositide-3-kinase (PI-3-kinase) pathway; (3) phospholipase C-gamma in the protein kinase C pathway; and (4) members of the src family of tyrosine kinases (Fig. 4-5) . Collectively, these four systems, in turn, generate a cascade of responses that ultimately signal irreversible commitment of the cell to enter S phase of the cell cycle. Some of these pathways also provide unique signals that stimulate cellular responses other than growth. Receptors Without Intrinsic Catalytic Activity
Receptors without intrinsic catalytic activity have an extracellular domain for ligand binding; a single transmembrane region; and a cytosolic domain, which directly associates with and activates one or more cytosolic protein tyrosine kinases, which, in turn, phosphorylate the receptor (Fig. 4-4) . Because receptors for many cytokines (Chapter 3) fall into this category, this group of receptors is sometimes referred to as the cytokine receptor superfamily. [6] G Protein-Linked Receptors
All G protein-linked receptors contain seven transmembrane loops and are frequently called seven-spanning receptors. Although not closely linked to the regulation of cell growth, this class of receptors is associated with a
93
variety of important functions. For example, receptors for the inflammatory chemokines (Chapter 3) as well as the hormones epinephrine and glucagon are in this class. Ligand binding activates a signal transducing G protein complex, which, in turn, activates an effector system that generates intracellular second messengers (Fig. 4-6) . [7] SIGNAL TRANSDUCTION SYSTEMS
Signal transduction is the process by which extracellular signals are detected and converted into intracellular signals, which, in turn, generate specific cellular responses. Signal transduction systems are typically arranged as networks of sequential protein kinases; the most important ones involved in the regulation of cell growth are the mitogen-activated protein kinase (MAP kinase), PI-3-kinase, inositol-lipid (IP3 ), cyclic adenosine monophosphate (cAMP), the JAK/STAT signaling system (Fig. 4-4) , and the stress kinase system. Mitogen-Activated Protein Kinase Pathway
The MAP kinase system is particularly important in signaling by growth factors. As we have seen, ligand binding by a receptor tyrosine kinase results in autophosphorylation of the receptor and binding of adapter proteins, such as GRB2 and SOS (Fig. 4-5) . These ultimately lead to activation of the Ras protein. Ras belongs to the guanosine triphosphatase (GTPase) superfamily of proteins that cycle between active and inactive forms. [8] The inactive Ras is in the guanosine diphosphate (GDP) binding form, which is converted by activation to the active GTP form, initiating a cascade of distal kinases, which culminates in changes in gene expression. Activation of Ras is counteracted by another protein called GAP (GTPase activating protein), which switches Ras to the inactive GDP form. Mutant forms of Ras, which bind but cannot hydrolyze GTP, are permanently fixed in the on state and are associated with increased cell proliferation seen in many types of human cancer (Chapter 8) . Activated Ras binds to another protein, Raf, which binds to and phosphorylates MEK, a member of the family of kinases collectively called MAP kinases. [9] The distal MAP kinase (ERK) translocates into the nucleus, where it phosphorylates specific transcription factors, such as c- jun and c- fos, which, in turn, activate gene expression. The net result of this pathway is activation of a protein phosphorylation cascade, which amplifies the signal and stimulates quiescent cells to enter the growth cycle.
Figure 4-4 Simplified overview of the major types of cell surface receptors and the principal signal transduction pathways (see text). Signaling events from the tyrosine kinase and seven transmembrane receptors are outlined in more detail in Figures 4-5 and 4-6 .
94
Phosphoinositide-3-Kinase Pathway
Although many growth factors act by binding to receptor tyrosine kinases, they do not all convey the same signals. For example, growth factors can differ in their ability to generate signals for cell proliferation and cell survival. The uncoupling of these events may be explained by differing ability of these growth factors to recruit and activate efficiently the PI-3-kinase pathway (Fig. 4-4) . [10] This kinase generates membrane-associated lipid mediators (such as phosphatidylinositol-3,4-bisphosphate), which act as second messengers to recruit and activate a series of intracellular kinases, for example, Akt. The activity of these kinases eventually leads to cellular responses that are correlated with cellular survival, such as phosphorylation of glycogen synthase kinase 3 and increased glycogen synthesis. [11] Inositol-Lipid Pathway
The IP3 signaling system can be coupled to either tyrosine kinase or seven-spanning G protein-linked receptors causing activation of a G protein (Go or Gq ), which then activates phospholipase Cgamma (Fig. 4-6) . Phospholipase Cgamma, in turn, cleaves phosphatidylinositol-4 ,5-bisphosphate (PIP2 ) to inositol 1,4,5-triphosphate (IP3 ) and 1,3-diacylglycerol (DAG). [12] The IP3 then diffuses in the cytoplasm and associates with IP3 -sensitive calcium channels in the membrane of the endoplasmic reticulum, causing release of calcium stores. DAG and calcium also activate protein kinase C, which then phosphorylates a variety of cellular components important in cell growth and metabolism. Cyclic Adenosine Monophosphate Pathway
Binding of hormones, such as epinephrine and glucagon, or chemokines to seven-spanning receptors is coupled through G proteins to activation of adenylate cyclase and generation of the second messenger cAMP (Fig. 4-4) . Elevated levels of cAMP activate protein kinase A, which, through a series of intermediate steps, stimulates expression of target genes. [13] JAK/STAT Pathway
As discussed earlier, members of the cytokine receptor superfamily lack intrinsic kinase activity. After ligand binding, the receptor associates with and activates one or more protein kinases present in the cytosol (Fig. 4-4) , designated Janus kinases (JAKs). [14]
The JAKs phosphorylate the receptors as well as downstream proteins designated
Figure 4-5 Signaling from tyrosine kinase receptors. Binding of a growth factor causes the receptor to dimerize and
autophosphorylate tyrosine residues. Binding of adapter (or bridging) proteins (e.g., GRB2 and SOS) couple the receptor in inactive Ras. Cycling of Ras between its inactive and active forms is regulated by GAP. Activated Ras interacts with and activates Raf. This kinase then phosphorylates a component of the MAP kinase signaling pathway, MEK, which then phosphorylates ERK (MAP kinase). Activated MAP kinase phosphorylates other cytoplasmic proteins and nuclear transcription factors generating cellular responses. The phosphorylated tyrosine kinase receptor can also bind other components, such as PI-3 kinase, which activates distinct signaling systems.
95
Figure 4-6 The inositol-lipid (IP3 ) signaling pathway. Binding of a ligand to a seven transmembrane receptor activates a G protein,
which in turn activates phospholipase C. This enzyme then cleaves phosphatidylinositol 4,5-bisphosphate (PIP2 ) to inositol 1,4,5-triphosphate (IP3 ) and 1,2-diacylglycerol (DAG). DAG activates protein kinase C, which phosphorylates a series of proteins altering cell function. The IP 3 diffuses through the cytoplasm and interacts with membrane channels in the endoplasmic reticulum, causing release of calcium ions and cellular responses.
STATs (signal transducers and activators of transcription). In general, the JAK/STAT system, like stress activated kinases,[15] mediates functional as opposed to proliferative responses. TRANSCRIPTION FACTORS
The signal transduction systems just described transfer information to the nucleus where specific changes occur in the regulation of gene expression. This regulation is frequently achieved at the level of transcription of genes, and the latter is controlled by regulatory factors known as transcription factors, which then have a vital role in controlling cell growth. Transcription factors exhibit a modular structure composed of specific types of domains--including domains for DNA binding and for transcriptional regulation (regulatory domain). The DNA binding domain permits the factor to bind specifically to short-sequence motifs of DNA by distinct molecular mechanisms (e.g., homeodomain, zinc finger). [16] The regulatory domain allows the protein either to increase (an activation domain) or to decrease (a repression domain) transcription. Transcription factors are phosphorylated by specific proximal kinases, and such phosphorylation can change the subcellular localization of the transcription factor or its affinity for DNA, which, in turn, alters gene expression. [17] Among the transcription factors regulating cell proliferation are a number of protooncogenes, in which mutations may be associated with tumors (c- myc), and various types of tumor-suppressor genes (or antioncogenes), such as p53 and the retinoblastoma gene (Chapter 8) . Transcription factors are also involved in the regulation of the cell cycle itself. Cell Cycle and the Regulation of Cell Division
Thus far, we have examined the molecular pathways stimulated by growth factors. But what are the mechanisms that control the passage of cells through specific phases of the cell cycle and the orchestration of events leading to cell division? It is now clear that two types of molecular controls regulate such events: (1) a cascade of protein phosphorylation pathways involving a group of proteins called cyclins and (2) a set of checkpoints that monitor completion of the molecular events and, if necessary, delay progression to the next phase of the cycle. CYCLINS AND CYCLIN-DEPENDENT KINASES
The entry and progression of cells through the cell cycle are controlled by changes in the levels and activities of cyclins. The levels of several of the cyclins (termed A, B, and E) peak during specific phases of the cell cycle, then are rapidly degraded as the cell enters the next phase of the cell cycle. [18] Cyclins perform their functions by forming complexes with a group of constitutively expressed proteins called cyclin-dependent kinases (CDKs).[19] Different combinations of cyclins and CDKs are associated with each of the important transitions in the cell cycle. The cyclin B/CDK1 function, which controls the transition from G2 to M is analyzed in some detail in Fig. 4-7 A. [20] As the cell moves into G2 , cyclin B is synthesized, and it binds to constitutive CDK1, creating the cyclin B/CDK1 complex, whose activity is necessary for cells to enter M phase. The
96
Figure 4-7 Schematic illustrating the role of cyclins, cyclin-dependent kinases, and inhibitors in regulating the cell cycle.A , In the
depicted example, the regulation of CDK1 kinase activity by cyclin B is illustrated. Binding of newly synthesized cyclin B to inactive CDK1 kinase at the beginning of G2 results in a complex that can be activated by phosphorylation. This active kinase complex then phosphorylates a number of proteins important in regulating the G2 to M transition. After mitosis, the cyclin B dissociates from the complex and is degraded, leaving the inactive CDK1 kinase, which can re-enter the cycle at the next G2 stage. (Adapted from Dr. Anindya Dutta, Brigham and Women's Hospital, Boston, MA.)B , Regulation of cyclin-dependent kinases, some of the inhibitors of which are listed. (Adapted from Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 274:1664, 1996.)
complex is activated by phosphorylation, and the active kinase then phosphorylates a variety of proteins involved in mitosis, DNA replication, depolymerization of the nuclear lamina, and mitotic spindle formation. After mitotic division, the relevant cyclins (in this case, cyclin B) are degraded by the ubiquitin-proteasome pathway. [21] In this pathway, proteins are first conjugated to the small protein cofactor ubiquitin, and the modified protein is specifically recognized and degraded within the proteasome, a large multisubunit proteolytic complex (Chapter 2) . In addition to synthesis and degradation, the active CDK complexes are regulated by binding of CDK inhibitors, such as p21 and p27, as well as by other kinases and phosphatases (Fig. 4-7 B). [22] The inhibitors control the cell cycle by balancing the activity of the CDKs. The interaction of these opposing signals helps determine whether a cell progresses through the cell cycle. Changes in the levels of these inhibitors, as
may occur in some tumors (Chapter 8) or possibly in aging cells (Chapter 2) , can alter the normal progression of the cell cycle. The G1 -S interface is another important intersection in the cell cycle. At this point, the cell commits either to replication of the genome or to quiescence or differentiation (or both). [23] One of the major controls on this transition is the state of phosphorylation of the retinoblastoma protein, Rb, a protein mutated in a variety of cancers and discussed in great detail in Chapter 8 . Normally, Rb sequesters members of E2F transcription factor family in an inactive complex during G0 and G1 . As G1 progresses, cyclins of the D class accumulate and activate specific CDKs, which hyperphosphorylate Rb, disrupting binding to E2F. Activated E2F, in turn, activates transcription of a number of genes required for S phase entry. CHECKPOINTS
Checkpoints represent a second mode of cell cycle regulation and provide a surveillance mechanism for ensuring that critical transitions occur in the correct order and that important events are completed with fidelity. C heckpoints sense problems in DNA replication, DNA repair, and chromosome segregation. [24] When checkpoints are activated, for example, by damaged or underreplicated DNA, signals are sent to the cell cycle machinery that arrest the cell cycle. By delaying progression through the cell cycle, checkpoints provide more time for repair and diminish the possibility of mutations. Checkpoint systems cause cell cycle arrest either by promoting inhibitory pathways or by inhibiting activating pathways (Fig. 4-7 B). For example, the most common tumor-suppressor gene, p53, is activated in response to DNA damage and inhibits the cell cycle by increasing expression of the CDK inhibitor, p21. It follows that loss of checkpoints may result in genomic instability, as has been seen in certain hereditary cancer syndromes and at early stages of the evolution of normal cells into cancer cells (Chapter 8) . Growth Inhibition The other side of the coin in cellular growth control is growth inhibition. The existence of growth inhibitory signals that maintain the integrity of a tissue has been suspected for decades from observations that populations of cells in culture or in vivo can limit one another's growth. Contact inhibition of growth in confluent cultures is one such manifestation of growth inhibition. There is also in vivo evidence for growth suppression. After partial hepatectomy, for example, cells stop multiplying when the liver has attained its normal preoperative size and configuration, suggesting the action of inhibitory signals. The molecular mechanisms of growth inhibition are similar to those of growth stimulation and intertwine along their intercellular routes. A good example of a growth
97
inhibitory signaling system involves the polypeptide growth factor transforming growth factor-beta (TGF-beta), described later. TGF-beta signals through cell surface receptors with serine/threonine kinase activity. [25] The activated receptor phosphorylates its own cytoplasmic domain as well as substrate proteins, known as SMADs. [26] TGF-beta inhibits cell cycle progression into S phase by affecting the function of both transcription factors and cell cycle control proteins. For example, it increases the expression of a CDK inhibitor (p27), which decreases CDK2 activity and also results in diminished phosphorylation of Rb protein in late G1 phase. [27] Hypophosphorylated Rb in turn represses transcription of genes that are normally expressed at S phase, resulting in growth inhibition (Chapter 8) . Growth Factors Having reviewed the molecular events in cell growth, we can now turn to a description of specific polypeptide growth factors. Some of the growth factors act on a variety of cell types, whereas others have relatively specific targets. Growth factors also have effects on cell locomotion, contractility, and differentiation--effects that may be as important to repair and wound healing as the growth-promoting effects. Table 4-1 lists some of the most important growth factors. Here we review only those that have broad targets and seem to be involved in general pathologic processes. More specific growth factors are alluded to in other sections of the book. TABLE 4-1 -- GROWTH FACTORS Epidermal growth factor (EGF) family EGF Transforming growth factor-alpha (TGFalpha) Platelet-derived growth factor (PDGF) Fibroblast growth factor (FGF) Basic Acidic Transforming growth factor beta-(TGF) family TGF-beta Bone morphogenic proteins Activins, others Vascular endothelial growth factors (VEGF) Angiopoietins (Ang) Insulin-like growth factors (IGF)
Hepatocyte growth factor (HGF) Connective tissue growth factor (CTGF) Myeloid colony-stimulating factors (CSFs) Granulocyte-macrophage CSF (GM-CSF) Granulocyte CSF (G-CSF) Macrophage CSF (M-CSF) Erythropoietin Cytokines Interleukins Tumor necrosis factor (TNF) Interferons alpha, beta Nerve growth factor (NGF)
1. EGF/TGF-alpha: EGF was first discovered by its ability to cause precocious tooth eruption and eyelid opening in newborn mice. [ 28] EGF binds to a receptor (c- erb B1) with tyrosine kinase activity, followed by the signal transduction events described earlier. [29] EGF is mitogenic for a variety of epithelial cells and fibroblasts in vitro and causes hepatic cell division in vivo. It is widely distributed in tissue secretions and fluids, such as sweat, saliva, urine, and intestinal contents. TGF-alpha was initially extracted from sarcoma virus-transformed cells and was thought to be involved in transformation of normal cells to cancer. TGF-alpha has extensive homology with EGF, binds to the EGF receptor, and produces most of the biologic activities of EGF. 2. PDGF: PDGF is a family of several closely related 30-kD dimers consisting of two chains designated A and B. All three isoforms of PDGF (AA, AB, and BB) are secreted and are biologically active. The PDGF isoforms exert their effects by binding to two cell surface receptors, designated alpha and beta, that have different ligand specificities. [30] PDGF is stored in the platelet alpha granules and released on platelet activation. It can also be produced by a variety of cells, including activated macrophages, endothelial cells, smooth muscle cells as well as many tumor cells. PDGF causes both migration and proliferation of fibroblasts, smooth muscle cells, and monocytes and has other proinflammatory properties as well. Transgenic animals that are deficient in either the A or B chain of PDGF show defects in the migration and proliferation of connective tissue cells, [31] suggesting that PDGF plays a special role in these processes. 3. FGFs: This is a family of growth factors of which acidic FGF (aFGF, or FGF-1) and basic FGF (bFGF or FGF-2) are the best characterized. [32] FGF-1 and FGF-2 are about 18 kD and are made by a variety of cells. Released FGF can associate with heparan sulfate in the ECM, which serves as a reservoir for growth factors controlling cell proliferation. FGF is recognized by a family of cell surface receptors
that have intrinsic tyrosine kinase activity after ligand-induced activation. A large number of functions are attributed to FGFs, including roles in the following: New blood vessel formation (angiogenesis): bFGF, in particular, has the ability to induce all the steps necessary for new blood vessel formation both in vivo and in vitro, as we shall see. Wound repair: FGFs participate in macrophage, fibroblast, and endothelial cell migration in the damaged tissue and migration of epithelium to form new epidermis (Chapter 3) . Development: FGFs play a role in skeletal muscle development and in lung maturation. For example, FGF-6 and its receptor induce myoblast proliferation and suppress myocyte differentiation, providing a supply of proliferating myocytes. bFGF is also thought to transform mesoderm to angioblasts during embryogenesis. Hematopoiesis: FGFs have been implicated in two aspects of hematopoiesis--development of specific lineages of blood cells and development of bone marrow stroma. 4. Vascular endothelial growth factor (VEGF): VEGF, also called vascular permeability factor, is a family of designated VEGF, VEGF-B, VEGF-C, and placental growth factor (PIGF) that promote blood vessel formation in 98
early development ( vasculogenesis) and have a central role in the growth of new blood vessels ( angiogenesis). [33] Members of the VEGF family have distinct functions. VEGF promotes angiogenesis in cancer, chronic inflammatory states, and healing wounds and is discussed in detail later in this chapter. VEGF-C induces specific lymphatic endothelial proliferation and hyperplasia of the lymphatic vasculature. [34] 5. TGF-beta and related growth factors: TGF-beta belongs to a family of homologous polypeptides that includes three major isoforms of TGF-beta (TGF-beta-1, TGF-beta-2, TGF-beta-3) and factors of such wide-ranging functions as bone morphogenetic proteins, activins, inhibins, and mullerian inhibiting substance. TGF-beta-1 is the most widespread in distribution in mammals. [35] It is a homodimeric protein of approximately 25 kD, produced by a variety of different cell types, including platelets, endothelial cells, lymphocytes, and macrophages. Native TGF-betas are synthesized as precursor proteins, which are proteolytically cleaved to yield the growth factor and a second latent component. [36] After secretion, activation must occur to release the biologically active dimer from the latent portions of the molecule. In contrast to most other growth-related polypeptides, TGF-beta functions both as an inhibitory and a stimulatory factor. TGF-beta is a growth inhibitor to most epithelial cell types in culture. Its effects on fibroblasts and smooth muscle cells depend on concentration and culture conditions. In low concentrations, it induces the synthesis and secretion of PDGF and is thus indirectly mitogenic. In high concentrations, it is growth inhibitory, owing to its ability to inhibit the expression of PDGF receptors. TGF-beta also stimulates fibroblast chemotaxis and the production of collagen and fibronectin by
cells, while inhibiting collagen degradation by decreasing proteases and increasing protease inhibitors. All these effects favor fibrogenesis, and there is increasing evidence that TGF-beta is involved in the development of fibrosis in a variety of chronic inflammatory conditions. 6. Cytokines: Although the cytokines have important functions as mediators of inflammation and immune responses (Chapters 3 and 7) , these proteins can be placed into the larger functional group of polypeptide growth factors, since many of them have growth-promoting activities to a variety of cells.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 5 - Hemodynamic Disorders, Thrombosis, and Shock EDEMA HYPEREMIA AND CONGESTION HEMORRHAGE HEMOSTASIS AND THROMBOSIS EMBOLISM INFARCTION SHOCK REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
113
Chapter 5 - Hemodynamic Disorders, Thrombosis, and Shock Richard N. Mitchell Ramzi S. Cotran
The health and well-being of cells and tissue depends not only on an intact circulation to deliver oxygen, but also on normal fluid homeostasis. This chapter reviews the major disturbances involving hemodynamics and the maintenance of blood flow. The pathologies include edema, vascular congestion, hemorrhage, thrombosis, embolism, infarction, and shock. All may be precipitated by abnormalities in either blood supply or fluid balance and result in severe morbidity or even mortality. Pulmonary edema, for example, occurring when there is increased hydrostatic pressure in the lung vasculature, may be the terminal complication of ischemic or valvular heart disease. Similarly, hemorrhage and shock may be the fatal sequelae of injury as diverse as trauma or infection. Thrombosis, embolism, and infarction underlie three of the most important causes of morbidity and mortality in Western society: myocardial infarction, pulmonary embolism, and cerebrovascular accident (stroke). Thus, the hemodynamic disorders described in this chapter are important in a wide spectrum of human disease.
EDEMA Approximately 60% of lean body weight is water, two thirds of which is intracellular with the remainder in the extracellular compartments, mostly as interstitial fluid (only about 5% of total body water is in blood plasma). The term edema signifies increased fluid in the interstitial tissue spaces. In addition, depending on the site, fluid collections in the different body cavities are variously designated hydrothorax, hydropericardium, and hydroperitoneum (the last is more commonly called ascites). Anasarca ia a severe and generalized edema with profound subcutaneous tissue swelling.
114
Table 5-1 (Table Not Available) lists the pathophysiologic categories of edema. The noninflammatory causes are described in further detail subsequently; the mechanisms
of inflammatory edema, largely related to local increases in vascular permeability, are described in Chapter 3 . In general, the opposing effects of vascular hydrostatic pressure and plasma colloid osmotic pressure are the major factors that govern movement of fluid between vascular and interstitial spaces. Normally, any outflow of fluid into the interstitium from the arteriolar end of the microcirculation is nearly balanced by inflow at the venular end; a small leftover amount of interstitial fluid is usually removed by the lymphatics. Either increased capillary pressure or diminished colloid osmotic pressure can result in increased interstitial fluid (Fig. 5-1) . As extravascular fluid accumulates in either case, the increased tissue hydrostatic pressure and plasma colloid osmotic pressure eventually achieve a new equilibrium, and water reenters the venules. Excess interstitial edema fluid is removed by lymphatic TABLE 5-1 -- PATHOPHYSIOLOGIC CATEGORIES OF EDEMA (Not Available) Modified from Leaf A. Cotran RS: Renal Pathophysiology, 3rd ed. New York Oxford University Press. 1985, p 146. Used by permission of Oxford University Press. Inc.
Figure 5-1 Factors affecting fluid balance across capillary walls. Capillary hydrostatic and osmotic forces are normally balanced so that there is no net loss or gain of fluid across the capillary bed. However, increased hydrostatic pressure or diminished plasma osmotic pressure leads to a net accumulation of extravascular fluid ( edema). As the interstitial fluid pressure increases, tissue lymphatics
remove much of the excess volume, eventually returning it to the circulation via the thoracic duct. If the ability of the lymphatics to drain tissue is exceeded, persistent tissue edema results.
drainage, ultimately returning to the bloodstream via the thoracic duct (Fig. 5-1) ; clearly, lymphatic obstruction (e.g., due to scarring or tumor) can also impair fluid removal and cause edema. Finally, a primary retention of sodium (and its obligatory associated water) in renal disease also results in edema. The edema fluid occurring in hydrodynamic derangements is typically a protein-poor transudate, with a specific gravity below 1.012. Conversely, because of increased vascular permeability, inflammatory edema is a protein-rich exudate, with a specific gravity usually over 1.020. Increased Hydrostatic Pressure Local increases in hydrostatic pressure may result from impaired venous outflow. For example, deep venous thrombosis in the lower extremities leads to edema, which is restricted to the affected leg. Generalized increases in venous pressure, with resulting systemic edema, occur most commonly in congestive heart failure (Chapter 13) affecting right ventricular cardiac function. Although increased venous hydrostatic pressure is important, the pathogenesis of cardiac edema is more complex (Fig. 5-2) . Congestive heart failure
is associated with reduced cardiac output and therefore reduced renal perfusion. Renal hypoperfusion, in turn, triggers the renin-angiotensin-aldosterone axis, inducing sodium and water retention by the kidneys (secondary aldosteronism). This process is putatively designed to increase intravascular volume and thereby improve cardiac output (via the Frank-Starling law) with restoration of normal renal perfusion. If the failing heart cannot increase cardiac output, however, the extra fluid load results only in increased venous pressure and eventually edema. [1] Unless cardiac output is restored or renal water 115
retention is reduced (e.g., by salt restriction, diuretics, or aldosterone antagonists), a cycle of renal fluid retention and worsening edema ensues. Although discussed here in the context of edema in congestive heart failure, salt restriction, diuretics, and aldosterone antagonists may also be used to manage generalized edema arising from a variety of other causes.
Figure 5-2 Sequence of events leading to systemic edema in heart failure, or with reduced plasma osmotic pressure, as in the
nephrotic syndrome. ADH, antidiuretic hormone; GFR, glomerular filtration rate.
Reduced Plasma Osmotic Pressure. Reduced plasma osmotic pressure can result from excessive loss or reduced synthesis of albumin, the serum protein most responsible for maintaining colloid osmotic pressure. An important cause of albumin loss is the nephrotic syndrome (Chapter 21) , characterized by a leaky glomerular capillary wall and generalized edema. Reduced albumin synthesis occurs in the setting of diffuse liver pathology (e.g., cirrhosis) (Chapter 19) or as a consequence of protein malnutrition (Chapter 10) . In each case, reduced plasma osmotic pressure leads to a net movement of fluid into the interstitial tissues and a resultant plasma volume contraction. Predictably, with reduced intravascular volume, renal hypoperfusion with secondary aldosteronism follows. The retained salt and water cannot correct the plasma volume deficit because the primary defect of low serum proteins persists. As with congestive heart failure, edema precipitated by hypoproteinemia is exacerbated by secondary salt and fluid retention. Lymphatic Obstruction. Impaired lymphatic drainage and consequent lymphedema is usually localized; it can result from inflammatory or neoplastic obstruction. For example, the parasitic infection filariasis often causes massive lymphatic and lymph node fibrosis in the inguinal region. The resulting edema of the external genitalia and lower limbs is so extreme it is called elephantiasis. Cancer of the breast may be treated by removal or irradiation (or both) of the breast and the associated axillary lymph nodes. The resection of the lymphatic channels as well as scarring related to the surgery and radiation can result in severe
edema of the arm. Sodium and Water Retention. Sodium and water retention are clearly contributory factors in several forms of edema; however, salt retention may also be a primary cause of edema. Increased salt, with the obligate accompanying water, causes both increased hydrostatic pressure (owing to expansion of the intravascular fluid volume) and
116
diminished vascular colloid osmotic pressure. Salt retention may occur with any acute reduction of renal function, including poststreptococcal glomerulonephritis and acute renal failure (Chapter 21) . MORPHOLOGY OF EDEMA.
Edema is most easily recognized grossly; microscopically, edema fluid generally manifests only as subtle cell swelling, with clearing and separation of the extracellular matrix elements. Although any organ or tissue in the body may be involved, edema is most commonly encountered in subcutaneous tissues, the lungs, and the brain. Severe, generalized edema is called anasarca. Subcutaneous edema may have different distributions depending on the cause. It can be diffuse or may be relatively more conspicuous at the sites of highest hydrostatic pressures. In the latter case, the edema distribution is typically influenced by gravity and is termed dependent. Edema of the dependent parts of the body (e.g., the legs when standing, the sacrum when recumbent) is a prominent feature of congestive heart failure, particularly of the right ventricle. Edema as a result of renal dysfunction or nephrotic syndrome is generally more severe than cardiac edema and affects all parts of the body equally. It may, however, be initially manifest in tissues with a loose connective tissue matrix, such as the eyelids, causing periorbital edema. Finger pressure over substantially edematous subcutaneous tissue displaces the interstitial fluid and leaves a finger-shaped depression, so-called pitting edema. Pulmonary edema is a common clinical concern (Chapter 16) most typically in the setting of left ventricular failure but also occurring in renal failure, adult respiratory distress syndrome (Chapter 16) , pulmonary infections, and hypersensitivity reactions. The lungs are two to three times their normal weight, and sectioning reveals frothy, blood-tinged fluid representing a mixture of air, edema fluid, and extravasated red blood cells. Edema of the brain may be localized to sites of injury (e.g., abscess or neoplasm) or may be generalized, as in encephalitis, hypertensive crises, or obstruction to the brain's venous outflow. Trauma may result in local or generalized edema depending on the
nature and extent of the injury. With generalized edema, the brain is grossly swollen with narrowed sulci and distended gyri showing signs of flattening against the unyielding skull (Chapter 30) . Clinical Correlation. Effects of edema may range from merely annoying to fatal. Subcutaneous tissue edema in cardiac or renal failure is important primarily because it signals underlying disease; however, when significant, it can impair wound healing or the clearance of infection. Pulmonary edema can cause death by interfering with normal ventilatory function. Not only does fluid collect in the alveolar septa around capillaries and impede oxygen diffusion, but also edema fluid in the alveolar spaces creates a favorable environment for bacterial infection. Brain edema is serious and can be rapidly fatal; if severe, brain substance can herniate (push out) through, for example, the foramen magnum, or the brain stem vascular supply can be compressed. Either condition can injure the medullary centers and cause death.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 6 - Genetic Disorders MUTATIONS MENDELIAN DISORDERS DISORDERS WITH MULTIFACTORIAL INHERITANCE NORMAL KARYOTYPE CYTOGENETIC DISORDERS SINGLE-GENE DISORDERS WITH NONCLASSIC INHERITANCE MOLECULAR DIAGNOSIS DIAGNOSIS OF GENETIC DISEASES REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
139
Chapter 6 - Genetic Disorders Genetic disorders are far more common than is widely appreciated. The lifetime frequency of genetic diseases is estimated to be 670 per 1000. [1] Included in this figure are not only the "classic" genetic disorders but also cancer and cardiovascular diseases, the two most common causes of death in the Western world. Both of these have major genetic components. Cardiovascular diseases, such as atherosclerosis and hypertension, result from complex interactions of genes and environment, and most cancers are now known to result from an accumulation of mutations in somatic cells (Chapter 8) . The genetic diseases encountered in medical practice
140
represent only the tip of the iceberg, that is, those with less extreme genotypic errors permitting full embryonic development and live birth. It is estimated that 50% of spontaneous abortuses during the early months of gestation have a demonstrable chromosomal abnormality; there are, in addition, numerous smaller detectable errors and many others still beyond our range of identification. About 1% of all newborn infants possess a gross chromosomal abnormality, and approximately 5% of individuals under the age of 25 years develop a serious disease with a significant genetic component. How many more mutations remain hidden? The answer to this question may be available in the not-too-distant future because of the Human Genome Project. By the year 2005, this project aims to obtain the complete sequence of the 3 billion base pairs of human DNA. Included in this pool of nucleotides is the genetic code for the approximately 100,000 human genes and their regulatory elements. This multinational effort will elucidate the "genetic architecture" of humans and generate the biologist's periodic table. [2] Much of the progress in medical genetics has resulted from the spectacular advances in molecular biology, involving recombinant DNA technology. The details of these techniques are well known and are not repeated here. Some examples, however, of the impact of recombinant DNA technology on medicine are worthy of attention. Molecular basis of human disease: Two general strategies have been used to isolate and characterize involved genes (Fig. 6-1) . The functional cloning, or classic,
approach has been successfully used to study a variety of inborn errors of metabolism, such as phenylketonuria and disorders of hemoglobin synthesis. Common to these genetic diseases is a knowledge of the abnormal gene product and the corresponding protein. When the affected protein is known, a variety of methods can be employed to isolate the normal gene, to clone it, and ultimately to determine the molecular changes that affect the gene in patients with the disorder. Because in many common single-gene disorders, such as cystic fibrosis, there was no clue to the nature of the defective gene product, an alternative strategy called positional cloning, or the "candidate gene," approach had to be employed. This strategy initially ignores the biochemical clues from the phenotype and relies instead on mapping the disease phenotype to a particular chromosome location. This mapping is accomplished if the disease is associated with a distinctive cytogenetic change (e.g., fragile X syndrome, discussed later) or by linkage analysis. In the latter, the approximate location of the gene is determined by linkage to known "marker genes" that are in close proximity to the disease locus. Once the region in which the mutant gene lies has been localized within reasonably narrow limits, the next step is to clone several pieces of DNA from the relevant segment of the genome. Expression of the cloned DNA in vitro, followed by identification of the protein products, can then be used to identify the aberrant protein encoded by the mutant genes. This approach has been used successfully in several diseases, such as cystic fibrosis, neurofibromatosis, Duchenne muscular dystrophy (a hereditary disorder characterized by progressive muscle weakness), polycystic kidney disease, and Huntington disease. Another powerful tool for studying the molecular pathogenesis of human diseases--both genetic and acquired--involves creation of rodent (mouse, rat) models of the disease. Two types of mutant mice can be created: transgenic and gene knockout. [3] [4] In transgenic mice, a molecularly cloned human DNA is introduced into the germ line of suitable mice by injecting it into the ovum. The transgenic progeny express the human DNA and often manifest the human disease. For example, mice transgenic for human c- myc, a cancer-associated gene, develop tumors, thus providing a mouse model for carcinogenesis (Chapter 8) . In the other type of mouse model, both of the copies of a mouse gene are "knocked out" by replacing the normal genes with inactive genes. Thus, for example, both alleles of the low-density lipoprotein (LDL)-receptor gene can be deleted, and the resultant LDL-receptor knockout mice develop hypercholesterolemia and atherosclerosis, mimicking the human disease familial hypercholesterolemia (see later). Production of human biologically active agents: An array of ultrapure biologically active agents can now be produced in virtually unlimited quantities by inserting the requisite gene into bacteria or other suitable cells in tissue culture. Some examples of genetically engineered products already in clinical use include tissue plasminogen activator for the treatment of thrombotic states, 141
growth hormone for the treatment of deficiency states, erythropoietin to reverse the anemia of renal disease, and myeloid growth and differentiation factors (granulocyte macrophage colony-stimulating factor, granulocyte colony-stimulating factor) to enhance production of monocytes and neutrophils in states of poor marrow function. Gene therapy: The goal of treating genetic diseases by transfer of somatic cells
transfected with the normal gene, although not yet attained, is on the horizon. Much interest is focused on transplantation of patients' hematopoietic stem cells that have been transfected with the cloned normal gene. The first attempts at human gene therapy have been undertaken in patients with immunodeficiency resulting from a lack of the enzyme adenosine deaminase (ADA). The expression of the transferred ADA gene in lymphoid cells restores enzyme levels in vivo, thereby reversing the state of immunoincompetence that characterizes ADA-deficient patients. In another strategy, being tested in patients with cystic fibrosis, the normal gene is delivered to the somatic cells by way of a harmless viral vector. [5] Disease diagnosis: Molecular probes are proving to be extremely useful in the diagnosis of both genetic and nongenetic (e.g., infectious) diseases. The diagnostic applications of recombinant DNA technology are detailed at the end of this chapter.
Figure 6-1 Schematic illustration of the strategies employed in functional and positional cloning. Functional cloning begins with
relating the clinical phenotype to biochemical-protein abnormalities, followed by isolation of the mutant gene. Positional cloning, also called candidate gene approach, begins by mapping and cloning the disease gene by linkage analysis, without any knowledge of the gene product. Identification of the gene product and the mechanism by which it produces the disease follows the isolation of the mutant gene.
With this background of developments in human genetics, we can turn next to the time-honored classification of human diseases into three categories: (1) those environmentally determined, (2) those genetically determined, and (3) those in which both environmental and genetic factors play a role. Obesity might appear to be representative of the first category; however, even here, with the discovery of genes that control satiety and energy metabolism (Chapter 10) , it is evident that overnutrition--and all disorders to a greater or lesser degree--is conditioned by the genotype. Into the third category just mentioned fall many of the important diseases of humans, such as peptic ulcer, diabetes mellitus, atherosclerosis, schizophrenia, and most cancers, in which clearly both nature and nurture play significant roles. It is beyond the scope of this book to review normal human genetics. It is beneficial to review some fundamental concepts that have bearing on the understanding of genetic diseases. First, however, several commonly used terms are clarified-- hereditary, familial, and congenital. Hereditary disorders, by definition, are derived from one's parents and are transmitted in the germ line through the generations and therefore are familial. The term congenital simply implies "born with." Some congenital diseases are not genetic, as, for example, congenital syphilis. Not all genetic diseases are congenital; patients with Huntington disease, for example, begin to manifest their condition only after the twenties or thirties.
MUTATIONS A mutation may be defined as a permanent change in the DNA. Mutations that affect the germ cells are transmitted to the progeny and may give rise to inherited diseases. Mutations that arise in somatic cells understandably do not cause hereditary diseases but are important in the genesis of cancers and some congenital malformations.
Based on the extent of genetic change, mutations may be classified into three categories. [6] Genome mutations involve loss or gain of whole chromosomes, giving rise to monosomy or trisomy. Chromosome mutations result from rearrangement of genetic material and give rise to visible structural changes in the chromosome. Mutations involving
Figure 6-2 Schematic illustration of a point mutation resulting from a single base pair change in the DNA. In the example shown, a
CTC to CAC change alters the meaning of the genetic code (GAG to GUG in the opposite strand), leading to replacement of glutamic acid by valine in the polypeptide chain. This change, affecting the sixth amino acid of the normal beta-globin (betaA ) chain, converts it to sickle beta-globin (betaS ).
142
Figure 6-3 Single-base deletion at the ABO (glycosyltransferase) locus, leading to a frameshift mutation responsible for the O allele. (From Thompson MW, et al: Thompson and Thompson Genetics in Medicine, 5th ed. Philadelphia, WB Saunders, 1991, p 134.)
changes in the number or structure of chromosomes are transmitted only infrequently because most are incompatible with survival. The vast majority of mutations associated with hereditary diseases are submicroscopic gene mutations. These may result in partial or complete deletion of a gene or, more often, affect a single base. For example, a single nucleotide base may be substituted by a different base, resulting in a point mutation (Fig. 6-2) . Less commonly, one or two base pairs may be inserted into or deleted from the DNA, leading to alterations in the reading frame of the DNA strand; hence these are referred to as frameshift mutations (Figs. 6-3 and 6-4) . The consequences of mutations are varied, depending on several factors, including the type of mutation and the genomic site affected by it. Details of specific mutations and their effects are discussed along with the relevant disorders throughout this text. Here we briefly review some general principles relating to the effects of gene mutations. Point mutations within coding sequences: A point mutation (single base substitution) may alter the code in a triplet of bases and lead to the replacement of one amino acid by another in the gene product. Because these mutations alter the meaning of the genetic code, they are often termed missense mutations. An excellent example of this type is the sickle mutation affecting the beta-globin chain of hemoglobin (Chapter 14) . Here the nucleotide triplet CTC (or GAG in messenger RNA [mRNA]), which codes for glutamic acid, is changed to CAC (or GUG in mRNA), which codes for valine (see Fig. 6-2) . This single amino acid substitution alters the physicochemical properties of hemoglobin, giving rise to sickle cell anemia. Besides producing an amino acid substitution, a point mutation may change an amino acid codon to a chain terminator, or stop codon ( nonsense mutation). Taking again the example of beta-globin, a point mutation affecting the codon for glutamine (CAG) creates a stop codon (UAG) if U is substituted for C (Fig. 6-5) .
This change leads to premature termination of beta-globin gene translation, and the resulting short peptide is rapidly degraded. The affected individuals lack beta-globin chains and develop a severe form of anemia called beta0 -thalassemia (Chapter 14) . Mutations within noncoding sequences: Deleterious effects may also result from mutations that do not involve the exons. As is well known, transcription of DNA is initiated and regulated by promoter and enhancer sequences that are found down-stream or up-stream of the gene. Point mutations or deletions involving these regulatory sequences may interfere with binding of transcription factors and thus lead to a marked reduction in or total lack of transcription. Such is the case in certain forms of hereditary hemolytic anemias. In addition, point mutations within introns lead to defective splicing of intervening sequences. This, in turn, interferes with normal processing of the initial mRNA transcripts and results in a failure to form mature mRNA transcripts. Therefore, translation cannot take place, and the gene product is not synthesized. 143
Deletions and insertions: Small deletions or insertions involving the coding sequence lead to alterations in the reading frame of the DNA strand; hence they are referred to as frameshift mutations (see Figs. 6-3 and 6-4 ). If the number of base pairs involved is three or a multiple of three, frameshift does not occur ( Fig. 6-6) ; instead an abnormal protein missing one or more amino acids is synthesized. Trinucleotide repeat mutations: Trinucleotide repeat mutations belong to a special category because these mutations are characterized by amplification of a sequence of three nucleotides. Although the specific nucleotide sequence that undergoes amplification differs in various disorders, almost all affected sequences share the nucleotides guanine (G) and cytosine (C). For example, in fragile X syndrome, prototypical of this category of disorders, there are 250 to 4000 tandem repeats of the sequence CGG within a gene called FMR-1. In normal populations, the number of repeats is small, averaging 29. It is believed that expansions of the trinucleotide sequences prevent normal expression of the FMR-1 gene, thus giving rise to mental retardation. Another distinguishing feature of trinucleotide repeat mutations is that they are dynamic (i.e., the degree of amplification increases during gametogenesis). These features, discussed in greater detail later, influence the pattern of inheritance and the phenotypic manifestations of the diseases caused by this class of mutations.
Figure 6-4 Four-base insertion in the hexosaminidase A gene in Tay-Sachs disease, leading to a frameshift mutation. This mutation is the major cause of Tay-Sachs disease in Ashkenazi Jews. (From Thompson MW, et al: Thompson and Thompson Genetics in Medicine, 5th ed. Philadelphia, WB Saunders, 1991, p 135.)
Figure 6-5 Point mutation leading to premature chain termination. Partial mRNA sequence of the beta-globin chain of hemoglobin
showing codons for amino acids 38 to 40. A point mutation (C and hence protein synthesis stops at the 38th amino acid.
U) in codon 39 changes glutamine (Gln) codon to a stop codon,
To summarize, mutations can interfere with protein synthesis at various levels. Transcription may be suppressed with gene deletions and point mutations involving promoter sequences. Abnormal mRNA processing may result from mutations affecting introns or splice junctions, or both. Translation is affected if a stop codon (chain termination mutation) is created within an exon. Finally, some point mutations may lead to the formation of an abnormal protein without impairing any step in protein synthesis. Mutations occur spontaneously during the process of DNA replication. Certain environmental influences, such as radiation, chemicals, and viruses, increase the rate of so-called spontaneous mutations. Because the mutagenic potential of environmental agents is linked to their role in carcinogenesis, they are discussed in Chapter 8 , Neoplasia. Against this background, we now turn our attention to the three major categories of genetic disorders: (1) disorders related to mutant genes of large effect, (2) diseases
Figure 6-6 Three-base deletion in the common cystic fibrosis (CF) allele results in synthesis of a protein that is missing amino acid 508 (phenylalanine). Because the deletion is a multiple of three, this is not a frameshift mutation. (From Thompson MW, et al: Thompson and Thompson Genetics in Medicine, 5th ed. Philadelphia, WB Saunders, 1991, p 135.)
with multifactorial (polygenic) inheritance, and (3) chromosomal disorders. The first category includes many relatively uncommon conditions, such as storage disorders and inborn errors of metabolism, all resulting from single-gene mutations of large effect. Because most of these follow the classic mendelian patterns of inheritance, they are also referred to as mendelian disorders. The second category includes some of the most common diseases of humans, such as hypertension and diabetes mellitus. They are called multifactorial because they are influenced by both genetic and environmental factors. The genetic component involves the additive result of multiple genes of small effect; the environmental contribution may be small or large, and in some cases, it is required for the expression of disease. The third category includes diseases that result from genomic or chromosomal mutations and are therefore associated with numerical or structural changes in chromosomes. To these three well-known categories must be added a heterogeneous group of single-gene disorders with nonclassic patterns of inheritance. This group includes disorders resulting from triplet repeat mutations, those arising from mutations in mitochondrial DNA, and those in which the transmission is influenced by genomic imprinting or gonadal mosaicism. Diseases within this group are caused by mutations in single genes, but they do not follow the mendelian pattern of inheritance. These are discussed later in this chapter.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 7 - Diseases of Immunity GENERAL FEATURES OF THE IMMUNE SYSTEM DISORDERS OF THE IMMUNE SYSTEM - Part 1 DISORDERS OF THE IMMUNE SYSTEM - Part 2 REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
188
Chapter 7 - Diseases of Immunity GENERAL FEATURES OF THE IMMUNE SYSTEM Although vital to survival, the immune system is similar to the proverbial two-edged sword. On the one hand, immunodeficiency states render humans easy prey to infections and possibly tumors; on the other hand, a hyperactive immune system may cause fatal disease, as in the case of an overwhelming allergic reaction to the sting of a bee. In yet another series of derangements, the immune system
189
may lose its normal capacity to distinguish self from nonself, resulting in the emergence of immunity against one's own tissues and cells (autoimmunity). This chapter considers diseases caused by too little immunity as well as those resulting from too much immunologic reactivity. We also consider amyloidosis, a disease in which an abnormal protein, derived in some cases from fragments of immunoglobulins, is deposited in tissues. First, we review some advances in the understanding of lymphocyte biology, then a brief description of the histocompatibility genes is given because their products are relevant to several immunologically mediated diseases and to the rejection of transplants. Cells of the Immune System T LYMPHOCYTES
As is well known, cellular immunity is mediated by thymus-derived (T) lymphocytes. In the blood, T cells constitute 60 to 70% of peripheral lymphocytes. T lymphocytes are also found in the paracortical areas of lymph nodes and periarteriolar sheaths of the spleen. Each T cell is genetically programmed to recognize a specific cell-bound antigen by means of an antigen-specific T-cell receptor (TCR). [1] In approximately 95% of T cells, the TCR consists of a disulfide-linked heterodimer made up of an alpha and a beta polypeptide chain (Fig. 7-1) , each having a variable (antigen-binding) and a constant region. In a minority of peripheral blood T cells, another type of TCR, composed of gamma and delta polypeptide chains, is found. The TCR gamma/delta cells tend to aggregate at epithelial interfaces, such as the mucosa of the respiratory and gastrointestinal tracts. Both the alpha/beta and the gamma/delta TCRs are
noncovalently linked to a cluster of five polypeptide chains, referred to as the CD3 molecular complex. The CD3 proteins are nonvariable. They do not bind antigen but are involved in the transduction of signals into the T cell after it has bound the antigen. TCR diversity is generated by somatic rearrangement of the genes that encode the alpha, beta, gamma, and delta TCR chains. As might be expected, every somatic cell has TCR genes from
Figure 7-1 The T-cell receptor (TCR) complex: schematic illustration of TCR and TCRalpha and TCRbeta polypeptide chains linked
to the CD3 molecular complex.
the germ line. During ontogeny, somatic rearrangements of these genes occur only in T cells; hence the demonstration of TCR gene rearrangements by Southern blot analysis is a molecular marker of T-lineage cells. Such analyses are used in classification of lymphoid malignancies (Chapter 15) . Furthermore, because each T cell has a unique DNA rearrangement (and hence a unique TCR), it is possible to distinguish polyclonal (non-neoplastic) T-cell proliferations from monoclonal (neoplastic) T-cell proliferations. In addition to CD3 proteins, T cells express a variety of other nonpolymorphic function-associated molecules, including CD4, CD8, and many so-called accessory molecules, such as CD2, CD11a, CD28, and CD40 ligand. Of these, CD4 and CD8 are particularly important. They are expressed on two mutually exclusive subsets of T cells. CD4 is expressed on approximately 60% of mature CD3+ T cells, whereas CD8 is expressed on about 30% of T cells. These T-cell membrane-associated glycoproteins serve as coreceptors in T-cell activation. During antigen presentation, CD4 molecules bind to the nonpolymorphic portions of class II major histocompatibility complex (MHC) molecules expressed on antigen-presenting cells (Fig. 7-2) . In contrast, CD8 molecules bind to class I MHC molecules. Because of these properties, CD4+ helper T cells can recognize antigen only in the context of class II MHC antigens, whereas the CD8+ cytotoxic T cells recognize cell-bound antigens only in association with class I MHC antigens. It is now well established that T cells need two signals for activation. Signal 1 is provided when the TCR is engaged by the appropriate MHC-bound antigen. The coreceptors CD4 and CD8 enhance this signal. Signal 2 is delivered by the interaction of the CD28 molecule on T cells with the costimulatory molecules B7-1 and B7-2 expressed on antigen-presenting cells (Fig. 7-2) . The importance of costimulation by this pathway is attested to by the fact that, in the absence of signal 2, the T cells undergo apoptosis or become unreactive. [2] The CD4+ and CD8+ T cells perform distinct but somewhat overlapping functions. The CD4+ T cell can be viewed as a master regulator--the conductor of a symphony orchestra, so to speak. By secreting soluble factors (cytokines), CD4+ T cells influence the function of virtually all other cells of the immune system, including other T cells, B cells, macrophages, and natural killer (NK) cells. The central role of CD4+ T cells is tragically illustrated when the human immunodeficiency virus (HIV) cripples the immune system by selective destruction of this T-cell subset. In recent years, two functionally different populations of CD4+ helper cells have been recognized. [3] The T-helper-1 (TH 1) subset synthesizes and secretes interleukin-2 (IL-2) and interferon-gamma
(IFN-gamma) but not IL-4 or IL-5, whereas TH 2 cells produce IL-4 and IL-5 but not IL-2 or IFN-gamma. This distinction is significant because the cytokines secreted by these subsets have different effects on other immune cells. In general, the TH 1 subset is involved in facilitating delayed hypersensitivity, macrophage activation, and synthesis of IgG2b antibodies. The TH 2 subset aids in the synthesis of other classes of antibodies, including IgE. The CD8+ T cells, similar to CD4+ T cells, can secrete cytokines, primarily of the TH 1 type, but they mediate their functions primarily by acting as cytotoxic cells.
190
Figure 7-2 Schematic representation of antigen recognition by CD4+ T cells. Note that the T-cell receptor (TCR heterodimer)
recognizes a peptide fragment of antigen bound to the major histocompatibility complex (MHC) class II molecule. The CD4 molecule binds to the nonpolymorphic portion of the class II molecule. The interaction between the TCR and the MHC-bound antigen provides signal 1 for T-cell activation. Signal 2 is provided by the interaction of the CD28 molecule with the costimulatory molecules (B7-1 and B7-2) expressed on antigen presenting cell.
B LYMPHOCYTES
B lymphocytes constitute 10 to 20% of the circulating peripheral lymphocyte population. They are also present in bone marrow; peripheral lymphoid tissues such as lymph nodes, spleen, or tonsils; and extralymphatic organs, such as the gastrointestinal tract. In lymph nodes, they are found in the superficial cortex. In the spleen, they are found in the white pulp. At both sites, they are aggregated in the form of lymphoid follicles, which on activation develop pale-staining germinal centers (Fig. 7-3) . On antigenic stimulation, B cells form plasma cells that secrete immunoglobulins, which, in turn, are the mediators of humoral immunity. B cells recognize antigen via the B-cell antigen receptor complex. Immunoglobulin M (IgM), present on the surface of all B cells, constitutes the antigen-binding component of the B-cell receptor. As with T cells, each B-cell receptor has a unique antigen specificity, derived, in part, from somatic rearrangements of immunoglobulin genes. Thus, the presence of rearranged immunoglobulin genes in a lymphoid cell is used as a molecular marker of B-lineage cells. In addition to membrane IgM, the B-cell antigen receptor complex contains a heterodimer of nonpolymorphic transmembrane proteins: Igalpha and Igbeta. Similar to the CD3 proteins of the TCR, Igalpha and Igbeta do not bind antigen but are essential for signal transduction through the receptor. B cells also express several other nonpolymorphic molecules that are essential for B-cell function. These include complement receptors, Fc receptors, and CD40. It is worthy of note that complement receptor-2 (CD21) is also the receptor for the Epstein-Barr virus (EBV), and hence B cells are readily infected by EBV. The CD40 molecule, a member of the tumor necrosis factor (TNF)-receptor family, plays an important role in the interaction of T helper cells and B cells. Activated T helper cells express CD40 ligand, which specifically binds to CD40 expressed on B cells. This interaction is essential for B-cell maturation and secretion of IgG, IgA, and IgE antibodies. [4] Patients with mutations in the CD40 ligand
have an immunodeficiency called X-linked hyper-IgM syndrome, described later. MACROPHAGES
Macrophages are a part of the mononuclear phagocyte system, and, as such, their origin, differentiation, and role in inflammation are discussed in Chapter 3 . Here we need only to emphasize that macrophages play important roles both in the induction and in the effector phase of immune responses. First, they are required to process and present antigen to immunocompetent T cells. T cells (in contrast to B cells) cannot be activated by soluble antigens; therefore, presentation of processed, membrane-bound antigens by macrophages or other antigen-presenting cells (e.g., dendritic cells and B cells) is obligatory for induction of cell-mediated immunity. Macrophages are important effector cells in certain forms of cell-mediated immunity, such as the delayed 191
hypersensitivity reaction. As mentioned earlier, macrophage activation is facilitated by cytokines, such as IFN-gamma produced by the TH 1 subset of CD4+ cells. Such activation enhances the microbicidal properties of macrophages and augments their ability to kill tumor cells. Macrophages are also important in the effector phase of humoral immunity. As discussed in Chapter 3 , macrophages phagocytose microbes that are opsonized (coated) by IgG or C3b.
Figure 7-3 Lymph node cortex showing a lymphoid follicle, the B cell-containing area. (Courtesy of Dr. Jon Aster, Brigham and Women's Hospital, Boston, MA.)
DENDRITIC CELLS
There are two types of cells with dendritic morphology that are functionally quite different. Both have numerous fine dendritic cytoplasmic processes, from which they derive their name. One type is called interdigitating dendritic cells, or just dendritic cells.[4A] These cells are nonphagocytic, and they express high levels of MHC class II molecules as well as the costimulatory molecules B7-1 and B7-2. Thus, they are ideally suited for presenting antigens to CD4+ T cells and are believed to be the most potent antigen-presenting cells for naive T cells. Dendritic cells are widely distributed. They are found in lymphoid tissue and in the interstitium of many nonlymphoid organs, such as the heart and lungs. Similar cells within the epidermis have been called Langerhans cells. The other type of cells with dendritic morphology are present in the germinal centers of lymphoid follicles in the spleen and lymph nodes and are hence called follicular dendritic cells. These cells bear Fc receptors for IgG and hence can trap antigen bound to antibodies. Such cells play a role in ongoing immune response and
are discussed later in the section on acquired immunodeficiency syndrome (AIDS). NATURAL KILLER CELLS
Natural killer (NK) cells make up approximately 10 to 15% of the peripheral blood lymphocytes and do not bear T-cell receptors or cell surface immunoglobulins. Morphologically, NK cells are somewhat larger than small lymphocytes, and they contain abundant azurophilic granules (Fig. 7-4) . Hence, they are also called large granular lymphocytes. NK cells are endowed with an innate ability to lyse a variety of tumor cells, virally infected cells, and some normal cells, without previous sensitization. These cells are believed to be a part of the natural (as opposed to adaptive) immune system that may be the first line of defense against neoplasms or viral infections. Although they share some surface markers with T cells (e.g., CD2), NK cells do not rearrange T-cell receptor genes and are CD3 negative. Two cell surface molecules, CD16 and CD56, are widely used to identify NK cells. Of these, CD16 is of functional significance. It represents the Fc receptor for IgG and hence endows NK cells with another function--the ability to lyse IgG-coated target cells. This phenomenon, known as antibody-dependent cell-mediated cytotoxicity (ADCC), is described in greater detail later. NK cells express two types of receptors on their cell membrane. One type activates NK cell killing by recognizing ill-defined molecules on target cells; the other type inhibits the lytic pathway by recognition of self class I MHC molecules. These class I-
Figure 7-4 A highly activated natural killer cell with abundant cytoplasmic granules. (Courtesy of Dr. Noelle Williams, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
recognizing receptors on NK cells are biochemically distinct from T-cell receptors. It is believed that NK cells are inhibited from killing normal cells because all nucleated normal cells express self class I MHC molecules. If virus infection or neoplastic transformation perturbs or reduces the expression of class I molecules, inhibitory signals delivered to NK cells are interrupted, and lysis occurs (Fig. 7-5) . NK cells also secrete cytokines, such as TNF-alpha and granulocyte macrophage colony-stimulating factor (GM-CSF), and are believed to be an important source of IFN-gamma. Through these soluble mediators, NK cells can influence T- and B-cell function. IFN-gamma, in particular, favors the differentiation of TH 1 cells. Thus, activation of NK cells early in the immune response can favor induction of delayed hypersensitivity and secretion of opsonizing (IgG2b) antibodies by promoting the differentiation of TH 1 cells. The lytic activity of NK cells is greatly augmented by the cytokines IL-2 and IL-15. Hence these cytokines may be used to augment the tumoricidal activity of NK cells in vivo. Cytokines: Messenger Molecules of the Immune System The induction and regulation of the immune responses involve multiple interactions among lymphocytes, monocytes, inflammatory cells (e.g., neutrophils), and endothelial cells. Many such interactions are cognitive and so depend on cell-to-cell contact;
however, many interactions and effector functions are mediated by short-acting soluble mediators, called cytokines. This term includes the previously designated lymphokines (lymphocyte derived); monokines
192
Figure 7-5 Schematic representation of NK cell receptors and killing. Normal cells are not killed because inhibitory signals from
normal MHC class I molecules override activating signals. In tumor cells, or virus-infected cells, reduced expression or alteration of MHC molecules interrupts the inhibitory signals, allowing activation of NK cells and lysis of target cells.
(monocyte derived); and several other polypeptides that regulate the immunologic, inflammatory, and reparative host responses. Most cytokines have a wide spectrum of effects, and some are produced by several different cell types. The currently well-characterized and molecularly cloned cytokines are not listed here because any such list would soon be dwarfed by the torrent of new cytokines being isolated and reported every day. Instead, we classify the currently known cytokines into five categories and list some of their general properties: Cytokines that mediate natural immunity. Included in this group are IL-1, TNF-alpha, type 1 interferons, and IL-6. Certain of these cytokines (e.g., interferons) protect against viral infections, whereas others (e.g., IL-1, TNF-alpha, IL-6) initiate nonspecific inflammatory responses. Cytokines that regulate lymphocyte growth, activation, and differentiation. Within this category are IL-2, IL-4, IL-5, IL-12, IL-15, and transforming growth factor-beta (TGF-beta). Although some, such as IL-2 and IL-4, favor lymphocyte growth and differentiation, others, such as IL-10 and TGF-beta, down-regulate immune responses. Cytokines that activate inflammatory cells. In this category are IFN-gamma, TNF-alpha, lymphotoxin (TNF-beta), and migration inhibitory factor. Most of these cytokines serve to activate the functions of nonspecific effector cells. Cytokines that affect leukocyte movements are also called chemokines (Chapter 3) . They occur in two structurally distinct subfamilies, referred to as C-C and C-X-C chemokines, on the basis of the position of cysteine (c) residues. The C-X-C chemokines are produced by activated macrophages and tissue cells (e.g., endothelium), whereas the C-C chemokines are produced largely by T cells. IL-8 is an important C-X-C chemokine, whereas monocyte chemotactic proteins and monocyte inflammatory proteins exemplify C-C chemokines. [5] Cytokines that stimulate hematopoiesis. Many cytokines derived from lymphocytes or stromal cells stimulate the growth and production of new blood cells by acting on hematopoietic progenitor cells. Several members of this family are called colony-stimulating factors (CSFs) because they were initially detected by their ability to promote the in vitro growth of hematopoietic cell colonies from the bone marrow. Some members of this group (e.g., GM-CSF and G-CSF) act on committed progenitor cells, whereas others, exemplified by stem cell factor (c-kit ligand), act on
pluripotent stem cells. This subdivision of cytokines into functional groups, although convenient, is somewhat arbitrary because, as noted subsequently, many cytokines, such as IL-1, TNF-alpha, and IFN-gamma, are pleiotropic in their effects. GENERAL PROPERTIES OF CYTOKINES
Many individual cytokines are produced by several different cell types. For example, IL-1 and TNF-alpha can be produced by virtually any cell. The effects of cytokines are pleiotropic: They act on many cell types. For example, IL-2, initially discovered as a T-cell growth factor, is known to affect the growth and differentiation of B cells and NK cells as well. Cytokines induce their effects in three ways: (1) They act on the same cell that produces them ( autocrine effect), such as occurs when IL-2 produced by activated T cells promotes T-cell growth; (2) they affect other cells in their vicinity ( paracrine effect), as occurs when IL-7 produced by marrow stromal cells promotes the differentiation of B-cell progenitors in the marrow; and (3) they affect many cells systemically ( endocrine effect), the best examples in this category being IL-1 and TNF-alpha, which produce the acute-phase response during inflammation. Cytokines mediate their effects by binding to specific high-affinity receptors on their target cells. For example, IL-2 activates T cells by binding to high-affinity IL-2 receptors (IL-2R). Blockade of the IL-2R by specific antireceptor monoclonal antibodies prevents T-cell activation. This observation provides a means by which T-cell activation, when undesirable (as in transplant rejection), may be controlled. The knowledge gained about cytokines has practical therapeutic ramifications. First, by regulating cytokine production or action, it may be possible to control the harmful effects of inflammation or tissue-damaging immune reactions. Second, recombinant cytokines can be administered to enhance immunity against cancer or microbial infections (immunotherapy). Both of these avenues are currently being pursued on an experimental basis in humans.
193
Figure 7-6 Schematic representation of the HLA complex and its subregions. The relative distances between various genes and
regions are not drawn to scale.
Structure and Function of Histocompatibility Antigens Although originally identified as antigens that evoke rejection of transplanted organs, histocompatibility molecules are now known to be extremely important for the induction and regulation of the immune response and for certain nonimmunologic functions. The principal physiologic function of the cell surface histocompatibility molecules is to bind
peptide fragments of foreign proteins for presentation to appropriate antigen-specific T cells. Recall that T cells (in contrast to B cells) can recognize only membrane-bound antigens, and hence histocompatibility antigens are critical to the induction of T-cell immunity. The histocompatibility molecules and the corresponding genes are complex in structure and are still incompletely understood. Here we summarize only the salient features of human histocompatibility antigens, primarily to facilitate understanding of their role in rejection of organ transplants and in disease susceptibility. Several genes code for histocompatibility antigens, but those that code for the most important transplantation antigens are clustered on a small segment of chromosome 6. This cluster constitutes the human MHC and is also known as the human leukocyte antigen (HLA) complex (Fig. 7-6) because MHC-encoded antigens were initially detected on the white cells. The HLA system is highly polymorphic. This, as we see subsequently, constitutes a formidable barrier in organ transplantation. On the basis of their chemical structure, tissue distribution, and function, the MHC gene products are classified into three categories. Class I and class II genes encode cell surface glycoproteins, and class III genes encode components of the complement system (Chapter 3) . The last mentioned, as is well known, are soluble proteins; they are not discussed in this section. Class I antigens are expressed on all nucleated cells and platelets. They are encoded by three closely linked loci, designated HLA-A, HLA-B, and HLA-C (Fig. 7-6) . Each of these molecules is a heterodimer, consisting of a polymorphic alpha, or heavy, chain (44-kD) linked noncovalently to a smaller (12-kD) nonpolymorphic peptide called beta2 -microglobulin. The latter is not encoded within the MHC. The extracellular region of the heavy chain is divided into three domains: alpha1 , alpha2 , and alpha3 (Fig. 7-7) . Crystal structure of class I molecules has revealed that the alpha1 and alpha2 domains contain a cleft, or groove, where peptides bind to the MHC molecule. Biochemical analyses of several different class I alleles have revealed that almost all polymorphic residues line the sides or the base of the peptide-binding groove. As a result, different class I alleles bind to different peptide fragments. In general, class I MHC molecules bind to those peptides that are derived from proteins, such as viral antigens, synthesized within the cell. The
Figure 7-7 Schematic diagram of HLA class I molecule.
194
generation of peptide fragments within the cells, and their association with MHC molecules and transport to the cell surface, is a complex process. [6] Involved in this sequence are proteolytic complexes (proteosomes), which digest antigenic proteins into short peptides, and transport proteins, which ferry peptide fragments from the cytoplasm to the endoplasmic reticulum. Within the endoplasmic reticulum, peptides bind to the antigen-binding cleft of newly synthesized class I heavy chains, which then associate
with beta2 -microglobulin to form a stable trimer that is transported to the cell surface for presentation to the CD8+ cytotoxic T lymphocytes (Fig. 7-8) . In this interaction, the TCR recognizes the MHC-peptide complex, and the CD8 molecule, acting as a coreceptor, binds to the nonpolymorphic, alpha3 , domain of the class I heavy chain. CD8+ cytotoxic T cells can recognize viral (or other) peptides only if presented as a complex with self class I antigens. In the eyes of T cells, self MHC molecules are those that they "grew up with" during maturation within the thymus. Because one of the important functions of CD8+ T cells is to eliminate virus-infected T cells, it makes good sense to have widespread expression of class I HLA antigens. Class II antigens are coded for in a region called HLA-D, which has three subregions: HLA-DP, HLA-DQ, and HLA-DR. Each class II molecule is a heterodimer consisting of a noncovalently associated alpha chain and beta chain. Both chains are polymorphic, and each of three HLA-D
Figure 7-8 Schematic illustration of antigen recognition by CD8+ T cells. Note that the T-cell receptor (TCR heterodimer) recognizes
a complex formed by the peptide fragment of the antigen and MHC class I molecule. The CD8 molecule binds to the nonpolymorphic portion of the class I molecule and thus acts as an accessory structure during antigen recognition.
subregions encodes one or more alpha chains and beta chains (see Fig. 7-6) . The extracellular portions of the alpha and beta chains have two domains: alpha1 , alpha2 and beta1 , beta2 . Crystal structure of class II molecules has revealed that, similar to class I molecules, they have an antigen-binding cleft facing outward. [7] In contrast to class I molecules, however, the antigen-binding groove is formed by an interaction of the alpha1 and beta1 domains of both the chains, and it is in this portion that most class II alleles differ. Thus, it seems that, as with class I molecules, polymorphism of class II molecules is associated with differential binding of antigenic peptides. The nature of peptides that bind to class II molecules is different from that of peptides that bind to class I molecules. In general, class II molecules present exogenous antigens (e.g., extracellular microbes, soluble proteins) that are first internalized and processed in the endosomes or lysosomes. Peptides resulting from proteolytic cleavage then associate with class II heterodimers assembled in the endoplasmic reticulum. Finally, the peptide-MHC complex is transported to the cell surface, [8] where it can be recognized by CD4+ helper T cells. In this interaction, the CD4 molecule acts as the coreceptor. Because CD4+ T cells can recognize antigens only in the context of self class II molecules, they are referred to as class II restricted. In contrast to class I antigens, the tissue distribution of MHC class II molecules is largely restricted to antigen-presenting cells (macrophages, dendritic cells, and B cells). Expression of class II molecules can be induced on several other cell types, however, including endothelial cells and fibroblasts, by the action of IFN-gamma. The role of class II antigens in the induction of helper T cells has an important bearing on the genetic regulation of the immune response. How class II molecules regulate immune responses is not entirely clear, but there are two plausible mechanisms:
One possibility rests on the fact that different antigenic peptides bind to different class II gene products. It follows that an individual mounts a vigorous immune response against an antigen only if he or she inherits the gene(s) for those class II molecule(s) that can bind the nominal antigen and present it to helper T cells. The consequences of inheriting a given class II gene depend on the nature of the antigen bound by the class II molecule. For example, if the antigen was a peptide from ragweed pollen, the individual would be genetically prone to type I hypersensitivity disease. An inherited capacity to bind a bacterial peptide may provide resistance to disease by evoking an antibody response or perhaps induce an autoimmune response if the antibody cross-reacts with normal tissues (see later). The other possibility is related to the role of MHC molecules in shaping the T-cell repertoire. During intrathymic differentiation, only T cells that can recognize self MHC molecules are selected for export to the periphery (see later discussion of immunologic tolerance). Thus, the type of MHC molecules that T cells encounter during their differentiation influences the functional capacity of mature peripheral T cells.
195
TABLE 7-1 -- ASSOCIATION OF HLA WITH DISEASE Disease HLA Allele Relative Risk Ankylosing spondylitis
B27
87.4
Postgonococcal arthritis
B27
14.0
Acute anterior uveitis
B27
14.6
Rheumatoid arthritis
DR4
5.8
Chronic active hepatitis
DR3
13.9
Primary Sjogren syndrome
DR3
9.7
DR3
5.0
DR4
6.8
DR3/DR4
14.3
BW47
15.0
Insulin-dependent diabetes 21-Hydroxylase deficiency
HLA AND DISEASE ASSOCIATION
A variety of diseases have been found to be associated with certain HLA types (Table 7-1) . The best known is the association between ankylosing spondylitis and HLA-B27; individuals who possess this antigen have a 90-fold greater chance (relative risk) of developing the disease than those who are negative for HLA-B27. The diseases that show association with HLA can be broadly grouped into the following categories: (1)
inflammatory diseases, including ankylosing spondylitis and several postinfectious arthropathies, all associated with HLA-B27; (2) inherited errors of metabolism, such as 21-hydroxylase deficiency (HLA-BW47); and (3) autoimmune diseases, including autoimmune endocrinopathies, associated with alleles at the DR locus. The mechanisms underlying these associations are not fully understood. In some cases (e.g., 21-hydroxylase deficiency), the linkage results from the fact that the relevant disease-associated gene, in this case the gene for 21-hydroxylase, maps within the HLA complex. In the case of immunologically mediated disorders, it seems likely that the role of HLA class II molecules in regulating the immunoresponsiveness may be relevant. One may speculate therefore that an association between certain autoimmune diseases and HLA-DR antigens may result from an exaggerated or inappropriate immune response to autoantigens.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 8 - Neoplasia DEFINITIONS NOMENCLATURE CHARACTERISTICS OF BENIGN AND MALIGNANT NEOPLASMS EPIDEMIOLOGY MOLECULAR BASIS OF CANCER BIOLOGY OF TUMOR GROWTH CARCINOGENIC AGENTS AND THEIR CELLULAR INTERACTIONS HOST DEFENSE AGAINST TUMORS--TUMOR IMMUNITY CLINICAL FEATURES OF TUMORS REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
260
Chapter 8 - Neoplasia In the United States each year, well over 1 million individuals learn for the first time that they have some type of cancer. Many of these tumors can be cured. Nonetheless, according to American Cancer Society estimates, cancer caused approximately 564,000 deaths in 1998, accounting for about 23% of all deaths. [1] Only cardiovascular diseases cause more deaths. Some good news, however, has also emerged from the most recent statistics: For the first time in the last half century, cancer mortality has declined in each of the years from 1991 to 1995. Thus, there is progress, but the problem is still overwhelming. The discussion that follows deals with both benign tumors and cancers;
261
the latter receive more attention. The focus is on the basic morphologic and behavioral characteristics and present understanding of the molecular basis of carcinogenesis. We also discuss the interactions of the tumor with the host and the host response to tumor. Although the discussion of therapy is beyond the scope of this chapter, with many forms of malignancy, notably the leukemias and lymphomas, there are now dramatic improvements in 5-year survival rates. A greater proportion of cancers are being cured or arrested today than ever before.
DEFINITIONS Neoplasia literally means "new growth," and the new growth is a neoplasm. The term tumor was originally applied to the swelling caused by inflammation. Neoplasms also may induce swellings, but by long precedent, the non-neoplastic usage of tumor has passed into limbo; thus, the term is now equated with neoplasm. Oncology (Greek oncos=tumor) is the study of tumors or neoplasms. Cancer is the common term for all malignant tumors. Although the ancient origins of this term are somewhat uncertain, it probably derives from the Latin for crab, cancer--presumably because a cancer "adheres to any part that it seizes upon in an obstinate manner like the crab." Although all physicians know what they mean when they use the term neoplasm, it has been surprisingly difficult to develop an accurate definition. The eminent British oncologist Willis [2] has come closest: "A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the same excessive manner after cessation of the stimuli which evoked the change." To this characterization we might add that the abnormal mass is purposeless,
preys on the host, and is virtually autonomous. It preys on the host insofar as the growth of the neoplastic tissue competes with normal cells and tissues for energy supplies and nutritional substrate. Inasmuch as these masses may flourish in a patient who is wasting away, they are to a degree autonomous. Later it becomes evident that such autonomy is not complete. All neoplasms ultimately depend on the host for their nutrition and vascular supply; many forms of neoplasia require endocrine support.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 9 - Infectious Diseases GENERAL PRINCIPLES OF MICROBIAL PATHOGENESIS RESPIRATORY INFECTIONS GASTROINTESTINAL INFECTIONS PARASITIC INTESTINAL INFECTIONS SEXUALLY TRANSMITTED DISEASES GRAM-POSITIVE PYOGENIC BACTERIAL INFECTIONS INFECTIONS OF CHILDHOOD AND ADOLESCENCE OPPORTUNISTIC AND AIDS-ASSOCIATED INFECTIONS TROPICAL, ZOONOTIC, AND VECTOR-BORNE INFECTIONS REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
329
Chapter 9 - Infectious Diseases John Samuelson
330
GENERAL PRINCIPLES OF MICROBIAL PATHOGENESIS Despite improved living conditions, widespread vaccination, and availability of effective antibiotics, infectious diseases continue to take a heavy toll in the United States among persons with acquired immunodeficiency syndrome (AIDS), debilitated with chronic disease, or treated with immunosuppressive drugs. In developing countries, unsanitary living conditions and malnutrition contribute to a massive burden of infectious disease that kills more than 10 million persons each year. [1] Most of these deaths are among children, who suffer respiratory and diarrheal infections caused by viruses and bacteria. History Table 9-1 presents in chronologic sequence 12 major breakthroughs in our understanding of infectious diseases and their causes, selected with the intent of providing a historical perspective for the concepts of microbial pathogenesis to be discussed here. Jenner's discovery in 1796 that milkmaids working with cows were resistant to smallpox paved the way to our understanding of cross-reactive immunity. Vaccinia virus (cowpox) induces immune reactions that neutralize subsequent infection with the much more virulent variola virus of smallpox. Because of a heroic vaccination campaign by the World Health Organization (WHO) and others, smallpox is the first and only disease of humans that has been eradicated from the earth. Now the WHO has a worldwide vaccination campaign to eliminate poliovirus, first cultured by Enders in 1949. Oliver Wendell Holmes, who named anesthesia (and was father of the renowned Supreme Court justice), noted that puerperal infections of women after childbirth ("the black death of childbirth") were associated with particular physicians who attended the delivery. This first example of iatrogenic infections, now known to be caused by Staphylococcus, led to recommendations that physicians wash their hands before and after delivery and persuaded most middle-class women to have their children at home.
Pasteur demonstrated that infectious illnesses were caused by particular bacteria, many of which could be eliminated by moderate heating (pasteurization) of milk and other liquids. Koch's postulates established criteria for linking a specific microorganism to a specific disease: (1) the organism is regularly found in the lesions of the disease, (2) the organism can be isolated as single colonies on solid medium, (3) inoculation of this culture causes lesions in an experimental animal, and (4) the organism can be recovered from lesions in the animals. Lancefield's system of classifying bacteria by their surface antigens greatly facilitated the linkage of particular bacteria to specific illnesses. In the past decade, the revolution in molecular biology has led to a molecular form of Koch's postulates, which links a particular trait of an organism to a particular disease process [2] : (1) the phenotype or trait should be associated with virulent strains of the organism and not with avirulent strains; (2) specific inactivation of the gene associated with TABLE 9-1 -- TWELVE MAJOR DISCOVERIES IN MICROBIAL PATHOGENESIS Year Investigator Discovery 1796 Jenner
Vaccination against smallpox
1843 Holmes
Discovery of the iatrogenic nature of "black death of childbirth"
1865 Pasteur
Proof of germ theory and the beginning of modern biology
1882 Koch
Criteria for proof of causality in infectious disease
1884 Mechnikov
Description of phagocytosis by macrophages
1902 Ross
Identification of mosquito vector for Plasmodium falciparum malaria
1906 Ehrlich
Description of chemotherapeutic agents
1908 Ellerman and Bang
Viral oncogenesis in chickens
1933 Lancefield
Serotyping of organisms and association of bacterial clones with disease
1945 Avery
Identification of DNA as genetic material and the start of the molecular biology revolution
1949 Enders
Culture of viruses and production of the poliovirus vaccine
1983 Montagnier and Gallo
Identification of HIV as cause of AIDS
virulence--for example, by replacing the normal (called the wild type) gene with a changed or mutant gene-- should lead to a measurable decrease in pathogenicity; (3) replacement of the mutant gene with the wild type gene should restore full pathogenicity to the organism.
Mechnikov's discovery (1884) of the process of phagocytosis, whereby leukocytes ingest foreign particles, initiated the study of white cells and cell-mediated immunity in the protection against infection. [3] Ross's demonstration in Egypt of the mosquito as vector to malaria led to a series of public health interventions against mosquitoes including draining of swamps, widespread use of insecticides, and insecticide-impregnated bed nets, presently advocated by the WHO. Ehrlich described antimicrobial "silver bullets," including emetine against amebae, long before the discovery of penicillin by Fleming in 1928 and the development of antibiotics during and after World War II. Ellerman and Bang identified viral causes of cancer, which include hepatitis B virus (HBV) and liver cancer, Epstein-Barr virus (EBV) and lymphoma, human T-cell lymphotropic virus type I (HTLV-I) and leukemia, and human herpesvirus 8 (HHV-8) and Kaposi sarcoma. These are described in Chapter 8 . Avery's demonstration of DNA as the genetic material determining the capsule of virulent pneumococci began the molecular biologic revolution. The identification of human immunodeficiency virus (HIV) as the cause of AIDS, the devastating pandemic of the late 20th century, has led to effective methods of screening donor blood, numerous new concepts in viral pathogenesis, and dramatic advances in antiviral drugs. The entire genome has recently been sequenced from numerous microbes including Escherichia coli, Haemophilus influenzae, Helicobacter pylori, and Saccharomyces cerevisiae (bakers' yeast). [4] [5] These genome
331
sequences reveal all possible proteins that each organism may make, demonstrate how some genes are organized into expression groups or operons, and suggest possible targets for new antimicrobial drugs. By themselves, however, these gene sequences cannot reveal mechanisms of pathogenesis, which must be identified by experiment, nor do they identify surface proteins that might be used as vaccine candidates. New and Emerging Infectious Diseases Although infectious diseases such as leprosy have been known since biblical times and parasitic schistosomes have been demonstrated in Egyptian mummies, a surprising number of new infectious agents are described each year [6] (Table 9-2) . The causes of some infections with significant morbidity and mortality (e.g., Helicobacter gastritis, hepatitis B and hepatitis C, rotavirus diarrhea, and legionnaires pneumonia) were previously unrecognized, because the infectious agent was difficult to culture. [7] Some new infectious agents (e.g., Ebola virus, Hantavirus, and "flesh-eating bacteria" that cause streptococcal toxic shock syndrome) are newsworthy for their lethality, even though they are rare or infect persons in faraway places. [8] Other infectious agents may be genuinely new to humans (e.g., HIV that causes AIDS and Borrelia burgdorferi that causes Lyme disease) or may be secondary to severe immunosuppression caused by AIDS (e.g., cytomegalovirus [CMV], HHV-8, Mycobacterium avium-intracellulare, Pneumocystis carinii, and Cryptosporidium parvum).
TABLE 9-2 -- SOME RECENTLY RECOGNIZED INFECTIOUS AGENTS 1973 Rotavirus Infantile diarrhea 1975 Cryptosporidium parvum
Acute and chronic diarrhea
1977 Ebola virus
Epidemic hemorrhagic fever
Hantaan virus
Hemorrhagic fever with renal disease
Legionella pneumophila
Legionnaires pneumonia
Campylobacter jejuni
Enteritis
1980 HTLV-I
T-cell lymphoma or leukemia
1981 Staphylococcus aureus
Toxic shock syndrome
1982 HTLV-II
Hairy cell leukemia
Escherichia coli O157:H7 Hemorrhagic colitis and hemolytic-uremic syndrome Borrelia burgdorferi 1983 HIV Helicobacter pylori
Lyme disease AIDS Chronic gastritis
1985 Enterocytozoon bieneusi Chronic diarrhea 1988 HHV-6 Hepatitis E 1989 Hepatitis C Ehrlichia chaffeensis 1992 Vibrio cholerae O139 Bartonella henselae
Roseola subitum Enterically transmitted hepatitis Non-A, non-B hepatitis Human ehrlichiosis New epidemic cholera strain Cat-scratch disease
1993 Encephalitozoon cuniculi Opportunistic infections 1995 HHV-8
Kaposi sarcoma in AIDS
Adapted from Lederberg J: Infectious disease as an evolutionary paradigm. Emerg Infect Dis 3:417, 1997.
Figure 9-1 Asterisk-shaped inclusion body of Ehrlichia, cause of human granulocytic ehrlichiosis, within a neutrophil. (Courtesy of Dr. Sam Telford, Harvard School of Public Health.)
The patterns of disease caused by the new infectious agents may vary dramatically depending on geography: AIDS has been predominantly (but not exclusively) a disease of homosexuals and drug abusers in the United States and Western countries, while AIDS in Africa is predominantly a heterosexual disease that is much more frequent in areas where men remain uncircumcised. Changes in the environment occasionally drive
rates of infectious diseases: reforestation of the eastern part of the United States has led to massive increases in deer and mice, which carry the ticks that transmit Lyme disease, babesiosis, and ehrlichiosis (Fig. 9-1) . Failure of DDT to control mosquitoes that transmit malaria, in association with the development of drug-resistant parasites, has dramatically increased the morbidity and mortality of Plasmodium falciparum in Asia, Africa, and Latin America. Similarly, the development of new drug-resistant Mycobacterium tuberculosis, Neisseria gonorrhoeae, Staphylococcus aureus, and Enterococcus faecium has changed the treatment of these infections. In discussing the mechanisms of infectious disease, two separate but interrelated aspects must be considered: (1) the specific properties of the organisms causing the infection and (2) the host response to the infectious agents. This chapter begins with a review of the categories of infectious agents and a discussion of the mechanisms by which these organisms cause disease. These general principles are then illustrated with a selection of major human infectious diseases, organized by the organ system involved or the groups of patients frequently infected and including descriptions of the lesions caused by each organism. [9] [10] Detailed discussions of many other infectious diseases are presented elsewhere in this book (e.g., viral hepatitis in Chapter 19 ; pneumococcal pneumonia in Chapter 16 ; and HIV infection and AIDS in Chapter 7) . Categories of Infectious Agents Infectious agents that can enter the human host (endoparasites) belong to a wide range of classes and vary in
332
TABLE 9-3 -- CLASSES OF HUMAN ENDOPARASITES AND THEIR HABITATS Taxonomic Class Size Site of Sample Species and Its Disease Propagation Viruses
20-30 nm
Obligate intracellular
Poliovirus
Poliomyelitis
Chlamydiae
200-100 nm
Obligate intracellular
Chlamydia trachomatis
Trachoma
Rickettsiae
300-1200 nm
Obligate intracellular
Rickettsia prowazekii
Typhus fever
Mycoplasmas
125-350 nm
Extracellular
Mycoplasma pneumoniae
Atypical pneumonia
Bacteria, spirochetes, mycobacteria
0.8-15 mum
Cutaneous
Staphylococcus epidermidis
Wound infection
Mucosal
Vibrio cholerae
Cholera
Fungi imperfecti
Protozoa
Helminths
2-200 mum
Extracellular
Streptococcus pneumoniae
Pneumonia
Facultative intracellular
Mycobacterium tuberculosis
Tuberculosis
Cutaneous
Trichophyton sp.
Tinea pedis (athlete's foot)
Mucosal
Candida albicans
Thrush
Extracellular
Sporothrix schenckii
Sporotrichosis
Facultative intracellular
Histoplasma capsulatum
Histoplasmosis
Giardia lamblia
Giardiasis
Extracellular
Trypanosoma gambiense
Sleeping sickness
Facultative intracellular
Trypanosoma cruzi
Chagas disease
Obligate intracellular
Leishmania donovani
Kala-azar
Mucosal
Enterobius vermicularis
Oxyuriasis
Extracellular
Wuchereria bancrofti
Filariasis
Intracellular
Trichinella spiralis Trichinosis
1-50 mum Mucosal
3 mm-10 m
size from the nucleic acid-free prion to 2-nm poliovirus to 10-m tapeworms (Table 9-3) . In addition, several classes of arthropods are ectoparasites, that is, cause damage only through the skin. PRIONS
Prions, which are apparently composed only of a modified host protein, cause transmissible spongiform encephalopathies including kuru (associated with human cannibalism), Creutzfeldt-Jakob disease (associated with corneal transplants), [11] bovine spongiform encephalopathy (better known as mad cow disease), and atypical Creutzfeldt-Jakob disease transmitted to humans from bovine spongiform encephalopathy. They are discussed in detail in Chapter 30 . VIRUSES
All viruses depend on host cell metabolism for their replication, that is, are obligate intracellular parasites (Table 9-4) . They are classified by the nucleic acid content of their core (DNA or RNA) and by the shape of their protein coat or capsid, which can be
spherical if capsid proteins form an icosahedron or cylindrical if they form a helix. Many of the more than 400 viral species known to inhabit humans do not cause any disease, but some are frequent causes of acute illness (e.g., colds, influenza). Others are capable of lifelong latency and of long-term reactivation (herpesviruses) or may give rise to chronic disease (e.g., HBV). Together, viral pathogens account for a major share of all human infections. Different viral species can give rise to the same clinical picture (e.g., upper respiratory infection; see section on viral respiratory infections); conversely, a single virus can cause different lesions depending on host age or immune status (e.g., CMV). Further, the same virus may definitely cause one disease (e.g., coxsackievirus B and inflammatory cardiac disease) and be implicated in another (type I diabetes). [12] BACTERIOPHAGES, PLASMIDS, TRANSPOSONS
These are mobile genetic elements that encode bacterial virulence factors (e.g., adhesins, toxins, or enzymes that confer antibiotic resistance). They can infect bacteria and incorporate themselves into their genome (e.g., toxin genes of Vibrio cholerae and Shigella flexneri), thus converting an otherwise harmless bacterium into a virulent one or an antibiotic-sensitive organism into a resistant one. Exchange of these elements between bacterial strains and species therefore endows the recipients with a survival advantage or with the capacity to cause disease, or both. BACTERIA
Bacterial cells are prokaryotes that lack nuclei and endoplasmic reticulum. Their cell walls are relatively rigid, composed either of two phospholipid bilayers with a peptidoglycan layer sandwiched in between (gram-negative species) or of a single bilayer covered by peptidoglycan (gram-positive bacteria) (Table 9-5 and Fig. 9-2) . Bacteria synthesize their own DNA, RNA, and proteins but
333
TABLE 9-4 -- HUMAN VIRAL DISEASES AND THEIR PATHOGENS Viral Pathogen
Virus Family
Genomic Type
Disease Expression
Respiratory Adenovirus
Adenoviridae
DS DNA
Upper and lower respiratory tract infections, conjunctivitis, diarrhea
Echovirus
Picornaviridae
SS RNA *
Upper respiratory tract infection, pharyngitis, rash
Rhinovirus
Picornaviridae
SS RNA- * Upper respiratory tract infection
Coxsackievirus
Picornaviridae
SS RNA *
Coronavirus
Coronaviridae
SS RNA- * Upper respiratory tract infection
Pleurodynia, herpangina, hand-foot-and-mouth disease
Influenza viruses A, B Orthomyxoviridae SS RNA
Influenza
Parainfluenza virus 1-4
Paramyxoviridae
SS RNA
Upper and lower respiratory tract infections, croup
Respiratory syncytial virus
Paramyxoviridae
SS RNA
Bronchiolitis, pneumonia
Mumps virus
Paramyxoviridae
SS RNA
Mumps, pancreatitis, orchitis
Rotavirus
Reoviridae
DS RNA
Childhood diarrhea
Norwalk agent
Caliciviridae
SS RNA
Digestive
Gastroenteritis *
Hepatitis A virus
Picornaviridae
SS RNA
Acute viral hepatitis
Hepatitis B virus
Hepadnaviridae
DS DNA
Acute or chronic hepatitis
Hepatitis D virus
Viroid-like
SS RNA
With HBV, acute or chronic hepatitis
Hepatitis C virus
Flaviviridae
SS RNA
Acute or chronic hepatitis
Hepatitis E virus
Norwalk-like
SS RNA
Enterically transmitted hepatitis
Measles virus
Paramyxoviridae
SS RNA
Measles (rubeola)
Rubella virus
Togaviridae
SS RNA- * German measles (rubella)
Parvovirus
Parvoviridae
SS DNA
Erythema infectiosum, aplastic anemia
Vaccinia virus
Poxviridae
DS DNA
Smallpox vaccine
Varicella-zoster virus
Herpesviridae
DS DNA
Chickenpox, shingles
Herpes simplex virus 1
Herpesviridae
DS DNA
"Cold sore"
Herpes simplex virus 2
Herpesviridae
DS DNA
Genital herpes
Systemic With Skin Eruptions
Systemic With Hematopoietic Disorders Cytomegalovirus
Herpesviridae
DS DNA
Epstein-Barr virus
Herpesviridae
DS DNA
Cytomegalic inclusion disease Infectious mononucleosis §
HTLV-I
Retroviridae
SS RNA
HTLV-II
Retroviridae
SS RNA §
Retroviridae
SS RNA
§
Togaviridae
SS RNA *
Yellow fever virus
Togaviridae
SS RNA
*
Colorado tick fever virus
Reoviridae (Orbivirus)
SS RNA
Colorado tick fever
Regional hemorrhagic Arenaviridae fever viruses
SS RNA
Bolivian, Argentinian, Lassa fever
Bunyaviridae
SS RNA
Crimean-Congo, Hantaan, sandfly fever
Filoviridae?
SS RNA
Ebola, Marburg disease
Hantavirus
SS RNA
Korean, U.S. pneumonia
Papillomavirus
Papovaviridae
DS DNA
Condyloma; cervical carcinoma
Molluscum virus
Poxviridae
DS DNA
Molluscum contagiosum
Poliovirus
Picornaviridae
SS RNA *
Poliomyelitis
Rabiesvirus
Rhabdoviridae
SS RNA
Rabies
JC virus
Papovaviridae
DS DNA
Progressive multifocal leukoencephalopathy (opportunistic)
SS RNA *
Eastern, Western, Venezuelan, St. Louis, California group
HIV-1 and HIV-2
Adult T-cell leukemia; tropical spastic paraparesis Role still uncertain AIDS
Arboviral and Hemorrhagic Fevers Dengue virus 1-4
Dengue, hemorrhagic fever Yellow fever
Warty Growths
Central Nervous System
Arboviral encephalitis Togaviridae viruses
Bunyaviridae
SS RNA
*Positive-sense genome (nucleotide sequences directly translated). Negative-sense genome (complementary to positive-sense strand) Segmented genome §DNA step required in retroviral replication.
334
TABLE 9-5 -- BACTERIAL, SPIROCHETAL, AND MYCOBACTERIAL DISEASES Clinical or Species Frequent Disease Presentations Microbiologic Category Infections by pyogenic Staphylococcus aureus, S. Abscess, cellulitis, pneumonia, cocci epidermidis septicemia
Gram-negative infections, common
Streptococcus pyogenes, beta -hemolytic
Upper respiratory tract infection, erysipelas, scarlet fever, septicemia
Streptococcus pneumoniae (pneumococcus)
Lobar pneumonia, meningitis
Neisseria meningitidis (meningococcus)
Cerebrospinal meningitis
Neisseria gonorrhoeae (gonococcus)
Gonorrhea
*
Escherichia coli
*
Klebsiella pneumoniae
Enterobacter (Aerobacter) aerogenes
*
Proteus spp. (P. mirabilis, P. morgagni) *
*
Serratia marcescens
Urinary tract infection, wound infection, abscess, pneumonia, septicemia, endotoxemia, endocarditis
Pseudomonas spp. (P. aeruginosa) *
Bacteroides sp. (B. fragilis) Anaerobic infection
Gram-negative infections, rare
Legionella spp. (L. pneumophila)
Legionnaires disease
Klebsiella rhinoscleromatis, K. ozaenae
Rhinoscleroma, ozena
Haemophilus ducreyi
Chancroid (soft chancre)
Calymmatobacterium donovani
Granuloma inguinale
Bartonella bacilliformis
Carrion disease (Oroya fever)
Contagious childhood Haemophilus influenzae bacterial diseases
Enteropathic infections
Meningitis, upper and lower respiratory tract infections
Bordetella pertussis
Whooping cough
Corynebacterium diphtheriae
Diphtheria
Enteropathogenic E. coli
Invasive or noninvasive gastroenterocolitis, some with septicemia
Shigella sp. Vibrio cholerae Campylobacter fetus, C. jejuni Yersinia enterocolitica Salmonella spp. (1000 strains) Clostridial infections
Salmonella typhi
Typhoid fever
Clostridium tetani
Tetanus (lockjaw)
Clostridium botulinum
Botulism (paralytic food poisoning)
Clostridium perfringens, C. Gas gangrene, necrotizing septicum cellulitis *
Zoonotic bacterial infections
Clostridium difficile
Bacillus anthracis *
Listeria monocytogenes
Pseudomembranous colitis Anthrax (malignant pustule) Listeria meningitis, listeriosis
Yersinia pestis
Bubonic plague
Francisella tularensis
Tularemia
Human treponemal infections
Mycobacterial infections
Brucella melitensis, B. suis, B. abortus
Brucellosis (undulant fever)
Pseudomonas mallei, P. pseudomallei
Glanders, melioidosis
Leptospira spp. (many groups)
Leptospirosis, Weil disease
Borrelia recurrentis
Relapsing fever
Borrelia burgdorferi
Lyme borreliosis
Bartonella henselae
Cat-scratch disease; bacillary angiomatosis
Spirillum minus, Streptobacillus moniliformis
Rat-bite fever
Treponema pallidum
Venereal, endemic syphilis (bejel)
Treponema pertenue
Yaws (frambesia)
Treponema carateum (T. herrejoni)
Pinta (carate, mal del pinto)
*
Mycobacterium tuberculosis, M. bovis(Koch bacillus)
Tuberculosis
M. leprae (Hansen bacillus)
Leprosy
M. kansasii, M. avium, M. Atypical mycobacterial infections intracellulare
*
M. ulcerans Actinomycetaceae
*
Buruli ulcer
Nocardia asteroides
Actinomyces israelii
Nocardiosis Actinomycosis
*Important opportunistic infections
335
Figure 9-2 Actinomyces, a filamentous bacterium, within an airway (periodic acid-Schiff [PAS] stain).
depend on the host for favorable growth conditions. Some thrive mainly on the body's
surface layers; normal persons carry 10 bacteria on the skin, including Staphylococcus epidermidis and Propionibacterium acnes, the agent responsible for adolescent pimples. Normally, 10 bacteria reside inside the gastrointestinal tract, 99.9% of which are anaerobic, including Bacteroides species. Many bacterial pathogens invade host tissue and are capable of extracellular division (e.g., pneumococcus) or of both extracellular and intracellular division (e.g., Mycobacterium tuberculosis). Next to viruses, bacteria are the most frequent and diverse class of human pathogens and include many of the major pathogens discussed in this chapter and elsewhere throughout the text. CHLAMYDIAE, RICKETTSIAE, MYCOPLASMAS
These infectious agents are grouped together because they are similar to bacteria in that they divide by binary fission and are susceptible to antibiotics but lack certain structures (e.g., mycoplasmas lack a cell wall) or metabolic capabilities (e.g., chlamydiae lack adenosine triphosphate [ATP] synthesis). Chlamydiae, which are frequent causes of genitourinary infections, conjunctivitis, and respiratory infections of newborn infants, are discussed with the sexually transmitted diseases. Most rickettsiae are transmitted by insect vectors, including lice (epidemic typhus), ticks (Rocky Mountain spotted fever [RMSF], Q fever, and ehrlichiosis), and mites (scrub typhus). [13] Rickettsiae are obligate intracellular agents that replicate in the cytoplasm of endothelial cells (see section on vector-borne infections). By injuring the endothelial cells, rickettsiae cause a hemorrhagic vasculitis often visible as a rash but may also cause a transient pneumonia or hepatitis (Q fever) or injure the central nervous system and cause death (RMSF and epidemic typhus). Mycoplasmas and the closely related genus Ureaplasma are the tiniest free-living organisms known (125 to 300 nm). Mycoplasma pneumoniae spreads from person to person by aerosols, binds to the surface of epithelial cells in the airways by an adhesin called P1, and causes an atypical pneumonia characterized by peribronchiolar infiltrates of lymphocytes and plasma cells (Chapter 16) . Ureaplasmas are transmitted venereally and may cause nongonococcal urethritis. FUNGI
Fungi possess thick, ergosterol-containing cell walls and grow as perfect, sexually reproducing forms in vitro and as imperfect forms in vivo, which include budding yeast cells and slender tubes (hyphae) (Figs. 9-3 and 9-4) . Some produce spores, which are resistant to extreme environmental conditions, whereas hyphae may produce fruiting bodies called conidia. Some fungal species, for example, those of the Tinea group causing "athlete's foot," are confined to the superficial layers of the human skin; other "dermatophytes" preferentially damage the hair shafts or nails. Certain fungal species invade the subcutaneous tissue, causing abscesses or granulomas, as happens in sporotrichosis and in tropical mycoses. Deep fungal infections can spread systemically, destroying vital organs in immunocompromised hosts, whereas these fungal lesions heal spontaneously or remain latent in otherwise normal hosts. Some deep fungal species are limited to a particular geographic region (e.g., Coccidioides, Histoplasma, and Blastomyces). Opportunistic fungi (Candida, Aspergillus, Mucor), by contrast, are
ubiquitous contaminants colonizing the normal human skin or gut without causing illness. Only in immunosuppressed individuals do opportunistic fungi give rise to life-threatening infections. In addition, AIDS patients, late in their course, are frequent victims of the opportunistic fungus-like organism Pneumocystis carinii. PROTOZOA
Parasitic protozoa are single-celled organisms endowed with motility, pliable plasma membranes, and complex cytoplasmic organelles (Table 9-6) . The flagellate Trichomonas
Figure 9-3 Skin with massive infiltrate of Rhinosporidium, a tropical fungus.
336
Figure 9-4 Characteristic tissue forms of fungi.
vaginalis is transmitted sexually from person to person. The intestinal protozoa (e.g., Entamoeba histolytica and Giardia lamblia) are spread by the fecal-oral route. Blood-borne protozoa (e.g., Plasmodium species, Trypanosoma species, and Leishmania species) are transmitted by blood-sucking insects, in which they undergo a complex succession of life stages before being passed to new human hosts (Fig. 9-5) . Toxoplasma gondii is acquired either by contact with oocyst-shedding kittens or by eating cyst-ridden, undercooked meat. HELMINTHS
Parasitic worms are highly differentiated multicellular organisms. Their life cycles are complex; most alternate between sexual reproduction in the definitive host and asexual multiplication in an intermediary host or vector. Thus, depending on parasite species, humans may harbor either adult worms (e.g., Ascaris) or immature stages (e.g., Toxocara canis) or asexual larval forms (e.g., Echinococcus). Adult worms, once resident in humans, do not multiply in
337
TABLE 9-6 -- PROTOZOA PATHOGENIC FOR HUMANS Species Order Form, Size Disease
Luminal or Epithelial Entamoeba histolytica
Amebae
Trophozoite 15-50 mum
Amebic dysentery; liver abscess
Balantidium coli
Ciliates
Trophozoite 50-100 mum
Colitis
Naegleria fowleri
Ameboflagellates Trophozoite 10-20 mum
Meningoencephalitis
Acanthamoeba sp.
Ameboflagellates Trophozoite 15-30 mum
Meningoencephalitis or ophthalmitis
Giardia lamblia
Mastigophora
Trophozoite 11-18 mum
Diarrheal disease, malabsorption
Isospora belli
Coccidia
Oocyst 10-20 mum
Chronic enterocolitis or malabsorption or both
Cryptosporidium sp. Coccidia
Oocyst 5-6 mum
Enterocytozoon bieneusi
Microsporida
Spore
Diarrhea in AIDS patients
Trichomonas vaginalis
Mastigophora
Trophozoite 10-30 mum
Urethritis, vaginitis
Plasmodium vivax
Hemosporidia
Trophozoites, schizonts, gametes (all small and inside red cells)
Benign tertian malaria
Plasmodium ovale
Hemosporidia
Benign tertian malaria
Plasmodium malariae
Hemosporidia
Quartan malaria
Plasmodium falciparum
Hemosporidia
Malignant tertian malaria
Babesia microti, B. bovis
Hemosporidia
Trophozoites inside red cells
Babesiosis
Trypanosoma brucei,T. rhodesiense,T. gambiense
Hemoflagellates
Trypomastigote 14-33 mum
African sleeping sickness
Trypanosoma cruzi
Hemoflagellates
Trypomastigote 20 mum
Chagas disease
Leishmania donovani
Hemoflagellates
Amastigote 2 mum
Kala-azar
Bloodstream
Intracellular
Leishmania tropica,L. mexicana,L. braziliensis
Hemoflagellates
Amastigote 2 mum
Cutaneous and mucocutaneous leishmaniasis
Toxoplasma gondii
Coccidia (eimeriae)
Tachyzoite 4-6 mum Toxoplasmosis (cyst larger)
number but generate eggs or larvae destined for the next phase of the cycle. An exception is Strongyloides, the larvae of which can become infective inside the gut and cause overwhelming autoinfection in immunosuppressed persons. There are two important consequences of the lack of replication of adult worms: (1) disease is often caused by inflammatory responses to the eggs or larvae rather than to the adults (e.g., schistosomiasis) and (2) disease is in proportion to the number of organisms that have infected
Figure 9-5 Slender bloodstream parasites of African sleeping sickness.
the individual (e.g., 10 hookworms cause little disease, whereas 1000 hookworms cause severe anemia by consuming 100 ml of blood per day). Fortunately, most persons in endemic areas harbor few worms and are free of disease, and only a minority are heavily infected and ill. Parasitic worms are of three classes. The first class, roundworms (nematodes), is characterized by a collagenous tegument and a nonsegmented structure. These include Ascaris, hookworms, and Strongyloides among the intestinal worms and the filariae and Trichinella among the tissue invaders. The second class, flatworms (cestodes), comprises gutless worms, whose head (scolex) sprouts a ribbon of flat segments (proglottids) covered by an absorptive tegument. This class includes the pork, beef, and fish tapeworms and the cystic tapeworm larvae (cysticerci and hydatid cysts). The third class, flukes (trematodes), which are primitive leaflike worms with syncytial integument, includes the oriental liver and lung flukes and the blood-dwelling schistosomes, discussed later. ECTOPARASITES
Ectoparasites are arthropods (lice, ticks, bedbugs, fleas) that attach to and live on the skin. In addition, skin lesions can be caused by the stings of mosquitoes and bees. Scabies is an example of severe dermatitis elicited by mites burrowing into the stratum corneum (Chapter 27) . Skin nodules caused by burrowing botfly larvae are intensely inflamed and eosinophil enriched. In addition, attached arthropods
338
Figure 9-6 Tiny deer tick (bottom), which transmits Lyme disease and Babesia and Ehrlichia organisms, contrasted with a larger dog tick (top), which is not thought to transmit human infections. (Courtesy of Dr. F.R. Matuschka, Free University of Berlin, Germany.)
can be vectors for other pathogens that make characteristic skin lesions, for example, the expanding erythematous plaque caused by the Lyme disease spirochete Borrelia burgdorferi, which is transmitted by deer ticks (Fig. 9-6) . Transmission and Dissemination of Microbes HOST BARRIERS TO INFECTION
The first and most formidable barriers to infection are the intact host skin and mucosal surfaces and their secretory-excretory products. [14] For example, lysozyme secreted by the tear glands degrades the peptidoglycans of bacterial cell walls and protects the eyes from infection. Acid gastric juice is lethal for some enteric pathogens; for example, normal volunteers do not become infected by Vibrio cholerae unless they are fed 10 organisms. In contrast, Shigella and Giardia are relatively resistant to acid, and less than 100 organisms of each species is infective. In general, skin infections in normal persons tend to arise in damaged sites, that is, wounds, cuts, or burns, and can be caused by resident bacteria of relatively low virulence. In contrast, infections transmitted by the respiratory, gastrointestinal, or genitourinary route generally require virulent organisms capable of damaging or penetrating normal mucosal barriers. Host barriers to infection of the respiratory tracts, gastrointestinal tract, and skin are discussed in the sections devoted to these organs. SPREAD AND DISSEMINATION OF MICROBES
Once implanted, microbes spread on the surface of moist and warm mucosae faster than on cool and dry skin. Some of the superficial pathogens stay confined to the lumen of hollow viscera (e.g., cholera); others adhere to or proliferate exclusively in or on epithelial cells (e.g., papillomaviruses, dermatophytes). A variety of pathogenic bacteria, fungi, and helminths are invasive pathogens by virtue of their motility or ability to secrete lytic enzymes (e.g., streptococcal hyaluronidase, schistosome proteases). Microbial spread initially follows tissue planes of least resistance, for example, along aponeurotic compartments. Spread through serosal cavities (pleura, peritoneum, meninges) is particularly fast and dangerous. Microbes may also ascend the lymphatics from their entry site to the regional nodes and hence into the bloodstream (Fig. 9-7) . Thus, untreated staphylococcal infections may progress from a localized abscess or furuncle to regional lymphadenitis followed by bacteremia, endocarditis, or formation of multiple pyemic abscesses in distant metastatic sites (brain, kidney, bone). Depending on microbial species, secondary foci of infection, established through the bloodstream, take the form of abscesses or granulomas. They can be single and large (a solitary abscess or tuberculoma) or multiple and tiny, the size of millet seeds (e.g., miliary tuberculosis or Candida microabscesses). Viruses may propagate from cell to cell by fusion or axonal
transport (e.g., poliovirus), but like other intracellular pathogens (e.g., tubercle bacilli), they can enter the bloodstream and be carried to distant sites by migratory macrophages (HIV-1) or by circulating red cells (Colorado tick fever virus). The major manifestations of infectious disease may arise at sites distant from those of parasite entry. For example, chickenpox and measles viruses enter through the airways but manifest themselves first as rashes; poliovirus is ingested and multiplies inside the gut wall before proceeding to viremic invasion and killing of motor neurons. Several helminth parasites (e.g., hookworm) enter the skin as penetrating larvae but complete their migratory cycle and maturation inside the gut. Bloodstream invasion by sporadic low-virulence or nonvirulent microbes is a common event but is quickly suppressed by the normal host defenses. By contrast, sustained bloodstream invasion with dissemination of pathogens, that is, viremia, bacteremia, fungemia, or parasitemia, is a serious insult and manifests itself by fever, low arterial pressure, and multiple other systemic "septic" signs and symptoms. Massive bloodstream invasion by bacteria or their endotoxins can rapidly become fatal, even for previously healthy individuals. The placental-fetal route is an important mode of transmission (Chapter 11) . When infectious organisms reach the pregnant uterus through the cervical orifice or the bloodstream and are able to traverse the placenta, severe damage to the fetus may result. Bacterial or mycoplasmal placentitis may cause premature delivery or stillbirth. Treponema pallidum infecting the mother breaches the placenta by the end of the second trimester and 339
causes manifestations of congenital syphilis in the infant, ranging from dental deformities to stillbirth. By contrast, transmission of maternal viruses or of Toxoplasma infections is most dangerous during early pregnancy and can result in flagrant systemic disease of the fetus (e.g., CMV), fetal maldevelopment, deafness, and congenital heart disease (e.g., rubella). Central nervous system damage is particularly common in the so-called TORCH (Toxoplasma, rubella, CMV, herpesviruses, and other) infections (Chapter 11) . The same agents can also cause more subtle mental retardation or learning disabilities during childhood. Fetuses infected late during pregnancy or during passage through the birth canal and infants receiving virus through maternal milk usually fare better than those infected during early embryonal life; their lesions may resemble those of adult patients. Maternal transmission of HIV results in opportunistic infections in 50% of untreated children during the first year of life. Maternal transmission of HBV is common in third world countries and among the drug addicted. Such children are at high risk for liver cancer later during adult life.
Figure 9-7 Routes of entry, dissemination, and release of microbes from the body. (Adapted from Mims CA: The Pathogenesis of Infectious Disease, 4th ed. San Diego, CA, Academic Press, 1996.)
RELEASE AND TRANSMISSION OF MICROBES
For transmission to occur, microbial pathogens must be able to leave the host organism. Depending on the location of infection, release may be accomplished by skin shedding, mucosal contact, coughing, sneezing, shouting, or voiding of urine or feces. Microbes directly transmissible from person to person by contact or aerosol (e.g., measles or chickenpox) are termed contagious. Viruses infecting the salivary glands (e.g., herpesviruses, mumps viruses) are released principally by kissing or spitting. Other pathogens are infective mainly by prolonged intimate or mucosal contact, as occurs during sexual transmission (e.g., HIV-1, herpes simplex virus [HSV-2], papillomaviruses, chlamydiae, syphilis). Bacteria and fungi transmitted by the respiratory route are infective only when lesions are open to the airways (e.g., pulmonary tuberculosis). Many pathogens, from viruses to helminths, are transmitted by the fecal-oral route, that is, by ingestion of stool-contaminated food or water. Water-borne viruses involved in epidemic outbreaks include hepatitis A and E viruses, poliovirus, and rotavi-rus. [15]
340
To ensure transmission, organisms may form spores, protozoan cysts, or thick-shelled helminth eggs, which can survive in a cool and dry environment. Alternatively, some enteric pathogens are shed for long periods by asymptomatic carrier hosts (e.g., salmonellae). Transmission of microbes from skin to insect occurs during feeding, either because the pathogen circulates in the blood or because it resides in the skin. Some parasitic helminths shed eggs that gain access to new hosts by larval skin penetration rather than by oral intake (e.g., hookworms, schistosomes). Higher parasite phyla, that is, protozoa and helminths, have evolved complex transmission cycles involving a chain of intermediary and vector hosts bearing successive developmental parasite stages. Transmission of pathogens by the various routes listed occurs not only from human to human but also from animal to human (e.g., field mice are the "reservoir hosts" for Lyme disease) and vice versa. Diseases of this type are termed zoonotic infections. By contrast, transmission of HBV and HIV infections through blood and blood products is frequently caused by human agency, that is, needle sharing by addicts, virus-contaminated blood transfusions, cuts, needle-sticks, and other accidents. How Microorganisms Cause Disease Infectious agents establish infection and damage tissues in three ways: They can contact or enter host cells and directly cause cell death. They may release endotoxins or exotoxins that kill cells at a distance, release enzymes that degrade tissue components, or damage blood vessels and cause ischemic necrosis.
They induce host cellular responses that, although directed against the invader, may cause additional tissue damage, including suppuration, scarring, and hypersensitivity reactions. Thus, the defensive responses of the host are a two-edged sword: they are necessary to overcome the infection but at the same time directly contribute to tissue damage. Here we describe some of the particular mechanisms whereby viruses and bacteria damage host tissues. MECHANISMS OF VIRAL INJURY
Viruses damage host cells by entering the cell and replicating at the host's expense. Viral tropism--the tendency to infect some cells but not others--is in part caused by the binding of specific viral surface proteins to particular host cell surface receptor proteins, many of which have known functions. For example, EBV binds to the complement receptor on macrophages (CD2), rabies virus binds to the acetylcholine receptor on neurons, and rhinoviruses bind to the adhesion protein intercellular adhesion molecule 1 (ICAM-1) on mucosal cells. HIV, the cause of AIDS, binds to two different proteins on target cells, [16] [17] the CD34 protein on lymphocytes (but also present on macrophages and glial cells) and chemokine receptors on macrophages and microglia--CCR5, CCR3, or CCR2b (see discussion of HIV in Chapter 7) . The second major cause of viral tropism is the ability of the virus to replicate inside some cells but not in others. For example, JC papovavirus, which causes leukoencephalopathy (Chapter 30) , is restricted to oligodendroglia in the central nervous system because the promoter and enhancer DNA sequences upstream from the viral genes are active in glial cells but not in neurons or endothelial cells. Once attached, the entire virion or a portion containing the genome and essential polymerases penetrates into the cell cytoplasm by one of three ways: (1) translocation of the entire virus across the plasma membrane, (2) fusion of the viral envelope with the cell membrane, or (3) receptor-mediated endocytosis of the virus and fusion with endosomal membranes. Within the cell, the virus uncoats, separating its genome from its structural components and losing its infectivity. Viruses then replicate with use of enzymes, which are distinct for each virus family. For example, RNA polymerase is used by negative-stranded RNA viruses to generate positive-stranded mRNA, whereas reverse transcriptase is used by retroviruses to generate DNA from their RNA template and to integrate that DNA into the host genome. Viruses also use host enzymes for viral synthesis, which may be present in some differentiated tissues and not in others. Newly synthesized viral genomes and capsid proteins are then assembled into progeny virions in the nucleus or cytoplasm and are released directly (unencapsulated viruses) or bud through the plasma membrane (encapsulated viruses). In some cases (e.g., measles virus), viruses use actin filaments to transport them to the surface of host cells. [18] Viral infection can be abortive, with incomplete viral replicative cycle; latent, in which the virus (e.g., herpes zoster) persists in a cryptic state within the dorsal root ganglia and then presents as painful shingles; or persistent, in which virions are synthesized
continuously with or without altered cell function (e.g., hepatitis B). Viruses kill host cells in a number of ways (Fig. 9-8) : Viruses inhibit host cell DNA, RNA, or protein synthesis. For example, poliovirus inactivates cap-binding protein, which is essential for protein synthesis directed by capped host cell mRNAs, while allowing protein synthesis from uncapped poliovirus mRNAs. Viral proteins insert into the host cell's plasma membrane and directly damage its integrity or promote cell fusion (HIV, measles virus, and herpesviruses). Viruses replicate efficiently and lyse host cells (e.g., liver cells by yellow fever virus, and neurons by poliovirus). Viral proteins on the surface of the host cells are recognized by the immune system, and the host lymphocytes attack the virus-infected cells. For example, acute liver failure during hepatitis B infection may be accelerated by Fas ligands on cytotoxic T lymphocytes, which bind to Fas receptors on the surface of hepatocytes and induce apoptosis in target cells [19] (Chapter 1) . Respiratory syncytial virus, a major cause of lower respiratory infections in infants, causes release of cytokines interleukin (IL)-4 and IL-5 from TH 2 type cells, which induce 341
mast cell activation and eosinophil accumulation and result in asthma [20] (Chapter 16) . Viruses damage cells involved in host antimicrobial defense, leading to secondary infections. For example, viral damage to respiratory epithelium allows subsequent pneumonias caused by pneumococcus or Haemophilus, and HIV depletes CD4+ helper lymphocytes, which normally suppress opportunistic bacterial infections. Viral killing of one cell type causes the death of other cells that depend on them. For example, poliovirus causes motor neuron injury and atrophy of distal skeletal muscle supplied by such neurons. Slow virus infections (e.g., subacute sclerosing panencephalitis caused by measles virus) culminate in severe progressive disease after a long latency period. In addition to causing cell injury, viruses induce cell proliferation and transformation (e.g., HBV, human papillomavirus, or EBV), which result in neoplastic growth. The mechanisms of viral transformation are numerous [21] and are discussed in Chapter 8 .
Figure 9-8 Mechanisms by which viruses cause injuries to cells.
MECHANISMS OF BACTERIA-INDUCED INJURY Bacterial Virulence.
Bacterial damage to host tissues depends on their ability to adhere to host cells, invade
cells and tissues, and deliver toxic moieties. These virulence properties are determined by a multitude of genes and gene products. There are both similarities and differences in genes expressed by virulent and avirulent bacteria. For example, most of the genes necessary for virulence of Salmonella typhi, the cause of typhoid fever, are also present in nonpathogenic E. coli. [22] These "housekeeping" virulence genes encode proteins involved in nutrient assimilation, toxin transport, and, most important, gene regulation. In addition, virulent Salmonella or Shigella have numerous genes encoding proteins involved in host recognition and invasion, which are absent in avirulent E. coli. Such genes are sometimes called "pathogenicity islands," because they are physically associated--for example, a Shigella plasmid (circular DNA) encodes Shiga toxin and other adherence proteins, [23] which are expressed coordinately. Adherence and toxin genes of Vibrio cholerae are induced together by iron deprivation, while sets of Salmonella genes are coordinately expressed when the bacterium enters the acidic environment within the macrophage phagolysosome. Finally, a pathogenicity island called cag encoding a vacuolating toxin may convert Helicobacter pylori from an avirulent commensal bacterium into a gastritis-producing pathogen. [24] Important virulence genes of intracellular bacteria, which are induced by contact with host cells, encode proteins involved in so-called type III intracellular secretion systems, which deliver bacterial proteins directly into the host cell cytosol. [25] Bacterial Adhesins.
Bacterial adhesins that bind bacteria to host cells are limited in type but have a broad range of host cell specificity. The fibrillae covering the surface of gram-positive cocci such as Streptococcus are composed of M protein and lipoteichoic acids [26] (Fig. 9-9) . Lipoteichoic acids are hydrophobic and bind to the surface of all eukaryotic cells, although with a higher affinity to particular
342
Figure 9-9 Molecules on the surface of gram-negative and gram-positive bacteria involved in pathogenesis. Not shown is the type 3
secretory apparatus of gram-negative bacteria (see text).
receptors on blood cells and oral epithelial cells. Fimbriae or pili on the surface of gram-negative rods and cocci are nonflagellar filamentous structures composed of repeating subunits. Pili mediate binding of the phagemid carrying cholera toxin genes, which integrates into the Vibrio chromosome in the same way that retroviruses integrate into the chromosomes of infected host cells. [27] Other pili such as those on Neisseria gonorrhoeae mediate adherence of bacteria to host cells (Fig. 9-10) . The base of the subunit that anchors the pili to the bacterial cell wall is similar for widely divergent bacteria. At the tips of the pili are minor protein components that determine to which host cells the microbes will attach (bacterial tropism). In E. coli, these minor proteins are antigenically distinct and are associated with particular infections. For example, type I
proteins bind mannose and cause urinary tract infections, type P proteins
Figure 9-10 Gonococcal culture showing pili, as seen by scanning microscopy ( A ), and in clusters, as seen by transmission electron microscopy ( B ). (Courtesy of Dr. John Swanson, Rocky Mountain Laboratories, Hamilton, MT.)
343
bind galactose and cause pyelonephritis, and type S proteins bind sialic acid and cause meningitis. A single bacterium can express more than one type of pili as well as nonpilar adhesins. In contrast to viruses, which can infect a broad range of host cells, facultative intracellular bacteria infect mainly epithelial cells (Shigella and enteroinvasive E. coli), macrophages ( Mycobacterium tuberculosis and Mycobacterium leprae, Legionella pneumophila, and Yersinia), or both cell types (Salmonella typhi and Listeria monocytogenes). Entry into macrophages is for the most part directed by receptors that recognize antibodies or complement on the surface of bacteria (Chapter 3) . In addition, certain organisms such as Mycobacterium and Legionella inhibit the acidification that normally occurs when the endosome fuses with the lysosome and thus protect from lysosomal digestion. Many bacteria (e.g., Mycobacterium avium) can replicate within macrophages in the absence of a host immune response (e.g., lepromatous leprosy), but activated macrophages kill these bacteria and slow or suppress the infection. Entry into epithelial cells is dependent on an interaction between a bacterial surface and epithelial cell receptors, which stimulate host signaling pathways and subsequent cytoskeletal rearrangements. Many bacteria attach to integrins. For example, Legionella and M. tuberculosis bind to CR3, the cell receptor for complement iC3b. Some intracellular bacteria use a hemolysin to escape from the endocytic vacuole into the cytoplasm. [28] Once in the cytoplasm, certain bacteria (Shigella and E. coli) inhibit host protein synthesis, rapidly replicate, and lyse the host cells. Others such as L. monocytogenes, a cause of opportunistic meningitis infections, use host actin filaments to propel the bacteria within the cell. Bacterial Endotoxin.
Bacterial endotoxin is a lipopolysaccharide that is a structural component in the outer cell wall of gram-negative bacteria. Lipopolysaccharide is composed of a long-chain fatty acid anchor (lipid A) connected to a core sugar chain, both of which are the same in all gram-negative bacteria. Attached to the core sugar is a variable carbohydrate chain (O antigen), which is used to serotype and discriminate different bacteria. Most biologic activities of lipopolysaccharide, including the induction of fever, macrophage activation, and B-cell mitogenicity, come from lipid A and the core sugars and are
mediated by induction of host cytokines, including tumor necrosis factor (TNF) and IL-1 (Chapters 3 and 5) . [29] Bacterial Exotoxins.
Bacteria secrete a variety of enzymes (hemolysins, hyaluronidases, coagulases, fibrinolysins) that act on their respective substrates in vitro, but their role in human disease remains presumptive. In contrast, the role of bacterial exotoxins is well established, and the molecular mechanisms of most of their actions are known. The mechanism of action of diphtheria toxin, for example, is well understood. [30] The toxin is composed of fragment B, which is at the carboxyl end of the molecule and is essential for attachment to host cells, and fragment A, which is at the amino end and linked to fragment B by a disulfide bridge (Fig. 9-11) (Figure Not Available) . Bound diphtheria toxin enters the acidic endosome of cells, where it fuses with the Figure 9-11 (Figure Not Available) Inhibition of cellular protein synthesis by diphtheria toxin. (Adapted from Collier RJ: Corynebacteria. In Davis BD, et al [eds]: Microbiology, 3rd ed. New York, Harper & Row, 1990.)
endosomal membrane and enters the cell cytoplasm. There the disulfide bond of the toxin is broken, releasing the enzymatically active fragment A that catalyzes the covalent transfer of adenosine diphosphate (ADP)-ribose from nicotinamide adenine dinucleotide (NAD) to EF-2; the latter, a ribosomal elongation factor involved in protein synthesis, is thus inactivated. One molecule of diphtheria toxin can kill a cell by ADP-ribosylating more than a million EF-2 molecules. Diphtheria toxin creates a layer of dead cells in the throat, on which Corynebacterium diphtheriae outgrows competing bacteria. Subsequently, wide dissemination of diphtheria toxin causes the characteristic neural and myocardial dysfunction of diphtheria. The heat-labile enterotoxins of V. cholerae and of E. coli also have an A-B structure and are ADP-ribosyltransferases, but these enzymes catalyze transfer from NAD to the guanyl nucleotide-dependent regulatory component of adenylate cyclase. [31] This generates excess cyclic adenosine
344
monophosphate (cAMP), which causes intestinal epithelial cells to secrete isosmotic fluid, resulting in voluminous diarrhea and loss of water and electrolytes. Another well-understood toxin is the alpha toxin produced by the gram-positive anaerobic Clostridium perfringens, the agent of gas gangrene. The alpha toxin is a lecithinase that disrupts plasma membranes of erythrocytes, leukocytes, and endothelial cells, resulting in tissue injury. Finally and regrettably, toxin-producing bacteria, particularly spore-formers that may be transmitted by aerosols (e.g., Bacillus anthracis that makes anthrax toxin), are the agents of choice for biologic terrorism, capable of infecting and killing 80% of persons in
a single attack. [32] Immune Evasion by Microbes The humoral and cellular immune responses that protect the host from most infections and the mechanisms of immune-mediated damage to host tissues induced by microbes (e.g., anaphylactic reactions, immune complex reactions) are discussed in Chapter 7 . Conversely, microorganisms can escape the immune system by several mechanisms, including (1) being inaccessible to the immune response, (2) resisting complement-mediated lysis and phagocytosis, (3) varying or shedding antigens, and (4) causing specific or nonspecific immunosuppression. Here we cite some examples of these phenomena. Microbes that propagate in the lumen of the intestine (e.g., toxin-producing Clostridium difficile) or gallbladder (e.g., Salmonella typhi) are inaccessible to the host immune defenses, including secretory immunoglobulin (IgA). Viruses that are shed from the luminal surface of epithelial cells (e.g., CMV in urine or milk and poliovirus in stool) or those that infect the keratinized epithelium (poxviruses, which cause molluscum contagiosum) are also inaccessible to the host humoral immune system. Some organisms establish infections by rapidly invading host cells before the host humoral response becomes effective (e.g., malaria sporozoites entering liver cells; Trichinella and Trypanosoma cruzi entering skeletal or cardiac muscles). Some larger parasites (e.g., the larvae of tapeworms) form cysts in host tissues that are covered by a dense fibrous capsule that walls them off from host immune responses. Viruses have numerous means for circumventing the host immune response, including (1) blocking complement activation (e.g., vaccinia) or using complement receptors to enter B lymphocytes (e.g., EBV), (2) inhibiting interferon-induced antiviral responses (e.g., adenovirus, EBV, and HIV), (3) blocking production of cytokines or response to cytokines (cowpox, adenovirus, and HBV), (4) suppressing major histocompatibility complex (MHC) class I (e.g., adenovirus), and (5) reducing B-cell activation (e.g., EBV). [33 ] Many of these effects are mediated by viral homologs of host regulatory proteins (e.g., a serpin homolog of myxoma virus inhibits urokinase and plasminogen activator and so reduces inflammation). The carbohydrate capsule on the surface of all the major pathogens that cause pneumonia or meningitis (pneumococcus, meningococcus, Haemophilus) makes them more virulent by shielding bacterial antigens and preventing phagocytosis TABLE 9-7 -- PATHOGENS WITH SIGNIFICANT ANTIGENIC VARIATION Rhinoviruses Colds Influenza virus
Influenza
Neisseria gonorrhoeae
Gonorrhea
Borrelia hermsii
Relapsing fever
Borrelia burgdorferi
Lyme disease
Trypanosoma brucei
African sleeping sickness
Giardia lamblia
Giardiasis
Plasmodium falciparum
Severe malaria
of the organisms by neutrophils. Pseudomonas bacteria secrete a leukotoxin that kills neutrophils. Some E. coli have K antigens that prevent activation of complement by the alternative pathway and lysis of the cells. Conversely, some gram-negative bacteria have long polysaccharide O antigens, which bind host antibody and activate complement at such distance from the bacterial cells that the organisms fail to lyse. Staphylococci are covered by protein A molecules that bind the Fc portion of the antibody and so inhibit phagocytosis. Neisseria, Haemophilus, and Streptococcus all secrete proteases that degrade antibodies. Viral infection evokes neutralizing antibodies that prevent viral attachment, penetration, or uncoating. This highly specific immunity is the basis of antiviral vaccination, but it cannot protect against viruses with many antigenic variants (e.g., rhinoviruses or influenza viruses) (Table 9-7) . Pneumococci are capable of more than 80 permutations of their capsular polysaccharides, so in repeated infection the host is unlikely to recognize the new serotype. Neisseria gonorrhoeae have pilar (attachment) proteins composed of a constant region and a hypervariable region. The latter allows Neisseria to change its antigens during infection and prevent immune clearance. Similarly, the spirochete Borrelia recurrentis causes a relapsing fever by repeatedly switching its surface antigens before each successive clone is eliminated by the host, while the Lyme disease borreliae use similar mechanisms to vary their outer membrane proteins. [34] Successive clones of African trypanosomes also vary their major surface antigen to escape host antibody responses. Nearly 5% of the genome of Plasmodium falciparum, the cause of severe malaria, are var genes that encode variable proteins present on knobs on the surface of infected red cells. [35] Cercariae of Schistosoma mansoni shed parasite antigens that are recognized by host antibodies or activate complement by the alternative pathway, within minutes of penetrating the skin. Finally, viruses that infect lymphocytes (HIV and EBV) directly damage the host immune system and cause opportunistic infections (AIDS). Special Techniques for Diagnosing Infectious Agents Some infectious agents or their products can be directly observed in hematoxylin and eosin-stained sections (e.g.,
345
TABLE 9-8 -- SPECIAL TECHNIQUES FOR DIAGNOSING INFECTIOUS AGENTS Gram stain Most bacteria Acid-fast stain
Mycobacteria, nocardiae (modified)
Silver stains
Fungi, legionellae, pneumocystis
Periodic acid-Schiff
Fungi, amebae
Mucicarmine
Cryptococci
Giemsa
Campylobacteria, leishmaniae, malaria parasites
Antibody probes
Viruses, rickettsiae
Culture
All classes
DNA probes
Viruses, bacteria, protozoa
the inclusion bodies formed by CMV and herpesvirus; bacterial clumps, which usually stain blue; Candida and Mucor, among the fungi; most protozoans; and all helminths). Many infectious agents, however, are best visualized by special stains that identify organisms on the basis of particular characteristics of their cell walls or coat--Gram, acid-fast, silver, mucicarmine, and Giemsa stains--or after labeling with specific antibody probes (Table 9-8) . Regardless of the staining technique, organisms are usually best visualized at the advancing edge of a lesion rather than at its center, particularly if there is necrosis. Because these morphologic techniques cannot define species of organisms, determine drug sensitivity, or identify virulence characteristics, cultures of lesional tissue are performed. DNA probes identify microbes that grow slowly in culture (mycobacteria or CMV) or do not culture at all (hepatitis B and C viruses). DNA sequence analysis has been used to classify bacteria that have never been cultured, including those that cause Whipple disease (a gram-positive actinobacterium related to Actinomyces and Streptomyces[36] ) and bacillary angiomatosis (genus Bartonella). Finally, molecular biologic techniques to distinguish viruses, bacteria, and parasites have revolutionized epidemiologic studies of infectious agents in the hospitals and in the environment. [37] Regardless of the method of microbial identification, the final step in diagnosis of infectious pathogens is correlation of the suspect organism with the lesion caused and the signs and symptoms produced. Spectrum of Inflammatory Responses to Infection In contrast to the vast molecular diversity of microbes, the patterns of tissue responses to these agents are limited. At the microscopic level, therefore, many pathogens produce identical reaction patterns, and few features are unique or pathognomonic of each agent. Moreover, it is the interaction between the microorganism and the host that determines the histologic features of the inflammatory response. Thus, in a profoundly neutropenic host, pyogenic bacteria, which normally evoke vigorous leukocyte responses, may cause rapid tissue necrosis with little leukocyte exudation. Similarly, in a normal patient, M. tuberculosis causes well-formed granulomas with few mycobacteria present, whereas in an AIDS patient, the same mycobacteria multiply profusely in macrophages, which fail to coalesce into granulomas. Organisms induce five major patterns of tissue reaction.
SUPPURATIVE (POLYMORPHONUCLEAR) INFLAMMATION
Suppurative inflammation is characterized by increased vascular permeability and leukocytic infiltration, predominantly of neutrophils (Fig. 9-12) . The neutrophils are attracted to the site of infection by release of chemoattractants from the rapidly dividing, "pyogenic" bacteria that evoke this response, mostly extracellular gram-positive cocci and gram-negative rods. The bacterial chemoattractants include secreted bacterial peptides, which contain N-formylmethionine residues at their amino termini that are recognized by specific receptors on neutrophils. Alternatively, bacteria attract neutrophils indirectly by releasing endotoxin that stimulates macrophages to secrete IL-1 or TNF or by cleaving complement into chemoattractant peptides. Massing of neutrophils results in the formation of pus. The sizes of exudative lesions vary from tiny microabscesses formed in multiple organs in bacterial septicemia to diffuse involvement of entire lobes of the lung in pneumococcal infections. How destructive the lesions are depends on their location and the organism involved. For example, pneumococci spare alveolar walls, whereas staphylococci and Klebsiella species destroy them and form abscesses. Bacterial pharyngitis heals without sequelae, whereas untreated acute bacterial inflammation of a joint can destroy it in a few days. MONONUCLEAR AND GRANULOMATOUS INFLAMMATION
Diffuse, predominantly mononuclear interstitial infiltrates occur in response to viruses, intracellular bacteria, spirochetes, intracellular parasites, or helminths. Which mononuclear cell predominates within the inflammatory lesion depends on the host immune response to the organism. For
Figure 9-12 Pneumococcal pneumonia. Note the intra-alveolar polymorphonuclear exudate and intact alveolar septa.
346
Figure 9-13 Secondary syphilis in the dermis with perivascular lymphoplasmacytic infiltrate and endothelial proliferation.
example, mostly plasma cells are seen in the chancres of primary syphilis, mostly lymphocytes with active HBV infection or Lyme disease or in viral infections of the brain (Fig. 9-13) . These lymphocytes reflect cell-mediated immunity against the pathogen or the pathogen-infected cells. Granulomatous inflammation occurs when aggregates of altered macrophages form, sometimes around a central necrotic focus, or fuse together to form giant cells (Chapter 3) . These distinctive lesions are usually evoked by relatively slowly dividing infectious agents (e.g., M. tuberculosis or Histoplasma) or by those of relatively large size (e.g., schistosome eggs) in the presence of T cell-mediated
immunity. At the other extreme, macrophages may become filled with organisms, as occurs in M. avium infections in AIDS patients, who can mount no immune response to the organisms. For M. leprae and for cutaneous leishmaniasis, some individuals mount a strong immune response so their lesions contain few organisms, few macrophages, and many lymphocytes, whereas other individuals with a weak immune response have lesions with many organisms, many macrophages, and few lymphocytes. CYTOPATHIC-CYTOPROLIFERATIVE INFLAMMATION
These reactions are characteristic of virus-mediated damage to individual host cells in the absence of host inflammatory response. Some viruses replicate within cells and make viral aggregates that are visible as inclusion bodies (e.g., CMV or adenovirus) or induce cells to fuse and form polykaryons (e.g., measles virus or herpesviruses). Focal cell damage may cause epithelial cells to become discohesive and form blisters (e.g., herpes; Fig. 9-14) . Viruses can also cause epithelial cells to proliferate and form unusual individual and aggregate morphologic lesions (e.g., venereal warts caused by human papillomavirus or the umbilicated papules of molluscum contagiosum caused by poxviruses). Finally, viruses can cause dysplastic changes and cancers in epithelial cells and lymphocytes as discussed in Chapter 8. NECROTIZING INFLAMMATION
Clostridium perfringens and other organisms that secrete strong toxins cause such rapid and severe tissue damage that cell death is the dominant feature. Because so few inflammatory cells are involved, these lesions resemble ischemic necrosis with disruption or loss of basophilic nuclear staining and preservation of cellular outlines. Similarly, the parasite Entamoeba histolytica causes colonic ulcers and liver abscesses characterized by extensive tissue destruction with liquefactive necrosis, in the absence of a prominent inflammatory infiltrate. By entirely different mechanisms, viruses can cause necrotizing inflammation when host cell damage is particularly widespread and severe, as exemplified by total destruction of the temporal lobes of the brain by herpesvirus or the liver by HBV. CHRONIC INFLAMMATION AND SCARRING
The final common pathway of many infections is chronic inflammation, which may lead either to complete healing or to extensive scarring. For some organisms that are relatively inert, the exuberant scarring response is a major cause of dysfunction (e.g., the "pipe-stem" fibrosis of the liver caused by schistosome eggs or the constrictive fibrous pericarditis in tuberculosis) (Fig. 9-15) . These patterns of tissue reaction are useful as working tools in analyzing microscopic features of infective processes, but they rarely appear in pure form because they frequently overlap. For example, a cutaneous lesion of leishmaniasis may contain two separate histopathologic regions: a central ulcerated area filled with neutrophils and a peripheral region containing a mixed infiltrate of lymphocytes and mononuclear cells, where the leishmanial parasites are located. The lung of an AIDS patient may be infected with CMV that causes cytolytic changes and Pneumocystis that causes
interstitial inflammation. Similar patterns of inflammation can also be seen in tissue responses to physical or chemical agents and in inflammatory diseases of unknown cause.
Figure 9-14 Herpesvirus blister in mucosa (see Fig. 9-28 for viral inclusions).
347
Figure 9-15 Schistosoma haematobium infection of the bladder with numerous calcified eggs and extensive scarring.
This concludes our discussion of the general principles in the pathogenesis and pathology of infectious disease. We now turn to brief descriptions of specific infections as they affect different organ systems and distinct populations of patients. In each of these categories, we begin with viral infections, followed by bacterial, fungal, or parasitic diseases. In this discussion, we emphasize pathogenetic mechanisms and pathologic changes, rather than details of clinical features, which are available in clinical textbooks.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 10 - Environmental and Nutritional Pathology HUMANS AND THE ENVIRONMENT COMMON ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES - Part 1 COMMON ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES - Part 2 FOOD AND NUTRITION REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
403
Chapter 10 - Environmental and Nutritional Pathology Agnes B. Kane Vinay Kumar
HUMANS AND THE ENVIRONMENT Environmental and occupational health encompasses the diagnosis, treatment, and prevention of injuries and illnesses resulting from exposure to exogenous chemical or physical agents. Such exposure may occur in the workplace, or people may voluntarily expose themselves to these hazards, for example, by abusing drugs or ethanol and smoking cigarettes. These personal habits may lead to involuntary exposure of fetuses and infants to drugs, ethanol, or environmental tobacco smoke. People are often confused about the magnitude of the potential adverse health effects of exogenous physical and chemical agents. There is widespread concern about the potential chronic or delayed effects of exposure to low levels of contaminants in air, water, and food, and hence patients frequently seek advice and information from their health care professionals about the risk of disease associated with specific environmental and occupational exposures. This chapter provides a basic foundation in the most important diseases associated with environmental and occupational exposures, emphasizing the mechanisms leading to
404
these diseases. This framework will help physicians to recognize and treat injuries and illness resulting from environmental and occupational exposures and to educate their patients about the risks of these exposures. [1] Recognition of Occupational and Environmental Diseases Accidents, illness, and premature deaths caused by occupational exposures affect 120 million workers in the United States. The annual number of fatal workplace injuries was about 10,000 in 1992: 40% were caused by transportation accidents, 20% were due to
assaults and physical violence, 10% were caused by falls, 5% were caused by electrocutions, and 5% were caused by explosions and fires. Nonfatal injuries were estimated at 13,247 million; 6 million of these injuries resulted in disability. The economic cost of these occupational injuries is estimated to be $145 billion. [2] The incidence of nonfatal injuries is highest among construction workers, followed by people employed in agriculture, forestry, fishing, and manufacturing. In addition to injuries, occupational exposures contribute to a wide range of illnesses, including cancer and cardiovascular and cerebrovascular diseases, leading to premature death (Table 10-1) . It is estimated that in 1992, 862,000 new cases of occupational illnesses occurred; these resulted in 60,300 premature deaths, with an estimated economic cost of $25 billion. The total costs of occupational injuries and illnesses are greater than the costs associated with the treatment of acquired immunodeficiency syndrome (AIDS) and Alzheimer disease. The magnitude and extent of illness related to environmental exposures are difficult to ascertain. The Environmental Protection Agency estimates that more than 60,000 chemicals are currently used in the United States; approximately 1500 are pesticides and 5500 are food additives that affect our water and food supplies. Although not all of these chemicals have been tested, 600 have produced cancer in at least one rodent species. [2] Industrial chemicals, production byproducts, and metals are commonly detected at hazardous waste sites (Table 10-2) . It is estimated that 4 million people live within 1 mile of 785 heavily contaminated sites that are slated for clean-up ("superfund sites"). TABLE 10-1 -- ESTIMATED OCCUPATIONAL DISEASE MORTALITY IN THE UNITED STATES IN 1992 Cause of Death Number of Percentage Attributed to Deaths Occupation Cancer
517,090
6-10
Cardiovascular and cerebrovascular disease
101,846
5-10
Chronic respiratory disease
91,541
10
1,136
100
Nervous system disease
26,936
1-3
Renal disease
22,957
1-3
Pneumoconioses
From Leigh JP, et al: Occupational injury and illness in the United States. Estimates of costs, morbidity, and mortality. Arch Intern Med 157:1557, 1997.
TABLE 10-2 -- COMMON CHEMICALS AT HAZARDOUS WASTE SITES Chemical Number of Sites Metals
564
Volatile organic compounds
518
Polycyclic aromatic hydrocarbons
187
Polychlorinated biphenyls
162
Phthalate ester plasticizers
106
Pesticides
82
Dioxins
47
From Mitchell FL: Hazardous waste. In Rom WH (ed): Environmental and Occupational Medicine, 2nd ed. Boston, Little, Brown, 1992, p 1275. Up to 1.8 million workers are employed at hazardous waste sites.
[ 3]
There is considerable difference in the magnitudes of exposure in the occupational and environmental settings. Occupational exposures affect a defined cohort of workers who are exposed to chemicals in the range of parts per million (ppm); by contrast, environmental exposures to these same chemicals in the air, water, or hazardous waste sites may be in the parts per billion (ppb) or parts per trillion (ppt) range. The health effects of such chronic, low-level exposures are unknown. In the United States, four regulatory agencies determine exposure limits for environmental and occupational hazards: the Environmental Protection Agency, the Food and Drug Administration, the Occupational Safety and Health Administration, and the Consumer Products Safety Commission. The Environmental Protection Agency regulates exposure to pesticides, toxic chemicals, water and air pollutants, and hazardous wastes. The Food and Drug Administration regulates drugs, medical devices, food additives, and cosmetics. The Occupational Safety and Health Administration mandates that employers (including hospitals and physicians) provide safe working conditions for employees. All other products sold for use in homes, schools, or recreation are regulated by the Consumer Products Safety Commission. Physicians should be familiar with current approaches used by regulatory agencies in the United States and be prepared to explain the strengths and limitations of the scientific evidence in nontechnical terms. Unfortunately, the perception of risk by the public may differ from the risk determined by scientists. For example, estimated annual fatalities related to tobacco smoking predicted by technical experts (150,000) varied widely from the number of fatalities predicted by college students (2400). Physicians can help patients identify specific environmental and occupational hazards that may cause adverse health effects, educate them about the nature and magnitude of these risks, and encourage behaviors that reduce these risks. [4] Mechanisms of Toxicity Toxicology is the scientific discipline that studies the detection, effects, and mechanisms of action of poisons and toxic chemicals. Toxicity is a relative phenomenon that
405
depends on the inherent structure and properties of a chemical and on its dose. Dose-response curves are typically generated in laboratory animals exposed to various amounts of a chemical. A typical dose-response curve for acute toxicity is illustrated in Figure 10-1 . In this example, a measurable response occurs at a dose of 0.1 mg/kg; this is defined as the threshold dose. To the left of this dose, at subthreshold levels, there is no measurable response. For this chemical, this is the no observed effect level and can be considered a safe dose. This information is used to establish a daily or annual threshhold limit value or permissible exposure level for occupational exposures. Frequently, a plateau is reached at higher doses; this is defined as the ceiling effect.[5] It is uncertain whether carcinogens show a threshold effect or whether the dose-response curve should be extrapolated linearly to zero. [6] Despite the inherent limitations of toxicity testing in animals, several important toxicologic principles have been established by this experimental approach. Exogenous chemicals are absorbed after ingestion, inhalation, or skin contact, then distributed to various organs (Fig. 10-2) . Chemicals are frequently metabolized, often by multiple pathways, to products that may be more or less toxic than the parent chemical. One or more of these products then interacts with the target macromolecule, resulting in a toxic effect. [7] The site of toxicity is frequently the site where metabolism or excretion of toxic metabolites occurs. The dose administered (external dose) may not be the same as the biologic effective dose delivered to the target organ and target macromolecule. The basic principles of xenobiotic metabolism with some specific examples are discussed next. Most xenobiotics are lipophilic; this property facilitates their transport in the bloodstream by lipoproteins and penetration through lipid membranes. Lipophilic toxicants are metabolized to hydrophilic metabolites in two steps (Fig. 10-3) . In phase I reactions, a polar functional group is added to the parent compound. These are frequently oxidation reactions that produce reactive, electrophilic intermediates as a primary metabolite. This metabolite may be eliminated or it may participate in phase II reactions. These reactions produce conjugation products with endogenous substrates that are more water soluble and more readily excreted. There are genetic variations in the level of activity of these xenobiotic-metabolizing enzymes. For example, the mixed function oxidase system, or cytochrome P-450-dependent monooxygenase system (P-450), has multiple isozymes. Cytochrome P-450 enzymes are involved in detoxification of endogenous hormones and natural products as well as in activation of xenobiotics to reactive intermediates or ultimate carcinogens. The cytochrome P-450 gene CYP1A1 is induced by polycyclic aromatic hydrocarbons present in tobacco smoke. [8] Smokers who have inherited alleles of the CYP1A1 gene that confer higher activity and increased inducibility of this enzyme may be at higher risk of developing lung cancer [9] (Chapter 8) . Glutathione- S-transferases are enzymes involved in detoxification of xenobiotic metabolites by conjugation to glutathione. People with inherited GSTM1
deficiency (null phenotype) may be at increased risk for lung, bladder, and colon cancers. [9] Multiple pathways may be involved in metabolism of a chemical toxicant. Predominance of one pathway over 406
another may account for differences in toxicity and carcinogenicity assays between different species, sexes, and age groups. Endogenous factors such as nutritional and hormonal status alter enzyme activities involved in xenobiotic metabolism. Exogenous factors (e.g., chemicals, drugs, ethanol, stress) can induce or inhibit activities of xenobiotic-metabolizing enzymes. Other repair pathways may modify the interaction between the ultimate metabolite and target macromolecule, resulting in increased or decreased sensitivity to the toxic and carcinogenic effects of xenobiotics.
Figure 10-1 The dose-response curve for acute chemical toxicity. Th, threshold dose; STh, subthreshold levels. (From Hughes WW: Essentials of Environmental Toxicology: The Effects of Environmentally Hazardous Substances on Human Health. Washington, DC, Taylor & Francis, 1996, p 33.)
Figure 10-2 Absorption and distribution of toxicants. (From Hodgson E, Levi PE: Absorption and distribution of toxicants. In Hodgson E, Levi PE (eds): A Textbook of Modern Toxicology. Stamford, CT, Appleton & Lange, 1997, p 52.)
Figure 10-3 Biotransformation of lipophilic toxicants to hydrophilic metabolites. (Adapted from Hodgson E: Metabolism of toxicants. In Hodgson E, Levi PE (eds): A Textbook of Modern Toxicology. Stamford, CT, Appleton & Lange, 1997, p 57.)
With this background of the principles of xenobiotic metabolism, we now examine some biochemical pathways that are involved in the processing of toxic chemicals using specific examples that are relevant to human disease. Each of the two phases of xenobiotic metabolism is discussed separately. The most important phase I reactions are 1. Cytochrome P-450- dependent monooxygenase system. This system, located in the smooth endoplasmic reticulum, is composed of a heme protein (cytochrome P-450); NADPH-P-450 reductase, which transfers electrons from the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) to cytochrome P-450; and phosphatidylcholine. The activity of this system is highest in the liver, followed by the skin, lung, and gastrointestinal mucosa. Different P-450 isozymes have different tissue distributions; these isozymes show preferential activity toward different substrates. An example of activation of a xenobiotic by cytochrome P-450 is metabolism of benzo[a]pyrene to a secondary metabolite that binds covalently
to DNA and causes lung and skin tumors (Fig. 10-4 A). Benzo[a]pyrene is one of several chemical carcinogens present in cigarette smoke. 2. Flavin-containing monooxygenase system. This is also located in the smooth endoplasmic reticulum in the liver. As shown in Figure 10-4 A, it oxidizes nicotine in cigarette smoke as well as other amines. 3. Peroxidase-dependent cooxidation. This reaction is catalyzed by prostaglandin-H synthase, an enzyme involved in arachidonic acid metabolism. It is located in the smooth endoplasmic reticulum with high activity in seminal vesicles, kidneys, and the urinary bladder. It is involved in the metabolism of 2-naphthylamine, a chemical found in synthetic dyes that is associated with an increased risk of bladder cancer (Fig. 10-4) . All of these oxidative reactions may generate oxygen free radicals as byproducts. Some of the primary metabolites are also highly reactive radicals with unpaired electrons (e.g., nitrogen- and carbon-centered radicals derived from 2-naphthylamine; Fig. 10-4) . As discussed in Chapter 1 , our cells have multiple defense mechanisms against free radicals, including enzymes such as superoxide dismutases, catalase, and glutathione reductase. Vitamins C and E, as well as beta-carotene, also serve as endogenous antioxidants. Reduced glutathione is a major defense mechanism against oxygen free radicals and toxic metabolites of xenobiotics. Xenobiotic metabolism may lead to depletion of cellular reduced glutathione in the setting of (1) cysteine or selenium deficiency, the two cofactors required for glutathione synthetase, or (2) excessive redox cycling of chemicals such as the herbicide paraquat ( Fig. 10-4 A). This compound undergoes cyclic oxidation and reduction in the lungs, resulting in generation of excess reactive oxygen species that cause acute lung injury and pulmonary edema. Oxidant stress occurs when endogenous free radical defense mechanisms are overwhelmed. As mentioned earlier, the products of phase I reactions are often conjugated with endogenous substrates to yield water-soluble end products that can be excreted from the body. Examples of such phase II reactions are as follows: 1. Glucuronidation. An alternative pathway for metabolism of naphthylamine is oxidation by cytochrome P-450 followed by glucuronidation in the liver. The secondary glucuronide metabolite is excreted in the urine. Under the acidic conditions in the urine, it gives rise to the ultimate carcinogen, N-hydroxy-2-naphthylamine (Fig. 10-4 B). This sequence of metabolic reactions ultimately leads to an increased incidence in cancer of the urinary bladder in workers exposed to synthetic dyes. 2. Biomethylation. Inorganic mercury, usually in the form of HgCl2 , causes necrosis of the proximal convoluted tubules of the kidneys. Occupational exposure to inorganic 407
mercury compounds usually occurs in industries that manufacture germicides, fungicides, electronics, and plastics. Mercury can be methylated by aquatic microorganisms that are subsequently ingested by herbivorous fish (Fig. 10-4 B). These fish are ingested by carnivorous fish, which may be eaten by humans. This
is an example of bioaccumulation of a toxic chemical in the environment. The tragic consequences of human exposure to methylmercury were realized in the 1950s and 1960s after an epidemic of poisoning in Minamato, Japan. Industrial discharge of mercury into a bay resulted in bioaccumulation of this toxicant a million-fold in fish. People who ingested these fish developed delayed paralysis and death. Methylmercury is more easily absorbed from the gastrointestinal tract than is inorganic mercury and readily crosses the blood-brain barrier and the placenta. The fetus is especially susceptible to methylmercury; the consequences of maternal exposure are fetal brain damage, mental retardation, and death. Dimethyl mercury is even more toxic; it can be absorbed via the skin or inhaled and can lead to severe neurotoxicity and death. [9A] 408
3. Glutathione conjugation. A common pathway for detoxification of primary metabolites is conjugation to reduced glutathione; these water-soluble secondary metabolites are readily excreted in the bile and urine. Vinyl chloride monomer is widely used in the manufacture of plastics, and it can cause angiosarcoma of the liver in exposed workers. Vinyl chloride is activated to a reactive intermediate by cytochrome P-450 in the liver. This intermediate can bind covalently to cellular macromolecules or be metabolized to chloroacetaldehyde and conjugated to reduced glutathione and excreted (Fig. 10-4 B).
Figure 10-4 A, Xenobiotic metabolism: phase I reactions. FMO, flavin-containing monooxygenase; PHS, prostaglandin-H synthases. B, Xenobiotic metabolism: phase II reactions (see text for details). (Adapted from Parkinson A: Biotransformation of xenobiotics. In Klaasen CD (ed): Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th ed. New York, McGraw-Hill, 1996, pp 113-186; and Hodgson E, Levi PE (eds): A Textbook of Modern Toxicology. Stamford, CT, Appleton & Lange, 1997, pp 57, 95.)
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 1 - GENERAL PATHOLOGY 11 - Diseases of Infancy and Childhood BIRTH WEIGHT AND GESTATIONAL AGE BIRTH INJURIES CONGENITAL MALFORMATIONS PERINATAL INFECTIONS NEONATAL RESPIRATORY DISTRESS SYNDROME (RDS) ERYTHROBLASTOSIS FETALIS--HEMOLYTIC DISEASE OF THE NEWBORN INBORN ERRORS OF METABOLISM AND OTHER GENETIC DISORDERS SUDDEN INFANT DEATH SYNDROME TUMORS AND TUMOR-LIKE LESIONS OF INFANCY AND CHILDHOOD REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
459
Chapter 11 - Diseases of Infancy and Childhood Deborah Schofield Ramzi S. Cotran
Children are not merely little adults, and the diseases they get are not merely variants of adult diseases. Many childhood conditions are unique to, or at least take distinctive forms in, this stage of life and so are discussed separately in this chapter. Diseases originating in the perinatal period are important in that they account for significant morbidity and mortality in the United States. As would be expected, the chances for survival of live-born infants improves with each passing week. The mortality rate in the first week of life is more than 10 times greater than in the second week. This striking differential represents, at least in part, a triumph of improved medical care. Better prenatal care, more effective methods of monitoring the condition of the fetus, and judicious resort to cesarean section before term when there is evidence of fetal distress all contribute to bringing onto this "mortal coil" live-born infants who in past years might have been stillborn. These infants represent an increased number of high-risk infants. Nonetheless, the infant mortality rate in the United States has shown a decline from a level of 20.0 deaths per 1000 population in 1970 to about 7.5 in 1995. [1] Although the death rate has continued to decline for all infants, American blacks continue to have more than twice (14.9 deaths per 1000) that of American whites (6.3 deaths per 1000). In addition, the infant mortality rate of the United States ranks 21st among industrialized countries. Variations on
460
the reporting of events among countries, however, may account for much of the differences. For example, birth weight-specific mortality rates are as low in the United States as in any other country in the world. Each stage of development of the infant and child is prey to a somewhat different group of disorders. The data available permit a survey of four time spans: (1) the neonatal period (the first 4 weeks of life), (2) infancy (the first year of life), (3) 1 to 4 years of age, and (4) 5 to 14 years of age. The single most hazardous period of life is unquestionably the neonatal period. Never again is the individual confronted with more dramatic
challenges than in the transition from dependent, intrauterine existence to independent, postnatal life. From the moment the umbilical cord is severed, the circulation through the heart and lungs is radically rerouted. Respiratory function must take over the role of oxygenation of the blood. Maintenance of body temperature and other homeostatic constants must now be borne alone by the fledgling organism. All these adaptations render the neonate particularly vulnerable. The number of deaths within the first year of life is almost twice as great TABLE 11-1 -- CAUSES OF DEATH AND AGE Causes* Under 1 Year: All Causes
Rate 752.4
Perinatal conditions Disorders related to short gestation and unspecified low birth weight Respiratory distress syndrome Conditions related to maternal complications of pregnancy Conditions related to complications of placenta, cord, and membranes Intrauterine hypoxia and birth asphyxia Congenital anomalies Sudden infant death syndrome Infections and pneumonia Accidents and adverse effects 1- 4 Years: All Causes
40.4
Accidents and adverse effects Congenital anomalies Malignant neoplasms Homicide and legal intervention Diseases of the heart 5- 14 Years: All Causes
22.1
Accidents and adverse effects Malignant neoplasms Homicide and legal intervention Congenital anomalies Suicide 15- 24 Years: All Causes Accidents and adverse effects
98.5
Homicide Suicide Malignant neoplasms Diseases of the heart *Causes are listed in decreasing order of frequency. Causes and rates for infants and children up to 14 years of age are preliminary 1995 statistics. [1] Causes and rates for children aged 15 to 24 years are sex-averaged, provisional 1994 statistics (Singh GK, et al: Annual summary of births, marriages, divorces, and deaths: United States, 1994. Monthly Vital Statistics Report 43:26, 1995).
Rates are expressed per 100,000 population. Excludes congenital heart disease.
as the number of deaths occurring in children ages 1 to 14 years. The major causes of death in infancy and childhood are cited in Table 11-1 . Congenital anomalies, disorders relating to short gestation and low birth weight, and sudden infant death syndrome (SIDS) represent the leading causes of death in the first 12 months of life. Once the infant survives the first year of life, the outlook brightens measurably. In the next two age groups--1 to 4 years and 5 to 14 years--injuries resulting from accidents have become the leading cause of death (Table 11-1) . Among the natural diseases, in order of importance, congenital anomalies and malignant neoplasms assume major significance. It would appear then that, in a sense, life is an obstacle course. For the great majority, the obstacles are surmounted or, even better, bypassed. We now take a closer look at the specific conditions encountered during the various stages of infant and child development.
BIRTH WEIGHT AND GESTATIONAL AGE Infants born before completion of the normal gestation period have higher morbidity and mortality rates than full-term infants. The vital organs of preterm infants are immature and therefore unable to adapt readily to early extrauterine existence. Infants who have failed to complete normal intrauterine growth weigh less than full-term infants, and in the past, premature infants were defined as those having a birth weight of less than 2500 gm. It is inaccurate, however, to define prematurity by birth weight alone because weight is only one of several measures of intrauterine growth. For example, an infant weighing 2300 gm and born at 34 weeks of gestation is likely to be physiologically immature and therefore at greater risk for suffering the consequences of organ system immaturity (e.g., respiratory distress syndrome [RDS] or transient hyperbilirubinemia) than a full-term infant also weighing 2300 gm but with corresponding functional maturity of most organ systems. Therefore, a system of classification that takes into account both gestational age and birth weight has been adopted. Infants are classified as being Appropriate for gestational age (AGA) Small for gestational age (SGA)
Large for gestational age (LGA) Infants whose birth weight falls between the 10th and the 90th percentiles for a given gestational age are considered AGA, whereas those who fall above or below these norms are classified as LGA or SGA. With respect to gestational age, infants born before 37 or 38 weeks are considered preterm, whereas those delivered after the 42nd week are considered post-term. The usefulness of this classification system is illustrated in Figure 11-1 , which graphically depicts the correlation among gestational age, birth weight, and risk of perinatal mortality. For example, an AGA 1500-gm infant born at 32 weeks of gestation has a mortality risk of up to 20%, whereas an SGA, 700-gm
461
Figure 11-1 Neonatal mortality risk based on actual data from 14,413 live births at the University of Colorado Health Sciences Center
from 1974 to 1980. Differentially shaded areas correspond to different mortality risks. For example, an infant born at 36 weeks of gestation and weighing 1250 gm has a mortality risk of 6%. If the same infant weighs 3000 gm, the risk of mortality falls to 0.2%. (Redrawn from Koops B, et al: Neonatal mortality risk in relation to birth weight and gestational age: update. J Pediatr 101:969, 1982.)
infant born at a similar gestational age has a mortality risk of about 60%. The variation in mortality (and morbidity) rates seen in these different birth weight/gestational age groups is a reflection of the different and distinctive diseases with which these infants are afflicted. We briefly discuss the group of infants that are SGA because prematurity and low birth weight are factors accounting for a significant proportion of perinatal mortality. Intrauterine Growth Retardation It is generally accepted that at least one third of infants who weigh less than 2500 gm are born at term and that they are therefore undergrown rather than immature. Hence, intrauterine growth retardation (IUGR) commonly underlies SGA. Significant IUGR (usually asymmetric) is occasionally present in an infant whose weight falls above the 5th to 10th percentile for age. IUGR can be detected before delivery by ultrasonographic measurement of various fetal parameters, such as biparietal diameter, head circumference, abdominal circumference, femur length (as an indicator of fetal length), head-to-abdominal circumference ratio, femur length-to-abdominal circumference ratio, and total intrauterine volume. Although in a significant percentage of infants with IUGR the cause is unknown, those factors known to result in IUGR can be divided into three main groups: fetal, placental, and maternal. Fetal: Fetal factors are those that intrinsically reduce growth potential of the fetus despite an adequate supply of nutrients from the mother. Prominent among such fetal conditions are chromosomal disorders, congenital anomalies, and congenital infections.[2] Chromosomal abnormalities may be detected in up to 17% of fetuses sampled for IUGR and in up to 66% of fetuses with documented ultrasonographic malformations. [3] Among the first group, the abnormalities include triploidy (7%),
trisomy 18 (6%), trisomy 21 (1%), trisomy 13 (1%), and a variety of deletions and translocations (2%). Fetal infection should be considered in all infants with IUGR. Those most commonly responsible for IUGR are cytomegalovirus, rubella, syphilis, and toxoplasmosis. Infants who are SGA because of fetal factors are usually characterized by symmetric growth retardation (also referred to as proportionate IUGR), meaning that all organ systems are similarly affected. [4] Placental: During the third trimester of pregnancy, vigorous fetal growth places particularly heavy demands on the uteroplacental supply line. Therefore, the adequacy of placental growth in the preceding midtrimester is extremely important, and uteroplacental insufficiency is an important cause of growth retardation. This insufficiency may result from umbilical-placental vascular anomalies (such as single umbilical artery, abnormal cord insertion, placental hemangioma), placental abruption, placenta previa, placental thrombosis and infarction, placental infection, or multiple gestations (Chapter 24) . In some cases, the placenta may be small without any detectable underlying cause. Placental causes of IUGR tend to result in asymmetric (or disproportionate) growth retardation of the fetus with relative sparing of the brain. Physiologically, this general type of IUGR is viewed as a down-regulation of growth in the latter half of gestation because of limited availability of nutrients or oxygen. [5] Confined placental mosaicism is a more recently discovered cause of IUGR [6] and has been documented in up to 2% of viable pregnancies studied by chorionic villus sampling at 9 to 11 weeks' gestation. Chromosomal mosaicism, in general, results from viable genetic mutations occurring after zygote formation. Depending on the developmental timing and cell of origin of the mutation, variable forms of chromosomal mosaicism result. For example, genetic mutations occurring at the time of the first or second postzygotic division result in generalized constitutional mosaicism of the fetus and placenta. Conversely, if the mutation occurs later and within dividing trophoblast or extraembryonic progenitor cells of the inner cell mass (approximately 90% of the time), a genetic abnormality limited to the placenta results--confined placental mosaicism (Fig. 11-2) . The phenotypic consequences of such placental mosaicism depend on both the specific cytogenetic abnormality and the percentage of cells involved. Chromosomal trisomies, in particular trisomy 7, are the most frequent abnormality documented. Maternal: By far the most common factors associated with SGA infants are maternal because many conditions affecting the mother's health result in decreased placental blood flow. Vascular diseases, such as toxemia and chronic hypertension, are often the underlying cause. The list of other maternal conditions associated with 462
SGA infants is long, [7] but some of the avoidable factors worth mentioning are maternal narcotic abuse, alcohol intake, and heavy cigarette smoking. Drugs causing IUGR include both classic teratogens, such as antimetabolites, and some commonly administered therapeutic agents, such as phenytoin (Dilantin). Maternal malnutrition (in particular, prolonged hypoglycemia) may also affect fetal growth, but the association between SGA infants and the nutritional status of the mother is complex.
Figure 11-2 Diagrammatic representation of constitutional chromosomal mosaicism. A , Generalized. B , Confined to the placenta. C, Confined to the embryo. (Modified and redrawn from Kalousek DK: Confined placental mosaicism and intrauterine development. Pediatr Pathol 10:69, 1990.)
The SGA infant faces a difficult course, not only in the perinatal period, while struggle for survival is the main objective, but also in childhood and adult life. Depending on the underlying cause of IUGR and, to a lesser extent, the degree of prematurity, there is a significant risk of morbidity in the form of a major handicap, cerebral dysfunction, learning disability, or hearing and visual impairment. Immaturity of Organ Systems A major problem confronting the preterm infant regardless of birth weight is the functional and sometimes structural immaturity of various organs. Those who are also SGA are the most seriously handicapped. Because immaturity may be the direct cause of death in early preterm infants and significantly biases the probable outcome in others, it is appropriate to consider the features of immaturity of the more vital organs. LUNGS
During the first half of fetal life, the development of the lungs consists essentially of the formation of a system of branching tubes from the foregut that eventually give rise to the trachea, bronchi, and bronchioles. The alveoli begin to differentiate only at approximately the seventh month of gestation. They are at first imperfectly formed, with thick walls, large amounts of interlobular and intralobular connective tissue, and a cuboidal epithelium. The vascularization is buried within this connective tissue and is not in immediate contact with the alveolar spaces (Fig. 11-3) . Between the 26th and 32nd weeks of gestation, the cuboidal epithelium shows transition to the flat, type I alveolar epithelial cells as well as type II cells that contain lamellar bodies (Chapter 16) . Further maturation of the lungs leads to reduction in the interstitial tissues and increasing numbers of capillaries. Even at full term, however, the alveoli are small and the septa are considerably thicker than in the adult. Development of alveoli continues after birth, and the full adult complement of alveoli is reached at about 8 years of age. The immature lungs are grossly unexpanded, red, and meaty. The alveolar spaces are incompletely expanded and often lined by cuboidal epithelium and usually contain pink proteinaceous precipitate and occasional squamous epithelial
463
Figure 11-3 Schematic diagrams of fetal lung maturation.
cells. The presence of large amounts of amniotic debris, such as squames, lanugo hair, and mucus, usually indicates prenatal respiratory distress. KIDNEYS
In the preterm infant, the formation of glomeruli is incomplete. Primitive glomeruli can be seen in the subcapsular zone. These structures have an organoid, glandular appearance imparted by the presence of cuboidal cells in the parietal and visceral layers of Bowman capsule. The deeper glomeruli are well formed, however, and renal function is adequate to permit survival. BRAIN
The brain is also incompletely developed in the preterm infant. The surface is relatively smooth and devoid of the typical convolutions found in the cerebral hemispheres of the adult. The brain substance is soft, gelatinous, and easily torn. There is poorly developed myelination of the nerve fibers. To the best of present knowledge, despite this underdevelopment, the vital brain centers are sufficiently developed, even in the very immature infant, to sustain normal central nervous system function. Homeostasis is not perfect, however, and the preterm infant has difficulty in maintaining a constant normal level of temperature and has poor vasomotor control, irregular respirations, muscular inertia, and feeble sweating. LIVER
The liver, although large relative to the size of the preterm infant, suffers from lack of physiologic maturity. Some of this increase in size is due to persistence of extramedullary hematopoiesis in this organ. Many or most of the functions of the liver are marginally adequate to carry out the demands placed on them. Almost all newborns and particularly those of low birth weight have a transient period of physiologic jaundice within the first postnatal week. This jaundice stems from both breakdown of fetal red cells and inadequacy of the biliary excretory function of liver cells. Apgar Score The Apgar score, devised by Virginia Apgar, represents a clinically useful method of evaluating the physiologic condition and responsiveness of newborn infants and hence their chances of survival. [8] Table 11-2 (Table Not Available) indicates the five parameters to be scored and how they are quantitated. The newborn infant may be evaluated at 1 minute or at 5 minutes. A total score of 10 indicates an infant in the best possible condition. The correlation between the Apgar score and the mortality during the first 28 days of life is impressive. Infants with a 5-minute Apgar score of 0 to 1 have a 50% mortality within the first month of life. This
TABLE 11-2 -- EVALUATION OF THE NEWBORN INFANT* (Not Available) Modified from Apgar V: A proposal for a new method of evaluation of the newborn infact. Anesth Analg 32:260, 1953. *Sixty seconds after the complete birth of the infant (disregarding removal of the cord and placenta),the five objective signs are evaluated and each is given a score of 0, 1, or 2. A total score of 10 indicates an infant in the best possible condition.
464
drops to 20% with a score of 4 and to almost 0% when the score is 7 or better. [9] Despite the established value of the Apgar score in predicting perinatal morbidity, particularly in normal-birth-weight infants, it is not a reliable indicator of long-term neurologic morbidity. [10] Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 12 - Blood Vessels NORMAL VASCULATURE VASCULAR WALL CELLS AND THEIR RESPONSE TO INJURY VASCULAR DISEASES - Part 1 VASCULAR DISEASES - Part 2 REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 13 - The Heart NORMAL HEART PRINCIPLES OF CARDIAC DYSFUNCTION TYPES OF HEART DISEASE - Part 1 TYPES OF HEART DISEASE - Part 2 CARDIAC TRANSPLANTATION REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
543
Chapter 13 - The Heart Frederick J. Schoen
The human heart is a remarkably efficient, durable, and reliable pump that propels more than 6000 liters of blood through the body daily during an individual's lifetime, thereby providing the tissues with a steady supply of vital nutrients and facilitating the excretion of waste products. As might be anticipated, cardiac dysfunction can be associated with devastating physiologic consequences. Heart disease is the predominant cause of disability and death in
544
industrialized nations. In the United States, it currently accounts for about 40% of all postnatal deaths totaling about 750,000 individuals annually and nearly twice the number of deaths caused by all forms of cancer combined. The yearly economic burden of ischemic heart disease (IHD), the most prevalent subgroup, is estimated to be in excess of $100 billion. The major categories of cardiac diseases considered in this chapter include obstructive coronary artery disease (also called IHD), heart disease caused by systemic hypertension, heart disease caused by pulmonary diseases (cor pulmonale), valvular heart diseases, primary myocardial diseases, and congenital heart diseases. Pericardial diseases and cardiac neoplasms as well as cardiac transplantation are also briefly discussed. Before considering details of specific conditions, we review salient features of normal anatomy and function as well as the principles of cardiac hypertrophy and failure, the common end points of many different types of heart disease.
NORMAL HEART The normal heart weight varies with body height and weight; it averages approximately 250 to 300 gm in females and 300 to 350 gm in males. The expected thickness of the free wall of the right ventricle is 0.3 to 0.5 cm and that of the left ventricle 1.3 to 1.5 cm. Increases in cardiac size and weight accompany many forms of heart disease. Greater heart weight or ventricular thickness indicates hypertrophy, and an enlarged chamber size implies dilation. Wall thickness itself may not be a good measure of increased
cardiac mass. For example, an apparently normal (or less than normal) left ventricular thickness may be found in a markedly heavy, hypertrophied heart that has dilated before death. An increase in cardiac weight or size is termed cardiomegaly. Myocardium Basic to the heart's function is the near-inexhaustible cardiac muscle, the myocardium, composed primarily of a collection of branching and anastomosing striated muscle cells ( cardiac myocytes). They, in turn, have five major components: (1) cell membrane (sarcolemma) and T tubules, for impulse conduction; (2) sarcoplasmic reticulum, a calcium reservoir needed for contraction; (3) contractile elements; (4) mitochondria; and (5) the nucleus. Cardiac muscle cells contain many more mitochondria between myofibrils than skeletal muscle cells (approximately 23% of cell volume versus 2%), reflecting the extreme dependence of cardiac muscle on aerobic metabolism. The functional intracellular contractile unit of cardiac muscle is a sarcomere, an orderly arrangement of thick filaments composed principally of myosin, thin filaments containing actin as well as the regulatory proteins troponin and tropomyosin. As in skeletal muscle, the ends of each sarcomere are demarcated by a Z-line, to which the thin filaments are anchored. Relative to skeletal muscle, however, cardiac muscle has a more complex structure consisting of individual branching cells, usually containing one spindle-shaped nucleus each and many parallel myofilaments (arrays of sarcomeres in series). Contraction of cardiac muscle occurs by the cumulative effort of sliding of the actin filaments between the myosin filaments toward the center of each sarcomere. The lengths of sarcomeres range from 1.6 to 2.2 mum, depending on the state of contraction. Shorter sarcomeres have considerable overlap of actin and myosin filaments, with consequent reduction in contractile force, whereas longer lengths enhance contractility (Frank-Starling mechanism). Thus, moderate ventricular dilation increases the force of contraction. There is a point, however, with progressive dilation at which effective overlap of the actin and myosin filaments is reduced, and the force of contraction turns sharply downward, as occurs in heart failure. Because cardiac myocytes are so much larger than the intervening interstitial cells, they account for more than 90% of the volume of the myocardium. Myocytes, however, compose only approximately 25% of the total number of cells in the heart. The remainder are endothelial cells, mostly associated with the rich capillary network, and connective tissue cells. Inflammatory cells are rare and collagen is sparse in normal myocardium. Reflecting their different functional requirements, atrial myocytes are generally smaller in diameter and less structured than their ventricular counterparts. Some atrial cells also differ from ventricular cells in having distinctive electron dense granules in the cytoplasm called specific atrial granules. They are the site of storage of atrial natriuretic peptide, a polypeptide synthesized in the atrial muscle cells and secreted into the blood under conditions of atrial pressure elevation and distention. Atrial natriuretic peptide can produce a variety of physiologic effects, including vasodilation, natriuresis, suppression of the renin-angiotensin-aldosterone axis, and a fall in arterial pressure, [1] actions
beneficial in pathologic states such as hypertension and congestive heart failure. Functional integration of myocytes is mediated by structures unique to cardiac muscle called intercalated discs that join individual cells, within which specialized intercellular junctions permit both mechanical and ionic coupling. Most importantly, gap junctions facilitate synchronous myocyte contraction by providing electrical coupling with relatively unrestricted passage of ions across the membranes of adjoining cells. Gap junctions consist of clusters of plasma membrane channels that directly link the cytoplasmic compartments of neighboring cells. Abnormalities in the spatial distribution of gap junctions and their respective proteins in IHD and myocardial heart disease may contribute to electromechanical dysfunction (arrhythmias). [2] In addition, specialized excitatory and conducting myocytes within the cardiac conduction system are involved in the regulation of the rate and rhythm of the heart. Components include (1) the sinoatrial (SA) pacemaker of the heart, the SA node, located near the junction of the right atrial appendage with the superior vena cava; (2) the atrioventricular ( AV) node, located in the right atrium along the atrial septum; (3) the bundle of His, which courses from
545
the right atrium to the summit of the ventricular septum; and division of the bundle of His into limbs, and (4) the right and left bundle branches that further arborize in the respective ventricles. Blood Supply Generating energy almost exclusively by the oxidation of substrates, the heart relies heavily on an adequate flow of oxygenated blood through the coronary arteries. With origins from the aorta immediately distal to the aortic valve, the coronary arteries consist of 5 to 10 cm long, 2 to 4 mm diameter conduits that run along the external surface of the heart ( epicardial coronary arteries) and smaller vessels that penetrate the myocardium ( intramural arteries). The three major epicardial coronary arteries are (1) the left anterior descending (LAD) and (2) the left circumflex (LCX) artery, both arising as branches from a bifurcation of the left (main) coronary artery, and (3) the right coronary artery (RCA). Branches of the LAD are called diagonals and septal perforators, and those of the LCX are obtuse marginals. Most coronary arterial blood flow to the myocardium occurs during ventricular diastole, when the microcirculation is not compressed by the cardiac contraction. Knowledge of the areas of supply ( perfusion) of the three major coronary arteries helps correlate sites of vascular obstruction with regions of myocardial infarction. Most commonly, the LAD supplies most of the apex of the heart (the rounded point at the distal parts of the ventricles as contrasted with the wide proximal part, the base), the anterior wall of the left ventricle, and the anterior two thirds of the ventricular septum. By
convention, whichever coronary artery gives rise to the posterior descending branch and thereby perfuses the posterior third of the septum is called dominant (although the LAD and LCX collectively perfuse the majority of the left ventricular myocardium--the LAD itself about 50%). In a right dominant circulation, present in approximately four fifths of individuals, the circumflex branch of the left coronary artery generally perfuses only the lateral wall of the left ventricle, and the RCA supplies the entire right ventricular free wall and the posterobasal wall of the left ventricle and the posterior third of the ventricular septum. Thus, occlusions of the right as well as the left coronary arteries can cause left ventricular damage. Functionally the right and left coronary arteries behave as end arteries, although anatomically there are numerous intercoronary anastomoses in most hearts (called the collateral circulation). Little blood courses through these channels in the normal heart. When one artery is severely narrowed, however, blood flows via collaterals from the high to the low pressure system and causes the channels to enlarge. Progressive dilation of collaterals, stimulated by ischemia (see later), may play a role in providing blood flow to areas of the myocardium otherwise deprived of adequate perfusion. When blood flow is compromised and collateral blood flow is inadequate, however, the subendocardium (myocardium adjacent to the ventricular cavities) represents the area most susceptible to ischemic damage. Valves The four cardiac valves function to maintain unidirectional blood flow. During closure, the three cusps of the semilunar valves (aortic and pulmonary) overlap along an area (the lunula) between the free edge and the closing edge. The coaptation area is substantial; in the aortic valve, for example, the total cuspal area is approximately one third greater than the valve orifice area. Because only the portion of the cusps below the closing edge separates aortic from left ventricular cavity blood, the occasionally occurring defects or fenestrations of the cusp in the lunula usually do not compromise valve competence. Each aortic cusp has a small nodule ( nodule of Arantius) in the center of the free edge, which facilitates closure. On gross inspection, normal valve cusps appear thin and translucent. The free margins of the AV valves (mitral and tricuspid) are tethered to the ventricular wall by many delicate tendinous cords ( chordae tendineae), attached to papillary muscles that are contiguous with the underlying ventricular walls. Left ventricular papillary muscles are themselves positioned beneath the commissures and thereby receive cords from two adjacent leaflets. Thus, normal mitral valve competency depends on the coordinated actions of annulus, leaflets, cords, papillary muscles, and associated left ventricular wall (collectively the mitral apparatus) acting to maintain leaflet coaptation in the annulus. Tricuspid valve function depends on analogous structures. The function of semilunar valves similarly depends on the integrity and coordinated movements of the cusps and their attachments. Thus, dilation of the aortic root can hinder coaptation of the aortic valve cusps during closure, just as left ventricular dilation or a ruptured cord or papillary muscle can interfere with mitral closure, each resulting in regurgitant flow.
The cardiac valves are lined with endothelium; all have a similar, layered architecture consisting predominantly of a dense collagenous core ( fibrosa) close to the outflow surface and continuous with valvular supporting structures and loose connective tissue ( spongiosa) near to the inflow surface. [3] The fibrosa maintains the structural integrity of a valve, and the spongiosa functions as a shock absorber. In general, normal leaflets and cusps have scant blood vessels limited to the proximal portion because they are thin enough to be nourished by diffusion from the heart's blood. Effects of Aging on the Heart With an increasing number of persons surviving into their seventies and beyond, knowledge of changes in the cardiovascular system that frequently occur with aging is important. Changes occur in the pericardium, cardiac chambers, valves, epicardial coronary arteries, conduction system, myocardium, and aorta (Table 13-1) . [4] With advancing age, the amount of epicardial fat increases, particularly over the anterior surface of the right ventricle and in the atrial septum. Associated with increasing age and accentuated by systemic hypertension is a
546
TABLE 13-1 -- CHANGES IN THE AGING HEART Chambers Increased left atrial cavity size Decreased left ventricular cavity size Sigmoid-shaped ventricular septum Valves Aortic valve calcific deposits Mitral valve annular calcific deposits Fibrous thickening of leaflets Hooding of mitral leaflets toward the left atrium Lambl excrescences Epicardial Coronary Arteries Tortuosity Increased cross-sectional luminal area Calcific deposits Atherosclerotic plaque
Myocardium (Walls) Increased mass Increased subepicardial fat Brown atrophy Lipofuscin deposition Basophilic degeneration Amyloid deposits Aorta Dilated ascending aorta with rightward shift Elongated (tortuous) thoracic aorta Sinotubular junction calcific deposits Elastic tissue fragmentation and collagen accumulation Atherosclerotic plaque reduction in the size of the left ventricular cavity, particularly in the base-to-apex dimension. Accompanied by a rightward shift and tortuosity of a dilated ascending aorta, this chamber alteration causes the basal ventricular septum to bend leftward, bulging into the left ventricular outflow tract (termed sigmoid septum), and can simulate the obstruction to blood leaving the left ventricle that often occurs with hypertrophic cardiomyopathy (HCM) (discussed later). Several changes of the valves are noted, including calcification of the mitral annulus and aortic valve, the latter frequently leading to aortic stenosis (see discussion later). In addition, the valves develop fibrous thickening, and the mitral leaflets tend to buckle back toward the left atrium during ventricular systole, simulating a prolapsing (myxomatous) mitral valve (see later). Moreover, many older persons develop small filiform processes ( Lambl excrescences) on the closure lines of aortic and mitral valves that probably arise from organization of small thrombi on the valve contact margins. Compared with younger myocardium, elderly myocardium also has fewer myocytes, increased collagenized connective tissue, and, in some individuals, deposition of amyloid. In the muscle cells, lipofuscin deposits (Chapter 1) and basophilic degeneration, an accumulation within cardiac myocytes of a gray bluish-appearing byproduct of glycogen metabolism, may be present. Extensive lipofuscin deposition in a small, atrophied heart is often called brown atrophy. Although the morphologic changes described are common in elderly patients at necropsy and they may mimic disease, only in a minority are they associated with clinical cardiac dysfunction.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 14 - Red Cells and Bleeding Disorders NORMAL PATHOLOGY - Part 1 PATHOLOGY - Part 2 REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
601
Chapter 14 - Red Cells and Bleeding Disorders The bone marrow, lymph nodes, and spleen are involved in hematopoiesis. These organs and tissues have traditionally been divided into myeloid tissue, which includes the bone marrow and the cells derived from it (e.g., erythrocytes, platelets, granulocytes, and monocytes), and lymphoid tissue, consisting of thymus, lymph nodes, and spleen. This subdivision is artificial with respect to both the normal physiology of hematopoietic cells and the diseases affecting them. For example, although bone marrow is not the site where most of the mature lymphoid cells are found, it is
602
the source of lymphoid stem cells. Similarly, leukemias, which are neoplastic disorders of the leukocytes, originate within the bone marrow but involve the lymph nodes and spleen quite prominently. Some red cell disorders (hemolytic anemias) result from the formation of autoantibodies, signifying a primary disorder of the lymphocytes. Thus, it is not possible to draw neat lines between diseases involving the myeloid and lymphoid tissues. Recognizing this difficulty, we have somewhat arbitrarily divided diseases of the hematopoietic tissues into two chapters. In the first, we consider diseases of red cells and those affecting hemostasis. In the second, we discuss diseases affecting the leukocytes and the lymph nodes and disorders affecting primarily the spleen and thymus.
NORMAL A complete discussion of normal hematopoiesis is beyond our scope, but certain features are helpful to an understanding of the diseases of blood. NORMAL DEVELOPMENT OF BLOOD CELLS In the human embryo, clusters of stem cells, called blood islands, appear in the yolk sac in the third week of fetal development. [1] Recent data suggest that hematopoietic stem cells may also arise in the intraembryonic aorta/gonad/mesonephros and that germ cells may give rise to hematopoietic stem cells. At about the third month of embryogenesis, some of these cells migrate to the liver, which then becomes the chief site of blood cell formation until shortly before birth. Beginning in the fourth month of development, hematopoiesis commences in the bone marrow. At birth, all the marrow throughout the
skeleton is active and is virtually the sole source of blood cells. In the full-term infant, hepatic hematopoiesis has dwindled to a trickle but may persist in widely scattered small foci, which become inactive soon after birth. Up to the age of puberty, all the marrow throughout the skeleton is red and hematopoietically active. Usually by 18 years of age only the vertebrae, ribs, sternum, skull, pelvis, and proximal epiphyseal regions of the humerus and femur retain red marrow, the remaining marrow becoming yellow, fatty, and inactive. Thus, in adults, only about half of the marrow space is active in hematopoiesis. Several features of this normal sequence should be emphasized. By the time of birth, the bone marrow is virtually the sole source of all forms of blood cells and a major source of lymphocyte precursors. In the premature infant, foci of hematopoiesis are frequently evident in the liver and, rarely, in the spleen, lymph nodes, or thymus. However, significant postembryonic extramedullary hematopoiesis is abnormal in the full-term infant. With an increased demand for blood cells in the adult, the fatty marrow may become transformed to red, active marrow. Moreover, this is accompanied by increased productive activity throughout the marrow. These adaptive changes are capable of increasing red cell production (erythropoiesis) sevenfold to eightfold. Thus, if the marrow precursor cells are not destroyed by metastatic cancer or irradiation, for example, and necessary substrate is available (e.g., adequate amounts of iron, protein, requisite vitamins), such loss of red cells as may occur in hemolytic disorders produces anemia only when the marrow compensatory mechanisms are outstripped. Under these circumstances, extramedullary hematopoiesis may reappear, first within the liver and then in the spleen and lymph nodes. Origin and Differentiation of Hematopoietic Cells
There is little doubt that the formed elements of blood--erythrocytes, granulocytes, monocytes, platelets, and lymphocytes--have a common origin in a pluripotent hematopoietic stem cell. [1] This common precursor then gives rise to lymphoid stem cells and the trilineage myeloid stem cells, which are committed to produce lymphocytes and the myeloid cells, respectively (Fig. 14-1) . The recently identified lymphoid stem cell gives rise to precursors of T cells (pro-T cells), B cells (pro-B cells), and possibly natural killer (NK) cells. [1A] The details of lymphoid differentiation are not discussed here, but it is worth pointing out that unlike myeloid differentiation, there are no distinctive, morphologically recognizable stages. For definition, reliance must be placed on the detection of differentiation-specific antigens by monoclonal antibodies (Chapter 15) . From the multipotent myeloid stem cell arise at least three types of committed stem cells capable of differentiating along the erythroid/megakaryocytic, eosinophilic, and granulocyte-macrophage pathways. The committed stem cells have been called colony-forming units (CFU) because they give rise to colonies of differentiated progeny in vitro (Fig. 14-1) . From the various committed stem cells are derived intermediate stages and ultimately the morphologically recognizable precursors of the differentiated cell lines, that is, proerythroblasts, myeloblasts, megakaryoblasts, monoblasts, and eosinophiloblasts. These in turn give rise to mature progeny. Since the mature blood elements have a finite life span, it follows that their numbers must be constantly replenished. This can be realized if the stem cells possess the capacity not only to differentiate but also to renew themselves. Thus, self-renewal is an important property of stem cells. The pluripotent stem cells have the greatest capacity for self-renewal, but
normally most of them are not in cell cycle. As commitment proceeds, self-renewal ability becomes limited, but a greater fraction of the stem cells are found to be in cycle. For example, few trilineage myeloid stem cells are normally in cell cycle, but up to 50% of CFU-GM (the precursors of granulocytes and macrophages) are synthesizing DNA. This suggests that normally the pool of differentiated cells is replenished mainly by the proliferation of restricted stem cells. Although the earliest recognizable precursors (e.g., myeloblasts or proerythroblasts)
603
Figure 14-1 Differentiation of hematopoietic cells. SCF, stem cell factor; Flt3L, Flt3 ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor. (Modified from Wyngaarden JB, et al [eds]: Cecil Textbook of Medicine, 19th ed. Philadelphia, WB Saunders, 1992, p 820.)
604
are in active cell division, they cannot self-replicate; that is, they differentiate and "die." By definition, then, they are not stem cells. Since most forms of marrow failure or neoplastic disorders (e.g., aplastic anemias, leukemias, polycythemia) are disorders of stem cells, much interest is centered on the physiologic mechanisms that regulate the proliferation and differentiation of progenitor cells. Involved in these processes are soluble factors as well as stromal cells of the bone marrow. Among the hematopoietic growth factors, some, such as stem cell factor (also called c- kit ligand) and flt3-ligand (flt3-L), act on the most immature stem cell. Others, such as the granulocyte-macrophage colony-stimulating factor (GM-CSF), act on CFU-GM. Because genes for most of the growth factors have been cloned, large amounts of recombinant proteins can be generated. Some recombinant factors are currently being used to stimulate hematopoiesis. Included in this group are erythropoietin, GM-CSF, G-CSF, and thrombopoietin. Normal Anatomy and Morphology of Bone Marrow.
The bone marrow not only is a reservoir of stem cells but also provides a unique microenvironment in which the orderly proliferation and differentiation of precursor cells takes place. In addition, it regulates the release of fully differentiated cells into the circulation. Under the electron microscope, the marrow cavity appears to be a vast network of thin-walled sinusoids lined by a single layer of endothelial cells. Basement membrane and adventitial cells are present, but they form a discontinuous layer outside the endothelium. In between the sinusoidal network lie clusters of hematopoietic cells and fat cells. Differentiated blood cells enter the sinusoids by transcellular migration through the endothelial cells. That this process is finely regulated is attested to by the fact that when hematopoiesis takes place at extramedullary sites, for example, the spleen (Chapter 15) , the peripheral blood contains all forms of abnormal as well as
primitive blood cells that do not enter the blood in normal medullary hematopoiesis. MORPHOLOGY.
Although the morphology of the hematopoietic cells within the bone marrow is best studied in smears of marrow aspirates, useful information can also be obtained by studying the histology of bone marrow biopsy specimens. For example, a reasonable estimate of marrow activity may be obtained by examining the ratio of fat cells to hematopoietic elements in bone marrow biopsy samples. In normal adults, this ratio approaches 1:1, but with marrow hypoplasia (e.g., aplastic anemia), the proportion of fat cells is greatly increased, and conversely, fat cells may virtually disappear in diseases characterized by increased hematopoiesis (e.g., hemolytic anemias). When subjected to fixatives and tissue staining methods, the cells of the bone marrow and peripheral blood differ in appearance from those in air-dried Giemsa- or Wright-stained preparations. While the earliest cells of the myeloid and erythroid lineages (myeloblasts, pronormoblasts) can usually be distinguished in stained marrow aspirates, it is extremely difficult, if not impossible, to differentiate in tissue sections the various "blast" forms. Often, tentative identification must be made on the basis of "the company they keep." Thus, a primitive cell found in relation to a focus of granulocytes is likely to be a myeloblast. The relative proportion of cells in the bone marrow is almost always deranged in diseases of the blood and bone marrow. The marrow normally contains about 60% granulocytes and their precursors; 20% erythroid precursors; 10% lymphocytes and monocytes and their precursors; and 10% unidentified or disintegrating cells. Thus, the normal myeloid to erythroid ratio is 3:1. The dominant cell types in the myeloid compartment include myelocytes, metamyelocytes, and granulocytes. In the erythroid compartment, the dominant forms are polychromatophilic and orthochromic normoblasts. We now turn to consider the various disorders of the red blood cells.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 15 - White Cells, Lymph Nodes, Spleen, and Thymus White Cells and Lymph Nodes Spleen Thymus REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
644
Chapter 15 - White Cells, Lymph Nodes, Spleen, and Thymus Jon Aster Vinay Kumar
645
White Cells and Lymph Nodes NORMAL WHITE CELLS AND LYMPH NODES The origin and differentiation of white cells (granulocytes, monocytes, and lymphocytes) were briefly discussed in Chapter 14 . Lymphocytes and monocytes not only circulate in the blood and lymph, but also accumulate in discrete, organized masses, the so-called lymphoreticular system. Components of this system include lymph nodes, thymus, spleen, tonsils, adenoids, and Peyer patches. Less discrete collections of lymphoid cells occur in the bone marrow, lungs, gastrointestinal tract, and other tissues. Lymph nodes are the most widely distributed and easily accessible component of the lymphoid tissue and are hence frequently examined for the diagnosis of lymphoreticular disorders. Therefore, it is advantageous to review the normal morphology of lymph nodes (shown schematically in Fig. 15-1) . Lymph nodes are discrete structures surrounded by a capsule composed of connective tissue and a few elastic
Figure 15-1 Normal lymph node architecture. A , Schematic diagram of a lymph node illustrating the blood and lymphatic supply and the distribution of B- and T-cell zones. B , Low-power view of a lymph node. (Modified from Abbas AK, et al [eds]: Cellular and Molecular Immunology, 3rd ed. Philadelphia, WB Saunders, 1997, p 30.)
646
fibrils. The capsule is perforated by multiple afferent lymphatics that empty into a fenestrated subcapsular peripheral sinus. Lymph extravasates from this sinus and slowly percolates through the node, eventually collecting in medullary sinusoids and exiting through a single efferent lymphatic vessel in the hilus, which also serves as the point of penetration by a single small artery and vein. Situated in the cortex subjacent to the peripheral sinus are spherical aggregates of lymphoid cells, the so-called primary follicles, that represent the B-lymphocyte areas. Between the primary follicles is the paracortex, a region rich in T lymphocytes. Deep to the cortex lies the medulla, a region containing numerous plasma cells and relatively few lymphocytes. This morphologic description of the lymph node is highly idealized and falsely static. As secondary lines of defense, they are constantly responding to stimuli, even in the absence of clinical disease. Within several days of antigenic stimulation, the primary follicles enlarge and develop pale-staining germinal centers composed of follicular center cells that are surrounded by mantle zones containing small unchallenged B cells. In some reactive conditions, a rim of B lymphoid cells with slightly more cytoplasm accumulates outside of the mantle zone; cells occupying this region are called marginal zone B cells. The paracortical T-cell zones also frequently undergo hyperplasia. The degree and pattern of morphologic change depend on the inciting factor and the intensity of the subsequent immune response. Trivial injuries and infections effect subtle changes in lymph node histology, while more significant bacterial infections inevitably produce enlargement of nodes and sometimes leave residual scarring. For this reason, lymph nodes in the adult are almost never "normal" and usually bear the scars of previous events. Except in children, it is difficult to find architecturally unaltered nodes, and in histologic evaluations it is often necessary to distinguish changes secondary to past experience from those related to present disease. Disorders of white cells may be classified into two broad categories: proliferative and those characterized by a deficiency of leukocytes, that is, leukopenias. Proliferations of white cells may be reactive or neoplastic. Since their major function is host defense, reactive proliferation in response to an underlying primary, often microbial, disease is fairly common. Neoplastic disorders, although less frequent, are much more important. In the following discussion, we describe first the leukopenic states and summarize the common reactive disorders, then consider in some detail malignant proliferations of white cells. LEUKOPENIA The number of circulating white cells may be markedly decreased in a variety of disorders. An abnormally low white cell count ( leukopenia) usually results from reduced numbers of neutrophils ( neutropenia, granulocytopenia). Lymphopenia is less common, and in addition to the congenital immunodeficiency diseases (Chapter 7) , it is most commonly observed in specific settings, such as advanced human immunodeficiency virus (HIV) infection, after therapy with glucocorticoids or cytotoxic drugs, autoimmune
disorders, malnutrition, and certain acute viral infections. Only the more common leukopenias involving granulocytes are discussed further here. Neutropenia (Agranulocytosis)
Reduction in the number of granulocytes in the peripheral blood ( neutropenia) may be seen in a wide variety of circumstances. A marked reduction in neutrophil count has serious consequences by predisposing to infections. When of this magnitude, it is referred to as agranulocytosis. Pathogenesis.
A reduction in circulating granulocytes occurs if (1) there is reduced or ineffective production of neutrophils or (2) there is accelerated removal of neutrophils from the circulating blood. Inadequate or ineffective granulopoiesis is observed in the setting of Suppression of myeloid stem cells, as occurs in aplastic anemia (Chapter 14) and a variety of infiltrative marrow disorders (e.g., tumors, granulomatous disease)--in these conditions, granulocytopenia is accompanied by anemia and thrombocytopenia Suppression of the committed granulocytic precursors, which occurs after exposure to certain drugs, as discussed subsequently Disease states characterized by ineffective granulopoiesis, such as megaloblastic anemias caused by vitamin B12 or folate deficiency (Chapter 14) and myelodysplastic syndromes, in which defective precursors are susceptible to intramedullary death Rare inherited conditions (such as Kostmann syndrome) in which genetic defects in specific genes result in impaired granulocytic differentiation Accelerated removal or destruction of neutrophils is encountered with Immunologically mediated injury to the neutrophils, which may be idiopathic, associated with a well-defined immunologic disorder (e.g., systemic lupus erythematosus), or produced by exposure to drugs Splenic sequestration, in which excessive destruction occurs secondary to enlargement of the spleen, usually also associated with increased destruction of red cells and platelets Increased peripheral use, as may occur in overwhelming bacterial, fungal, or rickettsial infections Among the many associations mentioned, the most significant neutropenias (agranulocyloses) are produced by drugs. Certain drugs, such as alkylating agents and antimetabolites used in cancer treatment, produce agranulocytosis in a predictable, dose-related fashion. They cause a generalized suppression of the bone marrow, and therefore production of erythrocytes and platelets is also affected. Agranulocytosis may also be encountered as an idiosyncratic reaction to a large variety of agents. The roster of implicated drugs includes aminopyrine, chloramphenicol, sulfonamides, chlorpromazine, thiouracil, and phenylbutazone. The neutropenia induced by
chlorpromazine and related phenothiazines is believed to result from a toxic effect
647
on granulocytic precursors in the bone marrow. In contrast, agranulocytosis after administration of aminopyrine, thiouracil, and certain sulfonamides appears to stem from immunologically mediated destruction of mature neutrophils through mechanisms that are similar to those involved in drug-induced hemolytic anemias (Chapter 14) . In some patients with acquired neutropenia, no antecedent cause can be detected, but autoimmunity is suspected since serum antibodies directed against neutrophil-specific antigens can be detected. [1] Severe neutropenia may also occur in association with monoclonal proliferations of large granular lymphocytes (so-called LGL leukemia). [2] The mechanism of this neutropenia is not clear, but suppression of granulocytic progenitors in the bone marrow is considered most likely. MORPHOLOGY.
The anatomic alterations in the bone marrow depend on the underlying basis of the neutropenia. When it is caused by excessive destruction of the mature neutrophils, the marrow may be hypercellular with increased numbers of granulocytic precursors. Hypercellularity is also seen with ineffective granulopoiesis, as occurs in megaloblastic anemias and myelodysplastic syndromes. Agranulocytosis caused by agents that suppress the growth or lead to the destruction of granulocytic precursors is understandably associated with decreased numbers of maturing leukopoietic elements. Infections are a characteristic feature of agranulocytosis.
Ulcerating necrotizing lesions of the gingiva, floor of the mouth, buccal mucosa, pharynx, or anywhere within the oral cavity (agranulocytic angina) are quite characteristic of agranulocytosis. These ulcers are typically deep, undermined, and covered by gray to green-black necrotic membranes from which numerous bacteria or fungi can be isolated. Similar ulcerations may occur on the skin or in the vagina, anus, or gastrointestinal tract, but these sites are much less frequently involved. Severe necrotizing infections are also encountered, but less prominently, in the lungs, urinary tract, and kidneys. All these sites of infection are characterized by massive growth of bacteria (or other agents) with relatively poor leukocytic response. In many instances, the bacteria grow in colony formation (botryomycosis) as though they were cultured on nutrient media. The regional lymph nodes draining these infections are enlarged and inflamed. Clinical Course.
The symptoms and signs of neutropenias are those of bacterial or fungal infections. They include malaise, chills, and fever, followed in sequence by marked weakness and fatigability. In severe agranulocytosis with virtual absence of neutrophils, these
infections may become so overwhelming as to cause death within a few days. Characteristically the neutrophil count is reduced to less than 1000 cells/mm3 of blood, and when counts fall below 500/mm3 , serious infections tend to occur. Because infections in this setting are often fulminant, neutropenic patients are commonly treated with broad-spectrum antibiotics at the first sign of infection. Additionally, after treatment with myelosuppressive chemotherapy, granulocyte colony-stimulating factor (G-CSF) may be used to decrease the duration and severity of the granulocytic nadir. REACTIVE (INFLAMMATORY) PROLIFERATIONS OF WHITE CELLS AND NODES Leukocytosis
Leukocytosis is a common reaction in a variety of inflammatory states. Pathogenesis.
The peripheral blood leukocyte count is influenced by several factors, including The size of the myeloid (for granulocytes and monocytes) and lymphoid (for lymphocytes) precursor and storage cell pools The rate of release of cells from the storage pool into the circulation The proportion of cells that are marginating at any one time (the marginating pool) The rate of extravasation of cells from the peripheral blood into tissues As discussed in Chapters 3 and 14 , leukocyte homeostasis is maintained by cytokines, growth factors, and adhesion molecules, which affect commitment, proliferation, differentiation, and extravasation of leukocytes and their progenitors in each of these compartments. The mechanisms of leukocytosis vary depending on the affected leukocyte pool and the particular factor. We have seen, for example, that interleukin 1 (IL-1)-induced and tumor necrosis factor (TNF)-induced release of cells from the bone marrow storage pool causes leukocytosis in acute infection (Chapter 3) ; in chronic infections, there is in addition enlargement of the pool of proliferating bone marrow progenitor cells caused by IL-1-driven and TNF-driven increases in CSFs. Figure 15-2 (Figure Not Available) summarizes the major mechanisms of neutrophilic leukocytosis and their causes. Similar mechanisms underlie other types of leukocytosis. For example, IL-5 causes eosinophilic leukocytosis by stimulating the differentiation of eosinophilic precursor cells, while the c- kit ligand and IL-7 play a central role in lymphopoiesis and lymphocytosis. Such factors are differentially produced in response to various pathogenic stimuli, and as a result the five principal types of leukocytosis (neutrophilic, eosinophilic, and basophilic leukocytosis; monocytosis; and lymphocytosis) tend to be observed in particular clinical settings (Table 15-1) . In patients with sepsis or severe inflammatory disorders (such as Kawasaki disease), in addition to leukocytosis there may be morphologic changes in the neutrophils, such
648
Figure 15-2 (Figure Not Available) Mechanisms of neutrophilic leukocytosis. Neutrophils and their precursors are distributed in five
pools: a bone marrow precursor pool, which includes progenitor cells and more committed, mitotically active precursors; a bone marrow storage pool, consisting of mitotically inactive mature and slightly immature neutrophils (band forms); a peripheral blood marginating pool (Marg. Pool); a peripheral blood circulating pool (Circ. Pool); and a tissue pool. The relative size of each pool is represented by the size of its corresponding box. The peripheral blood neutrophil count measures only the circulating peripheral blood pool, which can be enlarged by increased release of cells from the marrow storage pool, increased demargination, diminished extravasation into tissues, or expansion of the marrow precursor cell pool. (Modified from Finch SC: Hematology, 3rd ed. New York, McGraw-Hill, 1983, p 795.)
Neutrophilic leukocytosis
TABLE 15-1 -- CAUSES OF LEUKOCYTOSIS Acute bacterial infections, especially those caused by pyogenic organisms; sterile inflammation caused by, for example, tissue necrosis (myocardial infarction, burns)
Eosinophilic leukocytosis (eosinophilia)
Allergic disorders such as asthma, hay fever, allergic skin diseases (e.g., pemphigus, dermatitis herpetiformis); parasitic infestations; drug reactions; certain malignancies (e.g., Hodgkin disease and some non-Hodgkin lymphomas); collagen vascular disorders and some vasculitides; atheroembolic disease (transient)
Basophilic leukocytosis (basophilia)
Rare, often indicative of a myeloproliferative disease (e.g., chronic myelogenous leukemia)
Monocytosis
Chronic infections (e.g., tuberculosis), bacterial endocarditis, rickettsiosis, and malaria; collagen vascular diseases (e.g., systemic lupus erythematosus); inflammatory bowel diseases (e.g., ulcerative colitis)
as toxic granulations, Dohle bodies, and cytoplasmic vacuoles (Fig. 15-3) . Toxic granules are coarse and darker than the normal neutrophilic granules and are believed to represent abnormal azurophilic (primary) granules. Do hle bodies are patches of dilated endoplasmic reticulum that appear as cerulean blue cytoplasmic puddles. In most instances, differentiation of reactive leukocytosis and leukocytosis caused by flooding of the peripheral blood by neoplastic white blood cells (leukemia) is not problematic, but difficulties may arise in two settings. Particularly in children, acute viral infections can produce the appearance of activated lymphocytes in the peripheral blood and marrow that resemble neoplastic lymphoblasts. Other times, particularly in inflammatory states, many immature granulocytes appear in the blood, simulating a picture of myelogenous leukemia ( leukemoid reaction). In both settings, differentiation of reactive and neoplastic leukocytosis may require additional laboratory studies, as discussed later. Infections and other inflammatory stimuli may not only cause leukocytosis, but also involve the lymph nodes, which act as defensive barriers. The infections that lead to lymphadenitis are numerous. Some that produce distinctive morphologic patterns are described in other chapters. In most instances, however, the lymphadenitis is entirely
nonspecific, designated acute or chronic nonspecific lymphadenitis.
649
Figure 15-3 Reactive changes in neutrophils. Neutrophils containing coarse purple cytoplasmic granules (toxic granulations) and blue cytoplasmic patches of dilated endoplasmic reticulum (Dohle bodies) (arrow) are observed in this peripheral blood smear taken from
a patient with bacterial sepsis.
Acute Nonspecific Lymphadenitis
Lymph nodes undergo reactive changes whenever challenged by microbiologic agents, cell debris, or foreign matter introduced into wounds or into the circulation. Acutely inflamed nodes are most commonly caused by direct microbiologic drainage and are seen most frequently in the cervical area in association with infections of the teeth or tonsils or in the axillary or inguinal regions secondary to infections in the extremities. Similarly, acute lymphadenitis is often found in mesenteric lymph nodes draining acute appendicitis. Other self-limited infections may also cause mesenteric adenitis and induce abdominal symptoms mimicking acute appendicitis, a differential diagnosis that plagues the surgeon. Systemic viral infections and bacteremia, particularly in children, often produce generalized lymphadenopathy. MORPHOLOGY.
Macroscopically the nodes become swollen, gray-red, and engorged. Histologically, there is prominence of the lymphoid follicles, with large germinal centers containing numerous mitotic figures. Histiocytes often contain particulate debris of bacterial origin or derived from necrotic cells. When pyogenic organisms are the cause of the reaction, the centers of the follicles may undergo necrosis; the entire node may sometimes be converted into a suppurative mass. With less severe reactions, there is sometimes a neutrophilic infiltrate about the follicles, and numerous neutrophils can be found within the lymphoid sinuses. The cells lining the sinuses become hypertrophied and cuboidal and may undergo hyperplasia. Clinically, nodes with acute lymphadenitis are enlarged because of the cellular infiltration and edema. As a consequence of the distention of the capsule, they are tender to touch. When abscess formation is extensive, they become fluctuant. The overlying skin is frequently red, and sometimes penetration of the infection to the skin surface produces draining sinuses, particularly when the nodes have undergone suppurative necrosis. As might be expected, healing of such lesions is associated with scarring. Chronic Nonspecific Lymphadenitis
Chronic reactions assume one of three patterns, depending on their cause. MORPHOLOGY
Follicular hyperplasia: Follicular hyperplasia is caused by inflammatory processes that activate B cells. It is distinguished by the prominence of large, round or oblong germinal centers (secondary follicles), which appear to bulge against a surrounding collar of small, resting B lymphocytes that constitute the mantle zone (Fig. 15-4) . Within opposing poles of a reactive germinal center, two distinct regions are usually discernible: (1) a dark zone containing proliferating blastlike B cells (centroblasts) and (2) a light zone composed of B cells with irregular or cleaved nuclear contours (centrocytes). Also present throughout the follicle are phagocytic macrophages containing nuclear debris (tingible body macrophages) and a meshwork of inconspicuous dendritic cells that function in antigen presentation. Plasma cells, histiocytes, and occasionally neutrophils or eosinophils may be found in the parafollicular regions, and there generally is striking hyperplasia of the mononuclear phagocytic cells lining the lymphatic sinuses. Some specific causes of follicular hyperplasia include rheumatoid arthritis, toxoplasmosis, and early stages of HIV infection. This form of lymphadenitis may be confused morphologically with follicular lymphomas (see later discussion of lymphoid neoplasms). It is beyond the scope of this chapter to go into all the subtle morphologic features in this differential diagnosis, but several points may be noted. Favoring reactive follicular hyperplasia are (1) preservation of the lymph node architecture, including interfollicular T-cell zones and the sinusoids; (2) marked variation in the shape and size of lymphoid nodules; and (3) the presence of frequent mitotic figures, phagocytic macrophages, and recognizable light and dark zones, all of which tend to be absent from neoplastic 650
follicles. Follicular hyperplasia is sometimes accompanied by marginal zone B-cell hyperplasia. In some immune reactions, particularly those caused by toxoplasmosis and early HIV infection, marginal zone B cells accumulate in a rim external to the mantle zone of germinal centers. Paracortical lymphoid hyperplasia: Paracortical lymphoid hyperplasia is characterized by reactive changes within the T-cell regions of the lymph node that encroach on and sometimes appear to efface the B-cell follicles. Within interfollicular regions, scattered activated T cells (immunoblasts) are often observed. These latter cells are three to four times the size of resting lymphocytes. In addition, there is hypertrophy of the sinusoidal and vascular endothelial cells and a mixed cellular infiltrate, principally of macrophages and sometimes of eosinophils. Such changes are encountered in immunologic reactions induced by drugs (especially phenytoin [Dilantin]); in acute viral infections, particularly infectious mononucleosis; and after vaccination against certain viral diseases. Sinus histiocytosis (also called reticular hyperplasia): Sinus histiocytosis refers to distention and prominence of the lymphatic sinusoids. Although nonspecific, this form of hyperplasia may be particularly prominent in lymph nodes draining cancers, such as carcinoma of the breast. The lining endothelial cells are markedly
hypertrophied, and the sinuses may be virtually engorged with histiocytes. In the setting of cancer, this pattern of reaction has been thought to represent an immune response on the part of the host against the tumor or its products.
Figure 15-4 Follicular hyperplasia. A , Low-power view showing a reactive follicle and surrounding mantle zone. The dark-staining
mantle zone is polarized, being much more prominent adjacent to the germinal center light zone in the left half of the follicle. The right half of the follicle consists of the dark zone. B , A high-power view of the dark zone shows several mitotic figures and numerous tingible body macrophages, indicative of ongoing apoptosis.
Characteristically, lymph nodes in chronic reactions are not tender because their capsules are not under increased pressure. Chronic lymphadenitis is particularly common in inguinal and axillary nodes, which drain relatively large areas of the body and so are frequently challenged. NEOPLASTIC PROLIFERATIONS OF WHITE CELLS Malignant proliferative diseases constitute the most important white cell disorders. The several categories of these diseases can be defined briefly as follows: Lymphoid neoplasms encompass a diverse group of entities. In many but not all instances, the phenotype of the neoplastic cell closely resembles that of a particular stage of normal lymphocyte differentiation, a feature that is used in the diagnosis and classification of these disorders. Myeloid neoplasms arise from hematopoietic stem cells that give rise to cells of the myeloid (i.e., erythroid, granulocytic, or thrombocytic) lineage. Three categories of myeloid neoplasia are recognized: acute myelogenous leukemias, in which immature progenitor cells accumulate in the bone marrow; myelodysplastic syndromes, associated with ineffective hematopoiesis and resultant 651
peripheral blood cytopenias; and chronic myeloproliferative disorders, in which increased production of one or more terminal differentiated myeloid elements (e.g, granulocytes) usually leads to an elevation of peripheral blood counts. The histiocytoses represent proliferative lesions of histiocytes, including rare neoplasms that present as malignant lymphomas. A special category of histiocytes referred to as Langerhans cells gives rise to a spectrum of neoplastic disorders, some of which behave as disseminated malignant tumors and others as localized benign proliferations. This group is called Langerhans cell histiocytoses. As can be seen, the neoplastic disorders of white cells are extremely varied. In the following sections, each of the categories is treated separately. Lymphoid Neoplasms
DEFINITIONS AND CLASSIFICATIONS
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms lymphocytic leukemia and lymphoma. Leukemia is used for lymphoid neoplasms that present with widespread involvement of the bone marrow, usually accompanied by the presence of large numbers of tumor cells in the peripheral blood. Lymphoma is used to describe proliferations arising as discrete tissue masses. Traditionally, these terms were attached to what were believed to be distinct entities The line between the lymphocytic leukemias and the lymphomas, however, often blurs. Many types of lymphoma occasionally present with a leukemic peripheral blood picture accompanied by extensive marrow involvement, and evolution to leukemia is not unusual with progression of incurable lymphomas. Conversely, tumors identical to leukemias sometimes arise as lymphomatous masses without evidence of bone marrow disease. Hence, when applied to particular neoplasms, the terms leukemia and lymphoma merely describe the usual tissue distribution of the disease. Within the broad group of lymphomas, Hodgkin disease (HD) (Hodgkin lymphoma) is segregated from all other forms, which constitute the non-Hodgkin lymphomas (NHL). As seen subsequently, HD is clinically and histologically distinct from the NHLs. In addition, it is treated in a unique fashion, making the differentiation of HD and NHL of great practical importance. The other important category of lymphoproliferative disease encompasses the plasma cell neoplasms, tumors composed of terminally differentiated B cells. Such tumors most commonly arise in the bone marrow, only rarely involving lymph nodes or producing a leukemic peripheral blood picture. In addition, as seen subsequently, certain features of their pathophysiology are related to the secretion of whole or partial immunoglobulin (Ig) fragments by the tumor cells. The clinical presentation of the various lymphoid neoplasms is dictated by the anatomic distribution of disease. Two thirds of NHLs and virtually all cases of HD present with nontender nodal enlargement (often >2 cm) that may be localized or generalized. The remaining one third of NHLs arise at extranodal sites (e.g., skin, stomach, brain). In contrast, the leukemic forms (lymphocytic leukemia) most commonly come to clinical attention because of signs and symptoms related to suppression of normal hematopoiesis by tumor cells in the bone marrow. Lymphocytic leukemias also characteristically infiltrate and enlarge the spleen and liver. Finally, plasma cell neoplasms involving the skeleton cause local bony destruction and hence often present with pain owing to pathologic fractures. Few areas of pathology have evoked as much controversy and confusion as the classification of NHL and related lymphoid neoplasms. In 1982, an international panel of hematopathologists attempted to stem the rising tide of classifications for NHL by proposing a Working Formulation for Clinical Usage, [3] which divided NHL on clinical grounds into three prognostic groups: low, intermediate, and high grade. Classification of NHL within each of these prognostic groups was based solely on morphologic criteria, particularly the pattern of tumor growth within lymph nodes (nodular or diffuse) and the
size of the tumor cells (small, large, or mixed small and large). This approach to classification had the advantage of being simple and has been widely used, but further immunophenotypic and genotypic characterization of lymphoid neoplasms made it clear that a number of distinct entities had been lumped together or completely ignored in the Working Formulation. Of practical importance, some of the neoplasms not formally recognized in the Working Formulation (e.g., mantle cell lymphoma and marginal zone lymphoma) have proven to be fairly unique in their clinical behavior and response to therapy. In an effort to correct the perceived deficiencies of the Working Formulation, a new classification emerged in 1994. Termed the Revised European-American Classification of Lymphoid Neoplasms (REAL), [4] it describes neoplasms that are believed to constitute distinct clinicopathologic entities based on clinical features, morphology, immunophenotype, and genotype; these entities are listed in Table 15-2 , along with their Working Formulation equivalents. The REAL classification includes the lymphocytic leukemias, NHLs, and plasma cell neoplasms, thus eliminating the previous division between the various lymphoid neoplasms, which are now sorted into four broad categories, based on immunophenotype: 1. 2. 3. 4.
Precursor B-cell neoplasms (neoplasms of immature B cells) Peripheral B-cell neoplasms (neoplasms of mature B cells) Precursor T-cell neoplasms (neoplasms of immature T cells) Peripheral T-cell and natural killer (NK) cell neoplasms (neoplasms of mature T cells and NK cells)
Diagnostic categories for HD were not modified by the REAL working group; the specific subtypes of HD are covered in a later section. 652
TABLE 15-2 -- REAL CLASSIFICATION OF THE LYMPHOID NEOPLASMS AND THEIR WORKING FORMULATION EQUIVALENTS REAL Classification Working Formulation Equivalent I. Precursor B-Cell Neoplasms Precursor B lymphoblastic leukemia/lymphoma *
Leukemias not included; lymphomas classified as high-grade, lymphoblastic
II. Precursor T-Cell Neoplasms Precursor T lymphoblastic leukemia/lymphoma *
Leukemias not included; lymphomas classified as high-grade, lymphoblastic
III. Peripheral B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma
Low-grade, small lymphocytic
Lymphoplasmacytic lymphoma
Low-grade, small lymphocytic plasmacytoid
Mantle cell lymphoma
Most classified as intermediate-grade, diffuse small cleaved cell
Follicular lymphoma Cytologic grade I
Low-grade, follicular, predominantly small cleaved cell
Cytologic grade II
Low-grade, follicular, mixed small and large cell
Cytologic grade III
Intermediate-grade, follicular, predominantly large cell
Marginal zone lymphoma
Most classified as low-grade, small lymphocytic
Hairy cell leukemia
Not included
Plasmacytoma/plasma cell myeloma Diffuse large B-cell lymphoma *
Burkitt lymphoma
Not included Intermediate-grade, diffuse large cell or high-grade, large cell immunoblastic High-grade, small noncleaved cell
IV. Peripheral T-Cell and Natural Killer Cell Neoplasms T-cell chronic lymphocytic leukemia
Low-grade, small lymphocytic
Large granular lymphocytic leukemia
Low-grade, small lymphocytic
Mycosis fungoides and Sezary syndrome
Low-grade, mycosis fungoides
Peripheral T-cell lymphoma, unspecified Variable; most often intermediate-grade, diffuse mixed small and large cell Angioimmunoblastic T-cell lymphoma
Variable; most often intermediate-grade, diffuse mixed small and large cell
Angiocentric lymphoma (NK/T-cell lymphoma [4A] )
Variable; most often intermediate-grade, diffuse mixed small and large cell
Intestinal T-cell lymphoma
Variable; most often high-grade, large cell immunoblastic
Adult T-cell leukemia/lymphoma
Variable; most often intermediate-grade, diffuse mixed small and large cell
Anaplastic large cell lymphoma
Variable; most often high-grade, large cell immunoblastic
Most common tumors in adults. *Most common tumors in children or adolescents.
Before discussing the specific entities described in the REAL classification, some important principles relevant to the lymphoid neoplasms need to be emphasized. The diagnosis of lymphoid neoplasia can be suspected from the clinical features, but histologic examination of lymph nodes or other involved tissues is required for diagnosis. Although all lymphoid neoplasms have traditionally been considered to be malignant, a wide range of behavior from seemingly benign to rapidly fatal is observed. It is perhaps more accurate to consider all clonal lymphoid proliferations as being potentially malignant because even the most indolent proliferations tend to transform over time into more aggressive, overtly malignant tumors. The vast majority of lymphoid neoplasms ( 80 to 85%) are of B-cell origin, with most of the remainder being T-cell tumors; only rarely are tumors of NK or histiocytic origin observed. Tumors of T and B cells may represent cells arrested at any stage along their differentiation pathways (Fig. 15-5) . Figure 15-5 also illustrates the genotypic and phenotypic characteristics of differentiating T and B cells that are useful in subdividing this group of tumors. Some additional cell surface markers helpful in the study of lymphomas and leukemias are listed in Table 15-3. As tumors of the immune system, lymphoid neoplasms tend to disrupt normal regulatory mechanisms, leading to frequent immune abnormalities. Both a loss of vigilance (as evidenced by susceptibility to infection) and a breakdown of tolerance (manifested by autoimmunity) may be seen, sometimes in the same patient. In a further, ironic twist, patients with inherited or acquired immunodeficiency are themselves at high risk of developing certain lymphoid neoplasms. All lymphoid neoplasms are derived from a single transformed cell and are therefore monoclonal. Antigen receptor genes rearrange during normal B-cell and T-cell differentiation through a mechanism that ensures that each lymphocyte makes a single, unique antigen receptor (Chapter 7) . In most lymphoid neoplasms, antigen receptor gene rearrangement precedes transformation; as a result, the daughter cells derived from the malignant progenitor share the same antigen receptor gene configuration and sequence and synthesize identical antigen receptor proteins (either Ig or T-cell receptors). For this reason, analysis of antigen receptor genes and their protein products is frequently used to differentiate monoclonal neoplasms from polyclonal reactive processes. 653
In addition, since a particular rearranged antigen receptor gene is unique to the neoplastic clone, it can be used as a highly specific marker that is useful for detecting minimal residual disease after treatment or recurrences before they become clinically apparent. [5] Neoplastic B and T cells tend to home to and grow in areas where their normal counterparts reside. This results in characteristic patterns of tissue involvement in certain lymphoid neoplasms. For example, follicular lymphomas proliferate in the
B-cell areas of the lymph node, producing a nodular or follicular pattern of growth, whereas T-cell lymphomas typically grow in paracortical T-cell zones. It is thought that the tendency of particular lymphoid neoplasms to involve certain extranodal tissues also stems from a combination of homing and local trophic factors. Given that normal B and T lymphoid cells recirculate through the lymphatics and peripheral blood to distant lymphoid tissues, it is not suprising that neoplastic lymphocytes show a similar wanderlust. Using sensitive molecular techniques, most tumors appear to be widely disseminated at the time of diagnosis. This fits well with the clinical observation that cure is possible in most lymphoid neoplasms only with systemic therapy. The most notable exception to this rule is HD, which can be cured with local therapy. HD spreads in an orderly fashion, and as a result staging is of great importance in determining therapy. In contrast, the spread of NHL is less predictable, and, as noted previously, most patients are assumed to have systemic disease at the time of diagnosis. Hence, staging in particular NHLs provides useful prognostic information but is generally not as important in guiding therapy as in HD.
Figure 15-5 Schematic illustration of the phenotypic and genotypic changes associated with the differentiation of B cells and T cells.
Not shown are some CD4+/CD8+ cells (common thymocytes) that also express CD3. Stages between resting B cells and plasma cells are not depicted. CD, cluster designation; TdT, terminal deoxynucleotidyl transferase; Ig, immunoglobulin; TCR, T-cell receptor.
We now turn to the specific entities of the REAL classification. In the discussion that follows, we begin with neoplasms of immature lymphoid cells, then move on to tumors of mature B cells, T cells, and NK cells. We describe a relatively large variety of distinctive clinicopathologic entities. It is worth remembering, however, that only four entities constitute the majority of lymphoid lymphomas and leukemias in adults: follicular lymphoma, large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and multiple myeloma. Similarly, two groups of neoplasms are most common (and therefore most important) in children and young adolescents: acute lymphoblastic leukemia/lymphoma and Burkitt lymphoma. Thus,
654
TABLE 15-3 -- SOME IMMUNE CELL ANTIGENS DETECTED BY MONOCLONAL ANTIBODIES Antigen Comments Designation Primarily T Cell Associated CD1
Expressed on cortical thymocytes and Langerhans histiocytes
CD2
Present on all T cells (thymic and peripheral) and NK cells
CD3
Expressed by thymocytes, peripheral T cells, and NK cells. Surface expression requires coexpression of T-cell receptor
CD4
Expressed on the helper subset of peripheral T cells, single positive medullary thymocytes, and CD4/CD8 double positive thymocytes
CD5
Expressed on all T cells and small subset of B cells
CD7
Expressed on all T cells and subset of myeloid cell precursors
CD8
Expressed on the cytotoxic subset of peripheral T cells, single positive medullary thymocytes, double positive cortical thymocytes, and some NK cells
Primarily B Cell Associated CD10
Expressed at high levels on marrow pre-B cells and follicular center B cells; also called CALLA
CD19
Present on marrow pre-B cells and mature B cells but not on plasma cells
CD20
Expressed on marrow pre-B cells after CD19 and mature B cells but not on plasma cells
CD21
EBV receptor; present on mature B cells and follicular dendritic cells
CD22
Present on mature B cells
CD23
Present on activated mature B cells
Primarily Monocyte or Macrophage Associated CD13
Expressed on immature and mature monocytes and granulocytes
CD14
Expressed on all monocytes
CD15
Expressed on all granulocytes; also expressed by Reed-Sternberg cells and variants in Hodgkin disease
CD33
Expressed on myeloid progenitors and monocytes
Primarily NK Cell Associated CD16
Present on all NK cells and granulocytes
CD56
Present on all NK cells and a subset of T cells
Primarily Stem Cell and Progenitor Cell Associated CD34
Expressed on pluripotent hematopoietic stem cells and progenitor cells of many lineages
Activation Markers CD30
Present on activated B cells, T cells, and monocytes
Present on All Leukocytes CD45
Also known as leukocyte common antigen (LCA)
CD, cluster designation; NK, natural killer; CALLA, common acute lymphoblastic leukemia antigen; EBV, Epstein-Barr virus. they are emphasized and described first (Table 15-4 A). The most salient
immunophenotypic, karyotypic, and clinical features of the less common or rare entities of the REAL classification are summarized in Table 15-4 B. PRECURSOR B-CELL AND T-CELL NEOPLASMS
Acute Lymphoblastic Leukemia/Lymphoma
Acute lymphoblastic leukemia/lymphoma (ALL) encompasses a group of neoplasms composed of immature, precursor B (pre-B) or T (pre-T) lymphocytes referred to as lymphoblasts. The majority ( approximately 85%) of ALLs are pre-B cell tumors that typically manifest as childhood acute leukemias with extensive bone marrow and variable peripheral blood involvement. The less common pre-T cell ALLs tend to present in adolescent males as lymphomas, often with thymic involvement. Considerable overlap is observed in the clinical behavior of pre-B cell and pre-T cell ALL; for example, pre-B cell tumors may present as lymphomas, and many pre-T cell tumors evolve to a leukemic peripheral blood picture. Malignant pre-B and pre-T lymphoblasts are also morphologically indistinguishable, and subclassification of ALL is thus dependent on immunophenotyping. Because of their morphologic and clinical similarities, the various forms of ALL are considered here together. Approximately 2500 new cases of ALL are diagnosed each year in the United States, with most cases occurring in individuals younger than 15 years of age. It is almost twice as common in whites as in nonwhites and is slightly more frequent in boys than in girls. The peak incidence in children is at approximately 4 years of age. ALL also occurs in adults of all ages, but much less frequently. MORPHOLOGY.
Because of differing responses to chemotherapeutic agents, it is of great practical importance to differentiate ALL from acute myelogenous leukemia (AML), a neoplasm of immature myeloid cells that may cause identical signs and symptoms. Morphologic features that favor a lymphoid derivation for blasts include relatively condensed chromatin; the absence of conspicuous nucleoli; and the presence of scant, agranular cytoplasm (Fig. 15-6) . Differentiation of AML and ALL on morphologic grounds alone is not possible in all cases, however, and for this reason leukemic blasts are typically analyzed for expression of myeloid and lymphoid surface markers (Fig. 15-7) . Histochemical stains are also helpful, as lymphoblasts (in contrast to myeloblasts) lack peroxidase-positive granules and often contain cytoplasmic aggregates of periodic acid-Schiff (PAS)-positive material. As noted, ALLs with lymphomatous presentations are mostly of pre-T cell type, 50 to 70% of which are associated with mediastinal masses
655
TABLE 15-4a -- SUMMARY OF THE MOST COMMON LYMPHOID NEOPLASMS Diagnosis Immunophenotype Genotype Salient Clinical Features Precursor B-cell Pre-B cells acute lymphoblastic expressing TdT and leukemia/lymphoma lacking surface Ig; almost all positive for CD19, variable expression of CD10 and CD20
Diverse chromosomal translocations, many involving Ig loci. t(12;21) involving TEL1 and AML1 genes most common rearrangement
Predominantly children with symptoms relating to pancytopenia secondary to marrow involvement
Precursor T-cell Pre-T cells acute lymphoblastic expressing CD1 and leukemia/lymphoma TdT; variable expression of other pan T-cell markers such as CD2, CD3, CD4, CD5, and CD8
Diverse chromosomal translocations, many involving T-cell receptor loci. Rearrangements of the TAL1 gene are most common
Adolescent males with mediastinal masses. Variable splenic, hepatic, and bone marrow involvement
Small lymphocytic lymphoma/chronic lymphocytic leukemia
Trisomy 12, deletions of 11q23, abnormalities of 13q, t(14;19) (rare)
Older patients with bone marrow, lymph node, spleen, and liver disease. Most present with leukemic picture. Autoimmune hemolysis and thrombocytopenia in a minority
Follicular lymphoma CD10-positive peripheral B-cell tumor; negative for CD5. Expresses high levels of surface Ig (usually IgG)
t(14;18) involving the BCL2 gene; results in overexpression of BCL2 protein
Older patients with generalized lymphadenopathy and marrow involvement
Diffuse large B-cell lymphoma
Diverse chromosomal aberrations. 30% contain the t(14;18); 20-30% have rearrangements of the BCL6 gene on chromosome 3
All ages, but most common in adults. Often appears as a single rapidly growing mass. 30% extranodal
CD5-positive peripheral B-cell tumor; also expresses CD23, but negative for CD10. Expresses low levels of surface IgM
Peripheral B-cell phenotype, with variable expression of CD5 and CD10. Usually surface Ig positive, negative for TdT
Burkitt lymphoma
Peripheral B cells Translocations expressing CD10 and involving c- myc surface IgM and Ig loci; usually t(8;14), but also t(2;8) or t(8;22). African (endemic) cases latently infected with EBV
Adolescents or young adults with jaw or extranodal abdominal masses. Uncommonly presents similar to a leukemia (B-cell ALL)
Multiple myeloma/solitary plasmacytoma
Terminally differentiated B-cell tumor; expresses CD38 and cytoplasmic Ig
Myeloma; older patients with lytic bone lesions, pathologic fractures, hypercalcemia, renal failure, and primary amyloidosis. Plasmacytoma: isolated plasma cell masses in bone or soft tissue (e.g., oropharnyx)
t(4;14)(p16.3;q32) (approximately 25% of cases), leading to increased expression of FGFR3
stemming from thymic involvement. Lymphadenopathy and splenomegaly are also more prevalent in pre-T cell ALL. Regardless of phenotype, the histologic appearance is similar, with normal tissue architecture completely effaced by lymphoblasts having scant cytoplasm and nuclei that are somewhat larger than those of small lymphocytes. The nuclear chromatin is delicate and finely stippled, and nucleoli are either absent or inconspicuous. In many cases, the nuclear membrane shows deep subdivision, imparting a convoluted (lobulated) appearance. In keeping with its aggressive growth, the tumor shows a high rate of mitosis, and as with other tumors having a high mitotic rate (e.g., Burkitt lymphomas), a starry sky pattern may be produced by interspersed benign macrophages. Immunophenotype and Genetics.
Immunostaining for terminal deoxytransferase (TdT), a specialized DNA polymerase that is expressed only by pre-B and pre-T lymphoblasts, is positive in greater than 95% of cases (Fig. 15-7) . Subclassification of ALL is based on the origin of the lymphoblasts and their stage of differentiation and is summarized in Table 15-5. Approximately 90% of patients with ALL have numerical or structural changes in the chromosomes of the leukemia cells, most commonly hyperdiploidy (>50 chromosomes), but also pseudodiploidy; t(12;21); t(9;22) [Philadelphia chromosome]; and t(4;11). These alterations correlate with immunophenoytpe and sometimes affect prognosis. It is noteworthy that pre-B and pre-T ALL are associated with distinct sets of translocations, indicating that different molecular mechanisms underlie their pathogenesis.
656
TABLE 15-4b -- SUMMARY OF THE LESS COMMON LYMPHOID NEOPLASMS Diagnosis Immunophenotype Genotype Salient Clinical Features Lymphoplasmacytic Peripheral B-cell lymphoma tumor; negative for CD5, CD10, and CD23. Expresses surface Ig (usually IgM) and cytoplasmic Ig in plasma cell component
t(9;14) in 50% of cases, apparently producing aberrant expression of PAX5, a transcription factor that is essential for normal B-cell differentiation
Older patients with marrow, lymph node, spleen, and liver disease. Often associated with a hyperviscosity syndrome (Waldenstrom macroglobulinemia). 10% have autoimmune hemolysis
Mantle cell lymphoma
CD5-positive peripheral B-cell tumor; negative for CD10 and CD23. Expresses surface IgM and IgD
t(11;14) involving the BCL1 gene; results in overexpression of BCL1 protein (also known as cyclin D1)
Older male patients with lymphadenopathy and marrow involvement. May arise at extranodal sites or present as splenomegaly
Marginal zone lymphoma
Peripheral B-cell tumor; negative for CD5, CD10, and CD23. Expresses surface Ig and may have cytoplasmic Ig in plasma cell component
Trisomy 18, t(11;18)
Frequently arises at extranodal sites in adult patients with chronic inflammatory diseases. Tends to remain localized for long periods of time
Hairy cell leukemia
Peripheral B-cell tumor coexpressing CD11c, CD25, and surface Ig
No specific chromosomal rearrangements
Older males with pancytopenia and splenomegaly
Peripheral T-cell lymphoma, unspecified
Mature T-cell tumor; positive for pan T-cell markers and usually CD4 or CD8. Negative for TdT and CD1
Diverse chromosomal translocations. Clonal T-cell receptor rearrangements
Usually adult patients with generalized lymphadenopathy, sometimes accompanied by pruritus
Adult T-cell CD4-positive mature leukemia/lymphoma T-cell tumor expressing CD25 (IL-2 receptor)
HTLV-1 provirus present in tumor cells
Adults with cutaneous lesions, marrow involvement, and hypercalcemia
Mycosis fungoides/Sezary syndrome
CD4-positive peripheral T-cell neoplasm expressing T-cell receptor alpha/beta
No specific chromosomal abnormality described
Adult patients with cutaneous patches, plaques, nodules, or generalized erythema
Large granular lymphocytic leukemia [6] [7] [8]
Two types: (1) CD8-positive T cell expressing T-cell receptor alpha/beta; and (2) true NK cell expressing CD2, CD16, and CD56
No specific chromosomal abnormality; NK tumors lack antigen receptor gene rearrangements
Adult patients with splenomegaly, neutropenia, and anemia, sometimes accompanied by autoimmune disease
Angiocentric lymphoma [9] (NK/T-cell lymphoma)
NK cell expressing CD2, cytoplasmic CD3, CD16, and CD56
No specific chromosomal abnormality. Clonal T-cell receptor rearrangements absent. Majority contain clonal EBV episomes
Adults with destructive sinonasal masses, often accompanied by hemophagocytic syndrome. Most common in China
TdT, terminal deoxytransferase; CD, cluster designation; Ig, immunoglobulin; EBV, Epstein-Barr virus; ALL, acute lymphoblastic leukemia/lymphoma; HTLV-1, human T-cell lymphotropic virus type 1; NK, natural killer.
Clinical Features.
Although ALL and AML are immunophenotypically and genotypically distinct, they typically present with similar clinical features. This similarity stems from the fact that in both diseases there is an accumulation of neoplastic blast cells in the bone marrow that suppress normal hematopoiesis by physical crowding and other poorly understood mechanisms. The resultant failure of normal hematopoiesis is manifested by anemia, neutropenia, and thrombocytopenia, which underlie the major clinical features of both AML and ALL. These are listed, along with those features that are somewhat more characteristic of ALL, as follows: Abrupt stormy onset: Most patients present within days to a few weeks of the onset of symptoms. Symptoms related to depression of normal marrow function: Symptoms include fatigue mainly as a result of anemia; fever, reflecting an infection caused by absence of
657
658
mature leukocytes; and bleeding (petechiae, ecchymoses, epistaxis, gum bleeding) secondary to thrombocytopenia. Bone pain and tenderness: Bone pain and tenderness result from marrow expansion with infiltration of the subperiosteum. Generalized lymphadenopathy, splenomegaly, and hepatomegaly: Lymphadenopathy, splenomegaly, and hepatomegaly are caused by neoplastic infiltration. Each is more common in ALL than in AML. In patients with pre-T cell ALL with a large mediastinal mass, symptoms related to invasion of large vessels or impending obstruction of airways may also be seen. Testicular involvement is also common in ALL. Central nervous system manifestations: Headache, vomiting, and nerve palsies resulting from meningeal spread are also more frequent in ALL than AML.
Figure 15-6 Morphologic comparison of lymphoblasts and myeloblasts. A , Acute lymphoblastic leukemia/lymphoma (ALL).
Lymphoblasts have fewer nucleoli than do myeloblasts, and the nuclear chromatin is more condensed. Cytoplasmic granules are absent. B , Acute myeloblastic leukemia (AML, M1 subtype). Myeloblasts have delicate nuclear chromatin, prominent nucleoli, and fine azurophilic granules in the cytoplasm. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
Figure 15-7 Immunophenotypic comparison of ALL and AML. A and B represent the phenotype of AML, M1 subtype (shown in 15-6 B ). The myeloid blasts, represented by the red dots, express CD34, a marker of multipotent stem cells, but do not express CD64, a marker of mature myeloid cells. In B the same myeloid blasts express CD33, a marker expressed by immature myeloid cells, and
some cells also express CD15, a marker of more mature myeloid cells. Thus, these blasts are minimally differentiated myeloid cells. C and D represent the phenotype of a precursor B-cell ALL (shown in Fig. 15-6 A ). Note that the lymphoblasts represented by the red dots express TdT and the B-cell marker CD22 (C). In D the same cells are seen to express two other B-cell markers, CD10 and CD19. Thus, these cells represent pre-B lymphoblasts. (Courtesy of Dr. Louis Picker, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
TABLE 15-5 -- IMMUNOLOGIC CLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA Category B Lineage Markers T Lineage Frequency Markers TdT CD19 CD10 Cmu SIg CD7 CD3 CD2 B lineage Very early pre-B
+
+
-
-
-
-
-
-
5-10%
Early pre-B
+
+
+
-
-
-
-
-
50-60%
Pre-B
+
+
+
+
-
-
-
-
20%
T lineage
+
-
-
-
-
+
+*
+
15%
TdT, terminal deoxytransferase; Cmu, cytoplasmic IgM heavy chain; SIg, surface immunoglobulin. * CD3 staining may be cytoplasmic or membranous.
Truly dramatic advances have been made in the treatment of ALL. With aggressive chemotherapy (given together with prophylactic treatment of the central nervous system), more than 90% of children with ALL achieve complete remission, and at least two thirds can be considered cured. Children 2 to 10 years of age with early pre-B phenotype and hyperploidy, as well as those with a t(12;21) translocation, have an excellent prognosis. Three factors have been consistently associated with a worse prognosis: (1) age under 2, possibly because of the strong association of infantile ALL with translocations involving the MLL gene on chromosome 11[10] ; (2) presentation in adolescence or adulthood; and (3) the presence of the t( 9;22) ( the Philadelphia chromosome). [11] The t(9;22) is seen in only 3% of childhood ALL but is observed in up to 25% of adult cases, which may partially explain the poor outcome in adults. [12] Allogeneic bone marrow transplantation offers hope for those in poor prognostic categories. PERIPHERAL B-CELL NEOPLASMS
Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chronic lymphocytic leukemia ( CLL) and small lymphocytic lymphoma ( SLL) are morphologically, phenotypically, and genotypically indistinguishable, differing only in the degree of peripheral blood lymphocytosis. Most patients have sufficient lymphocytosis to fullfill the diagnostic requirement for CLL (absolute lymphocyte count >4000/mm3 ), which is the most common leukemia of adults in the Western world. In contrast, SLL constitutes only 4% of NHL. CLL and SLL are much less common in Japan and other Asian countries. The tumor cells resemble a small subset of circulating B cells that express the surface marker CD5. MORPHOLOGY.
Lymph node architecture is diffusely effaced by a predominant population of small lymphocytes of 6-12 mu containing round to slightly irregular nuclei with condensed chromatin and scant cytoplasm (Fig. 15-8) . These cells are mixed with variable numbers of larger cells called prolymphocytes. In many cases, prolymphocytes gather together focally to form loose aggregates referred to as proliferation centers, so-called because they contain increased numbers of mitotically active cells. When present, proliferation centers are considered to be pathognomonic for CLL and SLL. [13] In CLL, the peripheral blood contains increased small, round lymphocytes with scant
cytoplasm (Fig. 15-9) . These cells are fragile and are frequently disrupted in the process of making the
Figure 15-8 Nodal involvement by small lymphocytic lymphoma/chronic lymphocytic leukemia. A , Low-power view showing diffuse effacement of nodal architecture. At high power ( B ), most of the tumor cells have the appearance of small round lymphocytes. A single "prolymphocyte," a larger cell with a centrally-placed nucleolus, is also present in this field. ( A courtesy of Dr. Jose Hernandez, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
659
Figure 15-9 Chronic lymphocytic leukemia. This peripheral blood smear is flooded with small lymphocytes with condensed chromatin
and scant cytoplasm. A characteristic finding is the presence of disrupted tumor cells (smudge cells). A coexistent autoimmune hemolytic anemia (see Chapter 14) has caused the appearance of spherocytes (hyperchromatic, round erythrocytes). In this case the severity of the anemia is such that immature erythroid forms are being released from the marrow; note the nucleated erythroid cell in the lower left-hand corner of the field. (Courtesy of Dr. Jacqueline Mitus.)
smear, producing so-called smudge cells. Involvement of the bone marrow is observed in all cases of CLL and most cases of SLL, taking the form of interstitial infiltrates or nonparatrabecular aggregates of small lymphocytes. Both the splenic white and red pulp and hepatic portal tracts (Fig. 15-10) are usually infiltrated by tumor cells, although the extent of involvement varies widely.
Figure 15-10 Small lymphocytic lymphoma/chronic lymphocytic leukemia in the liver. Low-power view of a typical periportal lymphocytic infiltrate. (Courtesy of Dr. Mark Fleming, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
Immunophenotype and Genetics.
CLL and SLL have a distinctive immunophenotype. The tumor cells express the pan B-cell markers CD19 and CD20. In addition, CD5, a T-cell marker that is expressed only on a small subset of normal B cells, is present on the tumor cells. They typically also have low-level surface expression of Ig heavy chain (usually IgM or IgM and IgD) and either kappa or lambda light chain. The most common chromosomal anomalies are trisomy 12, deletions of 13q12-14, and deletions of 11q, each of which is seen in 20 to 30% of cases. [14] [15] Clinical Features.
Most patients present at ages over 50 (median age, 60); a male predominance has been noted (2:1). Patients with CLL and SLL are often asymptomatic. When symptoms are present, they are nonspecific and include easy fatigability, weight loss, and anorexia. Generalized lymphadenopathy and hepatosplenomegaly are present in 50 to
60% of the cases. The total leukocyte count may be increased only slightly or may reach 200,000/mm3 . A small monoclonal Ig "spike" is present in the serum of some patients. CLL and SLL disrupt normal immune function through uncertain mechanisms. Hypogammaglobulinemia is common and contributes to increased susceptibility to bacterial infections. Conversely, some 10 to 15% of patients develop autoantibodies directed against red blood cells or platelets that produce autoimmune hemolytic anemia or thrombocytopenia. These autoantibodies are polyclonal IgGs that are produced not by the tumor cells themselves, but by non-neoplastic, self-reactive B cells. [16] The course and prognosis of CLL and SLL are extremely variable and depend primarily on the clinical stage. Overall the median survival is 4 to 6 years, but patients who present with minimal tumor burden may survive for 10 years or more. The presence of trisomy 12 and deletions of 11q correlate with higher-stage disease and portend a worse prognosis. [14] [15] An additional important factor in patient survival is the tendency of CLL and SLL to transform to more aggressive lymphoid neoplasms. Most commonly, this takes the form of prolymphocytic transformation (15 to 30% of patients) or transformation to diffuse large B-cell lymphoma (so-called Richter syndrome, seen in about 10% of patients). Prolymphocytic transformation is marked by appearance in the peripheral blood of large numbers of prolymphocytes, which are cells with a large nucleus containing a single, prominent, centrally placed nucleolus. In most cases, the transformed tumor is clonally related to the underlying CLL and SLL and retains a B-cell phenotype. Both prolymphocytic and large cell transformation are usually ominous events, with most patients surviving less than 1 year. [17] Follicular Lymphoma
Follicular lymphoma is the most common form of NHL in the United States, comprising about 45% of adult lymphomas. It usually presents in middle age and afflicts men and women equally. It is less common in Europe and rare in Asian populations. The neoplastic cells closely resemble normal germinal center B cells.
660
Figure 15-11 Non-Hodgkin lymphoma, follicular type, involving the lymph node. A , Nodular aggregates of lymphoma cells are present throughout the lymph node. At high magnification ( B ), small lymphoid cells with condensed chromatin and irregular or cleaved nuclear outlines (centrocytes) are mixed with a population of larger cells with nucleoli (centroblasts). ( A courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
MORPHOLOGY.
In most cases, at low magnification, a predominantly nodular or nodular and diffuse growth pattern is observed in involved lymph nodes (Fig. 15-11) . Two principal cell types are observed in varying proportions: (1) small cells with irregular or cleaved nuclear contours and scant cytoplasm referred to as centrocytes (small cleaved cells) and (2) larger cells with open nuclear chromatin, several nucleoli, and modest amounts of cytoplasm referred to as centroblasts (Fig. 15-11) . In most follicular lymphomas, small cleaved cells compose the majority of the cellularity. Peripheral blood involvement sufficient to produce lymphocytosis (usually <20,000/mm3 ) is seen in about 10% of patients. Bone marrow involvement occurs in 85% of patients and characteristically takes the form of paratrabecular lymphoid aggregates. Splenic white pulp (Fig. 15-12) and hepatic portal triads are also frequently involved. Immunophenotype and Genetics.
The neoplastic cells resemble normal follicular center B cells, expressing CD19, CD20, CD10 (common acute lymphoblastic leukemia antigen [CALLA]), and monotypic surface Ig. In contrast to CLL and SLL and mantle cell lymphoma, CD5 is not expressed. Follicular lymphoma cells also consistently express BCL2 protein, in distinction to normal follicular center B cells, which are BCL2 negative (Fig. 15-13) . The hallmark of follicular lymphoma is a ( 14; 18) translocation, which leads to the juxtaposition of the IgH locus on chromosome 14 and the BCL2 locus on chromosome 18. This translocation is seen in most but not all follicular lymphomas [18] and leads to overexpression of BCL2 protein. BCL2, as seen in Chapters 1 and 7 , is an antagonist of apoptotic cell death and appears to promote the survival of follicular lymphoma cells. Although reactive follicles contain numerous B cells undergoing apoptosis (as shown in Fig. 15-4) , neoplastic follicles characteristically lack apoptotic cells. Clinical Features.
Follicular lymphomas tend to present with painless lymphadenopathy, which is frequently generalized. Involvement of extranodal sites, such as the gastrointestinal tract, central nervous system, or testis, is relatively uncommon. Although follicular lymphoma is incurable, it often follows an indolent waxing and waning course. The overall median survival is 7 to 9 years and is not improved
Figure 15-12 Non-Hodgkin lymphoma, follicular type, involving the spleen. Prominent nodules represent white pulp follicles expanded
by follicular lymphoma cells. Other indolent B-cell lymphomas (small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma) can produce an identical pattern of involvement. (Courtesy of Dr. Jeffrey Jorgenson, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
661
Figure 15-13 BCL2 protein expression in reactive and neoplastic follicles. BCL2 protein was detected using an immunohistochemical technique that produces a brown stain. In reactive follicles ( A ), BCL2 is present in mantle zone cells but not follicular center B cells, whereas follicular lymphoma cells ( B ) exhibit strong BCL2 staining. (Courtesy of Dr. Jeffrey Jorgenson, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
by aggressive therapy; hence, the usual clinical approach is to palliate patients with low-dose chemotherapy or radiation when they become symptomatic. Histologic transformation occurs in 30 to 50% of follicular lymphomas, most commonly to diffuse large B-cell lymphoma. Rarely, follicular lymphoma transforms to an aggressive tumor resembling lymphoblastic lymphoma or leukemia, an event usually associated with acquisition of a chromosomal translocation involving the c- myc locus. Median survival is less than 1 year after transformation. Diffuse Large B-Cell Lymphoma
The diagnostic category of diffuse large B-cell lymphoma encompasses a heterogeneous group of tumors that together constitute about 20% of all NHL and 60 to 70% of aggressive lymphoid neoplasms. There is a slight male predominance, with a median age of about 60 years. The age range is wide, however, and diffuse large B-cell lymphoma constitutes about 5% of childhood lymphoma. MORPHOLOGY.
The common morphologic features that unite this group of neoplasms are a relatively large cell size (usually four to five times the diameter of a small lymphocyte) and a diffuse pattern of growth (Fig. 15-14) . In other respects, there is a fair degree of morphologic variation. In most cases, the tumor cells have a round or oval nucleus that appears vesicular owing to margination of chromatin at the nuclear membrane, but large multilobated or cleaved nuclei predominate in some cases. Nucleoli may be two to three in number and located adjacent to the nuclear membrane or single and centrally placed. Cytoplasm is usually present in moderate abundance and may be pale or basophilic. Other more anaplastic tumors may contain multinucleated cells with large, inclusion-like nucleoli that closely resemble Reed-Sternberg (RS) cells (the tumor cell of HD), and in some difficult cases, phenotyping must be relied on to distinguish these two entities. Immunophenotype and Genetics.
These mature B-cell tumors express CD19 and CD20. Tumors of follicular center cell origin often express CD10. Most have surface Ig, and all are negative for TdT. Within this group of tumors, about 30% contain the t(14;18), the characteristic chromosomal abnormality of follicular lymphoma. [18] Such tumors are considered to be
of follicular center cell origin. An additional 20 to 30% of tumors contain various translocations that have in common a breakpoint involving the BCL6 locus on chromosome 3. [19] The BCL6 gene encodes a zinc-finger transcription factor that is normally expressed in germinal centers, consistent with a role in control of B-cell differentiation. [20] Tumors with BCL6 rearrangements often arise at extranodal sites and uniformly lack BCL2 rearrangements, suggesting the existence of at least two unique pathogenetic pathways for these neoplasms. Special Subtypes.
Two of several distinctive subtypes of large B-cell lymphoma, occuring in the setting of immunodeficiency states, including AIDS, are of sufficient pathogenetic interest to merit discussion. Immunodeficiency-associated large B-cell lymphoma: These tumors arise in the setting of severe T-cell immunodeficiency (e.g., end-stage HIV infection, severe combined immunodeficiency, allogeneic bone marrow transplantation, solid organ transplantation). The neoplastic B cells are often latently infected with Epstein-Barr virus (EBV), which is thought to play a critical pathogenic role. Restoration of T-cell immunity may lead to regression of such EBV-positive proliferations. 662
Body cavity large B-cell lymphoma: These are large cell lymphomas that arise as malignant pleural or ascitic effusions. Most are seen in patients with advanced HIV infection, but a few cases have been observed in HIV-negative elderly adults. [21] The tumor cells often fail to express surface B-cell or T-cell markers but have clonal IgH gene rearrangements. In all cases, the tumor cells are infected with human herpesvirus 8, which may play a causal role in the development of this tumor. [22] Among the malignant lymphomas, human herpesvirus 8, which is also associated with Kaposi sarcoma (Chapter 7 and 12) , has been observed only in this particular subtype. [23]
Figure 15-14 Non-Hodgkin lymphoma, diffuse large B-cell type. Tumor cells have large nuclei, open chromatin, and prominent nucleoli. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
Clinical Course.
Patients with diffuse large B-cell lymphoma typically present with a rapidly enlarging, often symptomatic mass at a single nodal or extranodal site. Involvement of the gastrointestinal tract, skin, bone, or brain may be the presenting feature. Waldeyer ring, the oropharyngeal lymphoid tissues that include the tonsils and adenoids, is also commonly involved. There may be large destructive masses in the liver and spleen (Fig. 15-15) . Bone marrow involvement occurs late in the disease, and rarely a leukemic
picture may emerge. As a group, diffuse large B-cell lymphomas are aggressive tumors that are rapidly fatal if untreated. With intensive combination chemotherapy, however, complete remission can be achieved in 60 to 80% of the patients, and approximately 50% remain free from disease for several years and may be considered cured. Patients with limited disease fare better than patients with widespread disease or a large bulky tumor mass. [24] Tumors with BCL6 rearrangements appear to have a better prognosis, [25] while the presence of p53 mutations correlates with a worse outcome. [26] Burkitt Lymphoma
Within the category of Burkitt lymphoma fall (1) African (endemic) Burkitt lymphoma, (2) sporadic (nonendemic) Burkitt lymphoma, and (3) a subset of aggressive lymphomas occurring in patients infected with HIV. Burkitt lymphomas occurring in these settings are histologically
Figure 15-15 Non-Hodgkin lymphoma, large B-cell type, involving the spleen. The presence of an isolated large mass is typical. In contrast, indolent B-cell lymphomas usually produce multifocal expansion of white pulp (see Fig. 15-10) . (Courtesy of Dr. Mark Fleming, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
identical, but some clinical, genotypic, and virologic differences exist. The relationship of African Burkitt lymphoma to EBV is discussed in Chapter 7 . MORPHOLOGY.
Involved tissues are effaced by a diffuse infiltrate of intermediate-sized lymphoid cells, 10 to 25 mum in diameter, containing round or oval nuclei with coarse chromatin, several nucleoli, and a moderate amount of faintly basophilic or amphophilic cytoplasm (Fig. 15-16) . The nuclear size approximates that of benign macrophages within the tumor. A high mitotic index is typical, as is apoptotic tumor cell death, accounting for the presence of numerous tissue macrophages with ingested nuclear debris. Because these benign macrophages, which are diffusely distributed among the tumor cells, are often surrounded by a clear space, they create a characteristic starry sky pattern. Occasionally, patients with Burkitt lymphoma present with a leukemic picture. In such cases, the tumor cells in marrow aspirates have slightly clumped nuclear chromatin, two to five distinct nucleoli, and royal blue cytoplasm containing multiple, clear cytoplasmic vacuoles. Immunophenotype and Molecular Genetics.
These are tumors of relatively mature B cells expressing surface IgM; monotypic kappa or lambda light chain; and CD19, CD20, and CD10. All forms of Burkitt lymphoma are highly associated with translocations of the c-myc
gene on chromosome 8. The partner is usually the IgH locus (t(8;14)), but may also be the kappa (t(2;8)) or lambda (t(8;22)) light-chain locus. There are subtle differences in the position of the chromosomal breakpoints in African and nonendemic Burkitt lymphoma that suggest that these two forms arise in different B-cell populations. [27] Essentially all African tumors are latently infected with EBV, which is also present in about 25% of HIV-associated tumors and in a minority of sporadic cases. Molecular analysis has shown that the configuration of the viral DNA is identical in all tumor cells within individual cases, indicating that infection precedes cellular transformation. While supporting a direct role for EBV in lymphomagenesis, this finding also raises interesting questions about the EBV negative tumors: Is another infectious agent involved in such cases, or can mutations in critical genes in the host genome mimic the effects of the transforming proteins of EBV on cell growth and differentiation? Clinical Features.
Most tumors manifest at extranodal sites. Endemic African Burkitt lymphoma often presents as a mass involving the mandible and shows an unusual predilection for involvement of abdominal viscera, particularly the kidneys, ovaries, and adrenal. In contrast, nonendemic Burkitt lymphoma most often presents as an abdominal mass involving the ileocecum and peritoneum. Both the African and the sporadic cases are found largely in children or young adults, accounting for approximately 30% of childhood NHLs in the United States. Evolution to a leukemic
663
Figure 15-16 Burkitt lymphoma. At low power ( A ), numerous pale, tingible body macrophages are evident, producing a "starry sky" appearance. At high power ( B ), tumor cells have multiple small nucleoli and high mitotic index. The lack of significant variation in nuclear shape and size lends a monotonous appearance. ( B courtesy of Dr. Jose Hernandez, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
picture is uncommon, especially in African cases. Burkitt lymphoma is aggressive but responds well to short-term, high-dose chemotherapy, with many patients appearing to be cured. Plasma Cell Neoplasms, Multiple Myeloma, and Related Entities
Plasma cell neoplasms and related entities are a group of lymphoid neoplasms of terminally differentiated B cells that have in common the expansion of a single clone of Ig-secreting plasma cells and a resultant increase in serum levels of a single homogeneous Ig or its fragments. In many but not all cases, these clonal proliferations (often referred to as dyscrasias) behave as malignant diseases. Collectively, these disorders account for about 15% of deaths from malignant white cell disease. The monoclonal Ig identified in the blood is referred to as an M component in reference to myeloma. Since complete M components have molecular weights of 160,000 or
higher, they are restricted largely to circulating plasma and extracellular fluid. They may appear in the urine, however, when there is some form of glomerular damage with heavy proteinuria. In normal plasma cells, production and coupling of heavy and light chains is tightly balanced. This balance is frequently lost in neoplastic plasma cells, leading to production of excess light or heavy chains along with complete Ig. Occasionally, only light chains or heavy chains are produced, without complete Ig. The free light chains, known as Bence Jones proteins, are sufficiently small to be rapidly excreted in the urine and so are often totally cleared from the blood or present only at low levels. With renal failure or massive synthesis, however, they may appear in the blood in significant concentrations. Designations applied to disorders associated with abnormal Ig include gammopathy, monoclonal gammopathy, dysproteinemia, and paraproteinemia. A variety of clinicopathologic entities are associated with monoclonal gammopathies, as follows: Multiple myeloma ( plasma cell myeloma) is the most important and most common disorder. It is characterized by multiple tumorous masses of neoplastic plasma cells scattered throughout the skeletal system. Solitary myeloma, or solitary plasmacytoma, is an infrequent variant consisting of a solitary neoplastic mass of plasma cells found in bone or some soft tissue site. Waldenstro m macroglobulinemia is a syndrome stemming from serum hyperviscosity caused by high levels of IgM. It is most commonly seen in patients with lymphoplasmacytic lymphoma (and thus is discussed later in more detail under this entity) but may also be seen in association with tumors that morphologically resemble CLL and SLL and rare myelomas that secrete IgM. Although macroglobulinemia is unusual in myeloma, significant hyperviscosity is observed with some tumors, particularly those secreting large amounts of IgA or IgG3 . Heavy-chain disease is seen in a diverse group of disorders, including CLL and SLL, lymphoplasmacytic lymphoma, and an unusual small bowel lymphoma occurring in malnourished populations (so-called Mediterranean lymphoma). The common feature is synthesis and secretion of Ig heavy chain fragments. Primary or immunocyte-associated amyloidosis results from a monoclonal proliferation of plasma cells secreting free light chains (most commonly of lambda isotype) that are subsequently processed and deposited as amyloid. While some patients with primary amyloidosis have overt multiple myeloma, others have only a minor clonal population of marrow plasma cells (Chapter 7) . Monoclonal gammopathy of undetermined significance ( MGUS) refers to instances in which M components are identified in the blood of patients having no symptoms or signs of any of the better-characterized monoclonal gammopathies.
664
Against this background, we can turn to some of the specific clinicopathologic entities. Primary amyloidosis was discussed along with other disorders of the immune system in Chapter 7 .
Multiple Myeloma.
Multiple myeloma is a plasma cell neoplasm that is characterized by involvement of the skeleton at multiple sites. Although bony disease dominates the clinical picture, it can also spread to lymph nodes and extranodal sites, such as the skin. Multiple myeloma causes 1% of all cancer deaths in Western countries. Its incidence is higher in men than in women, in people of African descent relative to the U.S. population at large, and in older adults as compared to the young. Etiology and Pathogenesis.
Although cells with mature plasma cell morphology and function accumulate within lesions, phenotypic studies imply that the cell of origin is a less differentiated cell. Small lymphoid cells within the peripheral blood have been shown to express Ig identical to that of neoplastic plasma cells, suggesting that they represent a progenitor cell population. Additionally, myeloma cells may express antigens typically associated with myelomonocytic cells (CD33), megakaryocytes (GpIIb/IIIa), and erythroid cells (glycophorin). Whether this is an example of neoplasia-induced lineage infidelity or an indication that the true cell of origin is a multipotent hematopoietic stem cell is unclear. The proliferation and survival of myeloma cells seem to be dependent on several cytokines, most notably IL-6. Serum levels of this cytokine are increased in patients with active disease, and it appears that high serum IL-6 levels are associated with a poor prognosis. [28] IL-6 is produced by tumorous plasma cells and stromal cells in the marrow. [29] These observations have spurred therapeutic trials of antibodies directed against IL-6 in aggressive myeloma. [30] An interesting discovery is that marrow stromal cells of many myeloma patients are infected by human herpesvirus 8, [31] a virus implicated in other tumors (Kaposi sarcoma and certain large B-cell lymphomas), which carries a gene encoding a polypeptide structurally and functionally homologous to IL-6. In addition to causing the growth of myeloma cells, cytokines also mediate bone destruction-- the major pathologic feature of multiple myeloma. Loss of bone is in large part due to osteoclastic reabsorption induced by the tumor. A variety of cytokines produced by the tumor cells, particularly IL-1beta and IL-6, serve as osteoclast-activating factors. [29] The most frequent karyotypic abnormalities are deletions of 13q and rearrangements of 14q. Up to 30% of cases have a balanced translocation, t(4;14)(p16.3;q32), that places the FGFR3 (fibroblast growth factor receptor 3) gene under the control of IgH promoter elements. [32] This results in increased expression of FGFR3, a member of a family of tyrosine kinase receptors implicated in control of cellular proliferation (Chapter 8) . MORPHOLOGY.
Multiple myeloma presents most often as multifocal destructive bone lesions throughout the skeletal system. Although any bone may be affected, the following
distribution was found in a large series of cases: vertebral column, 66%; ribs, 44%; skull, 41%; pelvis, 28%; femur, 24%; clavicle, 10%; and scapula, 10%. These focal lesions generally begin in the medullary cavity, erode the cancellous bone, and progressively destroy the cortical bone. Pathologic fractures are often produced by plasma cell lesions; they are most common in the vertebral column but may affect any of the numerous bones suffering erosion and destruction of their cortical substances. The bony defects are typically filled with soft, red tumor with a gelatinous consistency. Most commonly, the lesions appear radiographically as punched-out defects, usually 1 to 4 cm in diameter (Fig. 15-17) , but in some of the cases only diffuse demineralization is evident. Microscopic examination of the marrow reveals an increased number of plasma cells, which usually constitute greater than 30% of all cells. These cells may diffusely infiltrate the marrow or be present in sheetlike masses that completely replace normal elements. Similar to their normal counterparts, neoplastic plasma cells tend to have a perinuclear hof (owing to a prominent Golgi apparatus) and an eccentrically placed nucleus, features that allow their recognition (Fig. 15-18) . Relatively normal-appearing plasma cells or a number of cytologic variants may predominate, including plasmablasts, having less condensed nuclear chromatin and prominent single nucleolus; bizarre multinucleated cells, which may
Figure 15-17 Multiple myeloma of the skull (radiograph, lateral view). The sharply punched-out bone lesions are most obvious in the
calvarium.
665
Figure 15-18 Multiple myeloma, bone marrow aspirate. Normal marrow cells are largely replaced by plasma cells, including atypical
forms with multiple nuclei, prominent nucleoli, and cytoplasmic droplets containing immunoglobulin.
in some cases constitute most of the cellularity; flame cells with fiery red cytoplasm; Mott cells, having multiple blue, grapelike cytoplasmic droplets; and cells containing a variety of other cytoplasmic inclusions, including fibrils, crystalline rods, Russell bodies, and their intranuclear counterpart, Dutcher bodies. With progressive disease, plasma cell infiltrations of soft tissues may be encountered in the spleen, liver, kidneys, lungs, and lymph nodes or more widely. Bence Jones proteins are excreted in the kidney and contribute to the renal involvement, generally called myeloma kidney, which is one of the more distinctive features of multiple myeloma. It is discussed in detail in Chapter 21 .
Clinical Course.
The peak age incidence of multiple myeloma is between 50 and 60 years. As previously stated, the clinical features of myeloma stem from the effects of (1) infiltration of organs, particularly bones, by the neoplastic plasma cells; (2) the production of excessive Ig, which often has abnormal physicochemical properties; and (3) the suppression of normal humoral immunity. Infiltration of bones is manifested by pain and pathologic fractures. Hypercalcemia resulting from bone resorption may give rise to neurologic manifestations, such as confusion, weakness, lethargy, constipation, and polyuria, and also contributes to renal disease. Decreased production of normal Ig sets the stage for recurrent infections with bacteria such as Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli. Cellular immunity is relatively unaffected. Of great significance is renal insufficiency, which is second only to infections as a cause of death. The pathogenesis of renal failure, which may occur in up to 50% of patients, is multifactorial and is discussed in Chapter 21 . The most important factor appears to be Bence Jones proteinuria, since the excreted light chains are toxic to the tubular epithelial cells. Amyloidosis of the AL type occurs in some patients owing to excessive production of Ig light chains. In 99% of patients with multiple myeloma, electrophoretic analysis reveals increased levels of Ig in the blood or light chains ( Bence Jones proteins) in the urine, or both. The monoclonal Ig produces a high spike when serum or urine is subjected to electrophoresis. Immunoelectrophoresis or immunofixation is used to identify the nature of monoclonal Ig (Fig. 15-19) . Quantitative analyses of monoclonal Ig usually reveal more than 3 gm of Ig per dl of serum and more than 6 mg of Bence Jones proteins per dl of urine. The most common serum monoclonal Ig (M protein) is IgG, which is found in 55% of patients. An
Figure 15-19 M-protein detection, multiple myeloma. Serum protein electrophoresis (SP) is used to screen for the presence of a
monoclonal immunoglobulin (M protein). Polyclonal IgG in normal serum (denoted by the arrow) appears as a broad band; in contrast, serum from a patient with multiple myeloma contains a single sharp protein band in this region of the electropherogram. The suspected monoclonal immunoglobulin is then confirmed and characterized by immunofixation. In this procedure the electrophoresed proteins within the gel are reacted with specific antisera. After extensive washing, only proteins cross-linked by the antisera are retained in the gel, which is then stained for protein. Note that the sharp band in the immunoglobulin region of the patient's SP is recognized by antisera against IgG heavy chain (G) and kappa light chain (kappa), indicating that this band is an IgGkappa M protein. The levels of polyclonal IgG, IgA (A), and lambda light chain (lambda) are also decreased in the patient serum relative to normal serum, a common finding in multiple myeloma. (Courtesy of Dr. David Sacks, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
666
additional 25% of cases are associated with an IgA M protein. Myelomas expressing IgM, IgD, or IgE occur but are rare. Excessive production and aggregation of M proteins leads to the hyperviscosity syndrome (described under lymphoplasmacytic lymphoma) in approximately 7% of patients, most of whom have tumors that secrete IgA or IgG 3 .
Bence Jones proteinuria and a serum M protein are both observed in 60 to 70% of all myeloma patients. In approximately 20% of patients, however, Bence Jones proteinuria is present as a isolated finding. It should also be noted that about 1% of myelomas are nonsecretory and thus occur in the absence of detectable serum or urine M proteins. Hence, the absence of paraproteinemia and paraproteinuria does not exclude myeloma. The clinicopathologic diagnosis of multiple myeloma rests on radiographic and laboratory findings. The radiographic changes are so distinctive that a reasonably certain diagnosis can usually be made. Classically the individual lesions appear as sharply punched-out defects having a rounded soap-bubble appearance on x-ray film, but generalized osteoporosis may also be seen. Marrow examination may reveal increased interstitial plasma cells or sheetlike aggregates that completely replace the normal elements. Extensive marrow involvement gives rise to a normocytic normochromic anemia, sometimes accompanied by moderate leukopenia and thrombocytopenia. Rarely, neoplastic plasma cells flood the peripheral blood, giving rise to plasma cell leukemia. The prognosis for this condition is variable but generally poor. Patients with multiple bony lesions, if untreated, rarely survive for more than 6 to 12 months, whereas occasional patients with indolent myeloma can survive for many years. Chemotherapy in the form of alkylating agents induces remission in 50 to 70% of patients, but the median survival is still a dismal 3 years. Biphosphonates, drugs that inhibit bone resorption, have shown some promise in reducing pathologic fractures and limiting hypercalcemia. Autologous bone marrow transplantation after intensive chemotherapy may improve survival but is noncurative. [33] Solitary Myeloma (Plasmacytoma).
About 3 to 5% of plasma cell neoplasms present as a solitary lesion of either bone or soft tissue. The bony lesions tend to occur in the same locations as in multiple myeloma. Extraosseous lesions are often located in the lungs, oronasopharynx, or nasal sinuses. Modest elevations of M proteins in the blood or urine may be found in a minority of patients. When patients with such localized disease are followed, progression to classic multiple myeloma becomes manifest in most patients with osseous plasmacytoma, whereas extraosseous tumors disseminate in only a minor fraction of patients. It appears that the solitary plasmacytoma involving the bones is an early stage of multiple myeloma, but in some individuals it may be present for 10 to 20 years without progression. Extraosseous plasmacytomas, particularly those involving the upper respiratory tract, represent limited disease that can often be cured by local resection. Monoclonal Gammopathy of Uncertain Significance (MGUS).
M proteins can be identified in the serum of 1% of asymptomatic healthy persons older than 50 years of age and in 3% older than 70 years of age. This dysproteinemia without
associated disease is considered MGUS, which is the most common form of monoclonal gammopathy. Approximately 20% of patients with MGUS develop an overt plasma cell dyscrasia (usually multiple myeloma) over a period of 10 to 15 years. The diagnosis of MGUS should be made with caution and after careful exclusion of other causes of monoclonal gammopathy, particularly indolent multiple myeloma. In general, patients with MGUS have less than 3 gm/dl of monoclonal protein in the serum and no Bence Jones proteinuria. Whether a given patient with MGUS will follow a benign course, as most do, or develop a well-defined plasma cell neoplasm cannot be predicted, and hence periodic assessment of serum M component levels and Bence Jones proteinuria is warranted. Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia)
Lymphoplasmacytic lymphoma (LPL) is a B-cell neoplasm of older adults that usually presents in the sixth or seventh decade of life. It has gone by a variety of monikers, including small lymphocytic lymphoma with plasmacytic differentiation and immunocytoma. Although bearing a superficial resemblance to CLL and SLL, it differs in that a substantial fraction of the tumor cells undergo terminal differentiation to plasma cells. Most commonly, the neoplastic plasma cells secrete monoclonal IgM, often in amounts sufficient to cause a hyperviscosity syndrome known as Waldenstro m macroglobulinemia. MORPHOLOGY.
Typically, there is a diffuse, sparse-to-heavy infiltrate in the bone marrow of lymphocytes, plasma cells, and intermediate plasmacytoid lymphocytes (so-called plymphocytes), often accompanied by a reactive hyperplasia of mast cells (Fig. 15-20) . PAS-positive inclusions containing Ig may be seen in the cytoplasm (Russell bodies) or nucleus (Dutcher bodies). Tumorous masses causing bony erosions, a feature characteristic of multiple myeloma (described later), are not seen. A similar polymorphous infiltrate may be present in the lymph nodes, spleen, or liver in patients having disseminated disease. Infiltration of the nerve roots, meninges, and more rarely the brain may also occur. Clinical Course.
The dominant presenting complaints are weakness, fatigue, and weight loss--all nonspecific symptoms. Approximately half the patients have lymphadenopathy, hepatomegaly, and splenomegaly. Anemia caused by marrow infiltration is often present and may be exacerbated by autoimmune hemolysis, which is seen in about 10% of patients. Hemolysis is caused by cold agglutinins, IgM antibodies that bind to erythrocytes at temperatures of less than 37°C. Patients with IgM-secreting tumors have additional complaints that stem from the
physicochemical properties of macroglobulin. [34] Because of its large size and increased
667
Figure 15-20 Lymphoplasmacytic lymphoma. Bone marrow biopsy shows a characteristic mixture of small lymphoid cells exhibiting
various degrees of plasma cell differentiation. In addition, a mast cell with purplish-red cytoplasmic granules is present at the left-hand side of the field.
concentration in blood, IgM tends to increase the viscosity of the blood, giving rise to a hyperviscosity syndrome. This syndrome is characterized by the following features: Visual impairment resulting from the striking tortuosity and distention of retinal veins as well as retinal hemorrhages and exudates Neurologic problems, such as headaches, dizziness, deafness, and stupor, stemming from sluggish blood flow and sludging Bleeding related to the formation of complexes between macroglobulins and clotting factors as well as interference with platelet functions Cryoglobulinemia resulting from precipitation of macroglobulins at low temperatures, producing symptoms such as Raynaud phenomenon and cold urticaria Lymphoplasmacytic lymphoma is an incurable progressive disease. Because IgM is mostly intravascular, symptoms caused by high levels of IgM (such as hyperviscosity and hemolysis) can be alleviated by plasmapheresis. Transformation to large cell lymphoma occurs uncommonly. Median survival is about 4 years. Mantle Cell Lymphoma
Mantle cell lymphoma comstitutes about 3% of NHL in the United States and a somewhat higher fraction of NHL in Europe (7 to 9%). It usually presents in people in the forties to fifties and shows a male predominance. As the name implies, the tumor cells closely resemble the normal mantle zone cells that surround follicular centers, and have distinctive cytogenetic and molecular abnormalities. MORPHOLOGY.
Two patterns of lymph node involvement are observed: (1) a mantle zone pattern in which tumor cells surround or efface B-cell follicles, producing a vaguely nodular appearance at low power, and (2) a diffuse pattern. Regardless of the pattern, in most cases, the proliferation consists of a homogeneous population of small lymphocytes with round to irregular to occasionally deeply clefted (cleaved) nuclear contours (Fig. 15-21) . Large cells resembling centroblasts are usually absent, as are proliferation centers, helping to distinguish mantle cell lymphoma from follicular lymphoma and CLL and SLL. [9] In most cases, the nuclear chromatin is condensed,
nucleoli are inconspicuous, and cytoplasm is scant. From 20 to 40% of patients have peripheral blood lymphocytosis, usually less than 20,000 mm3 . The majority of patients present with bone marrow involvement, which usually takes the form of nonparatrabecular and paratrabecular lymphoid aggregates.
Figure 15-21 Non-Hodgkin lymphoma, mantle cell type. At low power ( A ), neoplastic lymphoid cells surround a small, atrophic germinal center, exhibiting a mantle zone pattern of growth. A high-power view ( B ) shows a homogeneous population of small
lymphoid cells with somewhat irregular nuclear outlines, condensed chromatin, and scant cytoplasm. Large cells resembling "prolymphocytes" (seen in chronic lymphocytic leukemia) and centroblasts (seen in follicular lymphoma) are absent.
668
Splenic involvement is common, with tumor cells preferentially expanding white pulp zones, as is periportal infiltration of the liver. Extranodal disease is also relatively common in mantle cell lymphoma. Occasionally, multifocal mucosal involvement of the small bowel and colon produces lymphomatoid polyposis; of all forms of NHL, mantle cell lymphoma is most likely to spread in this fashion. Immunophenotype and Genetics.
Mantle cell lymphoma is a B-cell neoplasm that expresses CD19, CD20, moderately high levels of surface Ig heavy chain (usually IgM and IgD), and either kappa or lambda light chain. It is usually CD5 positive and CD23 negative, which can help to distinguish it from CLL and SLL. Expression of CD5 may be aberrant because normal mantle zone cells are CD5 negative. Further distinctiveness is conferred to mantle cell lymphoma by the frequent occurrence of an ( 11; 14) translocation involving the IgH locus on chromosome 14 and a locus on chromosome 11 variously known as BCL1 (not BCL2) or PRAD1. The t(11;14) is detected in about 70% of cases by cytogenetics and an even higher fraction of tumors analyzed by fluorescent in situ hybridization. [35] The BCL1 locus encodes cyclin D1, a protein involved in the regulation of G1 to S phase progression during the cell cycle. BCL1 rearrangements lead to increased expression of cyclin D1 protein, [36] which may contribute to tumorigenesis by causing loss of cell cycle control. Clinical Features.
Most patients present with generalized lymphadenopathy, bone marrow, and liver involvement. Splenomegaly is present in about 50% of patients. B symptoms (fever and weight loss) are observed in a minority of patients. The prognosis for mantle cell lymphoma patients is poor, as the median survival is only 3 to 4 years. Mantle cell lymphoma is not curable with conventional chemotherapy, and
most patients eventually succumb to organ dysfunction caused by tumor infiltration. For unclear reasons, histologic transformation occurs less frequently in mantle cell lymphoma than in CLL and SLL or follicular lymphoma. Marginal Zone Lymphoma (MALToma)
The category of marginal zone lymphoma encompasses a heterogeneous group of B-cell tumors that may primarily arise within the lymph nodes, spleen, or within extranodal tissues. Although all marginal zone lymphomas share certain morphologic and immunophenotypic features, those arising at extranodal sites deserve special attention because of their unusual pathogenesis. These are predominantly tumors of middle-aged adults and are exceptional in three regards: (1) they tend to arise within tissues involved by chronic inflammatory disorders of autoimmune ( e. g., the salivary gland in Sjo gren disease and the thyroid gland in Hashimoto thyroiditis) or infectious ( e. g., the stomach in Helicobacter gastritis) origin; (2) they remain localized for prolonged periods at sites of origin, spreading systemically only late in their course; and (3) they are composed of cells at various stages of B lymphoid differentiation, often including terminally differentiated plasma cells. Because these tumors were initially recognized at mucosal sites, they have been referred to as tumors of mucosaassociated lymphoid tissues (or MALToma). In most cases, the predominant tumor cell population bears a resemblance to normal marginal zone B cells, and under the REAL classification all are considered variants of marginal zone lymphoma. The process begins as a reactive, polyclonal immune reaction. [37] Over time, a monoclonal B-cell neoplasm emerges, probably because of acquired genetic changes, that is still dependent on reactive T helper cells for growth and survival. [38] With further clonal evolution, spread to distant sites and transformation to diffuse large B-cell lymphoma may occur. This theme of polyclonal-to-monoclonal transition during lymphomagenesis is also applicable to the pathogenesis of human T-cell lymphotropic virus type 1 (HTLV-1)-induced and EBV-induced lymphoma and is more fully discussed in Chapter 8 . Hairy Cell Leukemia
Hairy cell leukemia is a rare but distinctive B-cell neoplasm of uncertain origin that constitutes about 2% of all leukemias. It is predominantly a disease of middle-aged white men (male-to-female ratio of 4:1). MORPHOLOGY.
Hairy cell leukemia derives its picturesque name from the appearance of the leukemic cells, which have fine hairlike projections that are best recognized under the phase-contrast microscope (Fig. 15-22) . On routine peripheral blood smears, hairy cells have round, oblong, or reniform nuclei and modest amounts of pale blue cytoplasm, often with threadlike or bleblike extensions. The number of circulating cells is highly variable. The bone marrow is always involved by a diffuse interstitial infiltrate of cells with oblong or reniform nuclei, condensed chromatin, and abundant
pale cytoplasm. Because these cells are usually entrapped in an extracellular matrix composed of reticulin fibrils, tumor cells are frequently absent from bone marrow aspirate smears. The red pulp of the spleen is preferentially infiltrated by hairy cells, leading to a beefy red, gross appearance and obliteration of white pulp. Hepatic portal triads are also frequently infiltrated. Histochemistry and Immunophenotype.
A cytochemical feature that is characteristic of hairy cell leukemia is the presence of tartrate-resistant acid phosphatase in the neoplastic B cells. The hairy cells also usually express the pan B-cell markers CD19 and CD20, surface IgH (usually IgG), and either kappa or lambda light chain, the monocyte-associated antigen CD11c, CD25 (the IL-2 receptor), and plasma cell-associated antigen-1 (PCA-1). The precise cell of origin is unknown.
669
Figure 15-22 Hairy cell leukemia in peripheral blood. A , Phase contrast microscopy shows tumor cells with fine, hairlike cytoplasmic projections. In stained smears ( B ), these cells have round or folded nuclei and modest amounts of pale-blue, agranular cytoplasm. (Courtesy of Dr. David Weinberg, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
Clinical Features.
Clinical manifestations largely result from infiltration of bone marrow, liver, and spleen. Splenomegaly, often massive, is the most common and sometimes the only abnormal physical finding. Hepatomegaly is less common and not as marked, and lymphadenopathy is distinctly rare. Pancytopenia, resulting from marrow failure and splenic sequestration, is seen in more than half the cases. About one third of patients present with infections. One unusual feature is a high incidence of atypical mycobacterial infection, [39] possibly related in part to frequent monocytopenia. Hairy cell leukemia tends to follow an indolent course. For unclear reasons, the tumor cells are exceptionally sensitive to particular chemotherapeutic regimens, which produce long-lasting remissions in a majority of patients. [40] Whether such patients are truly cured is not yet known. PERIPHERAL T-CELL AND NATURAL KILLER CELL NEOPLASMS
Peripheral T-cell and NK cell neoplasms include a heterogeneous group of neoplasms having phenotypes resembling mature T cells or NK cells. Peripheral T-cell tumors comprise about 15% of NHLs in the United States and Europe but are substantially more common in Asia. NK cell tumors are rare in the Westen hemisphere but also relatively common in the Far East.
Peripheral T-Cell Lymphoma, Unspecified
Although the REAL classification includes a number of distinct forms of peripheral T-cell neoplasia, peripheral T-cell lymphomas as a group are heterogeneous and not easily categorized. In recognition of this, a "wastebasket" diagnostic category, peripheral T-cell lymphoma, unspecified, has been created. Although no morphologic feature is pathognomonic of peripheral T-cell lymphomas, certain findings are characteristic. The tumors diffusely efface the architecture of involved lymph nodes and are typically composed of a pleomorphic mixture of small, intermediate, and large-sized malignant T cells (Fig. 15-23) . They may have a prominent infiltrate of reactive cells such as eosinophils and macrophages, probably attracted by T cell-derived cytokines. Prominent angiogenesis is also sometimes seen. The diagnosis can be confirmed only by immunophenotyping. By definition, all peripheral T-cell lymphomas have a mature T-cell phenotype, lacking TdT and usually expressing CD2, CD5, surface CD3, and either T-cell alphabeta or deltagamma receptors. Many variations on this theme are possible, however, and some tumors have phenotypes that are considered aberrant for peripheral T cells, such as CD5 or
Figure 15-23 Peripheral T-cell lymphoma, unspecified, involving a lymph node. A spectrum of small, intermediate, and large lymphoid
cells, many with irregular nuclear contours, is seen.
670
CD7 negative. In a high fraction of cases, clonal rearrangements of at least one T-cell receptor locus are detected. Most patients present with generalized lymphadenopathy, sometimes accompanied by eosinophilia, pruritus, fever, and weight loss. Although cures of peripheral T-cell lymphoma have been reported, the incidence of relapse appears to be higher than that observed with aggressive mature B-cell neoplasms (e.g., diffuse large B-cell lymphoma). Adult T-Cell Leukemia/Lymphoma
Adult T-cell leukemia/lymphoma is a neoplasm of CD4+ T cells observed in patients infected by HTLV-1 (Chapter 7) . It is most frequent in regions where HTLV-1 is endemic (southern Japan and the Caribbean basin) and is characterized by skin lesions, generalized lymphadenopathy, hepatosplenomegaly, peripheral blood lymphocytosis, and hypercalcemia. The appearance of the tumor cells varies widely, but frequently cells with multilobated nuclei, described as cloverleaf or flower cells, are found in involved
tissues and peripheral blood. Less commonly, multinucleated giant cells resembling RS cells may be present. The tumor cells contain clonal HTLV-1 provirus, compatible with direct pathogenic involvement of the virus in this neoplasm. Most patients present with rapidly progressive disease that is fatal within months to 1 year despite aggressive chemotherapy. Less commonly, the tumor primarily involves the skin and follows a much more indolent course resembling mycosis fungoides. It should be noted that in addition to causing lymphoid malignancies, HTLV-1 infection can also give rise to a progressive demyelinating disease that affects the central nervous system and the spinal cord (Chapter 30) . Mycosis Fungoides and Sezary Syndrome
Mycosis fungoides and Sezary syndrome appear to be different manifestations of a single neoplastic entity. It is an indolent disorder of peripheral CD4+ T cells that is characterized by the involvement of skin and therefore belongs to the group of cutaneous T-cell lymphoid neoplasms. Clinically the cutaneous lesions of mycosis fungoides show three somewhat distinct stages (Chapter 27) . Briefly, mycosis fungoides presents with an inflammatory premycotic phase and progresses through a plaque phase to a tumor phase. Histologically, there is infiltration of the epidermis and upper dermis by neoplastic T cells, which have an extremely unusual cerebriform nucleus, characterized by marked infolding of the nuclear membrane. Disease progression is characterized by extracutaneous spread, most commonly to lymph nodes and bone marrow. Se zary syndrome is a variant in which skin involvement is characteristically manifested as a generalized exfoliative erythroderma. In contrast to mycosis fungoides, the skin lesions rarely proceed to tumefaction. In addition, there is an associated leukemia of Se zary cells that have the same cerebriform appearance noted in the tissue infiltrates of mycosis fungoides. Circulating tumor cells can also be identified in peripheral smears in up to 25% of cases of mycosis fungoides in the plaque or tumor phase, emphasizing the overlap between mycosis fungoides and Sezary syndrome. Although cutaneous disease dominates the clinical picture in these disorders, sensitive molecular analyses have shown that tumor cells are present in the lymph nodes and bone marrow early in the course of all patients, indicating that tumor cells circulate widely. The basis for the striking epidermotropism is uncertain; tumor cells may preferentially home to skin or be dependent on skin-specific factors for growth or survival. These are indolent tumors associated with a median survival of 8 to 9 years. Transformation to large cell lymphoma of T-cell type occasionally occurs as a terminal event. HODGKIN DISEASE
HD encompasses a group of disorders that differ from NHL in several respects. In contrast to NHLs, which frequently arise at extranodal sites and spread in an
unpredictable fashion, HD arises in a single node or chain of nodes and spreads characteristically to the anatomically contiguous nodes. It is characterized morphologically by the presence of distinctive neoplastic giant cells, RS cells, which induce the accumulation of reactive lymphocytes, histiocytes, and granulocytes. In contrast to other lymphoid neoplasms, the neoplastic cells of HD typically make up a minor fraction (1 to 5%) of the total tumor cell mass. The origin of the neoplastic cell in the more common forms of HD has yet to be identified with certainty and has a phenotype unique from that observed in other lymphoid neoplasms. HD accounts for 0.7% of all new cancers in the United States, with approximately 7400 new cases reported per year. Its importance stems from the fact that it is one of the most common forms of malignancy in young adults, with an average age at diagnosis of 32 years. Much progress has been made in the treatment of this disease in the last several decades, and it is now curable in most cases. Classification.
There are three major subtypes of HD: Nodular sclerosis Mixed cellularity Lymphocyte predominance Additional variants, such as lymphocyte depletion HD, are rare and controversial entities [4A] and are not discussed here. MORPHOLOGY.
The Reed-Sternberg Cell.
A distinctive tumor giant cell known as the RS cell is considered to be the true neoplastic element in HD, and identification of RS cells and their variants is therefore essential for the histologic diagnosis (Fig. 15-24) . Classic RS cells are quite large (15 to 45 mu in diameter), binucleate or bilobed, with the two halves often appearing as mirror images of each other. At other times, there are multiple nuclei, or the single nucleus is multilobate. The nucleus is enclosed
671
Figure 15-24 Reed-Sternberg cells and variants. A , Diagnostic Reed-Sternberg cell, with two nuclear lobes, large inclusion-like nucleoli, and abundant cytoplasm, surrounded by lymphocytes, macrophages, and an eosinophil. B , Reed-Sternberg cell, mononuclear variant. C, Reed-Sternberg cell, lacunar variant. This variant is usually seen in the nodular sclerosis subtype and has a
folded nucleus or multilobate nucleus lying within a clear space created by retraction of its cytoplasm during processing of the tissue. D, Reed-Sternberg cell, lymphohistiocytic (L+H) variant. Several such variants with folded or multilobate nuclei, small nucleoli, fine
chromatin, and abundant pale cytoplasm are present. ( A courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
within an abundant amphophilic cytoplasm and contains large, inclusion-like, owl-eyed nucleoli, generally surrounded by a clear halo, that are about the size of a small lymphocyte (5 to 7 mu in diameter). Several variants of RS cells are also encountered. Mononculear variants contain only a single round or oblong nucleus with a large inclusion-like nucleolus. Lacunar cells, seen predominantly in the nodular sclerosis subtype, have more delicate folded or multilobate nuclei surrounded by abundant pale cytoplasm that is often disrupted during the cutting of sections, leaving the nucleus sitting in an empty hole (the lacune). Lymphocytic and histiocytic variants (L+ H cells) with polypoid nuclei resembling popcorn kernels, inconspicuous nucleoli, and moderately abundant cytoplasm are specific to the lymphocyte predominance subtype. The morphologic diagnosis of HD is complicated by the occasional presence of cells similar or identical in appearance to RS cells in other conditions, such as infectious mononucleosis, solid tissue cancers, and NHL. Thus, although RS cells are requisite for the diagnosis, they must be present in an appropriate background of non-neoplastic inflammatory cells (lymphocytes, plasma cells, eosinophils). In difficult cases, immunohistochemical markers and molecular genetic studies help in establishing the diagnosis. Spread of HD and Staging.
The spread of HD is remarkably predictable: Nodal disease precedes splenic disease, splenic disease usually precedes hepatic disease, and hepatic disease usually precedes marrow involvement and extranodal disease. Because of this uniform pattern of spread, patients with limited disease can be cured with local radiotherapy. For this reason, the staging of
672
TABLE 15-6 -- CLINICAL STAGING OF HODGKIN AND NON-HODGKIN LYMPHOMAS (ANN ARBOR CLASSIFICATION) Stage Distribution of Disease *
I
Involvement of a single lymph node region (I) or involvement of a single extralymphatic organ or site (IE ).
II
Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited contiguous extralymphatic organ or tissue (IIE )
III
Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (IIIs ) and/or limited contiguous extralymphatic organ or site (IIIE , IIIES )
IV
Multiple or disseminated foci of involvement of one or more extralymphatic organs or tissues with or without lymphatic involvement
From Carbone PT, et al: Symposium (Ann Arbor): Staging in Hodgkin's disease. Cancer Res 31:1707, 1971. *All stages are further divided on the basis of the absence (A) or presence (B) of the following systemic symptoms: significant fever, night sweats, or unexplained weight loss of greater than 10% of normal body weight.
HD (Table 15-6) is not only predictive of prognosis, but also guides the choice of therapy. Staging involves careful physical examination and several investigative procedures, including computed tomography of abdomen and pelvis, chest radiography, and biopsy of the bone marrow. These modalities still fail to detect splenic disease reliably, and staging laparotomy, which allows direct visualization of the intra-abdominal nodes, liver biopsy, and removal of the spleen, is still used in some patients being considered for radiotherapy. The presence of constitutional symptoms (fever, night sweats, and weight loss) are characteristic of HD but can also be seen in other lymphoid neoplasms. With this background, we turn to the morphologic classification of HD into its subgroups and point out some of the salient immunophenotypic and clinical features of each (Table 15-7) . Later the manifestations common to all are presented. Hodgkin Disease, Nodular Sclerosis Type.
The most common form of HD, constituting 65 to 75% of cases, the nodular sclerosis type is characterized by two features: (1) the presence of a particular variant of the RS cell, the lacunar cell (Fig. 15-24 C), and (2) the presence of collagen bands that divide the lymphoid tissue into circumscribed nodules (Fig. 15-25) . The fibrosis may be scant or abundant, and the neoplastic cells are found in a polymorphous background of small T lymphocytes, eosinophils, plasma cells, and macrophages. Classic RS cells are less frequent than in the mixed cellularity and lymphocyte depletion types. The tumor cells have a characteristic immunophenotype: positive for CD15 and CD30 and negative for CD45, B-cell, and T-cell markers. In early nodal disease, the tumor cells preferentially involve the paracortical T-cell zones. As in other forms of HD, involvement of the spleen, liver, bone marrow, and other organs and tissues may appear in due course and take the form of irregular, tumor-like nodules resembling that present in the nodes. The nodular sclerosis type is the only form of HD that is more common in women and strikes adolescents or young adults. It has a propensity to involve the lower cervical, supraclavicular, and mediastinal lymph nodes. The prognosis is excellent.
TABLE 15-7 -- CLASSIFICATION OF HODGKIN DISEASE Subtype Morphology and Immunophenotype Typical Clinical Features Nodular sclerosis
Frequent lacunar cells and occasional diagnostic RS cells; background infiltrate composed of T lymphocytes, eosinophils, macrophages, and plasma cells; fibrous bands dividing cellular areas into nodules. RS cells CD15+, CD30+.
Stage 1 or 2 disease most common. Frequent mediastinal involvement. Females affected more than males, most patients young adults.
Mixed cellularity
Frequent mononuclear and diagnostic RS cells; background infiltrate rich in T lymphocytes, eosinophils, macrophages, plasma cells. RS cells CD15+, CD30+.
More than 50% present as stage 3 or 4 disease. Males affected more than females. Biphasic incidence, peaking in young adults and again in adults>55.
Lymphocyte predominance
Frequent L+H (popcorn cell) variants in a background of follicular dendritic cells and reactive B cells. RS cells CD20+, CD15-, CD30-.
Young males with cervical or axillary lymphadenopathy. Mediastinal disease uncommon.
Lymphocyte depletion
Rare and somewhat controversial, with frequent RS or RS cells. Most cases prove to be large cell lymphoma. CD15+, CD30+.
Older male patients with disseminated disease. Also seen in HIV patients and developing countries.
RS, Reed-Sternberg; HIV, human immunodeficiency virus; L+H, lymphocytic-histiocytic.
673
Figure 15-25 Hodgkin disease, nodular sclerosis type. A low-power view shows well-defined bands of pink, acellular collagen that have subdivided the tumor cells and associated reactive infiltrate into nodules. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
Hodgkin Disease, Mixed Cellularity Type.
This form of HD constitutes about 25% of cases. The mixed cellularity type is rendered distinctive by diffuse effacement of lymph nodes by a heterogeneous cellular infiltrate, which includes small lymphocytes, eosinophils, plasma cells, and benign macrophages admixed with the neoplastic cells (Fig. 15-26) . Classic RS cells and mononculear variants are usually plentiful. The immunophenotype is identical to that observed in
the nodular sclerosis type. Small lymphocytes in the background are predominantly T cells, and early nodal disease preferentially involves paracortical T-cell zones. Uncommonly the background infiltrate is composed predominantly of a monotonous population
Figure 15-26 Hodgkin disease, mixed cellularity type. A diagnostic, binucleate Reed-Sternberg cell is surrounded by multiple cell types, including eosinophils (bright red cytoplasm), lymphocytes, and histiocytes. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
of polyclonal small T lymphocytes with few admixed macrophages or other reactive elements. In such lymphocyte-rich cases, immunophenotyping may be needed to exclude the lymphocyte predominance type of HD or an unusual NHL. The mixed cellularity form of HD is more common in men. Compared to the lymphocyte predominance and nodular sclerosis subtypes, it is more likely to be associated with older age, B symptoms, and advanced tumor stage. Nonetheless, the overall prognosis is good. Hodgkin Disease, Lymphocyte Predominance Type.
This uncommon variant, accounting for approximately 6% of all cases, is characterized by nodal effacement by a vaguely nodular infiltrate of small lymphocytes admixed with variable numbers of benign histiocytes (Fig. 15-27) . Typical RS cells are extremely difficult to find. More common are so-called lymphohistiocytic (L+ H) variants that have a delicate, multilobed nucleus that has been likened in appearance to popcorn ( popcorn cell). Other cells, such as eosinophils, neutrophils, and plasma cells, are scanty or absent, and there is little evidence of necrosis or fibrosis. Increasingly, evidence is accruing that supports a follicular B-cell origin for the neoplastic cells of this subtype. In contrast to other forms of HD, the tumor cells are positive for CD45 and CD20, a B-cell marker, and negative for CD15 and CD30. [41] [42] The L+H cells within individual tumors share identical IgH gene rearrangments and have VH segments that have undergone somatic hypermutation, [43] [44] a modification that normally occurs only in follicular B cells. Finally, in contrast to other forms of HD, approximately 3 to 5% of tumors transform to diffuse large cell lymphomas, which are uniformly of B-cell type.
Figure 15-27 Hodgkin disease, lymphocyte predominance type. Numerous mature-looking lymphocytes surround scattered, large, pale-staining L+H variants ("popcorn" cells). (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
674
A majority of patients are men, usually younger than 35 years of age, presenting with limited disease. Most patients have cervical or axillary lymphadenopathy. Mediastinal disease is rarely seen, and bone marrow involvement is rare. The overall prognosis is excellent. Etiology and Pathogenesis.
It is now widely accepted that HD is a clonal neoplastic disorder and that the RS cells and variants represent the transformed cells. In all likelihood, the characteristic accumulation of reactive cells occurs in response to cytokines secreted by the RS cells. Many cytokines, including IL-4, IL-5, TNF-alpha, GM-CSF, and transforming growth factor-beta (TGF-beta), have been detected in HD. Of these, IL-5 synthesis by RS cells correlates with eosinophil accumulation (a feature of mixed cellularity and nodular sclerosis subtypes). [45] TGF-beta, a fibrogenic cytokine, is found almost exclusively in the nodular sclerosis variant, where it is produced by eosinophils. [46] Thus, the specific histologic pattern of HD may be determined by the unique combination of cytokines secreted by RS cells and the non-neoplastic cellular infiltrate. [47] In the specific case of the lymphocyte predominance subtype, the evidence for a B-cell origin is fairly convincing. In the other subtypes of HD, the origin of these cells remains an enigma. The extensive studies on RS cell derivation in the nodular sclerosis and mixed cellularity subtypes can be summarized as follows: RS cells are aneuploid and contain clonal cytogenetic aberrations, [48] but no consistent abnormality has been detected. RS cells express surface markers, such as MHC class II antigens and B7, that are characteristic of antigen-presenting cells, such as macrophages or B lymphocytes. [49 ] Antigens specific for B cells or, in some cases, specific for T cells have been detected on RS cells and variants. [50] Certain markers specific for cells derived from the monocyte/macrophage series, however, are also expressed in a high fraction of cases. [51] Molecular analysis of Ig gene rearrangements has tended to support a B lymphoid origin. In one particularly well-studied case, a cell line derived from a patient with mixed cellularity HD was shown to have clonal rearrangements of the IgH and kappa light chain loci. [52] [53] Using single cell dissection, the identical rearrangements were then shown to be present in RS cells in the patient's tissues. Some, but not all, investigators have also detected clonal Ig rearrangements in the RS cells of nodular sclerosis and mixed cellularity HD. [54] These studies indicate that RS cells in the mixed cellularity and nodular sclerosis subtypes often have molecular features of B lymphocytes, yet have some phenotypic attributes of monocyte/macrophages. It seems likely that cases with Ig rearrangements are most probably of B lymphoid origin, while the origin of tumors lacking Ig rearrangements remains uncertain.
Assuming that B lymphoid cells are the target of transformation in at least some cases of the mixed cellularity and nodular sclerosis subtypes, what causes the neoplastic change? For years, EBV has been suspected as an etiologic agent. Patients with a history of infectious mononucleosis or with elevated titers of antibodies against EBV antigens incur a slightly higher risk of HD. The seroepidemiologic evidence has been bolstered by molecular studies. EBV genomes and EBV-specific RNA transcripts can be identified in RS cells in 40% of cases of nodular sclerosis HD and 60 to 70% of cases of mixed cellularity HD [55] [56] [57] but is not seen in the lymphocyte predominance type. The configuration of the EBV DNA is the same in all tumor cells within a given case, indicating that infection occurred before cellular transformation. [58] Additionally, EBV-positive tumor cells express latent membrane protein-1, [59] a protein encoded by the EBV genome that has been shown to have transforming activity. Hence, EBV infection may be one of several steps involved in the pathogenesis of HD. It remains possible that other, as yet unknown, infectious agents could also be involved in HD, particularly in those cases that are EBV negative. Clinical Course.
HD, similar to NHL, usually presents with a painless enlargement of lymph nodes. Although distinction between HD and NHL can be made only by examination of a lymph node biopsy, several clinical features favor the diagnosis of the HD (Table 15-8) . Younger patients with the more favorable histologic types tend to present in clinical stage I or II and are usually free from systemic manifestations. Patients with disseminated disease (stages III and IV) and the mixed cellularity or lymphocyte depletion subtypes are more likely to present with B symptoms. One curious paraneoplastic symptom that is rare but specific to HD is pain in involved lymph nodes that occurs only with consumption of alcohol. [60] Cutaneous energy resulting from depressed cell-mediated immunity is seen in most cases. The basis of this immune dysfunction is poorly understood, but it tends to persist even in sucessfully treated patients, possibly indicating that HD arises in the background of some underlying immune abnormality. With modern treatment protocols, tumor burden (i.e., stage) rather than histologic type is the most important prognostic variable. Currently the 5-year survival rate of patients with stages I and IIA is close to 90%, and many appeared to be cured. Even with advanced disease (stages IVA and IVB), 60 to 70% 5-year disease-free survival can be achieved.
TABLE 15-8 -- CLINICAL DIFFERENCES BETWEEN HODGKIN AND NON-HODGKIN LYMPHOMAS Hodgkin Disease Non-Hodgkin Lymphoma More often localized to a single axial group of nodes (cervical, mediastinal, para-aortic)
More frequent involvement of multiple peripheral nodes
Orderly spread by contiguity
Noncontiguous spread
Mesenteric nodes and Waldeyer ring rarely involved Extranodal involvement uncommon
Waldeyer ring and mesenteric nodes commonly involved Extranodal involvement common
675
Progress in the treatment of HD has created a new set of problems. Long-term survivors of chemotherapy and radiotherapy have an increased risk of developing second cancers. Myelodysplastic syndromes, AML, and lung cancer lead the list of second malignancies, but also included are NHL, breast cancer, gastric cancer, sarcoma, and malignant melanoma. [61] The risk of breast cancer is particularly high in women treated with radiation to the chest during adolescence, [62] and the risk of other solid tumors also seems to correlate with radiotherapy, whereas alkylating chemotherapeutic drugs appear to be responsible for the increased risk of AML and myelodysplasia. Non-neoplastic complications of radiotherapy have included pulmonary fibrosis and accelerated atherosclerosis. It appears that new combinations of chemotherapeutic drugs and more judicious use of radiotherapy may avoid these complications and yet be equally curative. Myeloid Neoplasms
The common feature that unites this heterogeneous group of neoplasms is an origin in a progenitor cell that normally gives rise to terminally differentiated cells of the myeloid series ( erythrocytes, granulocytes, monocytes, and platelets). As such, these diseases almost always primarily involve the bone marrow and to a lesser degree the secondary hematopoietic organs (spleen, liver, and lymph nodes) and present with altered hematopoiesis. Three broad categories of myeloid neoplasia exist: 1. AML, characterized by accumulation of immature myeloid cells in the bone marrow 2. Myelodysplastic syndromes (MDS) associated with ineffective hematopoiesis and associated cytopenias 3. Chronic myeloproliferative disorders (MPDs), usually associated with an increased production of terminally differentiated myeloid cells The pathogenesis of myeloid neoplasms is best understood in the context of normal hematopoiesis, which involves a hierarchy of hematopoietic progenitor cells. At the top of the hierarchy sits the true pluripotent stem cell, which gives rise to multipotent progenitor cells that are committed to lymphoid or myeloid differentiation. The latter, in turn, produces more committed progenitors, which eventually give rise to terminally differentiated cells of a single type (e.g., erythrocyte, monocyte). In addition to giving birth to more committed daughter cells, hematopoietic progenitor cells must also be able to replicate themselves without differentiating (or else they would eventually disappear),
a process known as self-renewal. Exactly how this balance between "stemness" and commitment to various cell fates is controlled is uncertain, but it appears to be disturbed in myeloid neoplasms. The manifestations of myeloid neoplasms are likely influenced by three factors: (1) the position of the transformed cell within the hierarchy of progenitors, (2) the effect of transforming events on the capacity for self-renewal, and (3) the effect of the transforming events on differentiation. We return to these themes as each type of myeloid neoplasia is discussed. Given that all forms of myeloid neoplasia originate from a transformed hematopoietic progenitor cell, it should come as no surprise that the divisions between these neoplasms sometimes blur. Myeloid neoplasms, similar to other malignancies, tend to evolve over time to more aggressive forms of disease. In particular, both MDS and chronic MPDs often transform to AML. In the specific case of one of the MPDs, chronic myelogenous leukemia (CML), transformation to ALL may also be seen, probably because the tumor originates from a transformed pluripotent stem cell. ACUTE MYELOGENOUS LEUKEMIA
AMLs affect primarily adults, peaking in incidence between the ages of 15 and 39 years, but are also observed in children and older adults. They constitute only 20% of childhood leukemias. AML is quite heterogeneous, reflecting the complexities of myeloid cell differentiation. Pathophysiology.
AML, similar to other forms of neoplasia, is associated with acquired (or, rarely, inherited) genetic alterations that result in the replacement of normal marrow elements by relatively undifferentiated blasts exhibiting one or more types of early myeloid differentiation. The replication rate of these blasts is actually lower than that of normal myeloid progenitors. Hence, the most important net effect of the genetic alterations is likely to be the inhibition of terminal differentiation (commitment). As mentioned earlier in the discussion of ALL, neoplastic myeloid precursor cells accumulate in the marrow and suppress remaining normal hematopoietic progenitor cells by physical replacement as well as by other unknown mechanisms. Failure of normal hematopoiesis results in anemia, neutropenia, and thrombocytopenia, which are the basis for most of the major clinical complications seen in AML. Therapeutically the aim is to clear the bone marrow of the leukemic clone, thus permitting resumption of normal hematopoiesis. This can be accomplished by treatment with cytotoxic drugs or, in the specific case of acute promyelocytic leukemia, by overcoming the block in differentiation. Classification.
In the revised FAB classification (Table 15-9) , AML is divided into eight (M0 to M7) categories. [63] This scheme takes into account both the degree of maturation (M0 to M3) and the lineage of the leukemic blasts (M4 to M7). Histochemical stains for peroxidase,
specific esterase, and nonspecific esterase play an important role in classifying these tumors. Monoclonal antibodies that recognize common and lineage-specific determinants on myeloid cells are also useful in the diagnosis of AML (see Table 15-3) , especially when morphologic and histochemical features are equivocal. MORPHOLOGY.
The diagnosis of AML is based on finding greater than 30% myeloid blasts in the bone marrow. In most cases, myeloid blasts can be distinguished from lymphoblasts in the usual Wright-Giemsa stain. Several types of myeloid blasts are recognized, but more than one type of blast, or blasts with hybrid features, can be seen
676
TABLE 15-9 -- REVISED FAB CLASSIFICATION OF ACUTE MYELOGENOUS LEUKEMIAS Class Incidence Marrow Morphology and Comments (% of AML) M0--Minimally 2-3% differentiated AML
Blasts lack definitive cytologic and cytochemical markers of myeloblasts (e.g., myeloperoxidase negative) but express myeloid lineage antigens and resemble myeloblasts ultrastructurally.
M1--AML without differentiation
20%
M2--AML with maturation
30-40%
Full range of myeloid maturation through granulocytes. Auer rods present in most cases. Presence of t(8;21) defines a prognostically favorable subgroup.
M3--Acute promyelocytic leukemia
5-10%
Majority of cells are hypergranular promyelocytes, often with many Auer rods per cell. Patients are younger (median age 35-40 yr) and often develop DIC. The t(15;17) translocation is characteristic.
M4--Acute myelomonocytic leukemia
15-20%
Myelocytic and monocytic differentiation evident. Myeloid elements resemble M2 AML. Monoblasts are positive for nonspecific esterases. Presence of chromosome 16 abnormalities defines a subset (M4eo) with marrow eosinophilia and excellent prognosis.
Very immature but 3% are peroxidase positive. Few granules or Auer rods and little maturation beyond the myeloblast stage.
M5--Acute monocytic leukemia
10%
In M5a subtype, monoblasts (peroxidase-negative, nonspecific esterase-positive) and promonocytes predominate in marrow and blood. In M5b subtype, mature monocytes predominate in the peripheral blood. M5a and M5b occur in older patients. Characterized by high incidence of organomegaly, lymphadenopathy, and tissue infiltration.
M6--Acute erythroleukemia
5%
Dysplastic erythroid precursors (some megaloblastoid, others with giant or multiple nuclei) predominate, and within the nonerythroid cells, >30% are myeloblasts; seen in advanced age; makes up 1% of de novo AML and 20% of therapy-related AML.
M7--Acute megakaryocytic leukemia
1%
Blasts of megakaryocytic lineage predominate. Blasts react with platelet-specific antibodies directed against GPIIb/IIIa or vWF. Myelofibrosis or increased marrow reticulin seen in most cases.
AML, acute myelogenous leukemia; DIC, disseminated intravascular coagulation; GP, glycoprotein; vWF, von Willebrand factor; FAB, French-American-British. in individual patients. Myeloblasts have delicate nuclear chromatin, two to four nucleoli, and more voluminous cytoplasm than lymphoblasts (see Fig. 15-6) . The cytoplasm often contains fine, azurophilic, peroxidase-positive granules. Distinctive red-staining rodlike structures called Auer rods, which represent abnormal azurophilic granules, are also present in many cases and are particularly numerous in the M3 type (acute promyelocytic leukemia) (Fig. 15-28) . Histochemical stains may help to bring out the presence of rare Auer rods because they are intensely peroxidase positive. The presence of Auer rods is taken to be definitive evidence of myeloid differentiation. Monoblasts (Fig. 15-29) often have folded or lobulated nuclei, lack Auer rods, and usually do not express peroxidase but can be identified by staining for nonspecific esterase. M6 AML, so-called erythroleukemia, is somewhat of a misnomer. In this subtype, greater than 50% of the cells are erythroid progenitors, and among the nonerythroid nucleated cells, greater than 30% of the cellularity is composed of myeloblasts. M7 AML,
Figure 15-28 AML (acute promyelocytic leukemia [M3 subtype]). Bone marrow aspirate shows neoplastic promyelocytes with
abnormally coarse and numerous azurophilic granules. Other characteristic findings include the presence of several cells with bilobed nuclei and a cell in the center of the field that contains multiple needle-like Auer rods. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
677
Figure 15-29 Acute monocytic leukemia (AML, M5a subtype). A peripheral smear shows one monoblast and five promonocytes with folded nuclear membranes. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
acute megakaryocytic leukemia, is often associated with marrow fibrosis, probably secondary to fibrogenic cytokines released from leukemic megakaryoblasts. Diagnosis of the M7 subtype usually requires the demonstration of platelet-specific markers on blast cells. [64] The number of leukemic cells in the peripheral blood is highly variable, sometimes being more than 100,000 cells/mul, but being under 10,000 cells/mul in about 50% of the patients. Occasionally the peripheral smear may not contain any blasts (aleukemic leukemia). For this reason, bone marrow examination is essential to exclude acute leukemia in patients with pancytopenia. Chromosomal Abnormalities.
Special high-resolution banding techniques have revealed chromosomal abnormalities in approximately 90% of all AML patients. In 50 to 70% of the cases, the karyotypic changes can be detected by standard cytogenetic techniques. Many of the nonrandom chromosomal abnormalities have prognostic implications that are independent of other clinical prognostic factors. [65] Particular chromosomal abnormalities correlate with the clinical setting in which the tumor occurs. AML arising de novo in patients with no risk factors are often associated with balanced chromosomal translocations. In contrast, AMLs that follow an MDS or that occur after exposure to DNA-damaging agents (such as chemotherapy or radiation therapy) are commonly associated with deletions or monosomies involving chromosomes 5 and 7 and usually lack chromosomal translocations. The exception to this rule is AMLs occurring after treatment with chemotherapeutic drugs that inhibit the enzyme topoisomerase II, which are often associated with translocations involving the MLL gene on chromosome 11 at band q23. [66] The t(15;17) translocation characteristic of acute promyelocytic leukemia (M3) is of particular interest not only because of its pathogenetic importance, but also because of its effect on therapy. This translocation results in the fusion of a truncated retinoic acid receptor-alpha ( RAR-alpha) gene on chromosome 17 to the PML (for promyelocytic leukemia) gene on chromosome 15. [67] [68] [69] Analogous to the ABL-BCR fusion in chronic myeloid leukemia, the PML-RAR-alpha rearrangement produces a hybrid mRNA that can be detected in most cases of M3 AML. The fusion gene encodes an abnormal retinoic acid receptor that blocks myeloid cell differentiation, probably by interfering with the function of other retinoid receptors. [70] Notably, pharmacologic doses of the vitamin A derivative all-trans-retinoic acid overcome this block in vitro and in vivo, causing neoplastic promyelocytes to differentiate into neutrophils. [71] Similar to normal neutrophils, neutrophils derived from the neoplastic clone are short-lived and rapidly die, thus clearing the marrow and allowing for resumption of normal hematopoiesis. Remarkably the same effect is also observed in patients treated with arsenic trioxide,
which appears somehow to promote the degradation of the PML-RAR-alpha fusion protein. [72] Although retinoic acid differentiation therapy induces remissions in a high fraction of patients with acute promyelocytic leukemia, all patients ultimately relapse, probably because retinoic acid fails to prevent continued self-renewal of the neoplastic progenitor cell. Nonetheless, this is the first example in which the molecular pathogenesis of a malignant tumor can be correlated with specific therapy. Clinical Features.
The clinical findings in AML are similar to ALL. Most patients present within weeks or a few months of the onset of symptoms with findings related to anemia, neutropenia, and thrombocytopenia, most notably fatigue, fever, and spontaneous mucosal and cutaneous bleeding. Many times, the bleeding diathesis caused by the thrombocytopenia is the most striking clinical and anatomic feature of the disease. Petechiae and ecchymoses are seen in the skin. Hemorrhages also occur into the serosal linings of the body cavities and into the serosal coverings of the viscera, particularly of the heart and lungs. Mucosal hemorrhages into the gingivae and urinary tract are common. Procoagulants released by leukemic cells, especially in acute promyelocytic leukemia (M3), may produce disseminated intravascular coagulation, further exacerbating the bleeding diathesis. Infections are common, particularly in the oral cavity, skin, lungs, kidneys, urinary bladder, and colon, and they are often caused by "opportunists" such as fungi, Pseudomonas, and commensals. Signs and symptoms related to infiltration of tissues are usually less striking in AML than in ALL. Mild lymphadenopathy and organomegaly may be appreciated. In tumors with monocytic differentiation (M4 and M5), infiltration of the skin (leukemia cutis) and the gingiva may be observed, likely reflecting the normal tendency of non-neoplastic monocytes to extravasate into tissues. Central nervous system spread is less common than in ALL but is still seen. Quite uncommonly, patients present with localized masses composed of myeloblasts in the absence of marrow or peripheral blood involvement. Patients with these tumors,
678
known variously as myeloblastomas, granulocytic sarcomas, or chloromas, almost inevitably progress to a typical AML picture over a period of up to several years. Prognosis.
AML is a difficult disease to treat. Approximately 60% of the patients achieve complete remission with chemotherapy, but only 15 to 30% of these remain free from disease for 5 years. As in ALL, prognosis is strongly influenced by particular chromosomal abnormalities. AMLs associated with an (8;21) chromosomal translocation or inversion of chromosome 16 have a relatively good prognosis, whereas those with the t(9;22)
(Philadelphia chromosome) or translocations involving chromosome 11q23 have a poor outcome. The prognosis is especially dismal for those patients with AML arising out of a myelodysplastic syndrome or occuring after genotoxic therapy; such tumors often exhibit deletions or monosomies of chromosomes 5 or 7. Because of the generally poor outcome with standard therapy, an increasing number of patients with AML are being treated with allogeneic bone marrow transplantation. MYELODYSPLASTIC SYNDROMES
Myelodysplastic syndrome (MDS) refers to a group of clonal stem cell disorders characterized by maturation defects resulting in ineffective hematopoiesis and an increased risk of transformation to AML. In patients with MDS, the bone marrow is partly or wholly replaced by the clonal progeny of a mutant multipotent stem cell that retains the capacity to differentiate into red cells, granulocytes, and platelets, but in a manner that is both ineffective and disordered. As a result, the bone marrow is usually hypercellular or normocellular, but the peripheral blood shows pancytopenia. MDS arises in two distinct settings: Idiopathic or primary MDS, occurring mainly in patients over age 50, often develops insidiously. Therapy-related MDS (t-MDS), a complication of previous myelosuppressive drug or radiation therapy, usually appears 2 to 8 years after exposure. All forms of MDS can transform to AML, but transformation occurs most rapidly and with highest frequency in patients with t-MDS. Although characteristic morphologic changes are typically seen in the marrow and the peripheral blood, definitive diagnosis frequently requires correlation with other laboratory tests. Cytogenetic analysis is particularly helpful in confirming the diagnosis because certain chromosomal aberrations (discussed subsequently) are often observed. Pathogenesis.
The pathogenesis of MDS is unknown. Although the marrow is usually hypercellular at diagnosis, it may also be normocellular or, less commonly, hypocellular. Given this, the usual explanation for suppression of normal hematopoiesis (crowding out of normal elements) is difficult to apply, leading to the suggestion that MDS may arise out of a background of stem cell damage. Both primary MDS and t-MDS occurring after exposure to radiation or alkylating chemotherapeutic drugs are associated with similar clonal chromosomal abnormalities, including monosomy 5 and monosomy 7, deletions of 5q and 7q, trisomy 8, and deletions of 20q. [65] MORPHOLOGY.
The most characteristic finding is disordered (dysplastic) differentiation affecting all three lineages (erythroid, myeloid, and megakaryocytic) (Fig. 15-30) . Within the erythroid series, common abnormalities include ringed sideroblasts, erythroblasts with iron-laden mitochondria that are visible as perinuclear granules in Prussian blue-stained
aspirates or biopsy specimens; megaloblastoid maturation resembling that seen in vitamin B12 and folate deficiency; and nuclear budding abnormalities, recognized as nuclei with misshapen, often polypoid outlines. Neutrophils may contain decreased numbers of secondary granules or contain toxic granulations and Dohle bodies. Pseudo-Pelger-Hue t cells, neutrophils with only two nuclear lobes, are frequently observed, and sometimes neutrophils appear that completely lack nuclear segmentation. Megakaryocytes with single nuclear lobes or multiple separate nuclei (pawn ball megakaryocytes) are also characteristic. Myeloblasts may be increased but by definition constitute less than 30% of the overall marrow cellularity. The peripheral blood often contains pseudo-Pelger-Huet cells, giant platelets, macrocytes, poikilocytes, and a relative or absolute monocytosis. Myeloblasts usually constitute less than 10% of the peripheral leukocytes. Clinical Course.
Primary MDS affects primarily individuals older than 60 years of age. As in acute leukemia, patients with this disorder present with weakness, infections, and hemorrhages, all owing to pancytopenia. Approximately half of the patients are asymptomatic, and the disease is discovered after incidental blood tests. On the basis of specific morphologic features in the marrow and peripheral blood, primary MDS is divided into five categories, each with a somewhat different risk for transformation to overt AML. [73] In general, subtypes that are defined by having a higher proportion of blast cells in the marrow or peripheral blood are associated with a poorer prognosis. The presence of multiple clonal chromosomal abnormalities and the severity of peripheral blood cytopenias are independent risk factors that also portend a worse outcome. The median survival in primary MDS varies from 9 to 29 months, but some individuals in good prognostic groups may live for 5 years or more. Overall, progression to AML occurs in 10 to 40% of individuals and is often accompanied by the appearance of additional clonal cytogenetic changes. Other patients succumb to complications of thrombocytopenia (bleeding) and neutropenia (infection). The outlook is even more grim in patients with t-MDS, who have an overall median survival of only 4 to 8 months. Cytopenias tend to be more severe than in primary MDS, and many patients progress rapidly to AML.
679
Figure 15-30 Myelodysplasia. Characteristic forms of dysplasia are shown. A , Nucleated red cell progenitors with multilobated or multiple nuclei. B , Ringed sideroblasts, erythroid progenitors with iron-laden mitochondria, seen as blue perinuclear granules (Prussian blue stain). C, Pseudo-Pelger-Huet cells, neutrophils with only two nuclear lobes instead of the normal three to four, are observed at the top and bottom of this field. D, Megakaryocytes with multiple nuclei, instead of the normal single multilobated nucleus. ( A , B , and D, marrow aspirates; C, peripheral blood smear.)
Treatment options in MDS are limited. In younger patients, allogeneic bone marrow transplantation offers some hope for reconstitution of normal hematopoiesis and long-term survival. Older patients with MDS are treated supportively with antibiotics and blood product transfusions. CHRONIC MYELOPROLIFERATIVE DISORDERS
In most chronic myeloproliferative disorders (MPDs), the target of neoplastic transformation is a multipotent progenitor cell capable of giving rise to mature erythrocytes, platelets, granulocytes, and monocytes. The singular exception is chronic myelogenous leukemia (CML), in which the pluripotent stem cell that can give rise to lymphoid and myeloid cells seems to be affected. Similar to AML, the neoplastic cells and their offspring flood the bone marrow and suppress residual normal progenitor cells; however, chronic MPDs differ in that terminal differentiation is initially unaffected. This combination leads to marrow hypercellularity and increased hematopoiesis, often accompanied by elevated peripheral blood counts. Certain features are common to each of the four chronic MPDs: (1) CML, (2) polycythemia vera (PCV), (3) essential thrombocytosis, and (4) myelofibrosis with myeloid metaplasia. The neoplastic stem cells have the capacity to circulate and home to secondary hematopoietic organs, particularly the spleen, where they give rise to extramedullary hematopoiesis. As a result, all chronic MPDs cause varying degrees of splenomegaly. They also share the propensity to terminate in a spent phase characterized by marrow fibrosis and peripheral blood cytopenias. Further, all can progress over time to acute leukemia, but only CML does so invariably. In contrast to the lymphoid neoplasms and AML, the pathologic findings in the chronic MPDs are not specific, having a considerable degree of overlap with one another and some reactive conditions that produce marrow hyperplasia. Diagnosis and classification depend on correlation of morphologic findings with other clinical and laboratory
680
findings. Cytogenetic and molecular analyses also play an important role, as patients with CML uniformly possess the Philadelphia chromosome (Ph1 ) or variants thereof, whereas patients with other chronic MPDs lack the Ph1 . Chronic Myelogenous Leukemia
CML is a disease primarily of adults between the ages of 25 and 60 years, with the peak incidence in the thirties and forties. Genetics.
CML is distinguished from other chronic MPDs by the presence of a distinctive molecular abnormality-- a translocation involving the BCR gene on chromosome 9 and the ABL gene on chromosome 22. The resultant BCR-ABL fusion gene directs the synthesis of a 210-kD fusion protein with tyrosine kinase activity. In more than 90% of CML cases, karyotyping reveals the Ph1 , usually representing the reciprocal translocation t(9;22)(q34;q11). In 5 to 10% of cases, however, the rearrangement can be complex or cytogenetically cryptic; in such cases, other methods such as fluorescent in situ hybridization (FISH) (Fig. 15-31) , or the reverse transcriptase-polymerase chain reaction (RT-PCR) must be used to
Figure 15-31 Detection of BCR-ABL fusion gene by fluorescent in situ hybridization (FISH). A , Idiogram depicting chromosomes 9 and 22 and the position of the ABL and BCR genes. The Philadelphia chromosome (Ph1 ) is created by a balanced chromosomal
translocation that replaces the telomeric portion of 22q with the telomeric portion of 9q. At a molecular level, the breaking and rejoining of the DNA results in the formation of fusion gene on the Ph1 derived from the 5 end of BCR and the 3 end of ABL, and hence brings BCR and ABL sequences that are normally far apart into close physical proximity. This abnormal colocalization of BCR and ABL can be detected by in situ hybridization with pairs of fluorescently tagged DNA probes complementary to genomic DNA sequences lying near BCR and ABL breakpoints. In B a green ABL probe and a red BCR probe have been hybridized to metaphase chromosomes and interphase nuclei prepared from the peripheral blood cells of a normal individual. Because of the pairing of sister chromatids during mitosis, signals on metaphase chromosomes may be seen as a single dot or a pair of closely spaced dots. Two pairs of red signals and two green signals are seen on the metaphase chromosomes, while two red and two green signals are present in the interphase nucleus, both indicating the presence of normal, spatially distant copies of ABL and BCR, respectively. C, In contrast, metaphase chromosomes and an interphase nucleus prepared from the bone marrow cells of a patient with CML show one normal ABL signal, one normal BCR signal, and an abnormal yellow signal created by superimposition of one BCR and one ABL signal, a finding indicative of the presence of a BCR-ABL fusion gene. (Courtesy of Dr. Cynthia Morton and Ms. Debbie Sandstrom, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
681
detect the BCR-ABL fusion gene or transcript. Introduction of the BCR-ABL fusion gene into murine bone marrow cells gives rise to a syndrome resembling human CML, [74] and hence its acquisition is considered to be a critical pathogenetic event. There is a marked increase in neoplastic granulocytic precursors in the marrow, which coexist with a smaller number of BCR-ABL negative (normal) progenitor cells. [75] Although granulocytic proliferation dominates, genotypic studies have shown that other myeloid lineages, B lymphoid cells, and possibly T lymphoid cells also carry the Ph1 or its molecular equivalent, indicating that the target of transformation is a pluripotent stem cell. Why there is preferential proliferation of granulocytic precursors is not known. MORPHOLOGY.
In contrast to normal bone marrow, which is usually about 50% cellular and 50% fat, CML marrows are usually 100% cellular, with most of the increased cellularity being composed of maturing granulocytic precursors. Increased numbers of megakaryocytes, often including small dysplastic forms, are frequently observed, whereas erythroid progenitors are usually present in normal or decreased numbers. A characteristic finding
is the presence of scattered storage histiocytes with wrinkled, sea-blue cytoplasm (sea-blue histiocytes); similar cells may be seen in other disorders with increased marrow cell turnover. Increased deposition of reticulin fibers is typical, but overt marrow fibrosis is rare at presentation. Peripheral blood examination reveals a marked leukocytosis, often exceeding 100,000 cells/mm3 (Fig. 15-32) . The circulating cells are predominantly neutrophils, metamyelocytes, and myelocytes, with less
Figure 15-32 Chronic myelogenous leukemia (CML). A peripheral blood smear shows many mature neutrophils, some metamyelocytes, and a myelocyte. (Courtesy of Dr. Robert W. McKenna, Department of Pathology, University of Texas Southwestern Medical School, Dallas, TX.)
Figure 15-33 CML of the spleen showing an enlarged spleen (2630 gm; normal, 150-200 gm) with greatly expanded red pulp stemming from neoplastic hematopoiesis. (Courtesy of Dr. Daniel Jones, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
than 10% myeloblasts. Peripheral blood eosinophilia and basophilia are also common, and up to 50% of patients have thrombocytosis early in the course of their disease. Neoplastic extramedullary hematopoiesis within the splenic red pulp produces marked splenomegaly (Fig. 15-33) that is often complicated by focal infarction. Extramedullary hematopoiesis may also lead to hepatomegaly and mild lymphadenopathy. Clinical Features.
The onset of CML is insidious, and the initial symptoms may be quite nonspecific. They are caused by mild to moderate anemia or by hypermetabolism owing to increased cell turnover and include easy fatigability, weakness, weight loss, and anorexia. Sometimes the first symptom is a dragging sensation in the abdomen caused by the extreme splenomegaly or acute onset of left-upper-quadrant pain caused by splenic infarction. CML is best differentiated from other chronic MPDs by detection of the BCR-cABL fusion gene, either through chromosomal analysis or PCR-based molecular tests. Another informative laboratory finding in CML is the almost total lack of leukocyte alkaline phosphatase. In contrast, leukemoid reactions and other chronic MPDs are usually associated with an elevated leukocyte alkaline phosphatase. The only other hematologic disorder associated with low leukocyte alkaline phosphatase is paroxysmal nocturnal hemoglobinuria, which does not resemble CML in other respects and is therefore easily distinguished. The course of CML is one of slow progression, and even without treatment a median survival of 3 years can be expected. After a variable period averaging 3 years, approximately 50% of patients enter an accelerated phase, during which there is a gradual failure of response to treatment accompanied by increasing anemia and thrombocytopenia and sometimes striking peripheral blood basophilia. Additional clonal cytogenetic abnormalities, such as trisomy 8, isochromosome 17q, or duplication of the
Ph1 , may also appear. Within 6 to 12 months, the accelerated phase terminates in a picture resembling acute leukemia
682
( blast crisis). In the remaining 50%, blast crises occur abruptly without an intermediate accelerated phase. In 70% of patients, the blasts have the morphologic and cytochemical features of myeloblasts, whereas in about 30% of patients the blasts contain the enzyme TdT and express early B lineage antigens such as CD10 and CD19. Rarely, the blasts resemble pre-T cells. These observations further support the notion that the target cell for transformation is a pluripotent stem cell. CML can be controlled during the stable phase with low-dose chemotherapy, which, however, does not prevent progression to blast crisis. For this reason, the best hope for long-term survival is allogeneic bone marrow transplantation, which is most effective when performed in the stable phase. In patients with a suitable donor, the cure rate is about 75%. Other therapies include interferon-alpha, which suppresses CML progenitor cells through poorly understood mechanisms and allows the progeny of normal stem cells to reconstitute the bone marrow, or purification of residual normal stem cells ex vivo by using cell culture conditions that suppress the growth of CML progenitors. The hope is that these normal stem cells could then be used to reconstitute hematopoiesis after potentially curative high-dose cytotoxic therapy. Polycythemia Vera
PCV is a neoplasm arising in a multipotent myeloid stem cell characterized by increased proliferation and production of erythroid, granulocytic, and megakaryocytic elements. Increased marrow production is reflected in the peripheral blood by erythrocytosis (polycythemia), granulocytosis, and thrombocytosis, but it is the absolute increase in red cell mass that is responsible for most of the clinical symptoms. PCV must be differentiated from relative polycythemia resulting from hemoconcentration (Chapter 14) and other causes of absolute polycythemia. Pathophysiology.
PCV progenitor cells require extremely small amounts of erythropoietin and other hematopoietic growth factors for proliferation and survival. [76] This accounts for the observation that PCV is associated with virtually undetectable levels of serum erythropoietin, whereas almost all other forms of absolute polycythemia are secondary to elevated erythropoietin. A thorough search for acquired erythropoietin receptor mutations in PCV has been unrevealing. The growth factor independence of PCV cells may be found to be caused by mutations in a factor or factors common to multiple hematopoietic growth factor signaling pathways. MORPHOLOGY.
The bone marrow is hypercellular, but some residual fat is often observed. The increase in erythroid progenitors can be quite subtle and is usually accompanied by increased numbers of maturing granulocytic precursors and megakaryocytes. At the time of diagnosis, a moderate to marked increased in marrow reticulin fibers is seen in approximately 10% of the patients. Mild organomegaly is common, being caused early in the course of PCV largely by congestion; at this stage, extramedullary hematopoiesis is minimal. The peripheral blood smear often shows increased basophils and abnormally large platelets. Late in the course of some patients, the marrow may progress to a spent phase characterized by fibrosis that fills the intertrabecular space and displaces hematopoietic cells. At this time, extramedullary hematopoiesis increases in the spleen and liver, producing more prominent organomegaly (Fig. 15-34) . Transformation to morphologically typical AML may also occur. Clinical Course.
PCV appears insidiously, usually in late middle age (median age at onset, 60 years). Most symptoms are related to the increased red cell mass, which is usually reflected by a markedly increased hematocrit. The elevation in hematocrit is usually accompanied by an increase in total blood volume, and together these two factors promote abnormal blood flow, vascular distention, and vascular stasis. Most of the excess blood is trapped in the venous circulation, which is greatly distended. Thus, patients are typically plethoric and somewhat cyanotic owing to stagnation and deoxygenation of blood in peripheral vessels. About 70% of patients are hypertensive. Headache, dizziness, and gastrointestinal symptoms are common. There is often intense pruritus and an increased tendency toward peptic ulceration, both possibly the result of an increased release of histamine from basophils. High cell turnover gives rise to hyperuricemia, and symptomatic gout is seen in 5 to 10% of cases.
Figure 15-34 Polycythemia vera, spent phase. Massive splenomegaly (3020 gm; normal, 150-200 gm) largely due to extramedullary hematopoiesis occurred in the setting of advanced marrow myelofibrosis. (Courtesy of Dr. Mark Fleming, Department of Pathology, Brigham and Women's Hospital, Boston, MA.)
683
More ominously, the abnormal blood flow ( and possibly the abnormal platelet function) leads to increased risk of both major bleeding and thrombotic episodes. About 25% of patients first come to clinical attention with thrombotic episodes, often manifesting as deep venous thrombosis, myocardial infarction, and stroke. Other common sites for thromboses include the hepatic veins (producing Budd-Chiari syndrome), the portal and mesenteric veins (leading to bowel infarction), and the venous sinuses of the brain (leading to hemorrhagic strokes). Minor hemorrhages (epistaxis, bleeding gums) are
also common, while life-threatening hemorrhages occur in 5 to 10% of cases. The hemoglobin concentration ranges from 14 to 28 gm/dl with hematocrit values of 60% or more. Occasionally, chronic bleeding may lead to iron deficiency. In some cases, the deficiency of iron may inhibit erythropoiesis sufficiently to lower the hematocrit into the normal range, a rare example of two defects counteracting one another to correct a laboratory abnormality. The white cell count is typically elevated, ranging between 12,000 and 50,000 cells/mm3 , and the platelet count is often greater than 500,000 cells/mm3 . In contrast to CML, leukocyte alkaline phosphatase levels are above normal and the Ph1 is absent. The platelets usually exhibit morphologic abnormalities manifested as giant forms and megakaryocytic fragments and show defects in functional aggregation studies. In patients who receive no treatment, death resulting from bleeding or thrombosis occurs within months after diagnosis. If the red cell mass is maintained at nearly normal levels by phlebotomies, however, median survival of 10 years can be achieved. Extended survival with treatment has revealed that the natural history of PCV involves a gradual transition to a spent phase, during which clinical and anatomic features of myelofibrosis with myeloid metaplasia develop. Approximately 15 to 20% of patients undergo such a transformation after an average period of 10 years. This transition is brought about by obliterative fibrosis in the bone marrow (myelofibrosis) and marked by the appearance of extensive extramedullary hematopoiesis, principally in the spleen, which enlarges greatly. The pathogenetic basis for this transformation is not known. Some patients with PCV develop a terminal AML, but at much lower frequency than in CML. AML occurs in 2% of patients treated with phlebotomy alone [77] but has been seen in up to 15% of those receiving myelosuppressive treatment with alkylating drugs or marrow irradiation with radioactive phosphorus, both of which are mutagenic. Because it is safe and effective, the current treatment of choice is phlebotomy. In contrast to CML, transformation to ALL is rarely observed, possibly indicating that the target of neoplastic transformation is a progenitor cell committed to myeloid differentiation. Essential Thrombocytosis
In this hematopoietic stem cell disorder, the least common form of MPD, increased proliferation and production is largely confined to the megakaryocytic elements, with most patients having platelet counts exceeding 600,000 mm3 (Fig. 15-35) . Because all of the chronic MPDs can be associated with thrombocytosis, essential thrombocytosis is a diagnosis of exclusion. By definition, features characteristic of other chronic MPDs are absent. It must also be distinguished from reactive causes of thrombocytosis, including inflammatory disorders, asplenism, and iron deficiency. The pathogenetic basis for essential thrombocytosis is unknown. Bone marrow examination is most helpful in excluding other chronic MPDs. Cellularity is usually mildly to moderately increased. Megakaryocytes are often markedly increased in number and include abnormally large forms. Deposition of delicate reticulin fibrils may
be seen, but the overt fibrosis characteristic of myelofibrosis with myeloid metaplasia is absent. Peripheral smears usually reveal abnormally large platelets (Fig. 15-35) , often accompanied by mild leukocytosis. The major clinical manifestations are thrombosis and hemorrhage, probably reflecting both qualitative and quantitative abnormalities in platelets. Essential thrombocytosis is an indolent disorder with long asymptomatic periods punctuated by occasional thrombotic or hemorrhagic crises. Median survival times are 12 to 15 years. Myelofibrosis with Myeloid Metaplasia
Myelofibrosis with myeloid metaplasia, similar to other chronic MPDs, is caused by neoplastic transformation of a multipotent myeloid stem cell. In contrast to other chronic MPDs, however, the hallmark of myelofibrosis with myeloid metaplasia is early progression to marrow fibrosis (myelofibrosis) that is histologically identical to the spent phase of the other chronic MPDs. Myelofibrosis suppresses bone marrow hematopoiesis, leading to peripheral blood cytopenias and extensive neoplastic extramedullary hematopoiesis in the spleen, liver, and lymph nodes.
Figure 15-35 Essential thrombocytosis (ET). A peripheral blood smear shows marked thrombocytosis, including giant platelets approximating the size of surrounding red cells. (Courtesy of Dr. Jacqueline Mitus.)
684
Pathophysiology.
The pathologic features of myelofibrosis with myeloid metaplasia stem from extensive collagen deposition by non-neoplastic fibroblasts in the marrow. This fibrosis inexorably displaces hematopoietic elements, including stem cells, from the marrow, leading to extensive extramedullary hematopoiesis in the spleen, liver, and sometimes lymph nodes. The marrow fibrosis appears to be caused by the inappropriate release of fibrogenic factors from neoplastic megakaryocytes. [78] [79] Two factors have been implicated: platelet-derived growth factor (PDGF) and TGF-beta. Both are synthesized by megakaryocytes and released into the surrounding tissues either by leakage from the abnormal (neoplastic) cells or after intramedullary death. As you recall, PDGF and TGF-beta are fibroblast mitogens. In addition, TGF-beta promotes fibrosis and causes angiogenesis, both of which are observed in myelofibrosis. As marrow fibrosis progresses, circulating hematopoietic stem cells seed the spleen and liver, leading to extramedullary hematopoiesis. MORPHOLOGY.
Early in the course, the marrow is often hypercellular with maturing cells of all lineages being increased. Morphologically the erythroid and granulocytic precursors appear
normal, but megakaryocytes are large, dysplastic, and abnormally clustered. During this cellular phase, fibrosis is minimal. With progression, the marrow becomes hypocellular and diffusely fibrotic. Even at this stage, clusters of atypical megakaryocytes may be found in the sea of fibrosis. Late in the disease course, the fibrotic marrow space may be largely converted to bone, a development that is termed osteosclerosis. Myelofibrotic obliteration of the marrow space leads to extensive extramedullary hematopoiesis, principally in the spleen, which is usually markedly enlarged, sometimes up to 4000 gm (see Fig. 15-39) . On section, such spleens are firm and diffusely red to gray, with obliterated white pulp. As with CML, multiple subcapsular infarcts may be present. Histologically, there is trilineage hematopoietic proliferation, often with a predominance of large, clustered megakaryocytes. Initially, extramedullary hematopoiesis is confined to the sinusoids, but later it may extend to involve the cords. The liver may be moderately enlarged, with sinusoidal foci of extramedullary hematopoiesis. Hematopoiesis may also spread to lymph nodes, but significant lymphadenopathy is uncommon. The peripheral blood reveals a number of characteristic findings in patients with full-blown myelofibrosis (Fig. 15-36) . Fibrotic distortion of the marrow microenvironment leads to inappropriate release of nucleated erythroid progenitors and early granulocytes. Release of immature cells from sites of extramedullary hematopoiesis also
Figure 15-36 Myelofibrosis with myeloid metaplasia (MMM), peripheral blood smear. Two nucleated erythroid precursors and several
teardrop-shaped red cells (dacryocytes) are evident. Immature myeloid cells were present in other fields. An identical picture can be seen in other diseases producing marrow distortion and fibrosis.
contributes to the peripheral blood picture. The presence of erythroid and granulocytic precursors in the peripheral blood is termed leukoerythroblastosis. In addition, numerous teardrop erythrocytes (dacryocytes) are observed. Although characteristic of myelofibrosis with myeloid metaplasia, leukoerythroblastosis and dacryocytes can be observed in many infiltrative disorders of the bone marrow, including granulomatous diseases and metastatic tumors. Other common, albeit nonspecific, peripheral blood findings include abnormally large platelets and basophilia. Clinical Course.
Myelofibrosis with myeloid metaplasia is uncommon in individuals younger than 60 years of age. Except when preceded by PCV or CML, it usually comes to clinical attention because of either progressive anemia or marked splenic enlargement, producing a sensation of fullness in the left upper quadrant. Nonspecific symptoms such as fatigue, weight loss, and night sweats result from increased metabolism associated with the expanded mass of hematopoietic cells. Owing to a high rate of cell turnover, hyperuricemia and secondary gout may complicate the picture. The laboratory findings are striking. There is usually a moderate to severe
normochromic normocytic anemia accompanied by leukoerythroblastosis. The white cell count is usually normal or reduced but may be markedly elevated (80,000 to 100,000 cells/mm3 ) during the early cellular phase. The platelet count is usually normal or elevated at the time of diagnosis, but thrombocytopenia supervenes as
685
the disease progresses. Biopsy of the marrow to detect the early deposition of reticulin or the more advanced fibrosis is essential for diagnosis. The course of this disease is difficult to predict. In different series, median survival time has varied from 1 to 5 years. [80] Threats to life are intercurrent infections, thrombotic episodes, bleeding related to platelet abnormalities, and, in 5 to 20% of cases, transformation to AML. In patients with extensive marrow fibrosis, AML may arise at unusual extramedullary sites, including lymph nodes and soft tissues. Langerhans Cell Histiocytosis
The term histiocytosis is an umbrella designation for a variety of proliferative disorders of histiocytes or macrophages. Some, such as the rare histiocytic lymphomas, are clearly malignant, whereas others, such as the reactive histiocytic proliferations in lymph nodes, are clearly benign. Between these two extremes is a small cluster of conditions characterized by proliferation of a special type of histiocyte called the Langerhans cell (Chapter 6) . The Langerhans cell histiocytoses represent clonal proliferations of these antigen-presenting dendritic cells, [81] which are normally readily seen in the skin but also found in other organs. In the past, these disorders were referred to as histiocytosis X and subdivided into three categories: Letterer-Siwe disease, Hand-Schu ller-Christian disease, and eosinophilic granuloma. These three conditions are now believed to represent different expressions of the same basic disorder. The tumor cells in each are dendritic and antigen presenting and express HLA-DR and CD1a. [82] They have abundant, often vacuolated cytoplasm, with vesicular oval or indented nuclei. Characteristic is the presence of HX bodies ( Birbeck granules) in the cytoplasm. Under the electron microscope, these are seen to have a pentalaminar, rodlike, tubular structure, with characteristic periodicity and sometimes a dilated terminal end ( tennis-racket appearance) (Fig. 15-37) . Because Birbeck granules are not seen in all tumor cells by electron microscopy, the detection of CD1a expression by immunohistochemical techniques aids in the diagnosis. Langerhans cell histiocytosis presents as three clinicopathologic entities. Acute disseminated Langerhans cell histiocytosis ( Letterer-Siwe disease) occurs most frequently before 2 years of age but occasionally may affect adults. The dominant clinical feature is the development of cutaneous lesions that resemble a seborrheic eruption secondary to infiltrations of Langerhans histiocytes over the front and back of the trunk and on the scalp. Most of those affected have concurrent hepatosplenomegaly, lymphadenopathy, pulmonary lesions, and eventually destructive
osteolytic bone lesions. Extensive infiltration of the marrow often leads to anemia, thrombocytopenia, and predisposition to recurrent infections such as otitis media and mastoiditis. The course of untreated disease is rapidly fatal. With intensive chemotherapy, 50% of patients survive 5 years.
Figure 15-37 Langerhans cell histiocytosis. An electron micrograph shows rodlike Birbeck granules with characteristic periodicity and a dilated terminal end. (Courtesy of Dr. George Murphy, University of Pennsylvania School of Medicine, Philadelphia.)
Unifocal and multifocal Langerhans cell histiocytosis ( unifocal and multifocal eosinophilic granuloma) are characterized by expanding, erosive accumulations of Langerhans cells, usually within the medullary cavities of bones. Histiocytes are variably admixed with eosinophils, lymphocytes, plasma cells, and neutrophils. The eosinophilic component ranges from scattered mature cells to sheetlike masses of cells. Virtually any bone in the skeletal system may be involved, most commonly the calvaria, ribs, and femur. Similar lesions may be found in the skin, lungs, or stomach, either as unifocal lesions or as components of the multifocal disease. Unifocal lesions usually affect the skeletal system. They may be asymptomatic or may cause pain and tenderness and, in some instances, pathologic fractures. This is an indolent disorder that may heal spontaneously or be cured by local excision or irradiation. Multifocal Langerhans cell histiocytosis usually affects children, who present with fever; diffuse eruptions, particularly on the scalp and in the ear canals; and frequent bouts of otitis media, mastoiditis, and upper respiratory tract infections. An infiltrate of Langerhans cells may lead to mild lymphadenopathy, hepatomegaly, and splenomegaly. In about
686
50% of patients, involvement of the posterior pituitary stalk of the hypothalamus leads to diabetes insipidus. The combination of calvarial defects, diabetes insipidus, and exophthalmos is referred to as the Hand-Schu ller-Christian triad. Many patients experience spontaneous regression; others can be treated with chemotherapy. ETIOLOGIC AND PATHOGENETIC FACTORS IN WHITE CELL NEOPLASIA: SUMMARY AND PERSPECTIVES Having described the many types of white cell neoplasms, it is worth reviewing common themes pertaining to their cause and pathogenetic mechanisms. Chromosomal translocations and oncogenes First we have seen that nonrandom karyotypic abnormalities, most commonly translocations, are present in the majority of white cell neoplasms. At a molecular
level, translocations typically result in the fusion of elements from two genes. In some translocations, the DNA breaks fall within the coding sequence of both involved genes, leading to formation of a fusion gene encoding a novel chimeric protein. In other translocations, the coding sequence of one gene is juxtaposed to the noncoding regulatory elements of the second gene (often an Ig or T-cell receptor locus), resulting in inappropriate expression. Certain chromosomal rearrangements involving protooncogenes are specifically associated with particular hematolymphoid tumors. For example, rearrangements of TAL-1 are seen only in pre-T cell ALL, whereas CBFbeta rearrangements are observed only in AML. In contrast, other oncogenes are dysregulated in histogenetically heterogeneous forms of white cell neoplasia. For example, the Ph1 may be found in AML, ALL, or CML. Such broad-spectrum oncogenes may have more general effects on the proliferation or differentiation of hematolymphoid progenitors. In some instances, dysregulation of specific oncogenes produces hematolymphoid tumors in experimental models closely resembling their human counterparts, demonstrating that these genetic lesions constitute a critical step in tumorigenesis. For example, the expression of the PML-RARalpha gene in the bone marrow progenitors of mice results in the development of an AML that is responsive to treatment with retinoic acid, [83] [84] as occurs in human M3 AML. Inherited genetic factors As was discussed in Chapter 8 , individuals with genetic diseases that promote genomic instability, such as Bloom syndrome, Fanconi anemia, and ataxia-telangiectasia, are at increased risk for development of acute leukemia. [85] In addition, Down syndrome (trisomy 21) and neurofibromatosis type I are both associated with an increased incidence of childhood leukemia. Viruses and environmental agents Three viruses, HTLV-1, EBV, and human herpesvirus 8, have been implicated as causative agents. The possible mechanisms of transformation by viral agents were discussed earlier (Chapters 7 and 8) . Several environmental agents that lead to chronic immune stimulation predispose to lymphoid neoplasia. The most clear-cut associations are Helicobacter pylori infection and gastric marginal zone lymphoma, [37] and gluten-sensitive enteropathy and intestinal T-cell lymphoma. [86] Iatrogenic factors Ironically, radiotherapy and certain forms of chemotherapy used to treat cancer increase the risk of subsequent hematolymphoid neoplasms, including MDS, AML, and NHL. This association is believed to stem from mutagenic effects of ionizing radiation and chemotherapeutic drugs on hematolymphoid progenitor cells.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 16 - The Lung NORMAL LUNG PATHOLOGY - Part 1 PATHOLOGY - Part 2 REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
697
Chapter 16 - The Lung Lester Kobzik
NORMAL LUNG The lungs are ingeniously constructed to carry out their cardinal function, the exchange of gases between inspired air and the blood. The right lung is divided into three lobes; the left lung has only two lobes, its middle lobe equivalent being the lingula. The lung airways--the main right and left bronchi--arise from the trachea then branch dichotomously, giving rise to progressively smaller airways. The right main stem bronchus is more vertical and
698
more directly in line with the trachea than is the left. As a consequence, aspirated foreign material, such as vomitus, blood, and foreign bodies, tends to enter the right lung rather than the left. Accompanying the branching airways is the double arterial supply to the lungs, that is, the pulmonary and bronchial arteries. In the absence of significant cardiac failure, the bronchial arteries of aortic origin can often sustain the vitality of the pulmonary parenchyma when pulmonary arterial supply is shut off, as by emboli. Progressive branching of the bronchi forms bronchioles, which are distinguished from bronchi by the lack of cartilage and submucosal glands within their walls. Further branching of bronchioles leads to the terminal bronchioles, which are less than 2 mm in diameter. The part of the lung distal to the terminal bronchiole is called the acinus, or the terminal respiratory unit; it is approximately spherical in shape, with a diameter of about 7 mm. Acini contain alveoli and are thus the site of gas exchange. As illustrated in Figure 16-8 A, an acinus is composed of respiratory bronchioles (emanating from the terminal bronchiole), which give off from their sides several alveoli; these bronchioles then proceed into the alveolar ducts, which immediately branch and empty into the alveolar sacs--the blind ends of the respiratory passages whose walls are formed entirely of alveoli. The alveoli open into the ducts through large mouths. In the correct plane of section, therefore, all alveoli are open and have incomplete walls. A cluster of
three to five terminal bronchioles, each with its appended acini, is usually referred to as the pulmonary lobule. As seen subsequently, this lobular architecture assumes importance in distinguishing the major forms of emphysema. From the microscopic standpoint, except for the vocal cords, which are covered by stratified squamous epithelium, nearly the entire respiratory tree, including the larynx, trachea, and bronchioles, is lined by pseudostratified, tall, columnar, ciliated epithelial cells, heavily admixed in the cartilaginous airways with mucus-secreting goblet cells. The bronchial mucosa also contains neuroendocrine cells that exhibit neurosecretory-type granules and contain serotonin, calcitonin, and gastrin-releasing peptide (bombesin). Numerous submucosal, mucus-secreting glands are dispersed throughout the walls of the trachea and bronchi (but not the bronchioles). The microscopic structure of the alveolar walls (or alveolar septa) consists, from blood to air, of the following (Fig. 16-1) : The capillary endothelium lining the intertwining network of anastomosing capillaries. A basement membrane and surrounding interstitial tissue separating the endothelial cells from the alveolar lining epithelial cells. In thin portions of the alveolar septum, the basement membranes of epithelium and endothelium are fused, whereas in thicker portions, they are separated by an interstitial space ( pulmonary interstitium) containing fine elastic fibers, small bundles of collagen, a few fibroblast-like interstitial cells, smooth muscle cells, mast cells, and rarely lymphocytes and monocytes. Alveolar epithelium, comprising a continuous layer of two principal cell types: flattened, platelike pavement type I pneumocytes (or membranous pneumocytes) covering 95% of the alveolar surface and rounded type II pneumocytes. Type II cells are important for at least two reasons: (1) They are the source of pulmonary surfactant, contained in osmiophilic lamellar bodies seen with electron microscopy, and (2) they are the main cell type involved in the repair of alveolar epithelium after destruction of type I cells. Alveolar macrophages, loosely attached to the epithelial cells or lying free within the alveolar spaces, derived from blood monocytes and belonging to the mononuclear phagocyte system. Often, they are filled with carbon particles and other phagocytosed materials.
Figure 16-1 Microscopic structure of the alveolar wall. Note that the basement membrane (yellow) is thin on one side and widened
where it is continuous with the interstitial space. Portions of interstitial cells are shown.
The alveolar walls are not solid but are perforated by numerous pores of Kohn, which permit the passage of bacteria and exudate between adjacent alveoli (see Fig. 16-20 B). Adjacent to the alveolar cell membrane is the pulmonary surfactant layer (discussed in Chapter 11 in the section on respiratory distress syndrome in newborns).
699
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 17 - Head and Neck ORAL CAVITY UPPER AIRWAYS EAR NECK SALIVARY GLANDS REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
756
Chapter 17 - Head and Neck Diseases of the head and neck range from the common cold to the uncommon neoplasms of the nose. Those selected for discussion are assigned, sometimes arbitrarily, to one of the following anatomic sites: (1) oral cavity, particularly oral soft tissues, including the tongue; (2) upper airways, including the nose, pharynx, larynx, and nasal sinuses; (3) ears; (4) neck; and (5) salivary glands.
ORAL CAVITY The oral cavity is a fearsome orifice guarded by ranks of upper and lower "horns" (lamentably, too subject to erosion), demanding constant gratification, and teeming with microorganisms, some of which are potentially harmful. Among the many disorders that affect its various parts, only the more important or frequent conditions involving the oral mucous membranes, lips, and tongue are considered. Disorders of the teeth and those limited to the gingiva are left for specialized dental texts, and those of the jaws for Chapter 28 . Inflammations The oral mucosa is highly resistant to its indigenous flora, having many defenses, including the competitive suppression
757
of potential pathogens by organisms of low virulence, the elaboration of secretory immunoglobulin A and other immunoglobulins by submucosal collections of lymphocytes and plasma cells, the antibacterial effects of saliva, and the diluting and irrigating effects of food and drink. Nonetheless, any lowering of these defenses, for example, with immunodeficiency or disruption of the microbiologic balance by antibacterial therapy, potentiates oral infection. Most of these infections are discussed in Chapter 9 , and here we only briefly recapitulate the principal features. HERPES SIMPLEX VIRUS INFECTIONS
Most orofacial herpetic infections (Chapter 9) are caused by herpes simplex virus type 1 (HSV-1) and are trivial "cold sores." Uncommonly, in children 2 to 4 years of age, they
take the form of severe diffuse involvement of the oral and pharyngeal mucosa, the tongue, and the gingiva marked by fiery redness and swelling, soon followed by clusters of vesicles (acute herpetic gingivostomatitis). MORPHOLOGY.
The vesicles range from lesions of a few millimeters to large bullae and, at first, are filled with a clear, serous fluid, but they often rupture to yield extremely painful, red-rimmed, shallow ulcerations. On microscopic examination, there is intracellular and intercellular edema (acantholysis), yielding clefts that may become transformed into macroscopic vesicles. Individual epidermal cells in the margins of the vesicle or lying free within the fluid sometimes develop eosinophilic intranuclear viral inclusions, or several cells fuse to produce giant cells (multinucleate polykaryons), changes that permit the diagnostic Tzanck test based on microscopic examination of the vesicle fluid. The vesicles and shallow ulcers usually spontaneously clear within 3 to 4 weeks, but the virus treks along the regional nerves and eventually becomes dormant in the local ganglia (e.g., the trigeminal). The great preponderance of adults harbor latent HSV-1, but in some individuals, usually young adults, the virus becomes reactivated to produce the common but usually mild cold sore. The influences predisposing to activation are poorly understood but are thought to include upper respiratory tract infections; excessive exposure to cold, wind, or sunlight; and allergic reactions. Recurrent herpetic stomatitis (in contrast to acute gingivostomatitis) takes the form of groups of small (1 to 3 mm) vesicles frequently on the lips, about the nasal orifices, or on the buccal mucosa. They resemble those already described in the primary infections but are much more limited in duration, are milder, usually dry up in 4 to 6 days, and heal within a week or 10 days. APHTHOUS ULCERS (CANKER SORES)
These extremely common superficial ulcerations of the oral mucosa affect up to 40% of the population in the United States. [1] They are more common in the first two decades of life, are painful and often recurrent, and tend to be prevalent within certain families. The lesions appear as single or multiple, shallow, hyperemic ulcerations covered by a thin exudate and rimmed by a narrow zone of erythema (Fig. 17-1) . The underlying inflammatory infiltrate is at first largely mononuclear, but secondary bacterial infection introduces numerous neutrophils. The lesions may spontaneously clear within a week or be stubbornly persistent for weeks. The causation of these lesions is obscure. Most ulcers are more painful than serious and require only symptomatic treatment. ORAL CANDIDIASIS (THRUSH)
The many localizations of candidal infection are fully described in Chapter 9 , and so it suffices here to merely emphasize that oral lesions typically take the form of a superficial, curdy, gray to white inflammatory membrane composed of matted organisms enmeshed in a fibrinosuppurative exudate that can be readily scraped off to reveal an underlying erythematous inflammatory base. As was pointed out, this fungus is a normal inhabitant of the oral cavity and causes mischief only in individuals who are diabetic, neutropenic, or immunoincompetent as in those with acquired immunodeficiency syndrome (AIDS); in those who have xerostomia or are otherwise debilitated; or when the normal flora of the oral cavity is perturbed by antibiotic therapy.
Figure 17-1 Aphthous ulcer of the tongue in a young woman. Doesn't it look painful? (Courtesy of Dr. John Sexton, Chief, Oral and Maxillofacial Surgery, Beth Israel Hospital, Boston, MA.)
758
GLOSSITIS
Although the designation glossitis implies inflammation of the tongue, it is sometimes applied to the beefy-red tongue encountered in certain deficiency states that results from atrophy of the papillae of the tongue and thinning of the mucosa, exposing the underlying vasculature. In some instances, the atrophic changes do indeed lead to inflammation and even shallow ulcerations. Such changes may be encountered in deficiencies of vitamin B12 (pernicious anemia), riboflavin, niacin, or pyridoxine. Similar alterations are sometimes encountered with sprue and iron deficiency anemia possibly complicated by one of the vitamin B deficiencies mentioned. The combination of iron deficiency anemia, glossitis, and esophageal dysphagia usually related to webs is known as the Plummer-Vinson or Paterson-Kelly syndrome. Glossitis, characterized by ulcerative lesions (sometimes along the lateral borders of the tongue), may also be seen with jagged carious teeth, ill-fitting dentures, and rarely syphilis, inhalation burns, or ingestion of corrosive chemicals. XEROSTOMIA
Xerostomia refers to dry mouth; this manifestation is a major feature of the autoimmune disorder Sjogren syndrome in which it is usually accompanied by dry eyes (Chapter 7) . A lack of salivary secretions may also be a residual of radiation therapy or may be drug induced by a wide variety of anticholinergic agents. The oral cavity may merely reveal dry mucosa or atrophy of the papillae of the tongue, with fissuring and ulcerations or, in Sjogren syndrome, concomitant inflammatory enlargement of the salivary glands. Reactive Lesions A number of soft tissue lesions of the oral cavity, which present as tumor masses, are
indeed reactive in nature and represent inflammations and benign hyperplasias induced by irritation or by unknown mechanism. (All suspicious lesions, however, should be examined by biopsy.) Three deserve mention. The irritation fibroma mostly occurs in the buccal mucosa along the bite line or at the gingivodental margin. It consists of a nodular mass of fibrous tissue, with few inflammatory cells, covered by squamous mucosa. The pyogenic granuloma (Fig. 17-2) is a highly vascular, peduncular lesion usually occurring in the gingiva of children, young adults, and, commonly, pregnant women (pregnancy tumor). These lesions, which can also be considered a form of capillary hemangioma (Chapter 12) , either regress, particularly after pregnancy, or undergo fibrous maturation and come to resemble a fibroma. The peripheral giant cell granuloma (giant cell epulis) is an unusual inflammatory lesion up to 1.5 cm in diameter that characteristically protrudes from the gingiva at some site of chronic inflammation. It is generally covered by intact gingival mucosa, but it may be ulcerated. On histologic evaluation, it is made up of a striking aggregation of multinucleate, foreign body-like giant cells separated by a fibroangiomatous stroma. Although not encapsulated, these lesions are usually well delimited and readily excised. They should be differentiated from central giant cell granulomas found within the maxilla or the mandible and from the histologically similar but frequently multiple reparative giant cell "brown tumors" seen in hyperparathyroidism (Chapter 28) . The former may be locally aggressive, and some have a tendency to recur.
Figure 17-2 "Pregnancy tumor" protruding from the margin of the upper gingiva. (Courtesy of Dr. John Sexton, Chief, Oral and Maxillofacial Surgery, Beth Israel Hospital, Boston, MA.)
Oral Manifestations of Systemic Disease As oral clinicians are at pains to emphasize, the mouth is a part of the body. Not surprisingly, then, many systemic diseases are associated with oral lesions. Some of the more common are cited in Table 17-1 , with a few words about the associated oral changes. Only one--hairy leukoplakia--is characterized in more detail. HAIRY LEUKOPLAKIA
Hairy leukoplakia is an uncommon oral lesion virtually restricted to patients with human immunodeficiency virus (HIV) infection. [2] Sometimes it calls attention to the existence of the infection. It takes the form of white, confluent patches of fluffy ("hairy") hyperkeratotic thickening situated anywhere on the oral mucosa. The distinctive microscopic appearance is attributable to piled up layers of keratotic squames based on underlying mucosal acanthosis. Sometimes there is koilocytosis of the superficial, nucleated epidermal cells, indicative of human papillomavirus (HPV) infection, and HIV transcripts have occasionally been
759
TABLE 17-1 -- ORAL MANIFESTATIONS OF SOME SYSTEMIC DISEASES Infections Scarlet fever
Fiery red tongue with prominent papillae--raspberry tongue; white coated tongue through which hyperemic papillae project--strawberry tongue.
Measles
A spotty enanthema in the oral cavity often precedes the rash; ulcerations on the buccal mucosa about Stensen duct produce Koplik spots
Infectious mononucleosis An acute pharyngitis and tonsillitis that may be coated with a gray-white exudative membrane; enlargement of lymph nodes in the neck Diphtheria
A characteristic dirty white, fibrinosuppurative, tough, inflammatory membrane over the tonsils and retropharynx
Human immunodeficiency virus (HIV) infection-AIDS
Predisposition to opportunistic oral infections, particularly with herpesvirus, Candida, and other fungi; sometimes oral lesions of Kaposi sarcoma and hairy leukoplakia (described in text)
Dermatologic Conditions Lichen planus
Reticulate, lacelike, white keratotic lesions that rarely become bullous and ulcerated; seen in more than 50% of patients with cutaneous lichen planus and, rarely, is the sole manifestation
Pemphigus
Usually vulgaris; vesicles and bullae prone to rupture, leaving hyperemic erosions covered with exudate
Bullous pemphigoid
Oral lesions resemble macroscopically those of pemphigus but can be differentiated histologically (Chapter 27)
Erythema multiforme
A maculopapular, vesiculobullous eruption that sometimes follows an infection elsewhere, ingestion of drugs, development of cancer, or a collagen vascular disease; when it involves the lips and oral mucosa, it is referred to as Stevens-Johnson syndrome
Hematologic Disorders Pancytopenia Severe oral infections in the form of gingivitis, pharyngitis, (agranulocytosis, aplastic tonsillitis; may extend to cellulitis of the neck (Ludwig anemia) angina) Leukemia
With depletion of functioning neutrophils, oral lesions may appear like those in pancytopenia
Monocytic leukemia
Leukemic infiltration and enlargement of the gingivae, often with accompanying periodontitis
Miscellaneous Melanotic pigmentation
May appear in Addison disease, hemochromatosis, fibrous dysplasia of bone (Albright syndrome), and Peutz-Jegher syndrome (gastrointestinal polyposis)
Phenytoin (Dilantin) ingestion
Striking fibrous enlargement of the gingivae
Pregnancy
A friable, red, pyogenic granuloma protruding from the gingiva ("pregnancy tumor")
Rendu-Osler-Weber syndrome
Autosomal dominant disorder with multiple aneurysmal telangiectases from birth beneath the skin or mucosal surfaces of the oral cavity, lips, gastrointestinal tract, respiratory tract, and urinary tract as well as in internal viscera
found. However, Epstein-Barr virus (EBV) is present in most cases, and it is now accepted that EBV is the major cause of the condition. [3] Sometimes there is superimposed candidal infection on the surface of the lesions, adding to the "hairiness." When the hairy leukoplakia is a harbinger of HIV infection, manifestations of AIDSrelated complex or AIDS generally appear within 2 or 3 years. Tumors and Precancerous Lesions Some common precancerous lesions and a variety of benign and malignant tumors occur in the oral soft tissues. Most of these tumors (e.g., hemangiomas, lymphomas) also occur elsewhere and are described adequately in other sections, and so only the precancerous leukoplakia, erythroplakia, papillomas, and squamous cell carcinoma are considered here. LEUKOPLAKIA AND ERYTHROPLAKIA
The term leukoplakia means simply white plaque. It may be produced by several known conditions, such as lichen planus and candidiasis, as well as by other rarer lesions. [4] However, 85% to 90% of all white plaques are caused by epidermal proliferations, and so most experts recommend the following definition: Leukoplakia is a white plaque on the oral mucous membranes that cannot be removed by scraping and cannot be classified clinically or microscopically as another disease entity. All other white lesions are specified as to cause (e.g., lichen planus, candidal membrane). Thus defined, leukoplakic plaques range from benign epithelial thickenings to highly atypical lesions with dysplastic changes that merge with carcinoma in situ. Thus, leukoplakia is a clinical term; until it is proved otherwise, it must be considered precancerous. Related to leukoplakia, but much less common and much more ominous, is erythroplakia (dysplastic leukoplakia). It represents a red, velvety, possibly eroded area
within the oral cavity that usually remains level with or may be slightly depressed in relation to the surrounding mucosa. The epithelial changes in such lesions tend to be markedly atypical, incurring a much higher risk of malignant transformation than that with leukoplakia. Intermediate forms are occasionally encountered that have the characteristics of both leukoplakia and erythroplakia, termed speckled leukoerythroplakia. Both leukoplakia and erythroplakia may be encountered in adults at any age, but they are usually found between the ages of 40 and 70 years, with a 2 to 1 male preponderance. Although these lesions have multifactorial origins, the use of tobacco (cigarettes, pipes, cigars, and particularly chewing tobacco and buccal pouches) is the most common antecedent. Other potentiating influences are alcohol, ill-fitting dentures, and chronic exposure to persistent irritants (lovers of hot pizza take note). HPV (human papillomavirus) sequences, particularly serotype 16, have been identified in tobacco-related lesions. [3]
760
MORPHOLOGY.
Leukoplakias may occur anywhere in the oral cavity (favored locations are buccal mucosa, floor of the mouth, ventral surface of the tongue, hard palate). They appear as solitary or multiple, white patches or plaques with indistinct or sharply demarcated borders (Fig. 17-3 A). They may be slightly thickened and smooth or wrinkled and indurated, or they may appear as raised, sometimes corrugated, verrucous plaques. On histologic examination, they present an epithelial spectrum ranging from hyperkeratosis overlying a thickened, acanthotic but orderly mucosal epithelium (Fig. 17-3 B) to lesions with markedly dysplastic changes sometimes merging into carcinoma in situ. The more dysplastic or anaplastic the lesion, the more likely a subjacent inflammatory infiltrate of lymphocytes and macrophages. The histologic changes in erythroplakia only rarely consist of orderly epidermal thickening; virtually all disclose superficial erosions with dysplasia, carcinoma in situ, or already developed carcinoma in the surrounding margins. An intense subepithelial inflammatory reaction with vascular dilation accounts for the red appearance of the lesion. The frequency of carcinoma in situ or overt cancerous changes in leukoplakia varies among reports from 1% to 16%, but a reasonable average is 5% to 6%. [5] Ominous features are a speckled appearance, warty or verrucous thickening, and occurrence in "high-risk sites" (e.g., floor of the mouth and ventral surface of the tongue); hence the need for biopsy of persistent lesions that fail to respond to such simple measures as avoidance of tobacco and alcohol. In the case of erythroplakia, the malignant transformation rate is about 50% (some would say higher).
SQUAMOUS CELL CARCINOMA
At least 95% of cancers of the oral cavity (including the tongue) are squamous cell carcinomas. The small residual includes adenocarcinomas (of mucous gland origin), melanomas, various carcinomas, and other rarities. They represent about 3% of all cancers in the United States, and so they are by no means uncommon. Although most are readily accessible to discovery and biopsy, it is disheartening that many are detected late, and 50% of these lesions prove fatal. Squamous cell carcinomas are most frequently diagnosed in persons between the ages of 50 and 70 years. Pathogenesis.
The genesis of these cancers is linked to the use of tobacco and alcohol. Nondrinking smokers have a 2-fold to 4-fold greater risk of developing these cancers than matched control subjects do, which increases to 6-fold to 15-fold with both drinking and smoking. Particularly implicated are chewing tobacco and buccal pouches. The use of marijuana also increases risk. A major regional predisposing influence is the chewing of betel nuts and pan in India and parts of Asia. On the more pleasant side of the equation, several studies have reported that consumption of fruit and vegetables significantly reduces the risk. [6] Protracted irritation, as from ill-fitting dentures, jagged teeth, or chronic infections, is no longer thought to be an important direct antecedent to oral cancer, but it may contribute to leukoplakia, which, as has already been noted, is a subsoil for the development of oral cancer. HPV serotypes 6, 16, and 18 have been identified in half of the oral carcinomas arising in the Waldeyer tonsillar ring and in 10% to 15% of those in the tongue and other parts of the oral cavity. [7] Actinic radiation (sunlight) and, particularly, pipe smoking are known predisposing influences to cancer of the lower lip. All these environmental influences presumably act on a fertile genetic soil, and indeed a number of chromosomal and molecular changes have been described in some but not all head and neck cancers. [8] These include deletions of chromosome regions 18q, 10p, 8p, and 3p; mutations in p53; and amplification of the INT2 and BCL1 oncogenes. [9] [10]
Figure 17-3 A , Leukoplakia of the hard palate. The numerous lesions have become virtually confluent. (Courtesy of Drs. E.E. Vokes, S. Lippman, et al, Department of Thoracic/Head and Neck Oncology, Texas Medical Center, Houston, TX. Reprinted with permission from The New England Journal of Medicine 328:184, 1993.) B , Leukoplakia caused by marked epithelial thickening and hyperkeratosis.
761
MORPHOLOGY.
Squamous cell carcinoma may arise anywhere in the oral cavity, but in large series, the favored locations are the floor of the mouth, tongue, hard palate, and base of tongue (Fig. 17-4) . In the early stages, cancers of the oral cavity appear either as raised, firm,
pearly plaques or as irregular, roughened, or verrucous areas of mucosal thickening, possibly mistaken for leukoplakia. Either pattern may be superimposed on a background of apparent leukoplakia or erythroplakia. As these lesions enlarge, they create protruding masses (Fig. 17-5) or undergo central necrosis, forming an irregular, shaggy ulcer rimmed by elevated, firm, rolled borders. On histologic examination, these cancers begin as in situ lesions, sometimes with surrounding areas of epithelial atypicality or dysplasia. They range from well-differentiated keratinizing neoplasms to anaplastic, sometimes sarcomatoid tumors, and from slowly to rapidly growing lesions. As a group, they tend, in time, to infiltrate locally before they metastasize to other sites. The routes of extension depend on the primary site. Favored sites of metastasis are mediastinal lymph nodes, lungs, liver, and bones. Unfortunately, such distant metastases are often occult at the time of discovery of the primary lesion. [11] As with all cancers, early diagnosis is the paramount prognostic factor. The prognosis is best with lip lesions, the 5-year recurrence-free rate approximating 90%, and poorest with tumors in the floor of the mouth and at the base of the tongue, yielding only 20% to 30% 5-year recurrence-free rates. All squamous cell carcinomas of the
Figure 17-4 Schematic representation of the sites of origin of squamous cell carcinoma of the oral cavity, in numerical order of
frequency.
Figure 17-5 Carcinoma of the tongue. The tumor of the base of the tongue appears as a bulbous protruding mass. (Courtesy of Drs. E.E. Vokes, S. Lippman, et al, Department of Thoracic/Head and Neck Oncology, Texas Medical Center, Houston, TX. Reprinted with permission from The New England Journal of Medicine 328:184, 1993.)
oral cavity take months to years to progress from carcinoma in situ to invasive cancer, and so every death they cause must be viewed as a preventable tragedy. Odontogenic Cysts and Tumors These are specialized lesions that frequently affect dental structures and are beyond the scope of this discussion. However, some of them are associated with other systemic syndromes, and others present as soft tissue lesions in the oral cavity. For example, odontogenic cysts in the jaw, lined with keratinizing epithelium, are a component of the nevoid basal cell carcinoma syndrome (Gorlin syndrome), which as we shall see is related to mutations in the tumor-suppressor gene PATCHED (Chapter 27) . Odontogenic tumors are a complex group of lesions with diverse histology and clinical behavior. [3] Some are true neoplasms with malignant potential, and others are hamartomas. The two most common clinically significant tumors are
Ameloblastoma, which arises from odontogenic epithelium and shows no ectomesenchymal differentiation. It is commonly cystic, slow forming, and locally invasive but has a benign course in most cases. Odontoma, the most common type of odontogenic tumor, which arises from epithelium but shows extensive depositions of enamel and dentin. Odontomas are probably hamartomas rather than true neoplasms and are cured by local excision.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 18 - The Gastrointestinal Tract Esophagus Stomach Small and Large Intestines Appendix Peritoneum REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
775
Chapter 18 - The Gastrointestinal Tract James M. Crawford
776
Esophagus NORMAL ESOPHAGUS The normal esophagus is a hollow, highly distensible muscular tube that extends from the pharynx to the gastroesophageal junction at the level of the T11 or T12 vertebra. Measuring between 10 and 11 cm in the newborn, it grows to a length of about 23 to 25 cm in the adult. Several points of luminal narrowing can be identified along its course--proximally at the cricoid cartilage, midway in its course alongside the aortic arch and at the anterior crossing of the left main bronchus and left atrium, and distally where it pierces the diaphragm. Manometric recordings of intraluminal pressures in the esophagus have identified two higher-pressure areas that remain relatively contracted in the resting phase. A 3-cm segment in the proximal esophagus at the level of the cricopharyngeus muscle is referred to as the upper esophageal sphincter. The 2- to 4-cm segment just proximal to the anatomic esophagogastric junction, at the level of the diaphragm, is referred to as the lower esophageal sphincter (LES). The wall of the esophagus consists of a mucosa, submucosa, muscularis propria, and adventitia, reflecting the general structural organization of the gastrointestinal tract. [1] The mucosa is composed of a nonkeratinizing stratified squamous epithelial layer that overlies a lamina propria. A small number of specialized cell types, such as melanocytes, endocrine cells, and Langerhans cells (Chapter 27) , are present in the deeper portion of the epithelial layer. The lamina propria is the nonepithelial portion of the mucosa, above the muscularis mucosae. It consists of areolar connective tissue and contains vascular structures and scattered leukocytes. The submucosa consists of loose connective tissue containing blood vessels, a rich network of lymphatics, a sprinkling of leukocytes with occasional lymphoid follicles, nerve fibers (including the ganglia of Meissner plexus), and submucosal glands. The
submucosal glands are considered to be continuations of the minor salivary glands of the oropharynx and are scattered along the entire esophagus but are more concentrated in the upper and lower portions. The muscularis propria of the proximal 6 to 8 cm of the esophagus also contains striated muscle fibers from the cricopharyngeus; this feature explains why skeletal muscle disorders can cause esophageal dysfunction. In sharp contrast to the rest of the gastrointestinal tract, the esophagus is mostly devoid of a serosal coat. In the mediastinum, the intimate anatomic proximity to important thoracic viscera is of significance in permitting the ready and widespread dissemination of infections and tumors of the esophagus into the posterior mediastinum. Spread is further facilitated by the rich network of mucosal and submucosal lymphatics that run longitudinally along the esophagus. The functions of the esophagus are to conduct food and fluids from the pharynx to the stomach and to prevent reflux of gastric contents into the esophagus. These functions require motor activity coordinated with swallowing--a wave of peristaltic contraction, relaxation of the LES in anticipation of the peristaltic wave, and closure of the LES after the swallowing reflex. The mechanisms governing this motor function are strikingly complex, involving both extrinsic and intrinsic innervation, humoral regulation, and properties of the muscle wall itself. The control of the LES function is poorly understood. Both active inhibition of the muscle by inhibitory neurons and cessation of tonic neural excitation to the sphincter play a role. Disruption of the vagal fibers by truncal or selective vagotomy, however, has virtually no effect on LES tone or relaxation. Maintenance of sphincteric tone is necessary to prevent reflux of gastric contents, which are under positive pressure relative to the esophagus. Many chemical agents (e.g., gastrin, acetylcholine, serotonin, prostaglandin F2alpha , motilin, substance P, histamine, and pancreatic polypeptide) increase LES tone, but their precise roles in normal physiologic function remain unclear. PATHOLOGY Lesions of the esophagus run the gamut from highly lethal cancers to the merely annoying heartburn (which has affected many a partaker of a large, spicy meal). Esophageal varices, the result of cirrhosis and portal hypertension, are of major importance, since their rupture is frequenthy followed by massive hematemesis (vomiting of blood) and exsanguination. Esophagitis and hiatal hernias are far more frequent and rarely life-threatening. Distressing to the physician is that all disorders of the esophagus tend to produce similar symptoms. Dysphagia (subjective difficulty in swallowing) is encountered both with deranged esophageal motor function and with diseases that narrow or obstruct the lumen. Heartburn (retrosternal burning pain) usually reflects regurgitation of gastric contents into the lower esophagus. Pain and hematemesis are sometimes evoked by esophageal disease, particularly by lesions associated with inflammation or ulceration of the esophageal mucosa. The clinical diagnosis of esophageal disorders often requires specialized procedures, such as esophagoscopy, radiographic barium studies, and
manometry.
777
Figure 18-1 Esophageal atresia and tracheoesophageal fistula. A , Blind upper and lower esophageal segments. B , Fistula between blind upper segment and trachea. C, Blind upper segment, fistula between blind lower segment and trachea. D, Blind upper segment only. E , Fistula between patent esophagus and trachea. Type C, in which the proximal esophagus ends in a blind pouch while the distal segment communicates with the trachea or a main stem bronchus, is the most common variety. (Adapted from Morson BC, Dawson IMP (eds): Gastrointestinal Pathology. Oxford, Blackwell Scientific Publications, 1972, p 8.)
Congenital Anomalies ATRESIA AND FISTULAS
Although developmental defects in the esophagus are uncommon, they must be corrected early, since they are incompatible with life. Because they cause immediate regurgitation when feeding is attempted, they are usually discovered soon after birth. Absence (agenesis) of the esophagus is extremely rare; much more common are atresia and fistula formation (Fig. 18-1) . In atresia, a segment of the esophagus is represented by only a thin, noncanalized cord, with a proximal blind pouch connected to the pharynx and a lower pouch leading to the stomach. Atresia is most commonly located at or near the tracheal bifurcation. Atresia rarely occurs alone but is usually associated with a fistula connecting the lower or upper pouch with a bronchus or the trachea. Often associated anomalies are congenital heart disease and other gastrointestinal malformations. Aspiration and paroxysmal suffocation from food are obvious hazards; pneumonia and severe fluid and electrolyte imbalances may also occur. STENOSIS, WEBS, AND RINGS
Non-neoplastic constrictions of the esophagus are most often acquired conditions. Stenosis consists of fibrous thickening of the esophageal wall, particularly the submucosa, with atrophy of the muscularis propria. The lining epithelium is usually thin and sometimes ulcerated. Mucosal webs are uncommon ledgelike, semicircumferential protrusions of the mucosa into the esophageal lumen. Those in the upper esophagus are often designated webs; those in the lower esophagus are designated Schatzki rings, located at or just above the esophagogastric 778
squamocolumnar junction. Well-developed webs rarely protrude more than 5 mm into the lumen, with a thickness of 2 to 4 mm. Upper esophageal webs are covered
by squamous mucosa and contain a vascularized fibrous tissue core; the lower esophageal Schatzki rings have on their undersurface columnar gastric epithelium. Stenosis is the result of severe esophageal injury with inflammatory scarring, as from gastroesophageal reflux, radiation, scleroderma, or caustic injury. Stenosis usually develops in adulthood and becomes manifest by progressive dysphagia, at first to solid foods only but eventually to all foods. Dysphagia constitutes the major symptom. In severe stenoses, virtually total obstruction may result. Esophageal webs and rings are encountered most frequently in women over age 40 and are of uncertain etiology. Episodic dysphagia is the main symptom associated with webs and rings, usually provoked when an individual bolts solid food. Pain is infrequent. When an upper esophageal web is accompanied by iron deficiency anemia, glossitis, and cheilosis, the condition is referred to as the Paterson-Brown-Kelly or Plummer-Vinson syndrome, with an attendant risk for postcricoid carcinoma. Lesions Associated With Motor Dysfunction
Gravity alone is not sufficient to move food from the pharynx to the stomach or to prevent reflux of gastric contents. Coordinated motor function is critical to proper function of the esophagus; witness the blissful suckling of the supine infant. The four major entities that are caused by or induce motor dysfunction of the esophagus are diagrammed in Figure 18-2 . ACHALASIA
Achalasia is characterized by three major abnormalities: (1) aperistalsis, (2) partial or incomplete relaxation of the LES with swallowing, and (3) increased resting tone of the LES. The pathogenesis of primary achalasia is poorly understood but is thought to involve degenerative changes in neural innervation, either intrinsic to the esophagus [2] or in the extraesophageal vagus nerves and the dorsal motor nucleus of the vagus. Secondary achalasia may arise in Chagas disease, in which Trypanosoma cruzi causes destruction of the myenteric plexus of the esophagus, duodenum, colon,
Figure 18-2 Major conditions associated with esophageal motor dysfunction (see text).
779
and ureter, with resultant dilation of these viscera. Diseases of the dorsal motor nuclei, particularly polio or surgical ablation, can cause an achalasia-like illness, as can diabetic autonomic neuropathy, and infiltrative disorders, such as malignancy, amyloidosis, and sarcoidosis. In most instances, however, achalasia occurs as a primary disorder of uncertain cause.
MORPHOLOGY.
In primary achalasia, there is progressive dilation of the esophagus above the level of the LES. The wall of the esophagus may be of normal thickness, thicker than normal owing to hypertrophy of the muscularis, or markedly thinned out by dilation. The myenteric ganglia are usually absent from the body of the esophagus but may or may not be reduced in number in the region of the lower sphincter. The mucosal lining may be unaffected, but sometimes inflammation, ulceration, or fibrotic thickening may be evident just above the lower sphincter. Clinical Features.
Achalasia usually becomes manifest in young adulthood but may appear in infancy or childhood. The classic clinical symptom of achalasia is progressive dysphagia. Nocturnal regurgitation and aspiration of undigested food may occur. The most serious aspect of this condition is the hazard of developing esophageal squamous cell carcinoma, said to occur in about 5% of patients, typically at an earlier age than those without this disease. Other complications include Candida esophagitis, lower esophageal diverticula (see later), and aspiration with pneumonia or airway obstruction. HIATAL HERNIA
Hiatal hernia is characterized by separation of the diaphragmatic crura and widening of the space between the muscular crura and the esophageal wall. Two anatomic patterns are recognized (Fig. 18-2) : the axial, or sliding hernia, and the nonaxial, or paraesophageal hiatal hernia. The sliding hernia constitutes 95% of cases; protrusion of the stomach above the diaphragm creates a bell-shaped dilation, bounded below by the diaphragmatic narrowing. In paraesophageal hernias, a separate portion of the stomach, usually along the greater curvature, enters the thorax through the widened foramen. The cause of hiatal hernia is unknown. Reflux esophagitis (discussed later) is frequently seen in association with sliding hernias, but compromise of the LES with regurgitation of peptic juices into the esophagus is probably the result of, rather than the cause of, a sliding hernia. The uncommon paraesophageal hernias may be caused by previous surgery, including operations for sliding hernia. Based on barographic studies, hiatal hernias are reported in 1 to 20% of adult subjects, increasing in incidence with age. Hiatal hernias, however, are well recognized in infants and children. Only about 9% of adults with a sliding hernia suffer from heartburn or regurgitation of gastric juices into the mouth. These symptoms are attributed to incompetence of the LES and are accentuated by positions favoring reflux (bending forward, lying supine) and obesity. Complications of hiatal hernias are numerous. Both types may ulcerate, causing bleeding and perforation. Paraesophageal hernias can become strangulated or obstructed, and early surgical repair has been advocated.
DIVERTICULA
A diverticulum is an outpouching of the alimentary tract that contains all visceral layers; a false diverticulum denotes an outpouching of mucosa and submucosa only. True diverticula are usually discovered in later life and may develop in three regions of the esophagus: Zenker diverticulum immediately above the upper esophageal sphincter Traction diverticulum near the midpoint of the esophagus Epiphrenic diverticulum immediately above the LES Disordered cricopharyngeal motor dysfunction is implicated in the genesis of Zenker diverticulum. Scarring resulting from mediastinal lymphadenitis (as from tuberculosis) was a presumed cause of traction on the esophagus, giving rise to midesophageal diverticula. Arguments, however, have been advanced in favor of traction diverticula actually arising from motor dysfunction or being a congenital lesion. Dyscoordination of peristalsis and LES relaxation are the proposed cause of epiphrenic diverticula. Zenker diverticula may reach several centimeters in size and accumulate significant amounts of food. Typical symptoms are food regurgitation in the absence of dysphagia and a mass in the neck; aspiration with resultant pneumonia is a significant risk. While midesophageal diverticula are generally asymptomatic, epiphrenic diverticula can give rise to nocturnal regurgitation of massive amounts of fluid. LACERATIONS (MALLORY-WEISS SYNDROME)
Longitudinal tears in the esophagus at the esophagogastric junction are termed Mallory-Weiss tears and are believed to be the consequence of severe retching. They are encountered most commonly in alcoholics, attributed to episodes of excessive vomiting and refluxing of gastric contents in the setting of an alcoholic stupor. [3] Since these tears may occur in persons who have no history of vomiting or alcoholism, other mechanisms must exist; underlying inapparent hiatal hernias have been implicated. MORPHOLOGY.
The linear irregular lacerations are oriented in the axis of the esophageal lumen and are several millimeters to several centimeters in length. They are usually found astride the esophagogastric junction or in the proximal gastric mucosa (Fig. 18-3) . The tears may involve only the mucosa or may penetrate deeply enough to perforate the wall. The histology is not distinctive and reflects trauma accompanied by fresh hemorrhage
780
Figure 18-3 Esophageal laceration (Mallory-Weiss tears). Gross view demonstrating longitudinal lacerations extending from
esophageal mucosa into stomach mucosa.
and a nonspecific inflammatory response. Infection of the mucosal defect may lead to an inflammatory ulcer or to mediastinitis. Clinical Features.
Esophageal lacerations account for 5 to 10% of upper gastrointestinal bleeding episodes. Most often, bleeding is not profuse and ceases without surgical intervention, although massive hematemesis may occur. Supportive therapy, such as vasoconstrictive medications and transfusions and sometimes balloon tamponade, is usually all that is required. Healing tends to be prompt, with minimal to no residua. The rare instance of esophageal rupture is known as Boerhaave syndrome and may be a catastrophic event. Esophagitis
Injury to the esophageal mucosa with subsequent inflammation is common worldwide. In the United States and other Western countries, esophagitis is present in about 5% of the adult population; much higher prevalence is encountered in selected regions, such as northern Iran and portions of China. REFLUX ESOPHAGITIS
Reflux of gastric contents into the lower esophagus is the first and foremost cause of esophagitis. Many causative factors are involved, less well characterized than the name implies: [4] Decreased efficacy of esophageal antireflux mechanisms, particularly LES tone. Central nervous system depressants, hypothyroidism, pregnancy, systemic sclerosing disorders, alcohol or tobacco exposure, or the presence of a nasogastric tube may be contributing causes. In most instances, no antecedent cause is identified. Presence of a sliding hiatal hernia. Inadequate or slowed esophageal clearance of refluxed material. Delayed gastric emptying and increased gastric volume, contributing to the volume of refluxed material. Reduction in the reparative capacity of the esophageal mucosa by protracted exposure to gastric juices. Any one of the aforementioned influences may assume primacy in an individual case, but more than one is likely to be involved in most instances. The acid-peptic action of gastric juices is critical to the development of esophageal mucosal injury; in severe
cases, refluxed bile from the duodenum also may contribute to the mucosal disruption. MORPHOLOGY.
The anatomic changes depend on the causative agent and on the duration and severity of the exposure. Simple hyperemia ( redness) may be the only alteration. In uncomplicated reflux esophagitis, three histologic features are characteristic (Fig. 18-4) : [5]
1. The presence of inflammatory cells, including eosinophils, neutrophils, and excessive numbers of lymphocytes, in the epithelial layer 2. Basal zone hyperplasia exceeding 20% of the epithelial thickness 3. Elongation of lamina propria papillae with congestion, extending into the top third of the epithelial layer Infiltrates of intraepithelial eosinophils are believed to be an early histologic abnormality, since they
Figure 18-4 Reflux esophagitis showing the superficial portion of the mucosa. Numerous eosinophils (arrows) are present within the
mucosa, and the stratified squamous epithelium has not undergone complete maturation owing to ongoing inflammatory damage.
781
occur even in the absence of basal zone hyperplasia. Intraepithelial neutrophils are markers of more severe injury, such as ulceration, rather than reflux esophagitis per se. Clinical Features.
Although largely limited to adults over age 40, reflux esophagitis is occasionally seen in infants and children. The clinical manifestations consist principally of dysphagia; heartburn; and sometimes regurgitation of a sour brash, hematemesis, or melena. The severity of symptoms is not related closely to the presence or degree of histologic esophagitis; most people experience reflux symptoms without damage to the distal esophageal mucosa, owing to the short duration of the reflux. Anatomic damage appears best correlated with prolonged exposure of the lower esophagus to refluxed material. Rarely, chronic symptoms are punctuated by attacks of severe chest pain that may be mistaken for a heart attack. The potential consequences of severe reflux esophagitis are bleeding, development of stricture, and a tendency to develop Barrett esophagus, with its attendant risks. BARRETT ESOPHAGUS
Barrett esophagus is a complication of long-standing gastroesophageal reflux, occurring
over time in up to 11% of patients with symptomatic reflux disease. In Barrett esophagus, the distal squamous mucosa is replaced by metaplastic columnar epithelium, as a response to prolonged injury. Barrett esophagus patients tend to have a long history of heartburn and other reflux symptoms and appear to have more massive reflux with more and longer reflux episodes than most reflux patients. It is unknown why the columnar epithelium develops in some patients with reflux and not in others. The pathogenesis of Barrett esophagus is not clear. [6] Inflammation and ulceration followed by ingrowth of pluripotent stem cells had been proposed; these cells would then differentiate into a columnar epithelium that is more resistant to acid peptic injury. More recent studies suggest that true metaplasia of the esophageal mucosa occurs because the columnar cells of Barrett esophagus can exhibit ultrastructural and cytochemical features of both a squamous and a columnar epithelial phenotype. MORPHOLOGY.
Barrett esophagus seen grossly (Fig. 18-5 A), or better still on endoscopy (Fig. 18-5 B), is apparent as a red, velvety mucosa located between the smooth, pale esophageal squamous mucosa and the more lush light brown-pink gastric mucosa. It may exist as tongues or patches (islands) extending up from the gastroesophageal junction or as a broad circumferential band displacing the squamocolumnar junction cephalad. A small zone of metaplastic mucosa may be present only at the esophagogastric junction (short-segment Barrett mucosa). Microscopically the esophageal squamous epithelium is replaced by metaplastic columnar epithelium, complete with mucosal glands. The metaplastic mucosa
Figure 18-5 A , Gross view of the distal esophagus (top) and proximal stomach (bottom) showing the granular zone of Barrett esophagus (arrowheads). B , Endoscopic view of Barrett esophagus showing red velvety gastrointestinal type mucosa extending from the gastroesophageal orifice. Note paler squamous esophageal mucosa. ( B, courtesy of Dr. F. Farraye, Brigham and Women's Hospital, Boston, MA.)
782
Figure 18-6 Barrett esophagus. Microscopic view showing mixed gastric and intestine-type columnar-epithelial cells in glandular
mucosa.
may contain only gastric surface and glandular mucus-secreting cells, making clinical distinction from a hiatal hernia difficult. Diagnosis is more readily made when the columnar mucosa contains intestinal goblet cells (Fig. 18-6) . Critical to the pathologic evaluation of patients with Barrett mucosa is the search for dysplasia, the presumed precursor of malignancy, in columnar epithelium with intestinal
metaplasia. Dysplasia is recognized by the presence of cytologic and architectural abnormalities extending to the luminal surface of the columnar epithelium. These abnormalities consist of enlarged, crowded, and stratified hyperchromatic nuclei and loss of intervening stroma between adjacent glandular structures. [7] Dysplasia is classified as low grade or high grade, with the predominant distinction being a basal epithelial orientation of all nuclei in low-grade dysplasia versus nuclei consistently reaching the apex of epithelial cells in high-grade dysplasia. Persistent high-grade dysplasia demands clinical intervention. Clinical Features.
In addition to the symptoms of reflux esophagitis, the clinical significance of Barrett esophagus relates to the secondary complications of local ulceration with bleeding and stricture. Of greatest importance is the development of adenocarcinoma, which, in patients with greater than 2 cm of Barrett mucosa, occurs at an estimated 30-fold to 40-fold increased rate over the general population. The presence of short-segment Barrett esophagus also appears to impart risk for adenocarcinoma but at what rate is not known. (See discussion under Carcinoma.) INFECTIOUS AND CHEMICAL ESOPHAGITIS
In addition to gastroesophageal reflux (which is, in fact, a chemical injury), esophageal inflammation may have many origins, as follows: Ingestion of mucosal irritants, such as alcohol, corrosive acids or alkalis (in suicide attempts), and excessively hot fluids (e.g., hot tea in Iran), as well as heavy smoking. Cytotoxic anticancer therapy, with or without superimposed infection. Infection after bacteremia or viremia. Herpes simplex viruses and cytomegalovirus are the more common offenders in the immunosuppressed. Fungal infection in debilitated or immunosuppressed patients or during broad-spectrum antimicrobial therapy. Candidiasis is by far the most common; mucormycosis and aspergillosis may occur. Uremia in the setting of renal failure. Esophageal inflammation may also arise after radiation treatment as well as in association with graft-versus-host disease or the desquamative dermatologic conditions of pemphigoid and epidermolysis bullosa. MORPHOLOGY.
Infectious and chemical causes of esophagitis exhibit their own characteristic features; the final common pathway for all is severe acute inflammation, superficial necrosis and ulceration with the formation of granulation tissue, and eventual fibrosis. In candidiasis, patches or all of the esophagus become covered by adherent gray-white pseudomembranes teeming with densely matted fungal hyphae. Herpes and cytomegalovirus cause punched-out ulcers of the esophageal
mucosa; the nuclear inclusions of herpesvirus are found in a narrow rim of degenerating epithelial cells at the margin of the ulcer, whereas cytomegalic change tends to be found in capillary endothelium and stromal cells in the base of the ulcer. Pathogenic bacteria account for 10 to 15% of cases of infective esophagitis and exhibit bacterial invasion of the lamina propria with necrosis of the squamous epithelium. Chemically induced injury (lye, acids, detergents) may produce only mild erythema and edema, sloughing of the mucosa, or outright necrosis of the entire esophageal wall. Localized esophageal ulceration may result from pharmaceutical tablets or capsules sticking in the esophagus. After irradiation of the esophagus, submucosal and mural blood vessels exhibit marked intimal proliferation with luminal narrowing. The submucosa becomes severely fibrotic, and the mucosa exhibits atrophy, with flattening of the papillae and thinning of the epithelium. Graft-versus-host disease shares features with the skin manifestations, e.g., karyorrhexis of basal epithelial cells, atrophy, and fibrosis of the lamina propria with minimal inflammation.
783
Clinical Features.
Infections of the esophagus may occur in otherwise healthy individuals but most often are in the debilitated or immunosuppressed. Chemical injury in children is usually accidental, as opposed to attempted suicide, which is an adult phenomenon. Esophageal Varices
Regardless of cause, portal hypertension, when sufficiently prolonged or severe, induces the formation of collateral bypass channels wherever the portal and caval systems communicate. The pathogenesis of portal hypertension and the locations of these bypasses are considered in Chapter 19 . Here we are concerned with the collaterals that develop in the region of the lower esophagus when portal blood flow is diverted through the coronary veins of the stomach into the plexus of esophageal mucosal and submucosal veins, thence into the azygos veins, and eventually into the systemic circulation. The increased pressure in the esophageal plexus produces dilated tortuous vessels called varices (Fig. 18-7 C). Varices develop in 90% of cirrhotic patients and are most often associated with alcoholic cirrhosis. Worldwide, hepatic schistosomiasis is the second most common cause of variceal bleeding. MORPHOLOGY.
Varices appear as tortuous dilated veins lying primarily within the submucosa of the distal esophagus and proximal stomach; mucosal venous channels directly beneath the esophageal epithelium may also become massively dilated. The net effect is irregular protrusion of the overlying mucosa into the lumen, although varices are collapsed in
surgical or postmortem specimens (Fig. 18-7 A). When the varix is unruptured, the mucosa may be normal, but often it is eroded and inflamed because of its exposed position. Variceal rupture produces massive hemorrhage into the lumen as well as suffusion of the esophageal wall with blood. In this instance, the overlying mucosa appears ulcerated and necrotic (Fig. 18-7 B). If rupture has occurred in the past, venous thrombosis and superimposed inflammation may be present. Clinical Features.
Varices produce no symptoms until they rupture, when massive hematemesis ensues. Among patients with advanced cirrhosis of the liver, half the deaths result from rupture of a varix. Some patients die as a direct consequence of the hemorrhage, and others die of hepatic coma triggered by the hemorrhage. Even when varices are present, they account for less than half of all episodes of hematemesis. Collectively, concomitant gastritis, esophageal laceration, and peptic ulcer are more common causes. Factors leading to rupture of a varix are unclear: Silent inflammatory erosion of overlying thinned mucosa, increased tension in progressively dilated veins, and vomiting with increased vascular hydrostatic pressure are likely to play roles. Once begun, the hemorrhage rarely subsides spontaneously, and endoscopic injection of thrombotic agents ( sclerotherapy) or balloon tamponade is usually required. When varices bleed, 40% of patients die in the first episode. Among those who survive, rebleeding occurs in more than half within 1 year, with a similar rate of mortality for each episode. Tumors BENIGN TUMORS
Benign tumors of the esophagus are mostly mesenchymal in origin and lie within the esophageal wall. Most common are benign tumors of smooth muscle origin, traditionally called leiomyomas and considered the benign end of a spectrum of gastrointestinal stromal tumors. Fibromas, lipomas, hemangiomas, neurofibromas, and lymphangiomas also may arise. Mucosal polyps are usually composed of a combination of fibrous, vascular, or adipose tissue covered by an intact mucosa, descriptively titled fibrovascular polyps or pedunculated lipomas depending on their composition. Squamous papillomas are sessile lesions with a central core of connective tissue and a hyperplastic papilliform squamous mucosa. In rare instances, a mesenchymal mass of inflamed granulation tissue, called an inflammatory polyp, may resemble a malignant lesion, hence its alternative name inflammatory pseudotumor. MALIGNANT TUMORS
In the United States, carcinomas of the esophagus represent about 6% of all cancers of the gastrointestinal tract but cause a disproportionate number of cancer deaths. [8] They remain asymptomatic during much of their development and are often discovered too late to permit cure. With rare exception, malignant esophageal tumors arise from the epithelial layer. For many years, most esophageal cancers were of squamous cell origin, but there has been a declining incidence of these tumors coupled with a steadily
increasing incidence of adenocarcinomas. Worldwide, squamous cell cancers constitute 90% of esophageal cancers, but in the United States squamous cell carcinoma and adenocarcinoma exhibit comparable incidence rates. Rare cancers (undifferentiated, carcinoid, malignant melanoma, and adenocarcinomas arising from the submucosal glands) are not discussed. Squamous Cell Carcinoma
Most squamous cell carcinomas occur in adults over age 50. The male-to-female ratio falls in the range of 2:1 to as high as 20:1. While squamous cell carcinoma of the esophagus occurs throughout the world, its incidence varies widely among countries and within regions of the same country. The region extending from Northern Iran across Central Asia to Northern China exhibits annual incidence rates exceeding 100 per 100,000, with deaths from cancer of the esophagus constituting more than 20% of all cancer deaths. Other areas of high incidence include Puerto Rico, South Africa, and Eastern Europe. In the United States, squamous cell carcinoma of the esophagus affects 2 to 8
784
Figure 18-7 Esophageal varices. A , View of the everted esophagus and gastroesophageal junction showing dilated submucosal veins (varices). The blue-colored varices have collapsed in this postmortem specimen. B , Low-power cross-section of a dilated submucosal varix that has ruptured through the mucosa. C, Hepatic venogram after injection of dye into portal veins (PV) to show a large tortuous gastroesophageal varix ( arrow ) extending superiorly from the patent main portal vein ( C, courtesy of Dr. Emily Sedgwick, Brigham and Women's Hospital, Boston, MA.)
persons per 100,000 yearly and is predominantly a disease of men (male-to-female ratio, 4:1). Blacks throughout the world are at higher risk than are whites, reaching a fourfold higher incidence in the United States. Etiology and Pathogenesis.
The marked differences in epidemiology strongly implicate dietary and environmental factors (Table 18-1) , with an ill-defined contribution from genetic predisposition. [9] The majority of cancers in Europe and the United States are attributable to alcohol and tobacco usage. Some alcoholic drinks contain significant amounts of such carcinogens as polycyclic hydrocarbons, fusel oils, and nitrosamines along with other mutagenic compounds. Nutritional deficiencies associated with alcoholism may contribute to the process of carcinogenesis. Alcohol and tobacco cannot be invoked as risk factors in many high-incidence regions of the world. The presence of carcinogens, such as fungus-contaminated and nitrosamine-containing foodstuffs in China, may play a significant role in the extraordinary incidence of carcinoma in this region. Dietary deficiencies in vitamins and essential metals have been documented in China and South Africa. Human
papillomavirus DNA is found frequently in esophageal squamous cell carcinomas from high-incidence regions. Its presence is infrequent, however, in cancer-bearing patients of North America. [10] Based on the aforementioned considerations, dietary and environmental factors have been proposed to increase risk, with nutritional deficiencies acting as promoters or potentiators
785
TABLE 18-1 -- FACTORS ASSOCIATED WITH THE DEVELOPMENT OF SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS Dietary Deficiency of vitamins (A, C, riboflavin, thiamine, pyridoxine) Deficiency of trace metals (zinc, molybdenum) Fungal contamination of foodstuffs High content of nitrites/nitrosamines Betel chewing Lifestyle Alcohol consumption Tobacco use Urban environment Esophageal Disorders Long-standing esophagitis Achalasia Plummer-Vinson syndrome Genetic Predisposition Long-standing celiac disease Ectodermal dysplasia, epidermolysis bullosa Tylosis palmaris et plantaris Racial disposition of the tumorigenic effects of environmental carcinogens. For example, methylating nitroso compounds in the diet and in tobacco smoke may be the reason for the broad spectrum of p53 point mutations, which are present in more than half of esophageal cancers. Mutations in p16 and allelic loss (loss of heterogeneity) involving other chromosomes are prevalent in these cancers as well, in keeping with the concept that
stepwise acquisition and accumulation of genetic alterations ultimately gives rise to cancer. [11] Notably absent from esophageal squamous cell carcinomas are K- ras and adenomatous polyposis coli (APC) gene mutations. Finally, the chronic esophagitis so commonly observed in persons living in areas of high incidence may itself be the result of chronic exposure to such carcinogens. This esophagitis results in an increased epithelial cell turnover, which, over a length of time in a continuously carcinogenic environment, progresses to dysplasia and eventually to carcinoma. MORPHOLOGY.
Similar to squamous cell carcinomas arising in other locations, those of the esophagus begin as apparent in situ lesions. When they become overt, about 20% of these tumors are located in the upper third, 50% in the middle third, and 30% in the lower third of the esophagus. Early lesions appear as small, gray-white, plaquelike thickenings or elevations of the mucosa. In months to years, these lesions become tumorous masses and may eventually encircle the lumen. Three morphologic patterns are described: (1) protruded (60% )-- a polypoid exophytic lesion that protrudes into the lumen (Fig. 18-8) ; (2) flat (15% )-- a diffuse, infiltrative form that tends to spread within the wall of the esophagus, causing thickening, rigidity, and narrowing of the lumen;
Figure 18-8 Large ulcerated squamous cell carcinoma of the esophagus.
and (3) excavated (25% )-- a necrotic cancerous ulceration that excavates deeply into surrounding structures and may erode into the respiratory tree (with resultant fistula and pneumonia) or aorta (with catastrophic exsanguination) or permeate the mediastinum and pericardium. The fortunate patient is found at the stage of superficial esophageal carcinoma, in which the malignant lesion is confined to the epithelial layer (in situ) or is superficially invading the lamina propria or submucosa (Fig. 18-9) . Most squamous cell carcinomas are moderately to well differentiated. Regardless of their degree of differentiation, most symptomatic tumors are quite large by the time they are diagnosed and have already invaded the wall or beyond. The
Figure 18-9 Squamous cell carcinoma of the esophagus. Low-power microscopic view showing invasion into the submucosa.
786
rich lymphatic network in the submucosa promotes extensive circumferential and
longitudinal spread, and intramural tumor cell clusters may often be seen several centimeters away from the main mass. Local extension into adjacent mediastinal structures occurs early and often in this disease. Tumors located in the upper third of the esophagus also metastasize to cervical lymph nodes; those in the middle third to the mediastinal, paratracheal, and tracheobronchial nodes; and those in the lower third most often to the gastric and celiac groups of nodes. Clinical Features.
Esophageal carcinoma is insidious in onset and produces dysphagia and obstruction gradually and late. Patients subconsciously adjust to their increasing difficulty in swallowing by progressively altering their diet from solid to liquid foods. Extreme weight loss and debilitation result from both the impaired nutrition and the effects of the tumor itself. Hemorrhage and sepsis may accompany ulceration of the tumor. Occasionally the first alarming symptom is aspiration of food via a cancerous tracheoesophageal fistula. Although the insidious growth of these neoplasms often leads to large lesions by the time a diagnosis is established, resectability rates have improved modestly (from <50% to >80%) with the advent of endoscopic screening in patient populations at risk. Five-year survival rates in patients with superficial esophageal carcinoma are about 75%, compared with 25% in patients undergoing curative surgery for more advanced disease and 5% for all patients with esophageal carcinoma. Local and distant recurrence after surgery is common. The presence of lymph node metastases at the time of resection significantly reduces the 5-year survival. Adenocarcinoma
Because of confusion with gastric cancers arising at the gastroesophageal junction, true esophageal adenocarcinomas were thought to be unusual. With increasing recognition of Barrett mucosa, it is apparent that most adenocarcinomas in the lower third of the esophagus are true esophageal cancers, rather than gastric cancers straddling the esophagogastric junction. [12] Accordingly, adenocarcinoma now represents up to half of all esophageal cancers reported in the United States. Etiology and Pathogenesis.
Although the pathogenesis of Barrett esophagus is unclear, genetic alterations in this disease are well documented. [7] Overexpression of p53 protein and increased proportions of cells with a G1/S DNA content are occasionally observed in metaplastic Barrett epithelium, presumably the result of chronic cell and DNA damage induced by gastric reflux. Allelic losses in 17p or point mutations in p53 are evident only in dysplastic foci, resulting in functional inactivation of the p53 gene and abrogation of cell cycle control at the G1/S transition. Clonal progression of dysplastic foci to frank adenocarcinoma then occurs, with accumulation of further chromosomal abnormalities. MORPHOLOGY.
Adenocarcinomas arising in the setting of Barrett esophagus are usually located in the
distal esophagus and may invade the adjacent gastric cardia. Initially appearing as flat or raised patches of an otherwise intact mucosa, they may develop into large nodular masses up to 5 cm in diameter or may exhibit diffusely infiltrative or deeply ulcerative features (Fig. 18-10 A). Microscopically, most tumors are mucin-producing
Figure 18-10 A , Gross view of an ulcerated, exophytic adenocarcinoma at the gastroesophageal junction, arising from mucosa of
Barrett esophagus. The gray-white esophageal squamous mucosa is on top, and the folds of gastric mucosa below. A small patch of white squamous epithelium remains in center of tumor. ( A, courtesy of Dr. James Gulizia, Brigham and Women's Hospital, Boston, MA.) B , Microscopic view of malignant intestinal-type glands in adenocarcinoma arising from Barrett esophagus.
787
glandular tumors exhibiting intestinal-type features (Fig. 18-10 B) or, less often, are made up of diffusely infiltrative signet-ring cells of a gastric type. Clinical Features.
Adenocarcinomas arising in Barrett esophagus chiefly occur in patients over 40 years of age, with a median age in the fifties. In keeping with Barrett esophagus, adenocarcinoma is more common in men than women, and whites are affected more frequently than blacks, in contrast to squamous cell carcinomas. As in other forms of esophageal carcinoma, patients usually present because of dysphagia. Progressive weight loss, bleeding, chest pain, and vomiting may occur. The prognosis of esophageal adenocarcinoma is as poor as that for other forms of esophageal cancer, with less than 30% 5-year survival. Identification and resection of early cancers with invasion limited to the mucosa or submucosa improves 5-year survival to greater than 80%. Although dysplasia appears to be a precursor for the development of adenocarcinoma, patients with low-grade dysplasia may not progress to cancer over long periods of follow-up, and apparent regression may occur.
Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
Part 2 - DISEASES OF ORGAN SYSTEMS 19 - The Liver and the Biliary Tract The Liver The Biliary Tract REFERENCES Contents - 1 - 2 - Index
Robbins Pathologic Basis of Disease Contents - 1 - 2 - Index
845
Chapter 19 - The Liver and the Biliary Tract James M. Crawford
846
The Liver NORMAL ANATOMY The right upper quadrant of the abdomen is dominated by the liver and its companion biliary tree and gallbladder. Residing at the crossroads between the digestive tract and the rest of the body, the liver has the enormous job of maintaining the body's metabolic homeostasis. This includes the processing of dietary amino acids, carbohydrates, lipids, and vitamins; synthesis of serum proteins; and detoxification and excretion into bile of endogenous waste products and pollutant xenobiotics. Hepatic disorders thus have far-reaching consequences. The normal adult liver weighs 1400 to 1600 gm, representing 2.5% of body weight. Incoming blood arrives by the portal vein (60% to 70% of hepatic blood flow) and hepatic artery (30% to 40%) through the "gateway" of the liver, the porta hepatis; the common hepatic bile duct exits in this same region. The initial branches of artery, vein, and bile duct lie just outside the liver, but the remaining branches ramify roughly in parallel within the liver to form portal triads or portal tracts. The vast expanse of hepatic parenchyma is serviced by fenestrated terminal twigs of the portal vein and hepatic artery system, which enter the parenchyma at frequent intervals. Blood is collected into ramifications of the hepatic vein, which exits by the "back door" of the liver into the closely apposed inferior vena cava. Microarchitecture.
The liver has classically been divided into 1- to 2-mm-diameter hexagonal lobules oriented around the terminal tributaries of the hepatic vein ( terminal hepatic venules or " central" veins). However, since hepatocytes near the central vein are most remote
from the blood supply, it has been argued that they are at the periphery of "metabolic lobules," referred to as acini. Conceptualized as roughly triangular, the acini have the terminal twigs of hepatic artery and portal vein extending out from the portal tracts at their bases and the terminal hepatic venules at their apices [1] (Fig. 19-1) . The parenchyma of the hepatic acinus is divided into three zones, zone 1 being closest to the vascular supply, zone 3 abutting the terminal hepatic venule, and zone 2 being intermediate. This zonation is of considerable metabolic consequence, since a lobular gradient of activity exists for many hepatic enzymes. [2] Moreover, many forms of hepatic injury exhibit a zonal distribution. The hepatic parenchyma is organized into cribriform, anastomosing sheets or "plates" of hepatocytes, seen in microscopic sections as cords of cells (Fig. 19-2) . Hepatocytes immediately abutting the portal tract are referred to as the limiting plate, forming a discontinuous rim around the mesenchyme of the portal tract. There is a radial orientation of the hepatocyte cords around the terminal hepatic vein. Hepatocytes exhibit minimal variation in overall size, but nuclei may vary in size, number, and ploidy, particularly with advancing age. Uninucleate, diploid cells tend to be the rule, but a significant fraction are binucleate, and the karyotype may range up to octaploidy. Between the cords of hepatocytes are vascular sinusoids. Arterial and portal venous blood traverses the sinusoids and exits into the terminal hepatic vein through innumerable orifices in the vein wall. Hepatocytes are thus bathed on two sides by well-mixed portal venous and hepatic arterial blood, representing 25% of the cardiac output and placing hepatocytes among the most richly perfused cells in the body. The sinusoids are lined by fenestrated and discontinuous endothelial cells, which demarcate an extrasinusoidal space of Disse, into which protrude abundant microvilli
Figure 19-1 Microscopic liver architecture depicted schematically. The classic hexagonal lobule is centered around a central vein
(terminal hepatic venule), with portal tracts at three of its apices. The triangular acinus has as its base the penetrating vessels, which extend from portal veins and hepatic arteries to penetrate the parenchyma. The apex is formed by the terminal hepatic vein. Zones 1, 2, and 3 represent metabolic regions increasingly distant from the blood supply.
847
Figure 19-2 Photomicrograph of liver. (Trichrome stain.) Note blood-filled sinusoids and cords of hepatocytes.
of hepatocytes. Scattered Kupffer cells of the monocyte-phagocyte system are attached to the luminal face of endothelial cells, and scattered fat-containing hepatic stellate cells (also called Ito cells) of mesenchymal origin are found in the space of Disse. These stellate cells play a role in the storage and metabolism of vitamin A and are transformed into collagen-producing myofibroblasts when there is inflammation and fibrosis of the liver, as we shall see.
Between abutting hepatocytes are bile canaliculi, which are channels 1 to 2 mum in diameter, formed by grooves in the plasma membranes of the facing cells and delineated from the vascular space by tight junctions. Numerous microvilli extend into these intercellular spaces, which constitute the outermost reaches of the biliary tree. Intracellular actin and myosin microfilaments surrounding the canaliculus help propel secreted biliary fluid along the canaliculi. [3] These channels begin in the centrilobular regions and progressively join to drain into the canals of Hering, the terminal parenchymal tributaries of the bile duct system. These canals are composed of a low cuboidal biliary epithelium. Biliary fluid is conveyed through their lumina to interlobular bile ducts within the portal tracts, which are lined by a more robust cuboidal epithelium. PATHOLOGY GENERAL MORPHOLOGIC AND FUNCTIONAL PATTERNS OF HEPATIC INJURY
The liver is vulnerable to a wide variety of metabolic, toxic, microbial, circulatory, and neoplastic insults. In some instances, the disease is primary to the liver, as in viral hepatitis and hepatocellular carcinoma. More often the hepatic involvement is secondary, often to some of the most common diseases in humans, such as cardiac decompensation, disseminated cancer, alcoholism, and extrahepatic infections. The enormous functional reserve of the liver masks to some extent the clinical impact of early liver damage. However, with progression of diffuse disease or strategic disruption of bile flow, the consequences of deranged liver function become life threatening. Before specific disease processes are discussed, four general aspects of liver disease are reviewed: (1) general morphologic patterns of hepatic injury, (2) hepatic formation of bile, (3) hepatic failure, and (4) cirrhosis. Hepatic Injury
From a morphologic standpoint, the liver is an inherently simple organ, with a limited repertoire of responses to injurious events. Regardless of cause, five general responses are seen. DEGENERATION AND INTRACELLULAR ACCUMULATION.
Damage from toxic or immunologic insult may cause hepatocytes to take on a swollen, edematous appearance (ballooning degeneration) with irregularly clumped cytoplasm and large clear spaces. Alternatively, retained biliary material may impart a diffuse foamy swollen appearance to the hepatocyte (foamy degeneration). Substances may accumulate in viable hepatocytes, including iron and copper. Accumulation of fat droplets within hepatocytes is known as steatosis. Multiple tiny droplets that do not displace the nucleus are known as microvesicular steatosis and appear in such conditions as alcoholic liver disease and acute fatty liver of pregnancy. A single large droplet that displaces the nucleus, macrovesicular steatosis, may be seen in the
alcoholic liver or in the livers of obese or diabetic individuals. NECROSIS AND APOPTOSIS.
Any significant insult to the liver may cause hepatocyte necrosis. In ischemic coagulative necrosis, the liver cells are poorly stained and "mummified" and often have lysed nuclei. With cell death that is toxic or immunologically mediated, isolated hepatocytes round up to form shrunken, pyknotic, and intensely eosinophilic Councilman bodies containing fragmented nuclei. This form of cell death is the consequence of apoptosis (Chapter 1) . Alternatively, hepatocytes may osmotically swell and rupture, so-called lytic necrosis. Necrosis frequently exhibits a zonal distribution. The most obvious is necrosis of hepatocytes immediately around the terminal hepatic vein (centrilobular necrosis), an injury that is characteristic of ischemic injury and a number of drug and toxic reactions. Pure midzonal and periportal necrosis
848
is rare; the latter may be seen in eclampsia. With most other causes of hepatic injury, a variable mixture of hepatocellular death and inflammation is encountered. The hepatocyte necrosis may be limited to scattered cells within hepatic lobules (focal necrosis) or to the interface between the periportal parenchyma and inflamed portal tracts (interface hepatitis). With more severe inflammatory injury, necrosis of contiguous hepatocytes may span adjacent lobules in a portal to portal, portal to central, or central to central fashion (bridging necrosis). Necrosis of entire lobules (submassive necrosis) or most of the liver (massive necrosis) is usually accompanied by hepatic failure. With disseminated candidal or bacterial infection, macroscopic abscesses may occur. INFLAMMATION.
Injury to the liver associated with an influx of acute or chronic inflammatory cells is termed hepatitis. Although hepatocyte necrosis may precede the onset of inflammation, the converse is also true. Attack on viable liver cells by sensitized T cells is a common cause of liver damage. Inflammation may be limited to the site of leukocyte entry (portal tracts) or spill over into the parenchyma. When hepatocytes undergo necrosis or apoptosis, scavenger macrophages engulf the dead cells within a few hours, generating clumps of inflammatory cells in an otherwise normal parenchyma. Foreign bodies, organisms, and a variety of drugs may incite a granulomatous reaction. REGENERATION.
The liver has enormous reserve, and regeneration occurs in all but the most
fulminant diseases. Hepatocellular proliferation is signified by mitoses, thickening of the hepatocyte cords, and some disorganization of the parenchymal structure. Bile duct epithelial proliferation engenders an excess number of bile duct profiles within portal tracts. When hepatocellular necrosis occurs and leaves the connective tissue framework intact, almost perfect restitution of liver structure can occur, even when the necrosis is massive or submassive. FIBROSIS.
Fibrous tissue is formed in response to inflammation or direct toxic insult to the liver. Unlike all other responses, which are reversible, fibrosis is generally an irreversible consequence of hepatic damage. Deposition of collagen has lasting consequences on hepatic patterns of blood flow and perfusion of hepatocytes. In the initial stages, fibrosis may develop around portal tracts or the terminal hepatic vein, or it may be deposited directly within the space of Disse. With continuing fibrosis, the liver is subdivided into nodules of regenerating hepatocytes surrounded by scar tissue, termed cirrhosis. This end-stage form of liver disease is discussed later in this section. The ebb and flow of hepatic injury may be imperceptible to the patient and detectable only by abnormal laboratory test results. Alternatively, hepatic function may be so impaired as to be life threatening. The major clinical consequences of liver disease are discussed next. Jaundice and Cholestasis
Hepatic bile formation serves two major functions: (1) the promotion of dietary fat absorption in the lumen of the gut through the detergent action of bile salts and (2) the elimination of waste products. Bile constitutes the primary pathway for elimination of bilirubin, excess cholesterol, and xenobiotics that are insufficiently water soluble to be excreted into urine. Because bile formation is one of the most sophisticated functions of the liver, it is also one of the most readily disrupted. Such disruption becomes clinically evident as yellow discoloration of the skin and sclerae ( jaundice or icterus, respectively), due to retention of pigmented bilirubin, and as cholestasis, characterized by systemic retention of not only bilirubin but also other solutes eliminated in bile. BILIRUBIN AND BILE FORMATION
Bilirubin is the end product of heme degradation (Fig. 19-3) . The majority of daily production (0.2 to 0.3 gm) is derived from breakdown of senescent erythrocytes by the mononuclear phagocyte system, especially in the spleen, liver, and bone marrow. Most of the remainder of bilirubin is derived from the turnover of hepatic hemoproteins (e.g., the P-450 cytochromes) and from premature destruction of newly formed erythrocytes in the bone marrow. The latter pathway is important in hematologic disorders associated with excessive intramedullary hemolysis of defective erythrocytes (ineffective erythropoiesis; Chapter 14) . Whatever the source, heme oxygenase oxidizes heme to biliverdin (step 1 in Figure
19-3) , which is then reduced to bilirubin by biliverdin reductase. Bilirubin thus formed outside the liver is released and bound to serum albumin (step 2). Albumin binding is necessary since bilirubin is virtually insoluble in aqueous solutions at physiologic pH. The small fraction of unbound bilirubin in plasma may increase in severe hemolytic disease or when protein-binding drugs displace bilirubin from albumin. Hepatic processing of bilirubin involves carrier-mediated uptake at the sinusoidal membrane (step 3), conjugation with one or two molecules of glucuronic acid by bilirubin uridine diphosphate-glucuronosyltransferase (UGT) in the endoplasmic reticulum (step 4), and excretion of the water-soluble, nontoxic bilirubin glucuronides into bile. Most bilirubin glucuronides are deconjugated by bacterial beta-glucuronidases and degraded to colorless urobilinogens (step 5). The urobilinogens, and the residue of intact pigment, are largely excreted in feces. Approximately 20% of the urobilinogens formed are reabsorbed in the ileum and colon, returned to the liver, and promptly re-excreted into bile. The small amount that escapes this enterohepatic circulation is excreted in urine.
849
Figure 19-3 Bilirubin metabolism and elimination. 1, Normal bilirubin production from heme (0.2-0.3 gm/day) is derived primarily from
the breakdown of senescent circulating erythrocytes, with a minor contribution from degradation of tissue heme-containing proteins. 2, Extrahepatic bilirubin is bound to serum albumin and delivered to the liver. 3, Hepatocellular uptake and (4) glucuronidation in the endoplasmic reticulum generate bilirubin mono- and diglucuronides, which are water soluble and readily excreted into bile. 5, Gut bacteria deconjugate the bilirubin and degrade it to colorless urobilinogens. The urobilinogens and the residue of intact pigments are excreted in the feces, with some reabsorption and excretion into urine.
The brilliant yellow color of bilirubin makes it an easily identified component of hepatic bile formation. However, bilirubin metabolism and excretion is but a minor cog in the hepatic machinery that secretes 12 to 36 gm of bile acids into bile per day. Bile acids are carboxylated steroid molecules derived from cholesterol and are the detergent molecules primarily responsible for promoting bile flow and the secretion of phospholipid and cholesterol. The primary human bile acids are cholic acid and chenodeoxycholic acid, which are secreted as taurine and glycine conjugates. Ten per cent to 20% of excreted bile acids is deconjugated in the intestines by bacterial action. Virtually all conjugated and deconjugated bile acids are reabsorbed, primarily through the action of a sodium-bile acid cotransporter in the apical membrane of ileal enterocytes, and are returned to the liver for uptake, reconjugation, and resecretion. Fecal loss of bile acids (0.2 to 0.6 gm/day) is matched by de novo hepatic synthesis of bile acids from cholesterol. The enterohepatic circulation of bile acids provides an efficient mechanism for maintaining a large endogenous pool of bile acids for digestive and excretory purposes. PATHOPHYSIOLOGY OF JAUNDICE
Both unconjugated bilirubin and bilirubin glucuronides may accumulate systemically and deposit in tissues, giving rise to the yellow discoloration of jaundice. This is particularly evident in the yellowing of the sclerae (icterus). There are two important
pathophysiologic differences between the two forms of bilirubin. Unconjugated bilirubin is virtually insoluble in water at physiologic pH and is tightly complexed to serum albumin. This form cannot be excreted in the urine even when blood levels are high. A small amount of unconjugated bilirubin is normally present as an albumin-free anion in plasma. This fraction of unbound bilirubin may diffuse into tissues, particularly the brain in infants, and produce toxic injury. The unbound plasma fraction may increase in severe hemolytic disease or when protein-binding drugs displace bilirubin from albumin. Hence, hemolytic disease of the newborn (erythroblastosis fetalis) may lead to accumulation of unconjugated bilirubin in the brain, which can cause severe neurologic damage, referred to as kernicterus). In contrast, conjugated bilirubin is water soluble, nontoxic, and only loosely bound to albumin. Because of its solubility and weak association with albumin, excess conjugated bilirubin in plasma can be excreted
850
TABLE 19-1 -- CAUSES OF JAUNDICE Predominantly Unconjugated Hyperbilirubinemia Excess production of bilirubin Hemolytic anemias Resorption of blood from internal hemorrhage (e.g., alimentary tract bleeding, hematomas) Ineffective erythropoiesis syndromes (e.g., pernicious anemia, thalassemia) Reduced hepatic uptake Drug interference with membrane carrier systems Some cases of Gilbert syndrome Impaired bilirubin conjugation Physiologic jaundice of the newborn (decreased UGT activity, decreased excretion) Breast milk jaundice (?inhibition of UGT activity) Genetic deficiency of bilirubin UGT activity (Crigler-Najjar syndrome types I and II) Gilbert syndrome (mixed etiologies) Diffuse hepatocellular disease (e.g., viral or drug-induced hepatitis, cirrhosis) Predominantly Conjugated Hyperbilirubinemia Decreased hepatic excretion of bilirubin glucuronides Deficiency in canalicular membrane transporters (Dubin-Johnson syndrome, Rotor syndrome)
UGT, uridine diphosphate-glucuronosyltransferase. in urine. With prolonged conjugated hyperbilirubinemia, a portion of circulating pigment may become covalently bound to albumin (the delta fraction). In the normal adult, total serum bilirubin levels vary between 0.3 and 1.2 mg/dl, and the rate of systemic bilirubin production is equal to the rates of hepatic uptake, conjugation, and biliary excretion. Jaundice becomes evident when the serum bilirubin levels rise above 2.0 to 2.5 mg/dl; levels as high as 30 to 40 mg/dl can occur with severe disease. Jaundice occurs when the equilibrium between bilirubin production and clearance is disturbed by one or more of the following mechanisms (Table 19-1) : (1) excessive production of bilirubin, (2) reduced hepatocyte uptake, (3) impaired conjugation, (4) decreased hepatocellular excretion, and (5) impaired bile flow (both intrahepatic and extrahepatic). The first three mechanisms produce unconjugated hyperbilirubinemia, and the last two predominantly conjugated hyperbilirubinemia. More than one mechanism may operate to produce jaundice, especially hepatitis, which may produce unconjugated and conjugated hyperbilirubinemia. Generally speaking, however, one mechanism predominates, so that knowledge of the predominant form of plasma bilirubin is of value in evaluating possible causes of hyperbilirubinemia. Of the various causes of jaundice listed in Table 19-1 , the most common are due to bilirubin overproduction (as from hemolytic anemias and resorption of major hemorrhages), hepatitis, and obstruction to the flow of bile (considered later in this chapter). Several particular conditions merit consideration. Neonatal Jaundice.
Because the hepatic machinery for conjugating and excreting bilirubin does not fully mature until about 2 weeks of age, almost every newborn develops transient and mild unconjugated hyperbilirubinemia, termed neonatal jaundice or physiologic jaundice of the newborn. Breast-fed infants tend to exhibit jaundice with greater frequency, possibly the result of beta-glucuronidases present in maternal milk. These enzymes deconjugate bilirubin glucuronides in the gut, increasing intestinal reabsorption of unconjugated bilirubin. Hereditary Hyperbilirubinemias.
In rare instances, there may be a genetic lack of bilirubin UGT (Table 19-2) . Crigler-Najjar syndrome type I, in which the enzyme is completely absent, is invariably fatal, causing death within 18 months of birth secondary to kernicterus. Multiple genetic defects in the locus coding for the bilirubin UDP-glucuronosyltransferase enzyme, UGT1, may give rise to this disorder. [4] The liver is incapable of synthesizing a functional enzyme, and the colorless bile TABLE 19-2 -- HEREDITARY HYPERBILIRUBINEMIAS
Disorder
Inheritance
Defects in Bilirubin Metabolism
Liver Pathology
Clinical Course
Unconjugated Hyperbilirubinemia Crigler-Najjar Autosomal syndrome type I recessive
Absent bilirubin UGT activity
Normal
Fatal in neonatal period
Crigler-Najjar syndrome type II
Autosomal Normal Decreased bilirubin dominant with UGT activity variable penetrance
Generally mild, occasional kernicterus
Gilbert syndrome
?Autosomal dominant
Normal
Innocuous
Pigmented cytoplasmic globules; ?epinephrine metabolites
Innocuous
Normal
Innocuous
Decreased bilirubin UGT activity
Conjugated Hyperbilirubinemia Dubin-Johnson syndrome
Autosomal recessive
Rotor syndrome Autosomal recessive
Impaired biliary excretion of bilirubin glucuronides due to a canalicular mem-brane-carrier defect ?Decreased hepatic uptake and storage ?Decreased biliary excretion
UGT, uridine diphosphate-glucuronosyltransferase.
851
contains only trace amounts of unconjugated bilirubin. The liver is morphologically normal by light and electron microscopy. Crigler-Najjar syndrome type II is a less severe, nonfatal disorder exhibiting a partial defect in bilirubin conjugation; the major consequence is extraordinarily yellow skin. A mutation that disrupts the hydrophobic core of the signal peptide for bilirubin UGT has been reported for this syndrome. [5] Almost all patients develop normally, but there is a risk for some neurologic damage from kernicterus. Gilbert syndrome is a relatively common, benign, somewhat heterogeneous inherited
condition presenting with mild, fluctuating hyperbilirubinemia. The primary cause is reduction in hepatic bilirubin glucuronidating activity to about 30% of normal levels. Missense mutations and molecular anomalies in the promoter regions of the UGT1 gene result in reduced expression of the enzyme. [6] Affecting some 6% of the population, the mild hyperbilirubinemia may go undiscovered for years and is not associated with functional derangements. When detected in adolescence or adult life, it is typically in association with stress, such as an intercurrent illness, strenuous exercise, or fasting. There is no clinical consequence of Gilbert syndrome except for the anxiety that a jaundiced sufferer might justifiably experience with this otherwise innocuous condition. Dubin-Johnson syndrome results from a hereditary defect in hepatocellular excretion of bilirubin glucuronides across the canalicular membrane. The defect is attributable to an absence of the canalicular transport protein for bilirubin glucuronides and related organic anions. [7] The liver is darkly pigmented owing to coarse pigmented granules within the cytoplasm of hepatocytes (Fig. 19-4) . Electron microscopy reveals coarse granules in hepatocellular lysosomes, which appear to be polymers of adrenaline (epinephrine) metabolites. The liver is otherwise normal. Apart from chronic or recurrent jaundice of fluctuating intensity, most patients are asymptomatic and have a normal life expectancy. Rotor syndrome is a rare, separate form of asymptomatic conjugated hyperbilirubinemia with multiple defects in hepatocellular uptake and excretion of bilirubin pigments. The liver is not pigmented. As with Dubin-Johnson syndrome, patients with Rotor syndrome exhibit jaundice but otherwise live normal lives. CHOLESTASIS
Cholestatic conditions, which result from hepatocellular dysfunction or intrahepatic or extrahepatic biliary obstruction, may also present with jaundice. Alternatively, pruritus is a common presenting symptom, presumably related to the elevation in plasma bile acids and deposition in peripheral tissues, particularly skin. Skin xanthomas (focal accumulations of cholesterol) sometimes appear, the result of hyperlipidemia and impaired excretion of cholesterol. A characteristic laboratory finding is elevated serum alkaline phosphatase, an enzyme present in bile duct epithelium and in the canalicular membrane of hepatocytes. An isozyme is normally present in many other tissues such as bone, and so the increased levels must be verified as being hepatic in origin. Other manifestations of reduced bile flow
Figure 19-4 Dubin-Johnson syndrome, showing abundant pigment inclusions in otherwise normal hepatocytes. (H&E.)
relate to intestinal malabsorption, including nutritional deficiencies of the fat-soluble vitamins A, D, and K. There is also a striking but heterogeneous group of autosomal recessively inherited conditions in which cholestasis results from impairment of bile salt or phospholipid
secretion. One form causes progressive intrahepatic cholestasis (Byler disease). The genetic defect appears to involve impaired biliary secretion of both bile acids and phosphatidylcholine. [8] MORPHOLOGY.
The morphologic features of cholestasis depend somewhat on its severity, duration, and underlying cause. Common to both obstructive and hepatocellular cholestasis is the accumulation of bile pigment within the hepatic parenchyma (Fig. 19-5) . Elongated green-brown plugs of bile are visible in dilated bile canaliculi. Rupture of canaliculi leads to extravasation of bile, which is phagocytosed by Kupffer cells. Droplets of bile pigment also accumulate within hepatocytes, which can take on a wispy appearance (feathery or foamy degeneration). Obstruction to the biliary tree, either intrahepatic or extrahepatic, induces distention of upstream bile ducts by bile. The bile stasis and back-pressure induce proliferation of the duct epithelial cells and looping and reduplication of ducts, termed bile duct proliferation. The labyrinthine ducts further slow the flow of bile and favor the formation of concrements, which obstruct their lumens. Associated portal tract findings include
852
Figure 19-5 Illustration of the morphologic features of cholestasis ( right ) and comparison with normal liver ( left). In the parenchyma (upper panel) , cholestatic hepatocytes (1) are enlarged with dilated canalicular spaces (2). Apoptotic cells (3) may be seen, and Kupffer cells (4) frequently contain regurgitated bile pigments. In the portal tracts of obstructed livers (lower panel) , there is also bile
duct proliferation (5), edema, bile pigment retention (6), and eventually neutrophilic inflammation (not shown). Surrounding hepatocytes (7) are swollen and undergoing toxic degeneration.
edema and periductular infiltrates of neutrophils. Prolonged obstructive cholestasis leads not only to foamy change of hepatocytes but also to focal destruction of the parenchyma, giving rise to bile lakes filled with cellular debris and pigment. Unrelieved obstruction leads to portal tract fibrosis, which initially extends into and subdivides the parenchyma with relative preservation of hepatic architecture. Ultimately, an end-stage, bile-stained, cirrhotic liver is created (biliary cirrhosis, discussed later). Extrahepatic biliary obstruction is frequently amenable to surgical alleviation; correct and prompt diagnosis is imperative. In contrast, cholestasis due to diseases of the intrahepatic biliary tree or hepatocellular secretory failure (collectively termed intrahepatic cholestasis) cannot be benefited by biliary surgery, and the patient's condition may be worsened by an operative procedure. There is thus some urgency in making a correct diagnosis of the cause of jaundice and cholestasis.
Hepatic Failure and Cirrhosis
The most severe clinical consequence of liver disease is hepatic failure. This may be the result of sudden and massive hepatic destruction. More often, it is the end point of progressive damage to the liver, either by insidious destruction of hepatocytes or by repetitive discrete waves of parenchymal damage. Whatever the sequence, 80% to 90% of hepatic functional capacity must be eroded before hepatic failure ensues. In many cases, the balance is tipped toward decompensation by intercurrent conditions that place demands on the liver. These include gastrointestinal bleeding, systemic infection, electrolyte disturbances, or severe stress such as major surgery or heart failure. In most cases of severe hepatic dysfunction, liver transplantation is the only hope for survival. The fortunate few can survive an acute event with conservative management until regeneration restores adequate hepatic function. Overall, mortality from hepatic failure is 70% to 95%. The morphologic alterations that cause liver failure fall into three categories: Massive hepatic necrosis. This is most often due to fulminant viral hepatitis (hepatotropic viruses or nonhepatotropic). Drugs and chemicals may also induce massive necrosis, including acetaminophen, halothane, antituberculosis drugs (rifampin, isoniazid), antidepressant monoamine oxidase inhibitors, industrial chemicals such as carbon tetrachloride, and mushroom poisoning ( Amanita phalloides). The mechanism may be direct toxic damage to hepatocytes (e.g., acetaminophen, carbon tetrachloride, mushroom toxins) but more often is a variable combination of toxicity and inflammation with immune-mediated hepatocyte destruction. Chronic liver disease. This is the most common route to hepatic failure and is the endpoint of relentless chronic hepatitis or alcoholic liver disease ending in cirrhosis. Hepatic dysfunction without overt necrosis. Less commonly, hepatocytes may be viable but unable to perform normal metabolic function, as with Reye syndrome, tetracycline toxicity, and acute fatty liver of pregnancy. Clinical Features.
Regardless of cause, the clinical signs of hepatic failure are much the same. Jaundice is an almost invariable finding. Hypoalbuminemia, which predisposes to peripheral edema, and hyperammonemia, which may play a role in cerebral compromise, are extremely worrisome developments. Fetor hepaticus, a characteristic body odor variously described as "musty" or "sweet and sour," occurs occasionally. It is related to the formation of mercaptans by the action of gastrointestinal bacteria on the sulfur-containing amino acid methionine and shunting of splanchnic blood from the portal into the systemic circulation (portosystemic shunting). Impaired estrogen metabolism and consequent hyperestrogenemia are the putative causes of palmar erythema (a reflection of local vasodilation) and spider angiomas of the skin. Each angioma is a central, pulsating, dilated arteriole from which small vessels radiate. In the
male, hyperestrogenemia also leads to hypogonadism and gynecomastia. Hepatic failure is life threatening, for a number of reasons. First, with severely impaired liver function, patients
853
are highly susceptible to failure of multiple organ systems. Thus, respiratory failure with pneumonia and sepsis combine with renal failure to claim the lives of many patients with hepatic failure. A coagulopathy develops, attributable to impaired hepatic synthesis of blood clotting factors II, VII, IX, and X. The resultant bleeding tendency may lead to massive gastrointestinal bleeding as well as petechial bleeding elsewhere. Intestinal absorption of blood places a metabolic load on the liver, which worsens the extent of hepatic failure. The outlook of full-blown hepatic failure is grave: a rapid downhill course is usual, with death occurring within weeks to a few months in about 80%. A fortunate few can be tided over an acute episode until hepatocellular regeneration restores adequate hepatic function. Alternatively, liver transplantation may save the patient. Two particular complications are important, since they herald the most grave stages of hepatic failure. Hepatic encephalopathy is manifested by a spectrum of disturbances in consciousness, ranging from subtle behavioral abnormalities to marked confusion and stupor to deep coma and death. Associated fluctuating neurologic signs include rigidity, hyperreflexia, and particularly asterixis: nonrhythmic, rapid extension-flexion movements of the head and extremities, best seen when the arms are held in extension with dorsiflexed wrists. Hepatic encephalopathy is caused by abnormal neurotransmission in the central nervous and neuromuscular systems[9] and appears to be associated with elevated blood ammonia levels, which impair neuronal function and promote generalized brain edema. Hepatorenal syndrome refers to the appearance of acute renal failure in patients with severe liver disease, in whom there are no intrinsic morphologic or functional causes for the renal failure. Kidney function promptly improves if hepatic failure is reversed. The pathogenesis of acute renal failure in this setting involves decreased renal perfusion as described in Chapter 21 . [10] Onset of this syndrome is typically heralded by a drop in urine output associated with rising blood urea nitrogen and creatinine concentrations. The prognosis is poor with a mortality of 80% to 95%. Alternatively, borderline renal insufficiency (serum creatinine concentration, 2 to 3 mg/dl) may persist for weeks to months, as in cirrhotic patients whose ascites is refractory to diuretic therapy. CIRRHOSIS
Cirrhosis is among the top ten causes of death in the Western world. Although it is
largely the result of alcohol abuse, other major contributors include chronic hepatitis, biliary disease, and iron overload. This end stage of chronic liver disease is defined by three characteristics: Bridging fibrous septa in the form of delicate bands or broad scars replacing multiple adjacent lobules Parenchymal nodules created by regeneration of encircled hepatocytes, varying from small (<3 mm in diameter, micronodules) to large (several centimeters in diameter, macronodules) Disruption of the architecture of the entire liver Several features should be underscored: The parenchymal injury and consequent fibrosis are diffuse, extending throughout the liver; focal injury with scarring does not constitute cirrhosis. Nodularity is requisite for the diagnosis and reflects the balance between regenerative activity and constrictive scarring. The fibrosis, once developed, is generally irreversible, although regression is observed in rare instances of schistosomiasis and hemochromatosis. Vascular architecture is reorganized by the parenchymal damage and scarring, with the formation of abnormal interconnections between vascular inflow and hepatic vein outflow channels. There is no satisfactory classification of cirrhosis save for specification of the presumed underlying cause. The terms micronodular and macronodular should not be used as a primary classification, although the size of the nodules may provide clues to etiology. Many forms of cirrhosis (particularly alcoholic) are initially micronodular, but there is a tendency for nodules to increase in size with time, counterbalanced by the constraints imposed by fibrous scarring. The etiology of cirrhosis varies both geographically and socially. The following is the approximate frequency of etiologic categories in the Western world: Alcoholic liver disease Viral hepatitis Biliary diseases Primary hemochromatosis
60-70% 10% 5-10% 5%
Wilson disease
rare
alpha1 -Antitrypsin deficiency
rare
Cryptogenic cirrhosis
10-15%
Infrequent types of cirrhosis include (1) the cirrhosis developing in infants and children with galactosemia and tyrosinosis (Chapter 11) ; (2) liver destruction by a diffusely
infiltrative cancer; (3) drug-induced cirrhosis (Chapter 10) ; and (4) syphilis (Chapter 9) . Severe sclerosis can occur in the setting of cardiac disease (called cardiac cirrhosis, discussed later). After all the categories of cirrhosis of known causation have been excluded, a substantial number of cases remain. The magnitude of this "wastebasket" category, referred to as cryptogenic cirrhosis, speaks eloquently to the difficulties in discerning the many origins of cirrhosis. Once cirrhosis is established, it is usually difficult to clearly distinguish an etiologic diagnosis on morphologic grounds alone. Pathogenesis.
The central pathogenetic process in cirrhosis is progressive fibrosis. In the normal liver, interstitial collagens (types I and III) are concentrated in portal tracts and around central veins, with occasional bundles in the space of Disse. The collagen (reticulin) coursing alongside hepatocytes is composed of delicate strands of type IV collagen in the space of Disse. In cirrhosis, types I and III collagen are deposited in the lobule, creating delicate or broad septal tracts. New vascular channels in the septa connect the vascular structures in the portal region (hepatic arteries and portal veins) and terminal hepatic veins, shunting blood around the parenchyma. Continued deposition of collagen in the space of Disse within preserved parenchyma
854
is accompanied by the loss of fenestrations in the sinusoidal endothelial cells. In the process, the sinusoidal space comes to resemble a capillary rather than a channel for exchange of solutes between hepatocytes and plasma. In particular, hepatocellular secretion of proteins (e.g., albumin, clotting factors, lipoproteins) is greatly impaired. The major source of excess collagen in cirrhosis appears to be perisinusoidal hepatic stellate cells (Ito cells), which lie in the space of Disse. Although normally functioning as vitamin A fat-storing cells, they become activated during the development of cirrhosis, lose their retinyl ester stores, and transform into myofibroblast-like cells. As depicted in Figure 19-6 , the stimuli for synthesis and deposition of collagen may come from several sources: Chronic inflammation, with production of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta, and interleukin-1 Cytokine production by stimulated endogenous cells (Kupffer cells, endothelial cells, hepatocytes, and bile duct epithelial cells) Disruption of the extracellular matrix Direct stimulation of stellate cells by toxins Acquisition of myofibers by perisinusoidal stellate cells and their transformation into myofibroblasts also increase vascular resistance within the liver parenchyma, since tonic contraction of these "myofibroblasts" constricts the sinusoidal vascular channels. Throughout the process of liver damage and fibrosis, remaining hepatocytes are
stimulated to regenerate, and they proliferate as spherical nodules within the confines of the fibrous septa. The net outcome is a fibrotic, nodular liver in which delivery of blood to hepatocytes is severely compromised, as is the ability of hepatocytes to secrete substances into plasma. Disruption of the interface between the parenchyma and portal tracts obliterates biliary channels as well. Thus, the cirrhotic patient may develop jaundice and even hepatic failure, despite having a liver of normal mass. Clinical Features.
All forms of cirrhosis may be clinically silent. When symptomatic, they lead to nonspecific clinical manifestations: anorexia, weight loss, weakness, osteoporosis, and, in advanced disease, frank debilitation. Incipient or overt hepatic failure may develop, usually precipitated by superimposition of a metabolic load on the liver, as from systemic infection or a gastrointestinal hemorrhage.
Figure 19-6 Proposed mechanisms for stimulation of collagen production by hepatic stellate cells in cirrhosis. Distortion of the
extracellular matrix; secretion of cytokines from endothelial cells, Kupffer cells, hepatocytes, and inflammatory cells such as lymphocytes; and the direct action of toxins (or their metabolites) have all been proposed as possible stimuli for transforming hepatic stellate cells (lipocytes) into collagen-secreting myofibroblasts.
855
Imbalances of pulmonary blood flow, which are poorly understood, may lead to severely impaired oxygenation ( hepatopulmonary syndrome), further stressing the patient. [11] The ultimate mechanism of most cirrhotic deaths is (1) progressive liver failure (discussed earlier), (2) a complication related to portal hypertension, or (3) the development of hepatocellular carcinoma. PORTAL HYPERTENSION
Increased resistance to portal blood flow may develop in a variety of circumstances, which can be divided into prehepatic, intrahepatic, and posthepatic causes. The major prehepatic conditions are obstructive thrombosis and narrowing of the portal vein before it ramifies within the liver. Massive splenomegaly may also shunt excessive blood into the splenic vein. The major posthepatic causes are severe right-sided heart failure, constrictive pericarditis, and hepatic vein outflow obstruction. These vascular disturbances are discussed later in this chapter. The dominant intrahepatic cause is cirrhosis, accounting for most cases of portal hypertension. Far less frequent are schistosomiasis, massive fatty change, diffuse fibrosing granulomatous disease such as sarcoidosis and miliary tuberculosis, and diseases affecting the portal microcirculation exemplified by nodular regenerative hyperplasia (also discussed later). Portal hypertension in cirrhosis results from increased resistance to portal flow at the level of the sinusoids, and compression of central veins by perivenular fibrosis and expansile parenchymal nodules. Anastomoses between the arterial and portal systems
in the fibrous bands also contribute to portal hypertension by imposing arterial pressure on the low-pressure portal venous system. The four major clinical consequences are (1) ascites, (2) the formation of portosystemic venous shunts, (3) congestive splenomegaly, and (4) hepatic encephalopathy (discussed earlier). These are illustrated in Figure 19-7 . Ascites
Ascites refers to the collection of excess fluid in the peritoneal cavity. It usually becomes clinically detectable when at least 500 ml has accumulated, but many liters may collect and cause massive abdominal distention. It is generally a serous fluid having less than 3 gm/dl of protein (largely albumin) as well as the same concentrations as in the blood of solutes such as glucose, sodium, and potassium. Influx of neutrophils suggests secondary infection, whereas red cells point to possible disseminated intraabdominal cancer. With long-standing ascites, seepage of peritoneal fluid through transdiaphragmatic lymphatics may produce hydrothorax, more often on the right side. The pathogenesis of ascites is complex, involving the following mechanisms [12] : Sinusoidal hypertension, altering Starling forces and driving fluid into the space of Disse, which is then removed by hepatic lymphatics; this movement of fluid is also promoted by hypoalbuminemia. Percolation of hepatic lymph into the peritoneal cavity. Normal thoracic duct lymph flow approximates 800 to 1000 ml/day. With cirrhosis, hepatic lymphatic flow may approach 20 L/day, exceeding thoracic duct capacity. Hepatic lymph is rich in proteins and low in triglycerides, which is reflected in the protein-rich ascitic fluid. Intestinal fluid leakage. Portal hypertension also engenders increased perfusion pressure in intestinal capillaries. The osmotic action of the protein-rich ascitic fluid promotes movement of additional fluid out of intestinal capillaries into the abdomen. Renal retention of sodium and water due to secondary hyperaldosteronism (Chapter 26) .
Figure 19-7 The major clinical consequences of portal hypertension in the setting of cirrhosis.
Portosystemic Shunts
With the rise in portal system pressure, bypasses develop wherever the systemic and portal circulation share common capillary beds. Principal sites are veins around and within the rectum (manifest as hemorrhoids); the cardioesophageal junction (producing esophagogastric varices); the retroperitoneum;
856
and the falciform ligament of the liver (involving periumbilical and abdominal wall
collaterals). Although hemorrhoidal bleeding may occur, it is rarely massive or life threatening. Much more important are the esophagogastric varices that appear in about 65% of patients with advanced cirrhosis of the liver and cause massive hematemesis and death in about half of them (see Fig. 18-7 C). Abdominal wall collaterals appear as dilated subcutaneous veins extending from the umbilicus toward the rib margins ( caput medusae) and constitute an important clinical hallmark of portal hypertension. Splenomegaly
Long-standing congestion may cause congestive splenomegaly. The degree of enlargement varies widely up to 1000 gm and is not necessarily correlated with other features of portal hypertension. Massive splenomegaly may secondarily induce a variety of hematologic abnormalities attributable to hypersplenism. INFECTIOUS DISORDERS
Inflammatory disorders of the liver dominate the clinical practice of hepatology. This is partly because virtually any insult to the liver can kill hepatocytes and recruit inflammatory cells [13] but also because inflammatory diseases are frequently long-term chronic conditions that must be managed medically. Among inflammatory disorders, infection ranks supreme. The liver is almost inevitably involved in blood-borne infections, whether they are systemic or arise within the abdomen. Those in which the hepatic lesion is prominent include miliary tuberculosis, malaria, staphylococcal bacteremia, the salmonelloses, candidiasis, and amebiasis. The foremost hepatic infections, however, are viral in origin. Viral Hepatitis
Systemic viral infections that can involve the liver include (1) infectious mononucleosis (Epstein-Barr virus), which may cause a mild hepatitis during the acute phase; (2) cytomegalovirus infection, particularly in the newborn or immunosuppressed patient; and (3) yellow fever, which has been a major and serious cause of hepatitis in tropical countries. Infrequently in children and immunosuppressed patients, the liver is affected in the course of rubella virus, adenovirus, herpesvirus, or enterovirus infections. [14] However, unless otherwise specified, the term " viral hepatitis" is reserved for infection of the liver caused by a group of viruses having a particular affinity for the liver (Table 19-3) . As these viruses cause overlapping patterns of disease, each virus is introduced before the pathology of viral hepatitis is discussed. HEPATITIS A VIRUS
Hepatitis A, long known as infectious hepatitis and the scourge of military campaigns since antiquity, is a benign, self-limited disease with an incubation period of 2 to 6 weeks. Hepatitis A virus (HAV) does not cause chronic hepatitis or a carrier state and only rarely causes fulminant hepatitis, and so the fatality rate associated with HAV is about 0.1%. HAV occurs throughout the world and is endemic in countries with substandard hygiene and sanitation, so that most native populations have detectable
anti-HAV by the age of 10 years. Clinical disease tends to be mild or asymptomatic and rare after childhood. In developed countries, the prevalence of seropositivity increases gradually with age, reaching 50% by age 50 years in the United States. In this population, acute HAV infection tends to be a sporadic overt febrile illness. Overall, HAV accounts for about 25% of clinically evident acute hepatitis worldwide.
TABLE 19-3 -- THE HEPATITIS VIRUSES Hepatitis Hepatitis Hepatitis Hepatitis D Hepatitis E A Virus B Virus C Virus Virus Virus
Hepatitis G Virus*
Agent
Icosahedral Enveloped Enveloped Enveloped capsid, dsDNA ssRNA ssRNA ssRNA
Transmission
Fecal-oral
Parenteral; Parenteral; Parenteral; Water-borne Parenteral close close close contact contact contact
Incubation period
2-6 wk
4-26 wk
2-26 wk
4-7 wk
Carrier state
None
0.1%-1.0% of blood donors in U.S. and Western world
0.2%-1.0% of blood donors in U.S. and Western world
1%-10% in Unknown drug addicts and hemophiliacs
1%-2% of blood donors in U.S.
Chronic hepatitis
None
5%-10% of >50% acute infections
<5% None coinfection, 80% superinfection
None
Yes
No increase above HBV
None
Hepatocellular No carcinoma
Yes
Unenveloped ssRNA ssRNA virus
2-8 wk
Unknown, but unlikely
Unknown
* At present, hepatitis G virus is not considered pathogenic.
857
HAV is a small, unenveloped, single-stranded RNA picornavirus that occupies its own genus, Hepatovirus. Ultrastructurally, HAV is an icosahedral capsid 27 nm in diameter. HAV is spread by ingestion of contaminated water and foods and is shed in the stool for 2 to 3 weeks before and 1 week after the onset of jaundice. Thus, close personal contact with an infected individual or fecal-oral contamination during this period accounts for most cases. This explains the outbreaks in institutional settings such as
schools and nurseries and the water-borne epidemics under overcrowded, unsanitary conditions. HAV is not shed in any significant quantities in saliva, urine, or semen. Among developed countries, sporadic infections may be contracted by the consumption of raw or steamed shellfish (oysters, mussels, clams), which concentrate the virus from seawater contaminated with human sewage. Because HAV viremia is transient, blood-borne transmission of HAV occurs only rarely, and therefore donated blood is not specifically screened for this virus. Serologic Diagnosis.
Specific antibody against HAV of the immunoglobulin (Ig) M type appears in blood at the onset of symptoms, constituting a reliable marker of acute infection (Fig. 19-8) . Fecal shedding of the virus ends as the IgM titer rises. The IgM response usually begins to decline in a few months and is followed by the appearance of IgG anti-HAV. The latter persists for years, perhaps for life, providing protective immunity against reinfection by all strains of HAV. HEPATITIS B VIRUS
Hepatitis B virus (HBV), the cause of "serum hepatitis," can produce (1) acute hepatitis, (2) nonprogressive chronic
Figure 19-8 Sequence of serologic markers in acute hepatitis A viral hepatitis.
hepatitis, (3) progressive chronic hepatitis ending in cirrhosis, (4) fulminant hepatitis with massive liver necrosis, (5) an asymptomatic carrier state, with or without progressive subclinical disease, and (6) the backdrop for hepatitis D virus (HDV). HBV also plays an important role in the development of hepatocellular carcinoma. The approximate clinical outcomes for HBV infection are depicted in Figure 19-9 . Liver disease due to HBV is an enormous problem globally, with an estimated worldwide carrier rate of 300 million; in the United States alone, there are 300,000 new infections per year. Unlike HAV, HBV remains in blood during the last stages of a prolonged incubation period (4 to 26 weeks) and during active episodes of acute and chronic hepatitis. It is also present in all physiologic and pathologic body fluids, with the exception of stool. HBV is a hardy virus and can withstand extremes of temperature and humidity. Thus, whereas blood and body fluids are the primary vehicles of transmission, virus may also be spread by contact with body secretions such as semen, saliva, sweat, tears, breast milk, and pathologic effusions. Transfusion, blood products, dialysis, needle-stick accidents among health workers, intravenous drug abuse, and homosexual activity constitute the primary risk categories for HBV infection. In one third of patients, the source of infection is unknown. In endemic regions such as Africa and Southeast Asia, spread from an infected mother to a neonate during birth ( vertical transmission) is common. These neonatal infections often lead to the carrier state for life.
HBV is a member of the Hepadnaviridae, a family of DNA-containing viruses that cause hepatitis in multiple animal species. The mature HBV virion is a spherical double-layered "Dane particle" that has an outer surface envelope of protein, lipid, and carbohydrate enclosing a slightly hexagonal core. The genome of HBV is a partially double stranded circular DNA molecule (Fig. 19-10) . The organization of the HBV genome is unique in that all regions of the viral genome encode protein sequences: A nucleocapsid "core" protein (HBcAg, hepatitis B core antigen) and a longer polypeptide transcript with a precore and core region, designated HBeAg (hepatitis B e antigen). Envelope glycoprotein (HBsAg, hepatitis B surface antigen). Infected hepatocytes are capable of synthesizing and secreting massive quantities of noninfective surface protein (HBsAg). A DNA polymerase that exhibits reverse transcriptase activity, and genomic replication occurs through an intermediate RNA template. A protein from the X region (HBX), which is necessary for virus replication and acts as a transcriptional transactivator of the viral genes and a wide variety of host gene promoters. HBX is also thought to play a key role in the causation of hepatocellular carcinoma. HBV infections pass through two phases. During the proliferative phase, HBV DNA is present in episomal form, with formation of complete virions and all associated antigens. Cell surface expression of viral HBsAg and HBcAg in association with the major histocompatibility complex (MHC) class I molecules leads to activation of cytotoxic CD8+ T lymphocytes and hepatocyte destruction.
858
Figure 19-9 Schematic of the approximate outcomes of hepatitis B infection in adults, with their approximate annual frequencies in the United States. (Population estimates courtesy of John L. Gollan, MD, PhD, Brigham and Women's Hospital, Boston, MA.)
An integrative phase, in which viral DNA is incorporated into the host genome, may occur in hepatocytes not destroyed by the immune response. With cessation of viral replication and the appearance of antiviral antibodies, infectivity ends and liver damage subsides. However, the risk of hepatocellular carcinoma persists. On occasion, infectious mutant strains of HBV emerge during active replication of the wild type HBV strain, and some may have ominous consequences. First, some mutants replicate successfully but are incapable of HBeAg expression, despite continued HBcAg production. The loss of circulating HBeAg, and hence of anti-HBe antibody formation, is associated with fulminant hepatitis. Second, vaccine-induced escape mutants appear to replicate in the presence of vaccine-induced immunity.
Serologic Diagnosis.
After exposure to HBV, the long asymptomatic 4- to 26-week incubation period (mean, 6 to 8 weeks) is followed by acute disease lasting many weeks to months (Fig. 19-11 A). Most patients experience a self-limited illness: HBsAg appears before the onset of symptoms, peaks during overt disease, and then declines to undetectable levels in 3 to 6 months. 859
HBeAg, HBV DNA, and DNA polymerase appear in the serum soon after HBsAg, and all signify active viral replication. IgM anti-HBc becomes detectable in serum shortly before the onset of symptoms, concurrent with the onset of elevated serum transaminase levels. During months, the IgM antibody is replaced by IgG anti-HBc. Anti-HBe is detectable shortly after the disappearance of HBeAg, implying that the acute infection has peaked and the disease is on the wane. IgG anti-HBs does not rise until the acute disease is over and is usually not detectable for a few weeks to several months after the disappearance of HBsAg. Anti-HBs may persist for life, conferring protection; this is the basis for current vaccination strategies using noninfectious HBsAg.
Figure 19-10 Diagrammatic representation of the structure and transcribed components of the hepatitis B virion.
Figure 19-11 Sequence of serologic markers for hepatitis B viral hepatitis demonstrating (A) acute infection with resolution and (B)
progression to chronic infection.
The carrier state is defined by the presence of HBsAg in serum for 6 months or longer after initial detection. The presence of HBsAg alone does not necessarily indicate replication of complete virions, and patients may be asymptomatic and without liver damage. In contrast, chronic replication of HBV virions is characterized by persistence of circulating HBsAg, HBeAg, and HBV DNA, usually with anti-HBc and occasionally with anti-HBs (Fig. 19-11 B). In these patients, progressive liver damage may occur.
860
Figure 19-12 Schematic of the potential outcomes of hepatitis C infection in adults in the United States. The population estimates are
for new infections. Including diagnoses of previously unsuspected cases of hepatitis C, the annual reported incidence of total cases actually exceeds 100,000, and total annual death rates from hepatitis C infection approach 10,000. (Population estimates based on the consensus report from the National Institutes of Health Consensus Development Conference. Hepatology 26:Suppl 1:1S-153S, 1997.)
HEPATITIS C VIRUS
Hepatitis C virus (HCV) is also a major cause of liver disease worldwide. The main routes of transmission are inoculations and blood transfusions. HCV is believed to be the most important cause of transfusion-associated hepatitis, being responsible for 90% to 95% of all cases. Sexual transmission and vertical transmission are infrequent. Sporadic hepatitis of unknown source accounts for 40% of cases. Seroprevalence in the United States population is less than 0.2%, but it is higher in house contacts, homosexuals, hemodialysis patients, hemophiliacs, and intravenous drug abusers (the last approaching 50% to 90%). Patients with unexplained cirrhosis and hepatocellular carcinoma have anti-HCV prevalence rates exceeding 50%. In contrast to HBV, HCV has a high rate of progression to chronic disease or eventual cirrhosis, exceeding 50% (Fig. 19-12) . Thus, HCV may in fact be the leading infectious cause of chronic liver disease in the Western world. HCV, and the closely related hepatitis G virus, occupy a genus in the Flaviviridae. HCV is a small, enveloped, single-stranded RNA virus with a genome that codes for a single polyprotein (Fig. 19-13) . This peptide is subsequently processed into functional proteins. The HCV virus is inherently unstable, giving rise to multiple types and subtypes. This variability has seriously hampered efforts to develop an HCV vaccine. In particular, elevated titers of anti-HCV IgG occurring after an active infection do not confer effective immunity. A characteristic feature of HCV infection, therefore, is repeated bouts of hepatic damage, the result of reactivation of a preexisting infection or emergence of an endogenous, newly mutated strain. Persistent infection and chronic hepatitis are the hallmarks of HCV infection, despite the generally asymptomatic nature of the acute illness. Cirrhosis can be present at the time of diagnosis or may develop during a period of 5 to 10 years.
Figure 19-13 Diagrammatic representation of the genomic structure of hepatitis C virus. A single open reading frame codes for core
(C) and envelope (E) proteins, as well as for a series of nonstructural (NS) proteins. Notably, most of the genome exhibits variability, with only the 5
end being well-conserved among different genotypes.
861
Serologic Diagnosis.
The incubation period for HCV hepatitis ranges from 2 to 26 weeks, with a mean between 6 and 12 weeks. HCV RNA is detectable in blood for 1 to 3 weeks, coincident with elevations in serum transaminases (Fig. 19-14 A). Circulating RNA persists in many patients despite the presence of neutralizing antibodies, including more than 90% of patients with chronic disease. The clinical course of acute HCV hepatitis is likely to be
milder than that of HBV, but individual cases may be severe and indistinguishable from HAV or HBV hepatitis. In chronic HCV infection, a characteristic clinical feature is episodic elevations in serum transaminases, with intervening normal or near-normal periods (Fig. 19-14 B). Alternatively, transaminases may be persistently elevated or may remain normal. HEPATITIS D VIRUS
Also called the delta agent and hepatitis delta virus, HDV is a unique RNA virus that is replication defective, causing infection only when it is encapsulated by HBsAg. Thus, although taxonomically distinct from HBV, HDV is absolutely dependent on the genetic information provided by HBV for multiplication and causes hepatitis only in the presence of HBV. Delta hepatitis thus arises in two settings [15] (Fig. 19-15) : Acute coinfection occurs after exposure to serum containing both HDV and HBV. The HBV must become established first to provide the HBsAg necessary for development of complete HDV virions. Superinfection of a chronic carrier of HBV with a new 862
inoculum of HDV (and HBV) results in disease about 30 to 50 days later. The carrier may have been previously "healthy" or may have had underlying chronic hepatitis.
Figure 19-14 Sequence of serologic markers for hepatitis C viral hepatitis demonstrating (A) acute infection with resolution and (B)
progression to chronic relapsing infection.
Figure 19-15 Differing clinical consequences of two patterns of combined hepatitis D virus and hepatitis B virus infection.
Simultaneous coinfection with HBV and HDV results in hepatitis ranging from mild to fulminant, with fulminant disease more likely (about 3% to 4%) than with HBV alone. Chronicity rarely develops. When HDV is superimposed on chronic HBV infection, three possibilities arise: (1) mild HBV hepatitis may be converted into fulminant disease; (2) acute, severe hepatitis may erupt in a previously healthy HBV carrier; or (3) chronic, progressive disease may develop (in 80% of patients), often culminating in cirrhosis. Infection by the delta agent is worldwide, but the prevalence varies greatly. In Africa, the Middle East, and southern Italy, 20% to 40% of HBsAg carriers have anti-HDV. In the United States, HDV infection is uncommon and largely restricted to drug addicts and hemophiliacs, who exhibit prevalence rates of 1% to 10%. Other high-risk groups for HBV, such as homosexual men and health care workers, are at low risk for HDV infection for unclear reasons. Surprisingly, HDV infection is uncommon in the large
population of HBsAg carriers in Southeast Asia and China. HDV is a 35-nm, double-shelled particle that by electron microscopy resembles the Dane particle of HBV. The external coat antigen of HBsAg surrounds an internal polypeptide assembly, designated delta antigen (HDAg). Associated with HDAg is a circular molecule of single-stranded RNA, whose length is smaller than the genome of any known animal virus. [16] This RNA is considered "genomic," but HDAg is the only HDV-encoded protein product detected to date. Serologic Diagnosis.
HDV RNA is detectable in the blood and liver just before and in the early days of acute symptomatic disease (Fig. 19-16 A). IgM anti-HDV is the most reliable indicator of recent HDV exposure, although its appearance is late and frequently short-lived. Nevertheless, acute coinfection by HDV and HBV is best indicated by detection of IgM against both HDAg and HBcAg (denoting new infection with hepatitis B). With chronic delta hepatitis arising from HDV superinfection (Fig. 19-16 B), HBsAg is present in serum and IgM anti-HDV persists for months or longer. HEPATITIS E VIRUS
Hepatitis E virus (HEV) hepatitis is an enterically transmitted, water-borne infection occurring primarily in young to middle-aged adults; sporadic infection and overt illness in children are rare. [17] Epidemics have been reported from Asia and the Indian subcontinent, sub-Saharan Africa, and Mexico. Sporadic infection seems to be uncommon and is seen mainly in travelers. A characteristic feature of the infection is the high mortality rate among pregnant women,
863
Figure 19-16 Sequence of serologic markers for hepatitis D viral hepatitis depicting (A) coinfection with hepatitis B virus (HBV) and (B)
superinfection of an HBV carrier.
approaching 20%. In most cases, the disease is self-limited; HEV is not associated with chronic liver disease or persistent viremia. The average incubation period after exposure is 6 weeks. HEV is an unenveloped single-stranded RNA virus that is structurally similar to the Caliciviridae. [18] A specific antigen (HEV Ag) can be identified in the cytoplasm of hepatocytes during active infection, and virions are shed in stool during the acute illness.
Serologic Diagnosis.
Before onset of clinical illness, HEV RNA and HEV virions can be detected in stool and liver. The onset of rising serum transaminases, clinical illness, and elevated IgM anti-HEV titers are virtually simultaneous. Symptoms resolve in 2 to 4 weeks, during which time the IgM is replaced with a persistent IgG anti-HEV titer. OTHER HEPATITIS VIRUSES
Epidemiologic studies have established that some cases of hepatitis are caused by infectious agents other than those listed earlier. A viral agent bearing similarities to HCV has been cloned and designated hepatitis G virus (HGV). Transmission by transfusion has been documented, and evidence of HGV exposure has been found in 1% to 2% of blood donors in the United States. However, HGV appears to be nonpathogenic, causing neither liver disease nor exacerbation
864
of liver disease. Designation of HGV as a "hepatitis" virus may therefore be premature. CLINICOPATHOLOGIC SYNDROMES
A number of clinical syndromes may develop after exposure to hepatitis viruses: Carrier state: without clinically apparent disease or with chronic hepatitis Asymptomatic infection: serologic evidence only Acute hepatitis: anicteric or icteric Chronic hepatitis: without or with progression to cirrhosis Fulminant hepatitis: submassive to massive hepatic necrosis Not all of the hepatotropic viruses provoke each of these clinical syndromes; with rare exception, HAV and HEV do not generate a carrier state or cause chronic hepatitis. Other infectious or noninfectious causes, particularly drugs and toxins, can lead to essentially identical syndromes. Therefore, serologic studies are integral for the diagnosis of viral hepatitis and the distinction between the various types. The Carrier State
A "carrier" is an individual without manifest symptoms who harbors and therefore can transmit an organism. With hepatotropic viruses, there are (1) those who harbor one of the viruses but are suffering little or no adverse effects (a "healthy" carrier) and (2) those who have chronic liver disease but are essentially free of symptoms or disability. Both constitute reservoirs of infection. The carrier state is best characterized for HBV. Infection early in life, particularly through vertical transmission during childbirth,
produces a carrier state 90% to 95% of the time. In contrast, only 1% to 10% of adult infections yield a carrier state. Individuals with impaired immunity are particularly likely to become carriers. HCV can also clearly induce a carrier state, which is estimated at 0.2% to 0.6% of the general United States population. Morphologically, carriers have normal livers, a few ground-glass hepatocytes with sanded nuclei (HBV), or, in the case of HCV, evidence of chronic hepatitis. Asymptomatic Infection
Not surprisingly, patients in this group are identified only incidentally on the basis of minimally elevated serum transaminases or after the fact by the presence of antiviral antibodies. Acute Viral Hepatitis
Any one of the hepatotropic viruses can cause acute viral hepatitis. Whatever the agent, the disease is more or less the same and can be divided into four phases: (1) an incubation period, (2) a symptomatic preicteric phase, (3) a symptomatic icteric phase, and (4) convalescence. The incubation period for the different viruses is given in Table 19-5 . Peak infectivity occurs during the last asymptomatic days of the incubation period and the early days of acute symptoms. The preicteric phase is marked by nonspecific, constitutional symptoms. Malaise is followed in a few days by general fatigability, nausea, and loss of appetite. Weight loss, low-grade fever, headaches, muscle and joint aches, and pains and diarrhea are inconstant symptoms. About 10% of patients with acute hepatitis, most often those with hepatitis B, develop a serum sickness-like syndrome. This consists of fever, rash, and arthralgias attributable to circulating immune complexes. The true origin of all these symptoms is suggested by elevated serum aminotransferase levels. Physical examination reveals a mildly enlarged, tender liver. In some patients, the nonspecific symptoms are more severe, with higher fever, shaking chills, and headache, sometimes accompanied by right upper quadrant pain and tender liver enlargement. Surprisingly, as jaundice appears and these patients enter the icteric phase, other symptoms begin to abate. The jaundice is caused predominantly by conjugated hyperbilirubinemia and hence is accompanied by dark-colored urine related to the presence of conjugated bilirubin. The stools may become light colored, and the retention of bile salts may cause distressing skin itching (pruritus). Laboratory findings include prolonged prothrombin time and hyperglobulinemia; the serum alkaline phosphatase is usually only mildly elevated. An icteric phase is usual in adults (but not children) with HAV but is absent in about half the cases of HBV and most cases of HCV. In a few weeks to perhaps several months, the jaundice and most of the other systemic symptoms clear as convalescence begins. Chronic Viral Hepatitis
Chronic hepatitis is defined as symptomatic, biochemical, or serologic evidence of
continuing or relapsing hepatic disease for more than 6 months, with histologically documented inflammation and necrosis. Although the hepatitis viruses are responsible for most cases of chronic hepatitis, there are many other causes of chronic hepatitis (described later). They include Wilson disease, alpha1 -antitrypsin deficiency, chronic alcoholism, drugs (isoniazid, methyldopa, methotrexate), and autoimmunity. From 1968 to the early 1990s, chronic hepatitis was classified according to the histologic extent of inflammation. However, it is now apparent that etiology rather than the histologic pattern is the single most important factor determining the probability of developing progressive chronic hepatitis. In particular, HCV is notorious for causing a chronic hepatitis evolving to cirrhosis in a high percentage of patients (see Fig. 19-14) , regardless of histologic features at the time of initial evaluation. The clinical features of chronic hepatitis are extremely variable and are not predictive of outcome. In some patients, the only signs of chronic disease are persistent elevations of serum transaminases, hence the misleading designation "transaminitis." The most common symptom is fatigue; less commonly, there are malaise, loss of appetite, and occasional bouts of mild jaundice. Physical findings are few, the most common being spider angiomas, palmar erythema, mild hepatomegaly, hepatic tenderness, and mild splenomegaly. Laboratory studies may reveal prolongation
865
Figure 19-17 Diagrammatic representation of the morphologic features of acute and chronic hepatitis.
of the prothrombin time and, in some instances, hyperglobulinemia, hyperbilirubinemia, and mild elevations in alkaline phosphatase levels. In cases of HBV and HCV infection, immune complex disease may occasionally develop secondary to the presence of circulating antibody-antigen complexes, taking the form of vasculitis (subcutaneous or visceral, Chapter 12) and glomerulonephritis (Chapter 22) . Cryoglobulinemia is found in about 35% of patients with chronic HCV hepatitis. MORPHOLOGY OF ACUTE AND CHRONIC HEPATITIS.
The general morphologic features of viral hepatitis are depicted schematically in Figure 19-17 . The morphologic changes in acute and chronic viral hepatitis are shared among the hepatotropic viruses and can be mimicked by drug reactions. Although most viruses do not impart specific cytopathic changes, HBV infection may generate " ground-glass" hepatocytes (Fig. 19-18) : a finely granular, eosinophilic cytoplasm shown by electron microscopy to be spheres and tubules of HBsAg. Other HBV-infected hepatocytes may have " sanded" nuclei due to abundant HBcAg, indicating active viral replication.
Acute Hepatitis.
With acute hepatitis, hepatocyte injury takes the form of diffuse swelling (ballooning degeneration), so that the cytoplasm looks empty and contains only scattered wisps of cytoplasmic
Figure 19-18 Ground-glass hepatocytes (arrow) in HBV infection (H & E.)
866
remnants. An inconstant finding is cholestasis, with bile plugs in canaliculi and brown pigmentation of hepatocytes. Fatty change is unusual except with HCV. Two patterns of hepatocyte cell death are seen. In the first, rupture of cell membranes leads to cytolysis. The necrotic cells appear to have "dropped out," with collapse of the collagen reticulin framework where the cells have disappeared; scavenger macrophage aggregates mark sites of dropout. The second pattern of cell death, apoptosis, is more conspicuous. Apoptotic hepatocytes shrink, become intensely eosinophilic, and have fragmented nuclei; effector T cells may still be present in the immediate vicinity. Apoptotic cells are also phagocytosed within hours by macrophages and hence may be difficult to find despite a brisk rate of hepatocyte injury. In severe cases, confluent necrosis of hepatocytes may lead to bridging necrosis connecting portal to portal, central to central, or portal to central regions of adjacent lobules, signifying a more severe form of acute hepatitis. Hepatocyte swelling and regeneration compress sinusoids, and the more or less radial array of the parenchyma is lost. Inflammation is a characteristic and usually prominent feature of acute hepatitis (Fig. 19-19) . Kupffer cells undergo hypertrophy and hyperplasia and are often laden with lipofuscin pigment because of phagocytosis of hepatocellular debris. The portal tracts are usually infiltrated with a mixture of inflammatory cells. The inflammatory infiltrate may spill over into the adjacent parenchyma to cause necrosis of periportal hepatocytes--this "interface hepatitis" can occur in both acute and chronic hepatitis. Finally, bile duct epithelia may become reactive and even proliferate to form poorly defined ductular structures, particularly in cases of HCV hepatitis.
Figure 19-19 Acute viral hepatitis showing disruption of lobular architecture, inflammatory cells in the sinusoids, and hepatocellular apoptosis (arrow).
Figure 19-20 Chronic viral hepatitis due to hepatitis C virus, showing portal tract expansion with inflammatory cells and fibrous tissue,
and interface hepatitis with spillover of inflammation into the adjacent parenchyma. A lymphoid aggregate is present.
Chronic Hepatitis.
The histologic features of chronic hepatitis range from exceedingly mild to severe. Smoldering hepatocyte necrosis throughout the lobule may occur in all forms of chronic hepatitis. In the mildest forms, significant inflammation is limited to portal tracts and consists of lymphocytes, macrophages, occasional plasma cells, and rare neutrophils or eosinophils. Lymphoid aggregates in the portal tract are often seen in HCV infection (Fig. 19-20) . Liver architecture is usually well preserved. Continued interface hepatitis and bridging necrosis are harbingers of progressive liver damage. The hallmark of irreversible liver damage is the deposition of fibrous tissue. At first, only portal tracts exhibit increased fibrosis, but periportal fibrosis occurs with time, followed by linking of fibrous septa between lobules (bridging fibrosis). Continued loss of hepatocytes and fibrosis results in cirrhosis, with fibrous septa and hepatocyte regenerative nodules. This pattern of cirrhosis is characterized by irregularly sized nodules separated by variable but mostly broad scars (Fig. 19-21) . Historically, this pattern of cirrhosis has been termed postnecrotic cirrhosis, but many other causes may give rise to a cirrhotic liver with large nodules, and the term is better avoided. In some cases that come to autopsy, the inciting cause of such broad scars cannot be determined at all ("cryptogenic cirrhosis"). The clinical course of viral hepatitis is unpredictable. Patients may experience spontaneous remission or may have indolent disease without progression for many years. Conversely, some patients have rapidly progressive disease and develop cirrhosis within a few years. The major causes
867
Figure 19-21 Cirrhosis resulting from chronic viral hepatitis. Note broad scar and coarse nodular surface.
of death are twofold: cirrhosis, with liver failure and hepatic encephalopathy or massive hematemesis from esophageal varices; and hepatocellular carcinoma in those with long-standing HBV (particularly neonatal) or HCV infection. Fulminant Hepatitis
When hepatic insufficiency progresses from onset of symptoms to hepatic encephalopathy within 2 to 3 weeks, it is termed fulminant hepatic failure. A less rapid
course, extending up to 3 months, is called subfulminant failure. Fulminant viral hepatitis is the cause of 50% to 65% of cases of fulminant hepatic failure. It can be induced by hepatitis viruses A, B, C, D (either coinfection or superinfection with B virus), and E. Reactivation of chronic hepatitis B or acute herpesvirus infection is sometimes the cause. Drug and chemical toxicity make up most of the remainder (25% to 30%), acting either as direct hepatotoxins or by idiosyncratic inflammatory reactions. Principally implicated are acetaminophen (in suicidal doses), isoniazid, antidepressants (particularly monoamine oxidase inhibitors), halothane, methyldopa, and the mycotoxins of the mushroom Amanita phalloides. Much more rare, but just as life threatening, are ischemic hepatic necrosis, obstruction of the hepatic veins, massive malignant infiltration of the liver, Wilson disease, hyperthermia (heat stroke), and microvesicular steatosis syndromes, particularly acute fatty liver of pregnancy. MORPHOLOGY.
All causative agents produce essentially identical morphologic changes that vary with the severity of the necrotizing process. With all, the distribution of liver destruction is extremely capricious: the entire liver may be involved, or only random areas. With massive loss of substance, the liver may shrink to as little as 500 to 700 gm. In so doing, it is transformed into a limp, red organ covered by a wrinkled, too-large capsule. On transection, necrotic areas have a muddy red, mushy appearance with blotchy bile staining. On microscopic examination, complete destruction of hepatocytes in contiguous lobules leaves only a collapsed reticulin framework and preserved portal tracts. There may be surprisingly little inflammatory reaction. Alternatively, with survival for several days, there is a massive influx of inflammatory cells to begin the phagocytic clean-up process. Survival of the patient for more than a week permits secondary regenerative activity of surviving hepatocytes. With zonal necrosis, the parenchymal framework is preserved, regeneration is orderly, and native liver architecture is restored in time. With more massive destruction of confluent lobules, regeneration is disorderly, yielding nodular masses of liver cells. Scarring may occur in patients with a protracted course of submassive or patchy necrosis, representing a route for developing so-called postnecrotic cirrhosis, as noted earlier. Fulminant hepatic failure may present as jaundice, encephalopathy, and fetor hepaticus, as described previously. Notably absent on physical examination are stigmata of chronic liver disease (e.g., gynecomastia, spider angiomas). Life-threatening extrahepatic complications include coagulopathy and bleeding, cardiovascular instability, renal failure, adult respiratory distress syndrome, electrolyte and acid-base disturbances, and sepsis. Overall mortality ranges from 25% to 90% in the absence of liver transplantation.
Bacterial, Parasitic, and Helminthic Infections
Extrahepatic bacterial infections, particularly sepsis, can induce mild hepatic inflammation and varying degrees of hepatocellular cholestasis. The latter effect is attributable to the effects of proinflammatory cytokines, released by Kupffer cells and endothelial cells in response to circulating endotoxin. A number of bacteria can infect the liver directly, including Staphylococcus aureus in the setting of toxic shock syndrome, Salmonella typhi in the setting of typhoid fever, and secondary or tertiary syphilis. Alternatively, bacteria may proliferate in a biliary tree compromised by partial or complete obstruction. The bacterial composition reflects the gut flora, and the severe acute inflammatory response within the intrahepatic biliary tree is called ascending cholangitis. Parasitic and helminthic infections are major causes of morbidity worldwide, and the liver is frequently involved. Diseases discussed in Chapter 9 include malaria, schistosomiasis, strongyloidiasis, cryptosporidiosis, leishmaniasis, and infections by the liver flukes Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini. A form of liver infection deserving special mention is the liver abscess. In developing countries, liver abscesses are common; most represent parasitic infections, for example, amebic, echinococcal, and (less commonly) other protozoal and helminthic organisms. In developed countries, liver abscesses
868
are uncommon; a low incidence of amebic diseases is encountered, usually in immigrants from endemic regions. Most abscesses are pyogenic, representing a complication of a bacterial infection elsewhere. The organisms reach the liver by (1) the portal vein, (2) arterial supply, (3) ascending infection in the biliary tract (ascending cholangitis), (4) direct invasion of the liver from a nearby source, or (5) a penetrating injury. The majority of hepatic abscesses used to result from portal spread of intra-abdominal infections (e.g., appendicitis, diverticulitis, colitis). With improved management of these conditions, spread now occurs primarily through the biliary tree or the arterial supply in patients suffering from some form of immune deficiency (e.g., old age with debilitating disease, immunosuppression, or cancer chemotherapy with marrow failure). In these settings, abscesses may develop without a primary focus elsewhere. MORPHOLOGY.
Pyogenic hepatic abscesses may occur as solitary or multiple lesions, ranging in size from millimeters to massive lesions many centimeters in diameter. Bacteremic spread through the arterial or portal system tends to produce multiple small abscesses, whereas direct extension and trauma usually cause solitary large abscesses. Biliary abscesses, which are usually multiple, may contain purulent material from adjacent bile ducts. Gross and microscopic features are those to be seen in any abscess. The
causative organism can occasionally be identified in the case of fungal or parasitic abscesses. On rare occasion, abscesses located in the subdiaphragmatic region, particularly amebic, may burrow into the thoracic cavity to produce empyema or a lung abscess. Rupture of subcapsular liver abscesses has also led to peritonitis or localized peritoneal abscesses. Liver abscesses are associated with fever and, in many instances, right upper quadrant pain and tender hepatomegaly. Jaundice may result from extrahepatic biliary obstruction. Although antibiotic therapy may control smaller lesions, surgical drainage is often necessary for the larger lesions. Because diagnosis is frequently delayed, and because patients are often elderly and have serious coexistent disease, the mortality rate with large liver abscesses ranges from 30% to 90%. With early recognition and management, up to 80% of patients may survive. [19] AUTOIMMUNE HEPATITIS
Autoimmune hepatitis is a syndrome of chronic hepatitis in patients with a heterogeneous set of immunologic abnormalities. The histologic features are indistinguishable from chronic viral hepatitis. This disease may run an indolent or severe course and typically responds dramatically to immunosuppressive therapy. Salient features include Female predominance (70%), particularly young to perimenopausal women The absence of viral serologic markers Elevated serum IgG levels (>2.5 gm/dl) High serum titers of autoantibodies in 80% of cases, including antinuclear, anti-smooth muscle, and antimitochondrial antibodies An increased frequency of HLA-B8 or HLA-DRw3 Other forms of autoimmune disease are present in up to 60% of patients, including rheumatoid arthritis, thyroiditis, Sjogren syndrome, and ulcerative colitis. A subgroup of younger patients exhibits antibodies either to liver/kidney microsomes or "soluble liver antigen" (cytokeratins 8 and 18), suggesting that three types of autoimmune hepatitis exist. Clinical presentation is similar to other forms of chronic hepatitis; these tend to be the more severely affected patients, for whom immunosuppressive therapy is indicated. Autoimmune hepatitis may present in an atypical fashion with associated disease involving other organ systems, hampering diagnostic efforts. Alternatively, clinical autoimmune hepatitis exhibiting destruction of bile ducts ("autoimmune cholangitis") may make distinction from primary biliary cirrhosis or primary sclerosing cholangitis (discussed later) difficult. [20] DRUG- AND TOXIN-INDUCED LIVER DISEASE
As the major drug metabolizing and detoxifying organ in the body, the liver is subject to potential damage from an enormous array of pharmaceutical and environmental
chemicals. [21] Injury may result (1) from direct toxicity, (2) by hepatic conversion of a xenobiotic to an active toxin, or (3) through immune mechanisms, usually by a drug or a metabolite acting as a hapten to convert a cellular protein into an immunogen. Principles of drug and toxic injury are discussed in Chapter 10 . Here it suffices to recall that drug reactions may be classified as predictable (intrinsic) reactions or unpredictable (idiosyncratic) ones. Predictable drug reactions may occur in anyone who accumulates a sufficient dose. Unpredictable reactions depend on idiosyncrasies of the host, particularly the host's propensity to mount an immune response to the antigenic stimulus and the rate at which the host metabolizes the agent. Major examples include chlorpromazine, an agent that causes cholestasis in those patients who are slow to metabolize it to an innocuous byproduct, and halothane, which can cause a fatal immune-mediated hepatitis in some patients exposed to this anesthetic on multiple occasions. A broad classification of offending agents is offered in Table 19-4 . It should be noted that The injury may be immediate or take weeks to months to develop, presenting only after severe liver damage has developed. The injury may take the form of hepatocyte necrosis, cholestasis, or insidious onset of liver dysfunction. 869
Drug-induced chronic hepatitis is clinically and histologically indistinguishable from chronic viral hepatitis, and hence serologic markers of viral infection are critical for making the distinction. Among the agents listed in Table 19-4 , predictable drug reactions are ascribed to acetaminophen, tetracycline, antineoplastic agents, Amanita phalloides toxin, carbon tetrachloride, and, to a certain extent, alcohol. Many others, such as sulfonamides, methyldopa, and allopurinol, cause idiosyncratic reactions. Reye syndrome, a potentially fatal syndrome of mitochondrial dysfunction in liver, brain, and elsewhere, occurs predominantly in children given acetylsalicylic acid (aspirin) for the relief of virus-induced fever. This disease, which features extensive accumulation of fat droplets within hepatocytes (microvesicular steatosis), is exceedingly rare. A causal relationship with use of salicylates was never established, but a national campaign in the 1970s and 1980s condemning the use of aspirin in children with febrile illness may have served to break the Reye syndrome epidemic. Drug-induced liver disease is usually followed by recovery on removal of the drug. Exposure to a toxin or therapeutic agent should always be included in the differential diagnosis of liver disease. Alcoholic Liver Disease
Excessive alcohol consumption is the leading cause of liver disease in most Western
countries. These United States statistics attest to the magnitude of the problem [22] : More than 10 million Americans are alcoholics. Alcohol abuse causes 200,000 deaths annually, the fifth-leading cause of death, many related to automobile accidents. Twenty-five per cent to 30% of hospitalized patients have problems related to alcohol abuse.
TABLE 19-4 -- DRUG- AND TOXIN-INDUCED HEPATIC INJURY Hepatocellular Damage Examples Microvesicular fatty change Macrovesicular fatty change Centrilobular necrosis
Diffuse or massive necrosis Hepatitis, acute and chronic Fibrosis-cirrhosis Granuloma formation Cholestasis (with or without hepatocellular injury)
Tetracycline, salicylates, yellow phosphorus, ethanol Ethanol, methotrexate, amiodarone Bromobenzene, CCl4 , acetaminophen, halothane, rifampin Halothane, isoniazid, acetaminophen, methyldopa, trinitrotoluene, Amanita phalloides (mushroom) toxin Methyldopa, isoniazid, nitrofurantoin, phenytoin, oxyphenisatin Ethanol, methotrexate, amiodarone, most drugs that cause chronic hepatitis Sulfonamides, methyldopa, quinidine, phenylbutazone, hydralazine, allopurinol Chlorpromazine, anabolic steroids, erythromycin estolate, oral contraceptives, organic arsenicals
Chronic alcohol consumption has a variety of adverse effects, as pointed out in Chapter 10 . Of greatest impact, however, are the three distinctive, albeit overlapping, forms of liver disease: (1) hepatic steatosis, (2) alcoholic hepatitis, and (3) cirrhosis, collectively referred to as alcoholic liver disease. Because the first two conditions may develop independently, they do not necessarily represent a continuum of changes. The morphology of the three forms of alcoholic liver disease is presented first, because this facilitates consideration of their pathogenesis. The various forms of alcoholic liver disease are depicted in Figure 19-22 . MORPHOLOGY.
Hepatic Steatosis (Fatty Liver).
After even moderate intake of alcohol, small (microvesicular) lipid droplets accumulate in hepatocytes. With chronic intake of alcohol, lipid accumulates to the point of creating large clear macrovesicular globules, compressing and displacing the nucleus to the periphery of the hepatocyte. This transformation is initially centrilobular, but it may involve the entire lobule in severe cases (Fig. 19-23) . In macroscopic appearance, the fatty liver of chronic alcoholism is a large (up to 4 to 6 kg) soft organ that is yellow, greasy, and readily fractured. Although there is little or no fibrosis at the outset, fibrous tissue develops around the central veins and extends into the adjacent sinusoids with continued alcohol intake. Up to the time that fibrosis appears, the fatty change is completely reversible if there is abstention from further intake of alcohol. Alcoholic Hepatitis.
This is characterized by the following: Hepatocyte swelling and necrosis. Single or scattered foci of cells undergo swelling (ballooning) and necrosis. The swelling results from the accumulation of fat and water as well as proteins that normally are exported. Mallory bodies. Scattered hepatocytes accumulate tangled skeins of cytokeratin intermediate filaments and other proteins, visible as eosinophilic cytoplasmic inclusions in degenerating hepatocytes (Fig. 19-24) . These inclusions are a characteristic but not specific feature of alcoholic liver disease, as they are also seen in primary biliary cirrhosis, Wilson disease, chronic cholestatic syndromes, and hepatocellular tumors. Neutrophilic reaction. Neutrophils permeate the lobule and accumulate around degenerating hepatocytes, particularly those having Mallory bodies. Lymphocytes and macrophages also enter portal tracts and spill into the parenchyma. 870
Fibrosis. Alcoholic hepatitis is almost always accompanied by a brisk sinusoidal and perivenular fibrosis; periportal fibrosis may occasionally predominate, particularly with repeated bouts of heavy alcohol intake. In some cases, there is cholestasis and mild deposition of hemosiderin (iron) in hepatocytes and Kupffer cells.
Figure 19-22 Alcoholic liver disease. The interrelationships among hepatic steatosis, hepatitis, and cirrhosis are shown, along with a
depiction of key morphologic features at the morphologic level.
Figure 19-23 Alcoholic liver disease: macrovesicular steatosis, involving most regions of the hepatic lobule. The intracytoplasmic fat is seen as clear vacuoles. Some early fibrosis (stained blue) is present. (Masson trichrome.)
In macroscopic appearance, the liver is mottled red with bile-stained areas. Although the liver may be of normal or increased size, it often contains visible nodules and fibrosis indicative of evolution to cirrhosis. Alcoholic Cirrhosis.
The final and irreversible form of alcoholic liver disease usually evolves slowly and insidiously. At first the cirrhotic liver is yellow-tan, fatty, and enlarged, usually weighing more than 2 kg. During the span of years, it is transformed into a brown, shrunken, nonfatty organ, sometimes less than 1 kg in weight. Arguably, cirrhosis may develop more rapidly in the setting of alcoholic hepatitis, within 1 to 2 years. Initially, the developing fibrous septa are delicate and extend through sinusoids from central vein to portal regions as well as from portal tract to portal tract. Regenerative activity of entrapped parenchymal hepatocytes generates fairly uniformly sized "micronodules." With time, the nodularity becomes more prominent; scattered larger nodules create a "hobnail" appearance on the surface of the liver (Fig. 19-25 A). As fibrous septa dissect and surround nodules, the liver becomes more fibrotic,
871
Figure 19-24 Alcoholic hepatitis. A , The cluster of inflammatory cells marks the site of a necrotic hepatocyte. A Mallory body is present in a second hepatocyte (arrow). B , Eosinophilic Mallory bodies are seen in hepatocytes, which are surrounded by fibrous
tissue. (H&E.)
loses fat, and shrinks progressively in size. Parenchymal islands are engulfed by ever wider bands of fibrous tissue, and the liver is converted into a mixed micronodular and macronodular pattern (Fig. 19-25 B). Ischemic necrosis and fibrous obliteration of nodules eventually create broad expanses of tough, pale scar tissue (Laennec cirrhosis). Bile stasis often develops; Mallory bodies are only rarely evident at this stage. Thus, end-stage alcoholic cirrhosis comes to resemble, both macroscopically and microscopically, the cirrhosis developing from viral hepatitis and other causes. Pathogenesis.
Short-term ingestion of up to 80 gm of ethanol (eight beers or 7 ounces of 80-proof liquor) generally produces mild, reversible hepatic changes, such as fatty liver. Daily intake of 80 gm or more of ethanol generates significant risk for severe hepatic injury, and daily ingestion of 160 gm or more for 10 to 20 years is associated more consistently
with severe injury. Only 10% to 15% of alcoholics, however, develop cirrhosis. For reasons that may relate to decreased gastric metabolism of ethanol and differences in body composition, women appear to be more susceptible to hepatic injury than are men. Individual, possibly genetic susceptibility must exist, but no reliable genetic markers of susceptibility have been
Figure 19-25 Alcoholic cirrhosis. A , The characteristic diffuse nodularity of the surface reflects the interplay between nodular
regeneration and scarring. The average nodule size is 3 mm in this close-up view. The greenish tint of some nodules is due to bile stasis. B , The microscopic view shows nodules of varying sizes entrapped in blue-staining fibrous tissue. The liver capsule is at the top. (Masson trichrome.)
872
identified. In addition, the relationship between hepatic steatosis and alcoholic hepatitis as precursors to cirrhosis, both causally and temporally, is not yet clear. Cirrhosis may develop without antecedent evidence of steatosis or alcoholic hepatitis. In the absence of a clear understanding of the pathogenetic factors influencing liver damage, no " safe" upper limit for alcohol consumption can be proposed (despite the current popularity of red wines for amelioration of coronary vascular disease). The pharmacokinetics and metabolism of alcohol are examined in Chapter 10 . Pertinent to our discussion is the detrimental effect of alcohol and its byproducts on hepatocellular function: Hepatocellular steatosis results from (1) the shunting of normal substrates away from catabolism and toward lipid biosynthesis owing to generation of excess nicotinamide adenine dinucleotide (NADH) by the two major enzymes of alcohol metabolism, alcohol dehydrogenase and acetaldehyde dehydrogenase, (2) impaired assembly and secretion of lipoproteins, and (3) increased peripheral catabolism of fat. Induction of cytochrome P-450 leads to augmented transformation of other drugs to toxic metabolites. Free radicals, generated during microsomal ethanol-oxidizing system oxidation of alcohol, react with cellular membranes and proteins. Alcohol directly affects microtubular and mitochondrial function and membrane fluidity. Acetaldehyde (the major intermediate metabolite of alcohol en route to acetate production) induces lipid peroxidation and acetaldehyde-protein adduct formation, further disrupting cytoskeletal and membrane function. Alcohol induces immunologic attack on hepatic neoantigens, possibly the result of alcohol-induced or acetaldehyde-induced alteration in hepatic proteins. In addition, alcohol is food and can become a major calorie source in the diet of an alcoholic, displacing other nutrients and leading to malnutrition and vitamin deficiencies (such as vitamin B12 ). This is compounded by impaired digestive function, primarily
related to chronic gastric and intestinal mucosal damage, and pancreatitis. Collagen deposition by perisinusoidal hepatic stellate cells is a response to many converging events [23] : Kupffer cell activation, with release of proinflammatory cytokines (TNF-alpha, interleukins 1 and 6, transforming growth factor-beta) Amplification of the cytokine stimuli by platelet-activating factor, a lecithin-related lipid released by endothelial cells and Kupffer cells Influx of neutrophils into the parenchyma in response to the proinflammatory cytokines, with release of their noxious substances These events are set in motion by the local toxic effects of alcohol and by alcohol-induced release of bacterial endotoxin into the portal circulation from a compromised gut. Alcohol also induces release of vasoconstricting endothelins from sinusoidal endothelial cells. Endothelins induce the myofibroblast-like hepatic stellate cells to contract, decreasing sinusoidal perfusion and causing regional hypoxia. The net effect is a chronic disorder featuring steatosis, hepatitis, progressive fibrosis, and marked derangement of vascular perfusion. In essence, alcoholic liver disease can be regarded as a maladaptive state in which cells in the liver respond in an increasingly pathologic manner to a stimulus (alcohol) that originally was only marginally harmful. Clinical Course.
Hepatic steatosis may become evident as hepatomegaly with mild elevation of serum bilirubin and alkaline phosphatase levels. Alternatively, there may be no clinical or biochemical evidence of liver disease. Severe hepatic compromise is unusual. Alcohol withdrawal and the provision of an adequate diet are sufficient treatment. In contrast, alcoholic hepatitis tends to appear relatively acutely, usually after a bout of heavy drinking. Symptoms and laboratory manifestations may be minimal or those of fulminant hepatic failure. Between these two extremes are the nonspecific symptoms of malaise, anorexia, weight loss, upper abdominal discomfort, and tender hepatomegaly and the laboratory findings of hyperbilirubinemia, elevated alkaline phosphatase levels, and often a neutrophilic leukocytosis. An acute cholestatic syndrome may appear, resembling large bile duct obstruction. The outlook is unpredictable; each bout of hepatitis incurs about a 10% to 20% risk of death. With repeated bouts, cirrhosis appears in about one third of patients within a few years. Alcoholic hepatitis may also be superimposed on established cirrhosis. With proper nutrition and total cessation of alcohol consumption, the alcoholic hepatitis may clear slowly. However, in some patients, the hepatitis persists despite abstinence and progresses to cirrhosis. The manifestations of alcoholic cirrhosis are similar to other forms of cirrhosis, presented earlier, and include those of portal hypertension (with life-threatening variceal hemorrhage), jaundice, ascites, and other stigmata (e.g., grossly distended abdomen, wasted extremities, caput medusae). Laboratory findings reflect the developing hepatic
compromise, with elevated serum transaminase levels, hyperbilirubinemia, variable elevation of serum alkaline phosphatase, hypoproteinemia (globulins, albumin, and clotting factors), and anemia. In some instances, liver biopsy may be indicated, since experience teaches that in about 10% to 20% of cases of presumed alcoholic cirrhosis, another disease process is found on biopsy. Last, cirrhosis may be clinically silent, discovered only at autopsy or when stress such as infection or trauma tips the balance toward hepatic insufficiency. The long-term outlook for alcoholics with liver disease is variable. Five-year survival approaches 90% in abstainers who are free of jaundice, ascites, or hematemesis; it drops to 50% to 60% in those who continue to imbibe. In the end-stage alcoholic, the proximate causes of death are (1) hepatic coma, (2) a massive gastrointestinal hemorrhage, (3) an intercurrent infection (to which these patients are predisposed), (4) hepatorenal syndrome after a bout of alcoholic hepatitis, and (5) hepatocellular carcinoma in 3% to 6% of cases. Mention must be made of an uncommon condition resembling alcoholic hepatitis occurring in patients who do
873
not drink alcohol. Entitled nonalcoholic steatohepatitis, this condition features liver biopsy findings of steatosis, a mixed inflammatory infiltrate of the parenchyma, Mallory hyaline, and sinusoidal fibrosis. [24] Patients are largely asymptomatic, with abnormalities in biochemical laboratory test results. Nonspecific constitutional symptoms of weakness, fatigue, and malaise may be present. Obesity is the most important risk factor; type II diabetes mellitus and hypertriglyceridemia are less common antecedent conditions. The chief risk is the development of cirrhosis, which occurs in a minority of patients. INBORN ERRORS OF METABOLISM AND PEDIATRIC LIVER DISEASE
A distinct group of liver diseases are attributable to disorders of metabolism. Genetic hemochromatosis, Wilson disease, and alpha1 -antitrypsin deficiency are well-characterized inherited disorders. Reye syndrome is not an inherited disease but has metabolic features suggesting a predisposition to its development. We must also consider here neonatal hepatitis, a broad disease category encompassing rare inherited diseases and neonatal infections. Hemochromatosis
Hemochromatosis is characterized by the excessive accumulation of body iron, most of which is deposited in parenchymal organs such as the liver and pancreas. Because humans do not have a major excretory pathway for iron, hemochromatosis results either from a genetic defect causing excessive iron absorption or as a consequence of parenteral administration of iron (usually in the form of transfusions). Genetic hemochromatosis, also called hereditary hemochromatosis, is a homozygous recessive
heritable disorder. Acquired forms of hemochromatosis with known sources of excess iron are called secondary hemochromatosis (Table 19-5) . As discussed in Chapter 14 , the total body iron pool ranges from 2 to 6 gm in normal adults; about 0.5 gm is stored in the liver, 98% of which is in hepatocytes. In genetic hemochromatosis, total iron accumulation may exceed 50 gm, more than one third of which accumulates in the liver. The following features characterize this disease: Fully developed cases exhibit (1) micronodular cirrhosis--all patients; (2) diabetes mellitus--75% to 80%; and (3) skin pigmentation--75% to 80% of cases. Iron accumulation is lifelong; symptoms usually first appear in the fifth to sixth decades of life. The hemochromatosis gene is located on the short arm of chromosome 6, close to the HLA gene locus. This gene, called HLA-H, encodes a novel HLA class I-like molecule that in some uncharacterized manner influences iron absorption. [25] The most common mutation is a cysteine to tyrosine substitution at amino acid 282, which inactivates this 343-amino acid protein; other alleles have also been identified. HLA-H is in linkage disequilibrium with HLA-A3, thus accounting for the association of this haplotype with genetic hemochromatosis. Males predominate (5 to 7:1) with slightly earlier clinical presentation, partly because physiologic iron loss (menstruation, pregnancy) delays iron accumulation in women.
TABLE 19-5 -- CLASSIFICATION OF IRON OVERLOAD I. Genetic Hemochromatosis II. Secondary Hemochromatosis A. Parenteral iron overload Transfusions Long-term hemodialysis Aplastic anemia Sickle cell disease Myelodysplastic syndromes Leukemias Iron-dextran injections B. Ineffective erythropoiesis with increased erythroid activity beta-Thalassemia Sideroblastic anemia Pyruvate kinase deficiency C. Increased oral intake of iron African iron overload (Bantu siderosis)
D. Congenital atransferrinemia E. Chronic liver disease Chronic alcoholic liver disease Porphyria cutanea tarda
In white populations of northern European extraction, the gene frequency has been estimated at approximately 6%. The frequency for homozygosity is 0.45% (1 of every 220 persons) and 11% (1 of every 9 persons) for heterozygosity, making genetic hemochromatosis one of the most common inborn errors of metabolism. Pathogenesis.
It may be recalled that the total body content of iron is tightly regulated, whereby the limited daily losses of iron are matched by gastrointestinal absorption. In genetic hemochromatosis, there is a primary defect in the intestinal absorption of dietary iron, leading to net iron accumulation of 0.5 to 1.0 gm/year. The disease manifests itself typically after 20 gm of storage iron has accumulated. The exact mechanism by which a defect in HLA-H engenders excessive iron absorption is not yet known. Regulated transfer of iron from intestinal mucosal cells to plasma may be involved, since HLA-H is expressed on the mucosal cell surface and interacts with circulating beta2 -microglobulin. [26] Mice defective in plasma beta2 -microglobulin develop a syndrome resembling genetic hemochromatosis. [27] Excessive iron appears to be directly toxic to host tissues by the following mechanisms: (1) lipid peroxidation through iron-catalyzed free radical reactions; (2) stimulation of collagen formation; and (3) direct interactions of iron with DNA, leading to lethal injury or predisposition to hepatocellular carcinoma. Whatever the deleterious effects of iron, they are reversible in cells not fatally injured, and removal of excess iron during therapy promotes recovery of tissue function. The most common causes of secondary hemochromatosis
874
are the hemolytic anemias associated with ineffective erythropoiesis, discussed in Chapter 14 . In these disorders, the excess iron may result not only from transfusions but also from increased intestinal absorption. Transfusions alone, as in aplastic anemias, lead to systemic hemosiderosis in which parenchymal organ injury tends to occur only in extreme cases. Alcoholic cirrhosis is often associated with a modest increase in stainable iron within liver cells. However, this represents alcohol-induced redistribution of iron, since total body iron is not significantly increased. A rather unusual form of iron overload resembling genetic hemochromatosis occurs in sub-Saharan Africa, the result of ingesting large quantities of alcoholic beverages fermented in iron
utensils (Bantu siderosis). Home brewing in steel drums continues to this day, and a genetic susceptibility in this population has been implicated. [28] MORPHOLOGY.
The morphologic changes in genetic hemochromatosis are characterized principally by (1) the deposition of hemosiderin in the following organs (in decreasing order of severity): liver, pancreas, myocardium, pituitary, adrenal, thyroid and parathyroid glands, joints, and skin; (2) cirrhosis; (3) pancreatic fibrosis. In the liver, iron becomes evident first as golden yellow hemosiderin granules in the cytoplasm of periportal hepatocytes, which stain blue with the Prussian blue stain (Fig. 19-26) . With increasing iron load, there is progressive involvement of the rest of the lobule, along with bile duct epithelium and Kupffer cell pigmentation. Iron is a direct hepatotoxin, and inflammation is characteristically absent. At this stage, the liver is typically slightly larger than normal, dense, and chocolate brown. Fibrous septa develop slowly, leading ultimately to a micronodular pattern of cirrhosis in an intensely pigmented liver.
Figure 19-26 Genetic hemochromatosis. Hepatocellular iron deposition is blue in this Prussian blue-stained section of an early stage
of the disease, in which parenchymal architecture is normal.
Biochemical determination of hepatic iron concentration in unfixed tissue is the standard for quantitating hepatic iron content. In normal individuals, the iron content of unfixed liver tissue is less than 1000 mug per gram dry weight of liver. Adult patients with genetic hemochromatosis exhibit more than 10,000 mug iron per gram dry weight; hepatic iron concentrations in excess of 22,000 mug per gram dry weight are associated with the development of fibrosis and cirrhosis. The pancreas becomes intensely pigmented, has diffuse interstitial fibrosis, and may exhibit some parenchymal atrophy. Hemosiderin is found in both the acinar and the islet cells and sometimes in the interstitial fibrous stroma. The heart is often enlarged and has hemosiderin granules within the myocardial fibers, inducing a striking brown coloration to the myocardium. A delicate interstitial fibrosis may appear. Although skin pigmentation is partially attributable to hemosiderin deposition in dermal macrophages and fibroblasts, most of the pigmentation results from increased epidermal melanin production. The combination of these pigments imparts a characteristic slate-gray color to the skin. With hemosiderin deposition in the joint synovial linings, an acute synovitis may develop. Excessive deposition of calcium pyrophosphate damages the articular cartilage, producing a disabling polyarthritis referred to as pseudogout. The testes may be small and atrophic but are not usually significantly pigmented. It is thought that the atrophy is secondary to a derangement in the hypothalamic-pituitary axis. Clinical Features.
Genetic hemochromatosis is more often a disease of males and rarely becomes evident
before age 40 years. The principal manifestations include hepatomegaly, abdominal pain, skin pigmentation (particularly in sun-exposed areas), deranged glucose homeostasis or frank diabetes mellitus due to destruction of pancreatic islets, cardiac dysfunction (arrhythmias, cardiomyopathy), and atypical arthritis. In some patients, the presenting complaint is hypogonadism (e.g., amenorrhea in the female, and loss of libido and impotence in the male). The classic triad of pigment cirrhosis with hepatomegaly, skin pigmentation, and diabetes mellitus may not develop until late in the course of the disease. Death may result from cirrhosis or cardiac disease. A significant cause of death is hepatocellular carcinoma; the risk is 200-fold greater than in the general population, and treatment for iron overload does not remove the risk for this aggressive neoplasm. Fortunately, genetic hemochromatosis can be diagnosed long before irreversible tissue damage has occurred. Screening involves demonstration of high levels of serum iron and ferritin, exclusion of secondary causes of iron overload, HLA gene molecular analysis, and liver biopsy if indicated. Screening of family members of probands is important. Heterozygotes for genetic hemochromatosis also accumulate excessive iron, but not to the degree required
875
to cause significant tissue damage. Homozygotes may be identified before onset of clinical disease. Patients with genetic hemochromatosis diagnosed in the subclinical, precirrhotic stage and treated by regular phlebotomy have a normal life expectancy. Wilson Disease
This autosomal recessive disorder is marked by the accumulation of toxic levels of copper in many tissues and organs, principally the liver, brain, and eye. Normally, 40% to 60% of daily ingested copper (2 to 5 mg) is absorbed in the stomach and duodenum and transported to the liver loosely complexed with albumin. Free copper dissociates and is transferred into hepatocytes, where it is incorporated into an alpha2 -globulin to form ceruloplasmin (a metallothionein) and resecreted into plasma. Ceruloplasmin accounts for 90% to 95% of plasma copper, although its biologic role is unknown since the contained six to seven atoms of copper per molecule are not readily exchangeable. Desialylated, senescent ceruloplasmin is endocytosed by the liver, degraded within lysosomes, and excreted into bile; this is the primary route for copper elimination. Estimated total body copper is only 50 to 150 mg. The gene for Wilson disease, designated ATP7B, is on chromosome 13 and encodes a transmembrane copper-transporting ATPase, located on the hepatocyte canalicular membrane. [29] The overwhelming majority of patients are compound heterozygotes containing different mutations of the Wilson disease gene on each allele. The overall frequency of mutated alleles is 1:200, engendering an incidence of the disease of approximately 1:30,000. Defective biliary excretion leads to copper accumulation in the liver in excess of the metallothionein-binding capacity, causing toxic liver injury. Usually
by 5 years of age, nonceruloplasmin-bound copper spills over into the circulation, causing hemolysis and pathologic changes at other sites such as brain, cornea, kidneys, bones, joints, and parathyroids. Concomitantly, urinary excretion of copper markedly increases from its normal minuscule levels. MORPHOLOGY.
The liver often bears the brunt of injury in Wilson disease; hepatic changes range from relatively minor to massive damage. Fatty change may be mild to moderate, with vacuolated nuclei (glycogen or water) and occasional hepatocyte focal necrosis. An acute hepatitis can exhibit features mimicking acute viral hepatitis, save possibly for the accompanying fatty change. A chronic hepatitis resembles chronic hepatitis of viral, drug, or alcoholic origin but may exhibit such distinguishing features as fatty change, vacuolated nuclei, and Mallory bodies. With progression of chronic hepatitis, cirrhosis will develop. Massive liver necrosis is a rare manifestation that is indistinguishable from that caused by viruses or drugs. Excess copper deposition can often be demonstrated by special stains (rhodanine stain for copper, orcein stain for copperassociated protein). Because copper also accumulates in chronic obstructive cholestasis, and because histology cannot reliably distinguish Wilson disease from viral and drug-induced hepatitis (and vice versa), demonstration of hepatic copper content in excess of 250 mug per gram dry weight is most helpful for making a diagnosis. In the brain, toxic injury primarily affects the basal ganglia, particularly the putamen, which demonstrates atrophy and even cavitation. Nearly all patients with neurologic involvement develop eye lesions called Kayser-Fleischer rings (green to brown deposits of copper in Descemet membrane in the limbus of the cornea)--hence the alternative designation of hepatolenticular degeneration. Clinical Features.
The age at onset and the clinical presentation of Wilson disease are extremely variable, but the disorder rarely manifests before age 6 years. The most common presentation is acute or chronic liver disease. Neuropsychiatric manifestations, including mild behavioral changes, frank psychosis, or a Parkinson disease-like syndrome, are the initial features in most of the remaining cases. The biochemical diagnosis of Wilson disease is based on a decrease in serum ceruloplasmin, increase in hepatic copper content, and increased urinary excretion of copper. Serum copper levels are of no diagnostic value, since they may be low, normal, or elevated, depending on the stage of evolution of the disease. Demonstration of Kayser-Fleischer rings further favors the diagnosis. Early recognition and long-term copper chelation therapy (as with D-penicillamine) have dramatically altered the usual progressive downhill course. alpha1 -Antitrypsin Deficiency
alpha1 -Antitrypsin deficiency is an autosomal recessive disorder marked by abnormally low serum levels of this major protease inhibitor (Pi). The major function of this protein is
the inhibition of proteases, particularly neutrophil elastase released at sites of inflammation. The deficiency leads to the development of pulmonary emphysema, because a relative lack of this protein permits tissue-destructive enzymes to run amok (discussed in Chapter 16) . alpha1 -Antitrypsin is a small, 394-amino acid plasma glycoprotein synthesized predominantly by hepatocytes. The gene, located on human chromosome 14, is polymorphic, and at least 75 alpha1 -antitrypsin forms have been identified, denoted alphabetically by their relative migration on an isoelectric gel. The most common genotype is PiMM, occurring in 90% of individuals. Most allelic variants exhibit conservative substitutions in the polypeptide chain and produce normal functioning levels of alpha1 -antitrypsin. Some deficiency variants, including the S variant, result in a reduction in serum concentrations of alpha1 -antitrypsin without clinical manifestations. However, homozygotes for the PiZZ protein have circulating alpha1 -antitrypsin levels that are
876
Figure 19-27 alpha 1 -Antitrypsin deficiency. Periodic acid-Schiff stain of the liver, highlighting the characteristic red cytoplasmic
granules. (Courtesy of Dr. I. Wanless, Toronto Hospital, Toronto, Ontario, Canada.)
only 10% of normal levels. These individuals are at high risk for developing clinical disease. Expression of alleles is autosomal codominant, and consequently PiMZ heterozygotes have intermediate plasma levels of alpha1 -antitrypsin. The gene frequency of PiZ is 0.0122 in the North American white population, yielding a PiZZ genotype frequency of approximately 1:7000. Rare variants termed Pi-null have no de